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Background: Bevacizumab (Avastin®, Roche), which is used in cancer therapy, is the ‘parent’ molecule
from which ranibizumab (Lucentis®, Novartis) was derived for the treatment of neovascular age-related
macular degeneration (nAMD). There were reports in the literature on the effectiveness of bevacizumab in
treating nAMD, but no trials. The cost per dose of bevacizumab is about 5–10% that of ranibizumab.
This trial was a head-to-head comparison of these two drugs.
Objective: To compare the clinical effectiveness and cost-effectiveness of ranibizumab and bevacizumab,
and two treatment regimens, for nAMD.
Design: Multicentre, factorial randomised controlled trial with within-trial cost–utility and cost-minimisation
analyses from the perspective of the UK NHS. Participants, health professionals and researchers were
masked to allocation of drug but not regimen. Computer-generated random allocations to combinations of
ranibizumab or bevacizumab, and continuous or discontinuous regimen, were stratified by centre, blocked
and concealed.
Setting: Twenty-three ophthalmology departments in NHS hospitals.
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Participants: Patients ≥ 50 years old with active nAMD in the study eye with best corrected distance visual
acuity (BCVA) ≥ 25 letters measured on a Early Treatment of Diabetic Retinopathy Study (ETDRS) chart.
Previous treatment for nAMD, long-standing disease, lesion diameter > 6000 µm, thick blood at the fovea
and any other confounding ocular disease were exclusion criteria. One eye per participant was studied; the
fellow eye was treated according to usual care, if required.
Interventions: Ranibizumab and bevacizumab were procured commercially. Doses were ranibizumab
0.5 mg or bevacizumab 1.25mg. The repackaged bevacizumab was quality assured. All participants were
treated at visits 0, 1 and 2. Participants randomised to the continuous regimen were treated monthly
thereafter. Participants randomised to the discontinuous regimen were not retreated after visit 2 unless
pre-specified criteria for active disease were met. If retreatment was needed, monthly injections over
3 months were mandated.
Main outcome measures: The primary outcome was BCVA. The non-inferiority margin was 3.5 letters.
Secondary outcomes were contrast sensitivity; near visual acuity; reading index; neovascular lesion
morphology; generic and disease-specific patient-reported outcomes, including macular disease-specific
quality of life; survival free from treatment failure; resource use; quality-adjusted life-years (QALYs); and
development of new geographic atrophy (GA) (outcome added during the trial). Results are reported for
the study eye, except for patient-reported outcomes.
Results: Between 27 March 2008 and 15 October 2010, 610 participants were allocated and treated
(314 ranibizumab, 296 bevacizumab; at 3 months, 305 continuous, 300 discontinuous). After 2 years,
bevacizumab was neither non-inferior nor inferior to ranibizumab [–1.37 letters, 95% confidence interval
(CI) –3.75 to +1.01 letters] and discontinuous treatment was neither non-inferior nor inferior to continuous
treatment (–1.63 letters, 95% CI –4.01 to +0.75 letters). Lesion thickness at the fovea was similar by drug
[geometric mean ratio (GMR) 0.96, 95% CI 0.90 to 1.03; p= 0.24] but 9% less with continuous treatment
(GMR 0.91, 95% CI 0.85 to 0.97; p= 0.004). Odds of developing new GA during the trial were similar by
drug [odds ratio (OR) 0.87, 95% CI 0.61 to 1.25; p= 0.46] but significantly higher with continuous
treatment (OR 1.47, 95% CI 1.03 to 2.11; p= 0.033). Safety outcomes did not differ by drug but mortality
was lower with continuous treatment (OR 0.47, 95% CI 0.22 to 1.03; p= 0.05). Continuous ranibizumab
cost £3.5M per QALY compared with continuous bevacizumab; continuous bevacizumab cost £30,220 per
QALY compared with discontinuous bevacizumab. These results were robust in sensitivity analyses.
Conclusions: Ranibizumab and bevacizumab have similar efficacy. Discontinuing treatment and restarting
when required results in slightly worse efficacy. Safety was worse with discontinuous treatment, although
new GA developed more often with continuous treatment. Ranibizumab is not cost-effective, although
it remains uncertain whether or not continuous bevacizumab is cost-effective compared with discontinuous
bevacizumab at £20,000 per QALY threshold. Future studies should focus on the ocular safety of the two
drugs, further optimisation of treatment regimens and criteria for stopping treatment.
Trial registration: Current Controlled Trials ISRCTN92166560.
Funding: This project was funded by the NIHR Health Technology Assessment programme and will be
published in full in Health Technology Assessment; Vol. 19, No. 78. See the NIHR Journals Library website
for further project information.
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Plain English summary
The study aimed to compare two drugs (bevacizumab and ranibizumab), and two dosing intensities(injections monthly or intermittently), for treating wet age-related macular degeneration (AMD).
Twenty-three hospitals took part. Broadly, we sought to include patients with wet AMD in the study eye,
who were older than 50 years. Each participant was allocated one of the drugs and one of the dosing
intensities, creating four combinations. The main outcome was the number of letters read on an eye chart
using the study eye. Other aspects of eyesight, the appearance of the affected part of the eye, possible
harms of treatment, patient-reported outcomes, and resources used to treat participants were measured.
The average improvement in eyesight was very similar with either drug. Monthly treatment was slightly
better than intermittent treatment. Quality of life and treatment satisfaction did not differ by drug or
dosing intensity. When our results were combined with those of other trials, there was no difference in
eyesight outcomes between drugs, but giving treatment monthly was slightly better. Hospitalisations
and deaths during the trial occurred equally often with either drug but less often with monthly than
intermittent treatment. Ranibizumab was 15 times more expensive than bevacizumab.
Our findings show that the two drugs improve eyesight by a very similar amount and that monthly
treatment improves eyesight slightly more than intermittent treatment. Safety appeared to be slightly
better when treatment was given monthly. Ranibizumab was not cost-effective compared with
bevacizumab. More work is being done on the safety aspects of these drugs and treatment schedules.
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Scientific summary
Introduction
Neovascular age-related macular degeneration (nAMD) is a bilateral condition causing severe central vision
impairment. Ranibizumab (Lucentis®, Novartis), an antibody to vascular endothelial growth factor (VEGF),
is an effective treatment. Bevacizumab (Avastin®, Roche), the parent molecule for ranibizumab, is licensed
for other indications but not nAMD. It was identified as having similar benefits but at much lower cost.
When the alternative treatments to the Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)
trial was conceived, there was no systematic review of VEGF inhibitors to treat nAMD, no head-to-head
comparison of the two drugs and no data on minimum treatment frequency.
Objectives
The trial had three objectives. To estimate:
i. the effectiveness of bevacizumab compared with ranibizumab
ii. the effectiveness of discontinuous versus continuous treatment regimens, with criteria for restarting
treatment when required in patients receiving discontinuous treatment
iii. the cost-effectiveness of the alternative treatment strategies outlined above.
Methods
Study design
Multicentre, randomised, controlled factorial trial and within-trial economic evaluation, comparing the two
drugs and two treatment regimens.
Settings and participants
Patients were recruited from UK NHS hospitals. Adults of ≥ 50 years of age, newly referred with nAMD in
either eye, a best corrected distance visual acuity (BCVA) of ≥ 25 letters and a foveal neovascular lesion
were eligible. Previous treatment for nAMD, fibrosis > 50% of the total lesion, greatest linear diameter of
> 6000 µm, thick blood involving the centre of the fovea, other active ocular disease causing vision loss or ≥ 8
dioptres of myopia in the proposed study eye were exclusion criteria.
Interventions
Participants were allocated to one of four combinations: intravitreal injection of ranibizumab (0.5 mg) or
bevacizumab (1.25mg), and ‘continuous’ or ‘discontinuous’ treatment regimens. All participants attended
monthly and were treated at visits 0, 1 and 2. Participants randomised to the continuous regimen were
treated monthly thereafter; participants randomised to the discontinuous regimen were treated only if
prespecified clinical and optical coherence tomography (OCT) criteria for active disease were met. If
retreatment was initiated, three further doses at monthly intervals were mandated.
Randomisation
Randomisation was stratified by centre and blocked. Allocations were computer generated and concealed.
Masking
Investigators, outcome assessors and patients were masked to the drug throughout and to treatment
regimen until visit 2 data were submitted.
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Outcomes
The primary outcome was BCVA, assessed at baseline 3, 6, 12, 18 and 24 months. The primary end point
was after 2 years of follow-up.
Secondary outcomes were:
(a) Contrast sensitivity, near visual acuity (NVA) and reading index.
(b) Lesion morphology [from colour fundus photography, fundus fluorescein angiography (FFA) and OCT].
(c) Two generic health status measures, European Quality of Life-5 Dimensions (EQ-5D) and Health Utilities
Index version 3 (HUI3), and two macular-disease specific instruments: the MacDQoL (Macular disease
Dependent Quality of Life: measuring the impact of macular disease on quality of life) and MacTSQ
(Macular disease Treatment Satisfaction Questionnaire: measuring satisfaction with treatment for
macular disease).
(d) Survival free from treatment failure.
(e) Resource use and quality-adjusted life-years (QALYs).
(f) Adverse events (AEs); the primary safety outcome was an arterial thrombotic event (ATE) or hospital
admission for heart failure.
(g) Development of geographic atrophy (GA) during the trial.
Follow-up
Participants were followed monthly for 2 years. Colour photographs and OCTs were captured every
3 months, and FFA at baseline, 12 and 24 months. Participants completed the EQ-5D and HUI3 at visits 0,
3, 12 and 24, and when a serious adverse event (SAE) had occurred since the previous visit. MacDQoL and
MacTSQ questionnaires were administered by telephone after visits 3, 12 and 24.
Sample size
We aimed to test non-inferiority hypotheses about visual function, with non-inferiority margins of 3 or
4 letters and analyses using one or two BCVA measurements, adjusted for baseline BCVA. Other
assumptions were:
l no interaction between drug and treatment regimen
l BCVA standard deviation (SD)= 14 letters
l 90% power, 2.5% significance
l correlation between baseline and follow-up BCVA= 0.5, and between follow-up BCVA= 0.8.
For a 3-letter non-inferiority margin, 600 participants were required.
A prespecified interim analysis was undertaken after participants had been followed for 1 year.
Statistical analyses
Intention-to-treat analyses were carried out. Continuously scaled outcomes at multiple time points were
analysed using linear mixed-effects methods. Binary outcomes were analysed using logistic regression, only
if ≥ 10 participants experienced the outcome. Time to first treatment failure was analysed using Cox
proportional hazards regression.
Effect estimates were reported separately by treatment regimen if the interaction of drug and treatment
regimen reached statistical significance; otherwise, main effects of drug and treatment regimen were
reported. No adjustment was made for multiple testing. Pre-planned subgroup analyses were tested
by adding subgroup-by-treatment interactions. Fixed-effects meta-analyses combining the results of
IVAN with other head-to-head trials were undertaken to place the trial findings within the context of
existing evidence.
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Economic evaluation
A within-trial economic evaluation was conducted to assess the incremental cost and cost-effectiveness of
discontinuous and continuous treatment using bevacizumab and ranibizumab from the cost perspective
of the NHS and the health perspective of participants. Health-care resource use was collected for all
trial participants. The analysis included the cost of study medication; drug administration/monitoring
consultations; any concomitant medication, ambulatory consultations and hospitalisations for ‘related’ AEs
or SAEs. Costs and QALYs were discounted at 3.5% per annum.
Results
Patient screening
In total, 693 patients were screened: 65 excluded and 628 randomised.
Recruitment
Recruitment occurred between 27 March 2008 and 15 October 2010, with the last follow-up on
7 November 2012. Five of 628 randomised participants were subsequently found to be ineligible and
13 were not treated, leaving 610 who received at least one injection in the IVAN study cohort.
Withdrawals
Sixty participants withdrew. The most common reasons for withdrawal were illness preventing attendance
and occurrence of a SAE.
Follow-up
In total, 525 of 610 participants completed the trial, with 87% of all scheduled visits attended. Missed
visits were distributed similarly across groups.
Trial cohort
Mean age was 77.7 years (SD 7.4 years); 244 (40%) participants were male, 64% were current or past
smokers and 19% had a history of dyspnoea. Characteristics were similar between groups, although more
participants allocated to bevacizumab than ranibizumab had angina (17% vs. 11%).
Treatment received
The number of injections administered was similar by drug (ranibizumab: median 18; bevacizumab: median 19).
More injections were given with continuous than discontinuous treatment (medians 23 vs. 13).
Success of masking
Ophthalmologists and participants reported not knowing which drug participants were receiving on > 97%
of 3-, 12- and 24-month visits.
Unmasking
Unmasking was not required.
Primary outcome: best corrected distance visual acuity
Mean BCVA at 2 years was 67.8 and 66.1 letters in ranibizumab and bevacizumab groups and 66.6
and 67.3 letters in continuous and discontinuous groups. The difference between drugs (bevacizumab
minus ranibizumab) was –1.37 letters [95% confidence interval (CI) –3.75 to +1.01 letters; p= 0.26] and
between treatment regimens (discontinuous minus continuous) was –1.63 letters (95% CI –4.01 to +0.75
letters; p= 0.18). Bevacizumab was neither inferior nor non-inferior to ranibizumab, and discontinuous was
neither inferior nor non-inferior to continuous treatment. There were no differences by subgroup for drugs
or treatment regimens (p≥ 0.26).
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A meta-analysis of changes in BCVA from baseline in seven trials showed that bevacizumab was
statistically non-inferior to ranibizumab (–0.38 letters, 95% CI –1.47 to +0.70 letters; p= 0.49). Only CATT
(Comparison of Age-related macular degeneration Treatment Trials) and IVAN compared treatment
regimens; their combined data showed that discontinuous treatment was significantly inferior to
continuous treatment (–2.23 letters, 95% CI –3.93 to –0.53 letters; p= 0.010).
Secondary measures of visual function at 2 years
Near visual acuity did not differ by drug [geometric mean ratio (GMR)= 0.94, 95% CI 0.85 to 1.04;
p= 0.23] but was better with continuous treatment (GMR= 0.90, 95% CI 0.82 to 0.99; p= 0.04). Reading
index was similar by drug and regimen. Contrast sensitivity did not differ significantly by drug, but was
better with continuous treatment (mean difference= –1.07, 95% CI –1.90 to –0.25; p= 0.011).
Lesion morphology at 2 years
There were no significant differences by drug or treatment regimen for dye leakage on FFA but fewer
participants treated with ranibizumab had fluid on OCT (50% vs. 59%; p= 0.065) and when treated
continuously [45% vs. 63%, odds ratio (OR)= 0.47, 95% CI 0.33 to 0.67; p< 0.001].
Total thickness, and retinal plus subfoveal fluid thickness, at the fovea did not differ by drug. However,
they were 9% and 8% less thick for continuous treatment (GMR= 0.91, 95% CI 0.85 to 0.97; p= 0.004;
GMR= 0.92, 95% CI 0.84 to 1.00; p= 0.046, respectively).
A meta-analysis of changes in total retinal thickness at the fovea suggested a non-statistically significant
difference in favour of ranibizumab (p= 0.12). The combined CATT and IVAN data showed a statistically
significant difference in favour of continuous treatment (p= 0.001).
New GA during the trial developed in 30% of participants. There was no difference by drug (28% for
ranibizumab vs. 31% for bevacizumab: OR= 0.87, 95% CI 0.61 to 1.25; p= 0.46) but GA developed
significantly more often in the continuous group (34% vs. 26%, OR= 1.47, 95% CI 1.03 to 2.11;
p= 0.03). This finding was confirmed in a meta-analysis (OR= 1.56, 95% CI 1.20 to 2.03; p= 0.001).
Adverse events
Overall, 171 participants had one or more SAEs, of whom 30 died. The primary safety end point frequency
did not differ significantly by drug (OR= 1.69, 95% CI 0.80 to 3.57; p= 0.16) or regimen (OR= 0.56,
95% CI 0.27 to 1.19; p= 0.13). Deaths were split equally by drug but occurred more frequently in the
discontinuous than continuous group (20 vs. 10, OR= 0.47, 95% CI 0.22 to 1.03; p= 0.05).
Gastrointestinal SAEs appeared to occur more frequently with bevacizumab. The percentages of patients
having any systemic SAE were similar by drug (ranibizumab 26%, bevacizumab 27%) and treatment
regimen (continuous 24%, discontinuous 29%); 39 non-ocular SAEs were classified as possibly, probably
or definitely related to treatment.
Meta-analyses of safety outcomes showed no differences by drug for deaths or ATEs but a significantly
increased risk of any systemic SAE for bevacizumab (OR= 0.77, 95% CI 0.64 to 0.92; p= 0.004).
The comparison by treatment regimen showed increased risks of death (OR= 0.49, 95% CI 0.27
to 0.86; p= 0.014) and any systemic SAE (OR= 0.81, 95% CI 0.65 to 1.01; p= 0.063) with
discontinuous treatment.
A post hoc meta-analysis of gastrointestinal SAEs showed a significantly increased risk of gastrointestinal
SAEs in the bevacizumab group (OR= 0.53, 95% CI 0.33 to 0.85; p= 0.009) but no difference by
treatment regimen (OR= 0.88, 95% CI 0.44 to 1.78; p= 0.73).
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Patient-reported outcomes
The MacDQoL and MacTSQ scores and EQ-5D utilities were very similar at 1 and 2 years, both by drug and
treatment regimen (p≥ 0.23).
Economic evaluation
All four groups accrued an average of 1.6 QALYs over 2 years, with no differences by drug or treatment
regimen (p≥ 0.381). Total 2-year costs ranged from £3002 per patient (95% CI £2601 to £3403) for
discontinuous bevacizumab to £18,590 per patient (95% CI £18,258 to £18,922) for continuous ranibizumab.
Ranibizumab was significantly more costly than bevacizumab (p< 0.001), costing an additional £14,989
per patient (95% CI £14,522 to £15,456) for continuous treatment and £8498 per patient (95% CI £7700
to £9295) for discontinuous treatment. As QALY differences were negligible, continuous ranibizumab cost
£3.5M per QALY gained compared with continuous bevacizumab. Bootstrapping demonstrated that we
can be > 99.99% confident that continuous ranibizumab is poor value for money compared with
discontinuous ranibizumab at a £20,000 per QALY ceiling ratio.
Patients receiving continuous versus discontinuous bevacizumab accrued higher total costs (£599, 95% CI
£91 to £1107; p= 0.021) but also accrued non-significantly more QALYs (mean difference: 0.020, 95% CI
–0.032 to 0.071; p= 0.452). Continuous bevacizumab therefore cost £30,220 per QALY gained compared
with discontinuous bevacizumab. However, this finding was substantially uncertain, with a 37% chance
that continuous bevacizumab is cost-effective at a £20,000 per QALY ceiling ratio.
Discussion
Main findings: study results
Comparisons by drug and treatment regimen for BCVA were inconclusive. However, the BCVA meta-analysis
showed that bevacizumab is non-inferior to ranibizumab and that discontinuous treatment is significantly
inferior to continuous treatment. Secondary visual function and lesion morphology outcomes were consistent
with the BCVA meta-analyses. New GA developed more often with continuous than discontinuous treatment.
Deaths and SAEs did not differ by drug. The meta-analyses of safety data by drug showed a significant
increase in the risk of any systemic SAE, and SAEs classified as gastrointestinal, with bevacizumab. There
were twice as many deaths in IVAN with discontinuous treatment, a finding confirmed in a meta-analysis.
The odds of any systemic SAE by treatment regimen also tended to favour continuous treatment.
The economic evaluation demonstrated that ranibizumab is not cost-effective compared with bevacizumab.
If hospitals in England were to switch from discontinuous ranibizumab to discontinuous bevacizumab,
the NHS could save at least £102M per year [including 20% value added tax (VAT)]. Discontinuous
bevacizumab is likely to be the most cost-effective treatment strategy evaluated in IVAN. However, this
finding is substantially uncertain, with a 37% chance that continuous bevacizumab is cost-effective.
Strengths and limitations
The IVAN trial should directly inform the use of anti-VEGF drugs in the NHS. Secondary visual function
outcomes supported the BCVA findings. Masking of the allocated drug and adherence to allocations of
drug and treatment regimen were excellent. Retention of the elderly participants was good, with only
10% withdrawing. A detailed health-economic evaluation was carried out.
Potency, stability and sterility of bevacizumab in pre-filled syringes were tested using methods approved
by the Medicines and Healthcare products Regulatory Agency. Our findings are generalisable only to
bevacizumab sourced from manufacturing pharmacies with appropriate quality control processes.
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Lessons for the future
Because the trial was considered to be ‘high risk,’ the IVAN trial design was modelled on commercial trials.
To better understand outcomes in a clinical setting IVAN could have been more pragmatic; for example,
we could have recruited both eyes, if both were eligible, and managed them according to same allocation.
In future, economic models to estimate the cost-effectiveness of interventions for nAMD should use robust
associations between VA and utility estimated from large data sets using methods recommended by the
National Institute for Health and Care Excellence. Our findings about the development of new GA
highlight that these models may need to consider a long time horizon.
Combination therapies are being investigated with the aim of reducing treatment frequency. Our finding
of possible risks of discontinuous treatment highlights the importance of careful monitoring of SAEs with
such treatment regimens.
Conclusion
The IVAN trial and meta-analyses of data from other trials show that the choice of anti-VEGF treatment
strategy is less straightforward than previously thought. Bevacizumab and ranibizumab have similar
efficacy. Continuous treatment avoids the need to monitor disease activity on every visit, with slightly
better functional outcomes. Our economic evaluation showed that ranibizumab represents poor value for
money, discontinuous bevacizumab is probably better value for money than continuous bevacizumab,
and monthly treatment with ranibizumab is unaffordable for publicly funded health systems.
Implications for health care
Findings from the IVAN trial:
l support using bevacizumab, which was non-inferior to ranibizumab, for both efficacy and safety
l highlight that economic models should use robust associations between VA and health-related quality
of life, estimated from large data sets and adopting a long time horizon
l identify the need to monitor the frequency of SAEs with combination treatment regimens designed to
reduce treatment frequency.
Recommendations for research
Research is needed to investigate:
l different models of service provision
l when treating nAMD may be futile
l the long-term consequences of anti-VEGF treatment
l reasons for poorer safety with discontinuous treatment.
Trial registration
This trial is registered as ISRCTN92166560.
Funding
Funding for this study was provided by the Health Technology Assessment programme of the National
Institute for Health Research.
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Chapter 1 Introduction
Background and rationale
Introduction
The onset of neovascularisation in age-related macular degeneration (AMD) is accompanied by central
distortion and blurring which, when left untreated, intensifies into a dense central scotoma.1 These visually
disabling effects of neovascular age-related macular degeneration (nAMD) are monitored by measuring
distance visual acuity (VA), which is a surrogate for central visual function; a drop of ≥ 15 letters in the
number of letters read on a logMAR [log(minimum angle of resolution)] letter chart (equivalent to the loss
of three lines of letters) is considered to be a visually significant event.2 Until 2005, all treatments that were
considered beneficial in the management of nAMD merely limited VA loss relative to untreated control
subjects or natural history.3,4 Thus, at that time successful treatment was defined in terms of slowing
down the rate of VA loss. The most effective treatment for nAMD was verteporfin (Visudyne, Novartis)
photodynamic therapy (PDT) which resulted in a reduction of the proportion of patients who suffered a
15-letter loss [three lines on the Early Treatment of Diabetic Retinopathy Study (ETDRS) VA chart] from
69% to 54%.3,5 The most impressive change that occurred around this time was the introduction of
ranibizumab (Lucentis®, Novartis). Ranibizumab is a monoclonal antibody to vascular endothelial growth
factor (VEGF), which is a potent mitogen and inducer of permeability in blood vessels.6 Two pivotal
ANCHOR (ANti-vascular endothelial growth factor antibody for the treatment of predominantly Classic
CHORoidal neovascularization in age-related macular degeneration) and MARINA (Minimally classic/occult
trial of the Anti-VEGF antibody Ranibizumab In the treatment of Neovascular Age-related macular
degeneration) clinical trials that established the superiority of ranibizumab as a treatment for nAMD
reported their findings.7,8 At 12 and 24 months, > 90% of eyes treated with ranibizumab (0.5 mg) avoided
the loss of three lines of VA compared with < 64% of eyes treated with PDT (the comparator in the
ANCHOR trial) or 62% of eyes treated with sham injections (the comparator in the MARINA trial). Even
more importantly, eyes treated with ranibizumab showed on average an increase in acuity of between 5
and 10 letters read on an ETDRS vision chart with some 30% achieving 70 letters (Snellen equivalent of
6/12), a level of vision which is compatible with visually demanding tasks such as fluent reading and
driving. These results exceeded all expectations, as trials of other therapeutic agents, including the VEGF
inhibitor pegaptanib (Macugen, Pfizer),3,4 had shown on average a reduction in acuity in treated eyes of
between two and three lines over 24 months.
Although the outcome after ranibizumab therapy was clearly impressive, this was achieved using an
intensive dosing schedule of monthly injections of the drug into the vitreous cavity of the eye. The method
of administration is an invasive procedure with the attendant risks of infection and iatrogenic eye trauma.
In addition, the requirement for monthly attendance over many years poses serious challenges for elderly
patients. Furthermore, such intensive treatment regimens also create difficulties in terms of resource
implications for health service providers. A small study [PIER: a study of rhuFAB V2 (ranibizumab) in
subjects with subfoveal choroidal neovascularization secondary to age-related macular degeneration],
which used a less intensive dosing schedule of three 4-weekly injections of ranibizumab 0.5mg followed
by retreatment at fixed 3-monthly intervals, did not yield equivalent VA results as those observed in the
MARINA and ANCHOR trials.9 Although mean VA improved in the PIER study in the first 3 months in a
manner similar to that seen in ANCHOR and MARINA, it gradually decreased thereafter, dropping back
by 12 months to the mean observed at baseline. By contrast, PrONTO [Prospective Optical Coherence
Tomography (OCT) Imaging of Patients with Neovascular Age-Related Macular Degeneration Treated with
intraOcular Ranibizumab], another small clinical trial of some 40 patients, suggested that a reduction in
treatment frequency could be achieved through rigorous tailoring of treatment to morphological
parameters without compromising VA outcomes.9,10 Taken together, these findings implied that there was
a variable need for retreatment among patients, and that a reduction in treatment frequency or alteration
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1
of dosing interval would require continuous monitoring and tailoring of therapy. The study design of the
ANCHOR and MARINA and other smaller randomised controlled trials (RCTs) that investigated effectiveness
of ranibizumab also did not permit conclusions to be drawn about the total duration of treatment required.
Although the role of ranibizumab in the management of nAMD was being investigated, another drug
[bevacizumab (Avastin®, Roche)] was identified by a number of small uncontrolled case series as having
equivalent visual benefits.11 Remarkable improvements in acuity and morphological findings following
intravitreal injection of bevacizumab were reported by investigators from countries across the world,12,13
primarily because it was available and the cost was more affordable. Bevacizumab (a pan-VEGF
monoclonal antibody, as is pegaptanib) is the parent molecule from which ranibizumab was derived and
the same manufacturer holds the patents and licences for both drugs. Bevacizumab was licensed for use in
colorectal cancer, and the therapeutic dose for systemic administration for this condition is approximately
1000 times greater than that required for intraocular use. Thus clinicians were able to offer a cheap
alternative to ranibizumab through unlicensed use of bevacizumab. The IVAN (Inhibit VEGF in Age-related
choroidal Neovascularisation) trial was developed to test whether or not visual results obtained with
bevacizumab were as good as those obtained with ranibizumab.
By virtue of their ability to inhibit all classes of VEGF, both ranibizumab and bevacizumab have the
potential to induce serious ocular and systemic side effects. VEGF is known to have an important
growth-promoting role in the retina14 and is also thought to maintain the fenestrated phenotype of the
choroidal vasculature.15 Therefore, there is concern that pan inhibition of VEGF over long periods of time
can cause atrophic changes in neural, retinal pigment epithelial (RPE) and vascular cells and tissues, with
serious consequences for visual function.
Although no such adverse effects have been detected in clinical trials using VEGF inhibition
strategies,4,7–10,16 the data available from trials relate to relatively short periods of follow-up, with few
patients having been followed beyond 2 years. Repeated intraocular penetration for drug delivery carries
a risk of endophthalmitis, traumatic cataract or retinal detachment. However, as shown by the VISION
(pegaptanib for neovascular age-related macular degeneration) clinical trials, adherence to protocols that
emphasise sterility and administration of the drug by experienced personnel reduces these risks to
acceptable levels.4
Systemic side effects remain a concern as the pooled findings from ANCHOR and MARINA trials revealed a
slight excess of thromboembolic events in the highest dose of ranibizumab groups and a small increase in
non-ocular haemorrhages in the treatment groups.7–9 In addition, circulating antibodies to ranibizumab
were discernible in serum samples in a significant proportion of patients who received ocular administration
of the drug.7,8 As bevacizumab had not been tested in a controlled trial environment, there was no orderly
collection of information on its potential to cause systemic drug toxicity. Therefore, the IVAN trial also
proposed the collection of serum samples from participants immediately prior to the Trial, and at the first
post-injection visit, for the assay of VEGF, the levels of VEGF inhibitors themselves and to detect circulating
antibodies to the inhibitors.
The IVAN trial also offered the opportunity for the creation of an accompanying biobank of serum and
deoxyribonucleic acid (DNA). The recent advances in pharmacogenomics have revealed that genetic
variation modifies the therapeutic response to drugs in a number of disease conditions.17 Thus, there
is increasing enthusiasm for linking DNA biobanks to RCTs in which participants are extremely well
phenotyped. Trials using VEGF inhibition strategies in cancer have shown that both survival and toxicity are
influenced by genetic variation.18 It is plausible that similar mechanisms may influence visual outcomes
following therapeutic VEGF inhibition in choroidal neovascularisation (CNV). The IVAN trial therefore
proposed the construction of a DNA biobank to test pharmacogenetic associations between treatment
responsiveness and key genetic polymorphisms.
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Summary of existing evidence
There was no systematic review of VEGF inhibitors in the treatment of nAMD due to AMD in 2007 when
the IVAN trial was conceived. Neither was there a head-to-head comparison of the two main inhibitors of
VEGF that were available at that time. There were no data on the minimum treatment frequency/duration
that is required to maintain the maximal visual benefit achieved with either of the drugs studied in IVAN,
and no trial had compared continuing monthly treatment with early cessation of VEGF inhibition with
treatment being restarted if signs of lesion reactivation were detected. Therefore, the research questions
that the IVAN study set out to address had not been investigated directly previously.
Importance of the health problem to the NHS
Epidemiological studies have shown that there are some 25,000 incident cases of nAMD each year in the
UK.1 RCTs had demonstrated the substantial benefit of ranibizumab for nAMD. Bevacizumab is considerably
cheaper than ranibizumab. The drug costs alone for monthly administration of ranibizumab were estimated
to be about £11,000 per patient per year and the cost of assessments and treatment delivery about £2500
per year, with a potential annual cost to the UK NHS of up to £300M per year. The cost-effectiveness of
VEGF inhibitor treatment is influenced greatly by the difference in drug cost, with ranibizumab being
20 times the price of bevacizumab. The costs of administering treatment are also high and there were no
recommendations about the likely duration of treatment required.
The absence of robust information about the safety of bevacizumab, and uncertainty about treatment
frequency for either drug, formed the basis for the alternative treatments in the IVAN trial.4 Accumulating
evidence that susceptibility to nAMD is influenced by the carriage of specific polymorphisms in a number of
genes which encode proteins involved in immune mediation and regulation,19–21 and the fact that antibodies
to the VEGF inhibitors had been found to develop over time, provided a strong rationale for the establishment
of a DNA and serum biobanks in the IVAN trial. While the IVAN trial was being designed, The Comparison of
Age-related macular degeneration Treatments Trials (CATT)22,23 was developed in parallel in the USA. With the
acquiescence of the funding organisations of the two trials, agreement was reached to share information
about the design and conduct of the trials, such as protocols and methods for the collection of adverse events
(AEs). This exchange of information allowed CATT22 and IVAN investigators to design the trials to facilitate
future meta-analyses of the outcomes of the two trials.
Aims and objectives
The aim of the IVAN trial was to investigate alternative VEGF inhibition treatment regimens for the
treatment of nAMD. We hypothesised that:
l Bevacizumab is not inferior to ranibizumab with respect to the benefits of VEGF inhibition in
maintaining/improving VA in eyes with nAMD.
l Treatment with VEGF inhibition can be ‘safely’ withdrawn at 3 months with monthly review to detect
reactivation, that is, criteria for restarting treatment can be prespecified to prevent any difference in
average VA compared with continuing monthly treatment.
The IVAN trial was designed as a non-inferiority trial because it was intended to show that bevacizumab
was not worse than the active control ranibizumab, as existing historical data suggested that both drugs
resulted in similar functional outcomes. We did not hypothesise that bevacizumab would be more effective
than ranibizumab with respect to VA. It was clearly not practicable to design an equivalence trial. We chose
the non-inferiority margin based on evidence of the effect of the active control (namely ranibizumab), as
well as existing data from another study. The drug effects are known to wear off over a 4-week period24
and our study design therefore mandated monthly visits for assessment and retreatment decision-making.
Evidence from the pivotal trials and subsequent studies had demonstrated that average VA improved
steadily from treatment inception over a period of 3 months. To maximise this benefit, we chose to have a
loading phase of 3 months, after which we introduced the opportunity to discontinue treatment if the
macula was judged to be fluid free.
DOI: 10.3310/hta19780 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 78
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Chakravarthy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
3
The trial had three specific inter-related objectives:
l To estimate the:
¢ relative effectiveness of two VEGF inhibitors, namely ranibizumab and bevacizumab, on visual
outcome in patients with nAMD; existing evidence of the benefit of VEGF inhibitors compared with
sham treatment precludes inclusion of a sham VEGF inhibition arm
¢ effectiveness of more frequent compared with less frequent VEGF inhibition in improving or
maintaining visual function, with stringent criteria for restarting treatment to prevent VA loss in
patients receiving less frequent treatment
¢ cost-effectiveness of the alternative treatment strategies outlined above.
In addition to estimating the effectiveness of the treatments on visual outcome, the trial was designed to
estimate differences in lesion morphology, quality of life and safety as secondary outcomes.
INTRODUCTION
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Chapter 2 Methods
Study design
The IVAN study was a multicentre, randomised controlled factorial trial. The trial is registered as
ISRCTN92166560. The research objectives were addressed by randomising participants to one of four
combinations of two treatment factors (Table 1). Participants, clinicians and trial personnel were masked
to the VEGF inhibitor to which a participant was assigned. Pharmacies dispensed the appropriate drug to
the ophthalmic clinic, as a pre-filled syringe for bevacizumab or in the commercially available vial for
ranibizumab. We aimed to achieve masking of the drug by using unmasked study teams (ophthalmologists
and nurses) who had no role in the outcome assessments in the trial. This method for masking had been
used extensively in trials that involve invasive methods of treatment delivery, as it is ethically unjustified to
inject a placebo into the eye because of the potential for serious adverse events (SAEs) related to the
procedure itself. All assessments and treatment management decisions were made by other trial personnel
who were masked to allocation to drug throughout the trial, and to allocation to treatment frequency until
after the third treatment. We chose not to mask participants, clinicians and trial personnel to whether or
not patients were allocated to continuous (i.e. monthly treatment) or discontinuous treatment (stop at
3 months with reinitiation of therapy if disease reactivation occurred).
Changes to study design after commencement of the study
The only change to the study design was a change to the method of masking the study drug, made in
October 2007, before recruitment to the trial began. Bevacizumab was supplied in a pre-filled syringe and
ranibizumab was supplied in a commercially manufactured vial. We originally intended that unmasked
injectors, with no other role in the trial, would ensure masking. However, nine of the smaller sites did not
have enough ophthalmologists to be able to guarantee the availability of an unmasked injector at every
visit. For these sites, an unmasked ophthalmic nurse was allowed to draw up ranibizumab into a syringe
identical to the pre-filled syringe of bevacizumab. Thus the injecting ophthalmologist was kept masked to
the identity of the drug and could therefore be allowed to perform other study procedures. All other trial
personnel involved in treatment decisions and outcome assessments remained masked. In December 2007,
we further clarified that the injector must be an ophthalmologist; it was always the case that the injections
should be performed by an ophthalmologist but we were asked to make this explicit in the protocol by the
IVAN Data Monitoring and Safety Committee (DMSC).
TABLE 1 Factorial study design
Treatment regimen Ranibizumab Bevacizumab
Continue treatment @ 3 months A B
Stop treatment @ 3 months C D
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Participants
Eligibility criteria
Inclusion criteria:
l adults of either sex, aged ≥ 50 years
l newly referred for the treatment of nAMD in the first or second eye
l best corrected distance visual acuity (BCVA) of ≥ 25 letters measured on a standard ETDRS chart
l any component of the neovascular lesion (CNV, blood, serous pigment epithelial detachment, elevated
blocked fluorescence) involving the centre of the fovea.
Exclusion criteria:
l previous treatment with PDT or a VEGF inhibitor in the eye being considered for inclusion
l argon laser treatment to the proposed study eye within the last 6 months
l long-standing CNV evidenced by the presence of fibrosis in excess of 50% of the total lesion
l greatest linear diameter of > 6000 μm (equivalent to about 12 disc diameters)
l presence of thick blood involving the centre of the fovea
l presence of other active ocular disease causing concurrent vision loss, for example diabetic retinopathy
l patients with eight or more dioptres of myopia
l pregnant and/or lactating women
l women with childbearing potential (i.e. not sterilised or not post-menopausal) who are unwilling to
use contraception
l men with a spouse or partner with childbearing potential unless the participant has agreed to
use condoms.
A past medical history of cardiovascular disease (CVD) or cardiovascular comorbidity, for example previous
myocardial infarction (MI), stroke or current angina, was not an exclusion criterion. However, such
conditions were documented carefully at the time of recruitment, and the potential benefits and harms of
treatment were discussed carefully with potential participants.
The eligibility criteria included some items that related to the proposed study eye and some items that
related to the person being screened for eligibility. The trial studied only one eye of each participant
(eligible ‘study eye’ in an eligible person). If a fellow eye developed nAMD during the trial, it was treated
with the optimum locally available treatment.
Changes to study eligibility criteria after commencement of the study
‘Patients with 8 or more dioptres of myopia’ was added as an exclusion criterion in June 2008 to ensure
consistency with other trials, such as the ANCHOR and MARINA trials.7,8
Settings
Patients were recruited to the IVAN trial from 23 ophthalmic units in NHS hospital trusts.
METHODS
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Interventions
After obtaining written informed consent, participants were allocated to one of four combinations of the
two treatment factors, intravitreal injections with ranibizumab or bevacizumab, on either ‘continuous’ or
‘discontinuous’ treatment regimens.
Drug doses were ranibizumab 0.5mg or bevacizumab 1.25mg.8,11,25 Ranibizumab and bevacizumab were
procured commercially. Bevacizumab was repackaged in pre-filled syringes in an aseptic manufacturing
facility in the Liverpool University Hospitals pharmacy. The potency, sterility and stability of the repackaged
bevacizumab aliquots were established prior to the start of the study.
The protocol required all participants to attend monthly (28- to 35-day interval) for clinical examination,
OCT and fundus photography. All participants were treated at visits 0, 1 and 2. Participants randomised to
the continuous regimen were treated monthly thereafter. Participants randomised to the discontinuous
regimen were not retreated after visit 2 unless prespecified clinical and OCT criteria for active disease were
met.26 If retreatment was needed, a further cycle of three doses delivered monthly was required.
The criteria for retreatment were divided into three levels arranged hierarchically (Figure 1).
If any of these criteria were met, participants in the discontinuous treatment arm were considered to have
failed stability criteria and treatment initiated. If treatment was reinitiated a further block of three
treatments, given at monthly intervals, was mandated (Figure 2).
1. Is there evidence from OCT of subretinal fluid in the study eye?
Yes No Not
sure
4. Is there evidence from OCT of persistent intraretinal fluid
    in the study eye?
5. Has the VA dropped by >_ 10 letters over the last 3 months?
6. Is there evidence of extension of the CNV?
7. Is there leakage from > 25% of the circumference of the CNV?
3. Is there fresh blood in the lesion in the study eye?
If the answer is YES to any of the above questions,
start a new 3-month cycle of treatment
If uncertain about one or more of the above criteria,
carry out fluorescein angiography
If the answer is YES to either of the above questions, start a new
3-month cycle of treatment regardless of OCT findings
If the answer is YES to both of the above questions, start a new
3-month cycle of treatment (NB: the presence of hyporeflective spaces
under the RPE on OCT are not considered an indicator of retreatment)
2. Is there evidence from OCT of an increase in intraretinal fluid
    in the study eye?
FIGURE 1 Criteria for treatment failure/restarting treatment.
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Outcomes
Primary outcome
The primary outcome was BCVA, measured as the number of letters read on a standard ETDRS chart.27 A
full assessment of BCVA was carried out at 3-, 6-, 12-, 18- and 24-month visits. BCVA was also measured
at every visit but a refraction – to check that the optical correction was carried out only at intermediate
visits if the VA had dropped by ≥ 15 letters or a refractive change – was suspected. The primary end point
was BCVA after 2 years of follow-up.
Secondary outcomes
l Clinical measures of vision, namely:
¢ Contrast sensitivity Contrast sensitivity is a global measure of macular function. It has been
suggested that it represents a better surrogate marker for visual function than BCVA by virtue of
the fact that some studies have observed better correlation with patient-reported outcomes.28
¢ Near visual acuity (NVA) NVA is measured in logMAR units using charts that utilise words of
specific character sizes and lengths. Therefore, unlike BCVA, which measures VA only at the point
of fixation, NVA is also thought to be a better metric of overall macular function. As BCVA
and NVA are not perfectly correlated, more information than just acuity is obtained by
measuring both.29
¢ Reading index This metric is a derivative of reading speed. Reading speed is a psychophysical test,
which measures ability to read a string of words without reference to context. It tests the ability of
the eye to scan along a line of words, and this function is impaired if visual deficits are present in
the parafoveal retina. Reading speed is measured using a print size subtending a visual angle that is
0.1 logMAR larger than the threshold NVA and expressed in units of words read per minute. The
reading index is the reading speed divided by the size of print read and thus makes allowance for
the visual angle.30,31
l Lesion morphology and metrics from angiograms and OCTs: a series of morphological outcomes were
generated from independent grading of colour fundus, fluorescein angiographic and tomographic
images. The outcomes were either binary (presence or absence) or continuous measures (area or
height). The features and measurements recorded are listed by imaging modality, and the
accompanying table (Table 2) provides definitions.
¢ Colour:
¢ presence of haemorrhage
¢ presence of fibrosis
¢ presence of geographic atrophy (GA).
¢ Fundus fluorescein angiography (FFA):
¢ presence of dye leakage
¢ area of active neovascularisation
¢ total lesion area
¢ area of fibrosis
¢ area of atrophy.
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TABLE 2 Definitions of measures of lesion morphology and metrics from colour fundus, fluorescein angiographic
and OCT images
Feature
Assessed
from
Type of
measurement Definition
Haemorrhage Colour Binary (present
or absent)
Any intraretinal, subretinal or subpigment epithelial blood
RPE tear Colour Binary (present
or absent)
An area devoid of RPE, crescentic in shape with elevation of the
straight edge
RPE tear FFA Binary (present
or absent)
An area of intense unchanging hyperfluorescence, crescentic
in shape
RPE tear OCT Binary (present
or absent)
Discontinuity of the RPE layer on any one of the six radial scans
Fibrosis Colour Binary (present
or absent)
Areas of pallor (yellow or whitish) with well-defined margins
Dye leakage FFA Binary (present
or absent)
Areas of featureless hyperfluorescence that increase in the late
frames and which may also exhibit well delineated
hyperfluorescence in the early frames
Atrophy FFA Binary (present
or absent)
Either geographic or non-GA of the RPE and choriocapillaris, seen
as diffuse areas of pallor or as sharply demarcated areas of pallor
through which the large choroidal vessels are visible
Active CNV FFA Continuous
(area, mm2)
Area of well-defined or ill-defined hyperfluorescence that is
ascribed to the presence of abnormal vasculature. This may be
classic (early well-defined hyperfluorescence), fibrovascular PED
consisting of speckled areas of hyperfluorescence that appear early
and which intensify and amalgamate in later frames of the
angiogram) and occult neovascularisation (areas of late leakage of
indistinct origin) and RAPs (early hyperfluorescence that is bright
and focal associated with a pigment epithelial detachment)
Total area
of lesion
FFA Continuous
(area, mm2)
All active CNV, plus any elevated blocked fluorescence or serous
PED contiguous to the lesion
Foveal
neuroretinal
thickness
OCT Continuous
(height, mm2)
A linear measurement of the distance between the inner and outer
boundary of the neurosensory retina at the foveal centre
Foveal SRF OCT Continuous
(height, µm)
Height of hyporeflective region separating the RPE band from the
outer boundary of the neurosensory retina at the foveal centre
Foveal PED OCT Continuous
(height, µm)
Elevation of the hyper-reflective band corresponding to the RPE and
or scar at the foveal centre
Total thickness at
the fovea
OCT Derived
continuous
variable (µm)
Sum of foveal neuroretinal thickness, SRF and PED
Maximum
retinal thickness
OCT Continuous
(height, µm)
Height from the inner limiting membrane to outer neurosensory
retina
New GA during
follow-up in trial
Colour
and FFA
Binary (present
or absent)
Area ≥ 175 µm greatest linear dimension with two or more relevant
features in colour images (well-defined margins; visibility of
choroidal vessels; scalloped edges) and consistent finding on FFA
(early hyperfluorescence, persisting through the FFA sequence and
fading in late images)
FFA, fundus fluorescein angiography; GA, geographic atrophy; PED, pigment epithelial detachment; RAP, retinal
angiomatous proliferation; SRF, subretinal fluid.
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¢ OCT:
¢ presence of fluid on OCT
¢ foveal:
¢ neuroretinal thickness
¢ height of subretinal fluid (SRF)
¢ height of pigment epithelial detachment (PED).
¢ At site of maximum retinal pathology:
¢ neuroretinal thickness
¢ height of SRF
¢ height of PED.
¢ Colour, FFA and OCT:
¢ presence of a RPE tear.
¢ Generic and vision-specific health-related quality of life (HRQoL), namely:
¢ European Quality of Life-5 dimensions (EQ-5D), three-level version32
¢ Health Utilities Index, version 3 (HUI3)33
¢ a measure of the impact of macular degeneration on quality of life [Macular disease
Dependent Quality of Life (MacDQoL)]34
¢ a measure of treatment satisfaction in patients with macular degeneration [Macular disease
Treatment Satisfaction Questionnaire (MacTSQ)].35
l Survival free from treatment failure (i.e. satisfying one or more of the criteria for retreatment).
l Resource use.
Best corrected visual acuity was recorded at every visit; other clinical measures of vision were measured at
baseline and visits 3, 6, 12, 18 and 24 only. Research OCT and colour images were done every 3 months
and FFA was done at baseline, visits 12 and 24. EQ-5D was measured at baseline, and visits 3, 12 and 24,
and MacDQoL and MacTSQ at visits 3, 12 and 24.
Adverse events
Adverse events, both serious and non-serious, were recorded at each visit and coded using Medical
Dictionary for Regulatory Activities (MedDRA, McLean, VA, USA) version 14.1. All SAEs were reviewed
by senior clinicians (UC, SPH, SD and AJL), masked to treatment allocation. The primary safety outcome
was the occurrence of an arteriothromboembolic event [arterial thrombotic event (ATE), as defined by the
Antiplatelet Trialists’ Collaboration36] or hospital admission for heart failure (HF).
Changes to study outcomes after commencement of the study
Heart failure was added as a SAE at the request of the DMSC in February 2008, and RPE tear, which is
part of the natural history of AMD and had been inadvertently missed, was added as an expected ocular
adverse event (AE) in June 2008.
The lesion morphology variables and metrics from angiograms and OCTs were not specified explicitly in
the study protocol, but the measures to be compared, their definition and derivation were defined
prospectively, before any analyses of these measures were undertaken.
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Prompted by the findings from the CATT at 2 years,22 colour and OCT images at baseline and most recent
available follow-up were regraded specifically to identify any new GA lesions – in either the study or fellow
eye – that had developed during the trial (Figure 3). This outcome was not specified in the study protocol.
Sample size
With respect to the primary outcome (BCVA), the trial is designed to answer non-inferiority questions.
Objective I: to compare the clinical effectiveness of the drugs
A small target difference was required to determine whether or not bevacizumab is inferior to
ranibizumab. We considered non-inferiority margins of 3 or 4 letters [0.20 to 0.30 standard deviations
(SDs), considered ‘small’37]. To help contextualise these differences, the 95% limits of agreement for
test–retest of VA among people with impaired but stable vision is 10 letters.38 We also considered analyses
using one or two VA measures (i.e. two post-randomisation repeated measures), adjusted for a baseline
measure of VA in both cases. We made the following additional assumptions:
l The drug comparison (ranibizumab vs. bevacizumab) would combine data from continuous and
discontinuous groups.
l SD for BCVA= 14 letters [based on baseline visual acuities for treated eyes in the Verteporfin
PhotoDynamic Therapy cohort study (VPDT), restricting to acuities ranging from 85 (6/6) to 25
(6/60) letters].
l 90% power, 2.5% significance (appropriate when testing two dimensions of the factorial design),
one-sided test (appropriate for a non-inferiority research question).
l Correlations between baseline (pre-) and follow-up (post) acuities= 0.5, and between-follow-up
acuities (post 1 and post 2)= 0.8; both of these correlations were calculated from longitudinal VA data
collected at 0, 6 and 12 months for patients treated with PDT at baseline in the VPDT.
l Table 3 gives the sample size for each of the ranibizumab and bevacizumab groups being compared
[i.e. for cells (A+C) and (B+D) in Table 1]. On the basis of these calculations, we planned to recruit
150 participants to each of the four cells described in Table 1, providing a sample size of 300 vs. 300
(fewer participants lost to follow-up) for the comparison between drugs. No adjustment was made for
dropout, estimated to be < 10% per year.7,8 Mixed models for analysis of repeated measures can
include any patient with at least one ‘post’ outcome measure, although missing data increase the
standard errors (SEs) for parameters estimated by the models.
The same sample size calculations and assumptions applied to other clinical visual function measures, for
which non-inferiority was hypothesised. The calculations and assumptions also applied to HRQoL,
treatment satisfaction, and resource use/cost (see Objective III: to estimate the cost-effectiveness of the
treatment strategies) except that the comparisons were two-sided, that is, the study was able to detect a
difference of 0.20–0.30 SDs with 90% power and 5% significance, as we hypothesised superiority of
bevacizumab for these outcomes.
Objective II: to compare the clinical effectiveness of the treatment regimens
Like objective I, this objective was also one of non-inferiority, as the main concern was that people
allocated to discontinuous treatment at 3 months do not suffer a visual function disadvantage. The
comparison of discontinuous vs. continuous VEGF inhibition (after the first 3 months) combined data for
groups allocated to ranibizumab and bevacizumab [i.e. cells (A+ B) vs. (C+D) in Table 1]. Other
assumptions set out above for objective I also applied to this objective. Therefore, these comparisons had
the same sample size as for objective I and hence the same power.
Objective III: to estimate the cost-effectiveness of the treatment strategies
This objective had the same sample size as for objective I and hence the same power but at a significance
level of 5% (two sided; see above).
METHODS
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Review of the sample size
In October 2009, when recruitment to IVAN was significantly slower than anticipated and 198 of the
planned 600 participants had been recruited, a review of the assumptions underpinning the sample size
calculation was undertaken (without reference to the group allocation). The results of the review (which
suggested that, for the continuously scaled outcomes a total sample size of 400 could be sufficient) were
presented to the Trial Steering Committee (TSC) and DMSC. After much discussion, both committees
recommended that the trial should continue to the planned recruitment of 600 patients, and accepted the
implications of extended time and costs. A request for a costed extension was subsequently submitted
and approved by the National Institute for Health Research (NIHR).
Interim analyses
A formal prespecified interim analysis was undertaken when all participants had been followed up to
1 year.26 No adjustment to the sample size and significance levels were made for this interim analysis.
Randomisation
Randomisation to one of the four treatment arms was stratified by centre, and blocked to ensure approximately
equal numbers of participants per group within a centre. Allocations were generated by computer, in advance
of starting the trial, by the coordinating centre, and concealed using an internet-based system provided by
Sealed Envelope Ltd (London, UK). Staff in participating centres gained limited access to the system using a
password. Information to identify a participant uniquely and to confirm eligibility had to be entered before the
system assigned a study number and hence the randomised treatment allocation was determined. This study
number was then written onto all patient case report forms (CRFs) and also on the prescription for study
drug issued to the local pharmacy. The prescription for each participant, together with a printout from the
randomisation system, was then sent to the local pharmacy. The local pharmacy staff took the prescription and
looked up the prescription log sheet for that participant according to study number. The prescription log, which
linked study number to drug allocation, was prepared by Bristol Clinical Trials and Evaluation Unit (CTEU) and
sent to the local pharmacy as part of site initiation, before recruitment at the site started.
Investigators and patients were masked to treatment regimen (continuous/discontinuous) until all data
for visit 2 had been submitted to Bristol CTEU. CRFs for visit 3 onwards were customised for a participant,
depending on the allocated treatment regimen. Participant-specific CRFs folders were made up by the
Bristol CTEU and sent to the centre at which a participant was being treated. Stickers were also added to
the spine of the CRF folder, identifying the treatment regimen to which a patient had been allocated
(green for continuous treatment, red for discontinuous regimen).
TABLE 3 Total sample size estimates for objective I
Equivalence margin One pre measure, one post measure One pre measure, two post measures
< 3 letters 688 596
< 4 letters 388 168
METHODS
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Masking
Participants, clinicians and trial personnel were masked to the VEGF inhibitor to which a participant was
assigned throughout the trial, and to the allocation of treatment frequency until after the third treatment. We
chose not to mask participants, clinicians and trial personnel to the continuous or discontinuous treatment
regimen after the first 3 months, on grounds of pragmatism and practicability. We were interested in the
effects of discontinuous treatment on treatment satisfaction. Masking treatment regimens would have required
sham injections to have been ‘given’ to patients allocated to the discontinuous regimen on visits when
treatment was not required.
Local pharmacies dispensed the appropriate drug to the ophthalmic clinic, as a pre-filled syringe for
bevacizumab or in the commercially available vial for ranibizumab. We intended that drug allocation
should be concealed by having separate masked assessment and unmasked treating teams. The study drug
was transported to clinic in a concealed container, which was then opened and the drug prepared by the
injecting ophthalmologist, out of sight of other study staff and participants. The injecting ophthalmologist
was not involved in any aspect of the study, and the drug allocation was not revealed to the participant
or to any other members of the study team. This system was achieved by 14 sites.
At the other nine sites, staffing levels could not support this system and an unmasked staff member
(usually the pharmacist or a research nurse) prepared the injection. Ranibizumab was prepared in a syringe
identical to those containing bevacizumab, and any drug labels were replaced with a label containing the
participant’s IVAN study number. The unmasked staff member presented this to the masked injector, while
ensuring that the original packaging and labels remained out of sight. The syringes were supplied by the
IVAN trial, obtained from the same source supplying syringes to the manufacturing pharmacy preparing
pre-filled syringes of bevacizumab. Those responsible for preparing the injections did not
perform assessments.
To assess the adequacy of masking, ophthalmologists and participants stated at visits 3, 12 and 24 (and at
exit visits if participants withdrew early), whether or not they knew the allocated drug (don’t know/
Lucentis/Avastin).
Lesion morphology was assessed by independent graders, masked to drug and treatment regimen, in the
UK Network of Ophthalmic Reading Centres. Because independent assessment of lesions could not be
done immediately, some randomised participants were subsequently found to be ineligible.
Data collection
Data collection in the IVAN study was performed over a 2-year period, during which time patients
attended 25 monthly visits. Most data were collected from patients using purpose-designed CRFs at these
visits (Table 4 shows the schedule of data collection).
Blood samples (1 × 10-ml ethylenediaminetetraacetic acid tube) for genetic analysis were collected at visit 0
(baseline) and sent to the Gift of Sight Research Centre in Southampton for storage and subsequent
analysis. Serum samples (2 × 6-ml serum separator tubes) were collected at visits 0, 1, 6, 11, 12, 18, 23
and 24; the samples at visits 6 and 18 were instituted only for participants recruited later in the trial after
observing marked changes in mean VEGF levels between visits 1 and 11 in participants recruited earlier in
the trial.39 If the participant did not attend one of these visits, samples collected at the following visit were
sent instead. These samples were sent to the Centre for Vision Science at Queen’s University Belfast
for serological analysis. All samples were sent using the Royal Mail Safebox system (guaranteed
next-day delivery).
DOI: 10.3310/hta19780 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 78
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Chakravarthy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
15
TA
B
LE
4
Sc
h
ed
u
le
o
f
d
at
a
co
lle
ct
io
n
Tr
ea
tm
en
t/
as
se
ss
m
en
t
Fo
llo
w
-u
p
m
o
n
th
/v
is
it
n
u
m
b
er
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Ex
it
D
em
og
ra
ph
y
✓
H
ei
gh
t
✓
W
ei
gh
t
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
a
Pa
st
m
ed
ic
al
hi
st
or
y
✓
C
ar
di
ov
as
cu
la
r
sy
m
pt
om
s
(C
C
S,
N
Y
H
A
,
an
kl
e
sw
el
lin
g/
H
F)
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
a
Bl
oo
d
pr
es
su
re
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
a
Bi
no
cu
la
r
ac
ui
ty
✓
✓
✓
✓
✓
✓
✓
✓
a
Re
fr
ac
tio
n
(s
ph
er
e,
cy
lin
de
r,
ax
is
)
✓
✓
b
✓
b
✓
✓
b
✓
b
✓
✓
b
✓
b
✓
b
✓
b
✓
b
✓
✓
b
✓
b
✓
b
✓
b
✓
b
✓
✓
b
✓
b
✓
b
✓
b
✓
b
✓
✓
a
D
is
ta
nc
e
BC
V
A
(le
tt
er
s
re
ad
)c
✓ B
✓ S
✓ S
✓ B
✓ S
✓ S
✓ B
✓ S
✓ S
✓ S
✓ S
✓ S
✓ B
✓ S
✓ S
✓ S
✓ S
✓ S
✓ B
✓ S
✓ S
✓ S
✓ S
✓ S
✓ B
✓
a
B
N
V
A
(lo
gM
A
R)
c
✓ B
✓ B
✓ B
✓ B
✓ B
✓ B
✓
a
B
Re
ad
in
g
in
de
x
(w
or
ds
/m
in
ut
e/
pr
in
t
si
ze
)c
✓ B
✓ B
✓ B
✓ B
✓ B
✓ B
✓
a
B
C
on
tr
as
t
se
ns
iti
vi
ty
(le
tt
er
s)
c
✓ B
✓ B
✓ B
✓ B
✓ B
✓ B
✓
a
B
Im
ag
in
g
(O
C
T,
ph
ot
os
)
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
a
Im
ag
in
g
(F
FA
)
✓
✓
d
✓
d
✓
d
✓
d
✓
d
✓
d
✓
d
✓
d
✓
d
✓
✓
d
✓
d
✓
d
✓
d
✓
d
✓
d
✓
d
✓
d
✓
d
✓
d
✓
d
✓
✓
a
M
ed
ic
at
io
ns
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
a
O
cu
la
r
hi
st
or
y
✓
O
cu
la
r
ex
am
in
at
io
n
(IO
P,
sl
it
la
m
p,
ca
ta
ra
ct
gr
ad
in
g,
po
st
er
io
r
se
gm
en
t
ab
no
rm
al
iti
es
)
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
a
O
cu
la
r
ex
am
in
at
io
n
(a
nt
er
io
r
se
gm
en
t,
le
ns
)
✓
METHODS
NIHR Journals Library www.journalslibrary.nihr.ac.uk
16
Tr
ea
tm
en
t/
as
se
ss
m
en
t
Fo
llo
w
-u
p
m
o
n
th
/v
is
it
n
u
m
b
er
0
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
Ex
it
El
ig
ib
ili
ty
fo
r
IV
A
N
✓
Se
ru
m
sa
m
pl
e
✓
✓
✓
✓
✓
✓
Bl
oo
d
sa
m
pl
e
(g
en
et
ic
s)
✓
In
je
ct
io
n
(d
at
e,
se
e
C
F,
IO
P,
an
tib
io
tic
s)
✓
✓
✓
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
✓
e
A
dv
er
se
re
ac
tio
n
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
A
Es
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
e
St
op
pi
ng
ru
le
s/
re
tr
ea
tm
en
t
cr
ite
ria
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
e
EQ
-5
D
f
✓
✓
✓
✓
H
U
I3
f
✓
✓
✓
✓
M
ac
D
Q
oL
✓
✓
✓
M
ac
TS
Q
✓
✓
✓
O
cu
la
r
sy
m
pt
om
s
–
us
e
of
m
ed
ic
al
se
rv
ic
es
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
a
N
on
-o
cu
la
r
sy
m
pt
om
s
–
us
e
of
m
ed
ic
al
se
rv
ic
es
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
a
Tr
av
el
ar
ra
ng
em
en
ts
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
✓
a
M
as
ki
ng
✓
✓
✓
✓
a
Re
as
on
s
fo
r
w
ith
dr
aw
al
✓
✓
✓
a
B,
bo
th
ey
es
;
C
C
S,
C
an
ad
ia
n
C
ar
di
ov
as
cu
la
r
So
ci
et
y;
IO
P,
in
tr
ao
cu
la
r
pr
es
su
re
;
N
Y
H
A
,
N
ew
Y
or
k
H
ea
rt
A
ss
oc
ia
tio
n;
S,
st
ud
y
ey
e.
a
C
ar
rie
d
ou
t
on
ly
if
pa
tie
nt
ph
ys
ic
al
ly
at
te
nd
ed
th
e
ex
it
vi
si
t.
b
C
op
ie
d
fo
rw
ar
d
fr
om
vi
si
t
0,
3,
6,
12
or
18
un
le
ss
te
st
s
ne
ed
to
be
re
pe
rf
or
m
ed
.
c
If
vi
si
t
3,
6,
9,
12
,
18
or
24
is
m
is
se
d
th
en
th
e
fu
ll
as
se
ss
m
en
t
is
co
m
pl
et
ed
at
th
e
ne
xt
vi
si
t
at
te
nd
ed
.
d
D
on
e
on
ly
if
re
qu
ire
d
fo
r
tr
ea
tm
en
t
fa
ilu
re
cr
ite
ria
.
e
Fo
r
pa
tie
nt
s
in
th
e
di
sc
on
tin
uo
us
ar
m
,
ca
rr
ie
d
ou
t
on
ly
if
pa
tie
nt
m
ee
ts
tr
ea
tm
en
t
fa
ilu
re
cr
ite
ria
or
is
pa
rt
of
a
cy
cl
e
of
th
re
e
tr
ea
tm
en
ts
.
f
A
ls
o
co
m
pl
et
ed
at
th
e
ne
xt
as
se
ss
m
en
t
at
te
nd
an
ce
af
te
r
an
y
SA
E
or
a
re
du
ct
io
n
in
BC
V
A
of
≥
15
le
tt
er
s.
DOI: 10.3310/hta19780 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 78
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Chakravarthy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
17
Colour photographs and OCTs were captured every 3 months, and FFA was captured at baseline,
12 and 24 months. Images were submitted to the Central Angiographic Resource Facility (CARF) for
analysis. If the criteria for treatment failure were met and a decision to restart treatment was made
(for participants allocated to the discontinuous treatment regimen) at an intervening visit between the
3-monthly visits, the colour photographs and OCT images captured at the visit were submitted to CARF.
The criteria for treatment failure were also applied to participants who were allocated to the continuous
treatment regimen, even though the resulting data did not influence the decision to treat (as these
participants were treated at every visit); the protocol required the colour photographs and OCT images
captured for these participants at these visits also to be submitted to CARF. If a FFA was required to
complete the assessment of criteria for retreatment, the FFA was also submitted to CARF. If a patient
withdrew from the study during a study visit, an exit visit was undertaken. As part of this exit visit, OCT
and FFA were taken and submitted to CARF.
Participants were asked to complete four HRQoL questionnaires and one questionnaire about symptoms
since the last visit (to ascertain adverse effects and resource use relating to the symptoms). The EQ-5D,
HUI3 and symptoms questionnaire were completed during the study visit. The EQ-5D and HUI3 were
administered at visits 0, 3, 12 and 24, and when a SAE had occurred since the previous visit. Collection
of participant responses to MacDQoL and MacTSQ questionnaires was coordinated centrally. A member of
the coordinating centre study team contacted participants by telephone approximately 2 weeks after
visits 3, 12 and 24.
A bespoke trial database was designed using Microsoft SQL Server 2008 (Microsoft Corporation, Redmond,
WA, USA). The database was intended to act as both a data storage facility and a trial management
resource. For example, the sites scheduled appointments using the database and the database issued
reminders when the telephone questionnaires were due. Activity reports were generated based on data
entered into the database, enabling the management of payments to sites (see Contractual and financial
arrangements). The database also provided a facility for tracking the progress of SAE reporting.
Owing to the large sample size and number of scheduled visits, a considerable amount of data validation
was applied to the database. The validation rules were determined as a result of detailed discussions
between clinical trial coordinators, research nurses, statisticians and database developers working on the
study, and were refined following any feedback from sites. Validation broadly included rules such as
ensuring that:
(a) the VA was recorded at all required time points and entered correctly; for example, the average value
of VA was calculated at each time point and any value entered that deviated significantly from the
average was queried to confirm it was correct
(b) injections were given in accordance to the trial protocol; for example, a query would be raised if a
patient on discontinuous treatment entered a 3-month treatment cycle and then failed to complete it
(c) AEs and SAEs were raised when required and that the event was followed through to completion.
Automated links between the IVAN database and the CARF system were set up so that queries could be
raised for any missing images and to check that images received at CARF were matched with the
correct event.
METHODS
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Statistical methods
Analyses of the primary and secondary efficacy outcomes were carried out on the basis of treatment
allocation, which was consistent with the analysis of CATT.22,23 The analysis population (and the safety
population) consisted of all randomised patients who received at least one injection. Patients who were
not treated or withdrew and were unwilling for data already collected to be used were excluded.
Reporting guidelines recommend that non-inferiority hypotheses and safety data are analysed by the
treatment received.40,41 As IVAN is a masked trial with respect to drug allocation, the drug treatment
received should equal the treatment allocated. If the drug received differed by visit (i.e. the wrong
treatment was given on one or more occasions), the patient was grouped according to the drug received
with greatest frequency. Grouping patients according to the amount of treatment received was not
straightforward, so for consistency of reporting, and on the recommendation of the IVAN DMSC, patients
were grouped according to the allocated treatment frequency.
Most outcomes were collected for the study eye (e.g. BCVA, other measures of visual function, lesion
morphology) but other outcomes were collected for the participant, notably data concerning systemic
AEs/SAEs and HRQoL. The unit of analysis for the former was, therefore, study eye, and for the latter it
was participant.
Continuous variables were summarised using the mean and SD [or median and interquartile range (IQR)
if the distribution is skewed], and categorical data were summarised as a number and percentage. The
primary outcome, BCVA, and other continuously scaled outcomes measured at multiple time points, were
analysed using linear mixed-effects methods, incorporating parameter estimates for the mean baseline
response where measured and for each treatment at each follow-up time (i.e. saturated model). Baseline
and subsequent values were modelled jointly to avoid the necessity to exclude or impute values for cases
with missing pre-treatment measures. Binary outcomes were compared using logistic regression, adjusted
for baseline values where measured, with treatment estimates presented as odds ratios (ORs). Formal
statistical comparisons were performed only if at least 10 participants in total experienced the outcome.
Time from completion of the loading dose of three treatments to the first treatment failure was analysed
using Cox proportional hazards regression, with treatment comparisons presented as hazard ratios (HRs)
and described graphically using Kaplan–Meier plots. The Cox model was also adjusted for whether or not
the patient had completed the full cycle in the loading phase (i.e. received three injections at visits 0, 1 and 2).
Assumptions underpinning the statistical models were checked using standard methods (e.g. residual plots,
tests for normality or for proportional hazards). If the assumptions were not satisfied then transformations
were explored. Outcomes analysed on a logarithmic scale were transformed back to the original scale after
analysis, and results presented as geometric mean ratios (GMRs). Outlying observations that meant models did
not fit the data adequately were excluded from analyses.
For EQ-5D, lesion area and MacTSQ at 2 years, no suitable transformation could be found and so data
were dichotomized (EQ-5D score, 1 vs. < 1; lesion present vs. absent; MacTSQ < median TSQ score over all
time points vs. ≥median TSQ score over all time points). For MacDQoL, the outcome was transformed
from original scale of –9 to +3 to a scale of –3 to +9), and analysed using a log transformation. The GMR
is, therefore, interpreted as the GMR of the MacDQoL score, and not of the MacDQoL score directly.
The interaction of VEGF inhibitor and treatment frequency was tested, and differences between
ranibizumab and bevacizumab were to be reported separately for the continuous and discontinuous
treatment arms only if the interaction term reached statistical significance (two sided) at the 5% level for
outcomes for which the results from the CATT22 suggested possible interaction (i.e. OCT measures of total
retinal thickness at the fovea and fluid, and presence of fluid on OCT) or at the 1% level for other
outcomes (chosen to reduce the type I error rate); however, this level of significance was not reached in
any of the models. As the interaction was not statistically significant, the main effects of ranibizumab
vs. bevacizumab and of continuous vs. discontinuous treatment after 2 years were reported. Likelihood
ratio tests were used in preference to Wald tests for hypothesis testing.
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All treatment comparisons at 2 years are presented as effect sizes with 95% CIs. For tests of superiority,
two-sided p-values of < 0.05 are considered to be statistically significant. For tests of non-inferiority,
bevacizumab was considered inferior to ranibizumab, and discontinuous treatment inferior to continuous
treatment if the lower limit of the 95% confidence interval (CI) for the difference between groups
was < –3.5 letters (inferiority margin set at 3–4 letters). No formal adjustment was made for multiple testing.
When interpreting the results, consideration has been given to the number of statistical tests performed.
The intention was to adjust all models for study centre. However, for some low-frequency outcomes
(e.g. safety) it was anticipated that this would not be feasible, so, for consistency, analyses were adjusted
for centre size, fitted as a fixed effect (see Appendix 5).
Best corrected distance visual acuity in the study eye, and several of the secondary outcomes, were
measured at all visits (see Table 4). However, the analysis of BCVA included only the ‘main’ study visits,
namely visits 0, 3, 6, 9, 12, 15, 18, 21 and 24. If the outcome was missing for one of these visits, but was
recorded at the next scheduled visit (i.e. 1 month later), this measurement was used in place of the missing
value. When this occurred, an indicator was included in the model (and retained, if statistically significant
at the 5% level) to denote that the measurement was taken 1 month later than intended.
For BCVA, if a participant could not read any letters from the chart, the following scores were assigned;
l ‘counting fingers’ 0 (which equates to no letters read at 1 m)
l ‘hand movements’ –15
l ‘perception of light’ –30.
The scores of –15 and –30, which equate to a doubling of the visual angle, were chosen to allow the
assignment of arbitrary points in deteriorating visual function to these categories.
The first step in assessing reading speed is to choose a Belfast chart that is appropriate for the patient’s
near vision. On occasions the incorrect chart was used. When a chart one size larger or smaller than the
correct size (based on the recorded NVA) was used, the data were used to calculate the reading index and
were included in the analysis. If the chart was more than one size larger or smaller than the correct size,
the data were treated as missing and the reading index was not calculated. Participants with a NVA logMAR
of 1.6 have vision, which is too poor for their reading ability to be measured, and, therefore, in the majority
of cases reading ability was not assessed. The reading index for these participants was imputed between
0.4 and 2.5 on the lognormal scale. This imputation method was chosen based on the distribution of values
for participants with a NVA logMAR of 1.6, who did have their reading ability assessed.
Several morphological outcomes were derived from colour, FFA and/or OCT measurements. Details of how
these measures were derived are described in Appendix 5. For all patient-reported outcome data, standard
rules have been used to derive outcome measures (see Appendix 5). EQ-5D scores are reported in two
sections: the first is the EQ-5D utility index, derived from responses to the five ordinal questions, and the
second is the visual analogue (‘thermometer’) scale. Using the MacDQoL questionnaire, an average
weighted impact score is derived from 22 out of the 23 questions (the question regarding work was
excluded, as it was irrelevant to the majority of participants). The MacTSQ questionnaire was used to
derive a single treatment satisfaction score comprising 12 questions.
Pre-planned subgroup analyses were defined as follows:
1. Baseline VA in study eye (< 55 vs. ≥ 55 letters read).
2. Baseline CNV size (< 6 vs. ≥ 6 disc areas).
3. Proportion of classic CNV (< 50% vs. ≥ 50%).
4. Presence of retinal angiomatous proliferation (RAP).
5. Fellow eye status (< 75 vs. ≥ 75 letters read). Differences between subgroups were tested by adding
subgroup by treatment interaction terms to the model.
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Two pre-planned sensitivity analyses of the primary outcome were carried out. First, we excluded
measurements taken 1 month later, when the main study visit was missed. Second, we included data only
for the study visits at which all functional outcomes were assessed (visits 0, 3, 6, 12, 18 and 24).
In all tables missing data are indicated by footnotes. Imputation for missing data, except as described
above, was not used, as few data were < 20% as prespecified in the statistical analysis plan (SAP).
Fixed-effects meta-analyses were performed to combine the results from the IVAN trial with other
head-to-head trials comparing bevacizumab and ranibizumab. There was no intention to perform a
systematic review. These meta-analyses were carried out to place the IVAN trial findings in the context of the
wider evidence base. Other head-to-head trials – namely the CATT,22 GEFAL (French Evaluation Group Avastin
versus Lucenti),42 MANTA (Multicenter ANti-VEGF Trial in Austria),43 LUCAS (LUcentis Compared to Avastin
Study), Subramanian et al.,44 and BRAMD [comparison of bevacizumab (Avastin) and ranibizumab (Lucentis) in
exudative age-related macular degeneration; unpublished data, presented at the 2013 meeting of European
Society of Retina Specialists] trials – were identified from non-systematic searches during the course of the IVAN
trial, through contacts with chief investigators of these trials and expert knowledge of the ophthalmologists in
the research team.
Fixed-effects models were used because we judged that the populations (people/eyes with nAMD), the settings
(specialist ophthalmology outpatient clinics) and the interventions (ranibizumab and bevacizumab) being
studied across trials were relatively homogeneous. This was not the case for comparisons of treatment regimen,
but, as only the IVAN trial and CATT22 contributed to these analyses, the fixed-/random-effects distinction is
irrelevant. No sensitivity or subgroup analyses were planned within the meta-analyses.
The availability of outcome data differed across the trials. Where available, 2-year data have been used,
otherwise data up to the 1-year point have been included. The following meta-analyses were performed:
change in BCVA from baseline, safety outcomes (mortality, ATEs, one or more SAE and gastrointestinal
disorders), change in total retinal thickness at the fovea from baseline, and new GA. Safety outcomes by
treatment regimen were available only for the CATT22 up to 1 year (after this time point, participants
allocated to monthly treatment in year 1 were rerandomised to monthly or pro re naba (prn) treatment in
year 2).
All statistical models were fitted in SAS version 9.3 (SAS Institute Inc., Cary, NC, USA). All other analyses
and data management were performed in Stata version 12.0 (StataCorp LP, College Station, TX, USA).
Health economics
Aims and research questions
The economic evaluation aimed to estimate the incremental cost and incremental cost-effectiveness of
continuous and discontinuous regimens of bevacizumab and ranibizumab. Cost-minimisation analysis
(CMA) was used to compare bevacizumab and ranibizumab in the absence of a clinically meaningful
difference in quality-adjusted life-years (QALYs), while cost–utility analysis (CUA) was used to compare
continuous and discontinuous treatment.
Analysis perspective
The economic evaluation took a NHS cost perspective, in accordance with recommendations by the
National Institute for Health and Care Excellence (NICE).45 The perspective for outcomes comprised the
patients undergoing treatment. Costs incurred by patients, their families or employers, and QALYs accrued
by carers or families, were, therefore, excluded from the analysis.
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Factorial design
As the IVAN trial is factorial (see Table 1), it is important to consider the likelihood of interactions between
anti-VEGF drug and treatment regimen, that is to evaluate whether or not the difference between the two
treatment regimens is likely to differ between bevacizumab and ranibizumab. A priori, there is no reason
to expect interactions for VA, particularly given the non-inferiority design and previous research suggesting
that interactions are generally unlikely unless both factors influence outcomes.46,47 Nonetheless,
interactions for AEs, HRQoL, survival or costs could occur if the number of injections required in the
discontinuous groups differs between drugs (e.g. due to differences in pharmacokinetic properties48–50).
However, the effect of treatment regimen will differ between drugs for anti-VEGF cost, as total drug cost equals
cost per dose multiplied by number of doses. When drug costs are analysed on a natural scale, this produces a
very large interaction for total costs and cost-effectiveness. For example, if bevacizumab costs £49 per dose and
ranibizumab costs £742.17 per dose,51 and, on average, patients receiving discontinuous treatment received
10 doses over the 2-year trial period vs. 24 for continuous treatment, the interaction would equal £9704
(£17,812 – £7422 – £1176+ £490), indicating that the cost of continuous ranibizumab is £9704 higher than
what we would expect if the effect of drug and treatment regimen were additive (i.e. had no interaction).
In contrast with the clinical analysis, mean costs and QALYs for each cell in the factorial design are
interpreted on an ‘inside the table’ basis,52 considering the four cells of the factorial design (see Table 1) as
mutually exclusive alternatives. However, when estimating costs and QALYs, we included only interaction
terms that were either statistically significant (p< 0.05) or larger than the main effect of drug or treatment
regimen. The estimated costs and QALYs for each cell are used to draw conclusions about relative costs
and cost-effectiveness for the following four pairwise comparisons:
l continuous ranibizumab compared with discontinuous ranibizumab
l continuous bevacizumab compared with discontinuous bevacizumab
l continuous ranibizumab compared with continuous bevacizumab
l discontinuous ranibizumab compared with discontinuous bevacizumab.
Form of analysis and primary outcome measure for economic analyses
Cost–utility analysis and CMA are commonly used frameworks for economic evaluation.53,54 In CUA, health
outcomes are measured in QALYs and the difference in cost between two treatments is divided by the
difference in the number of QALYs accrued, to calculate the cost per QALY gained. In CMA, it is implicitly
assumed that the treatments have identical health outcomes; treatments are, therefore, compared based
on cost alone, and the cheapest strategy is considered best value for money.
The IVAN trial was designed as a non-inferiority study and no differences in BCVA between drugs or treatment
regimens were expected. However, it was anticipated that differences in side effects or patient experience
between different injection frequencies could translate into QALY differences between drugs or between
treatment regimens, even in the absence of differences in VA. Furthermore, even where non-inferiority has
been demonstrated, conducting CMA (and therefore assuming that the difference in QALYs is exactly zero) can
bias the conclusions and estimates of uncertainty.54 However, such bias is unlikely if the difference in cost is so
large that no plausible difference in efficacy could cause the more costly treatment to be cost-effective.
In the IVAN trial, the large difference in drug costs is likely to drive conclusions about the incremental
cost-effectiveness of ranibizumab compared with bevacizumab. Using CMA to compare ranibizumab and
bevacizumab is, therefore, highly unlikely to bias conclusions or uncertainty estimates if bevacizumab
were non-inferior to ranibizumab for QALYs. We therefore prespecified a non-inferiority margin for the
comparison between ranibizumab and bevacizumab that determined whether or not conclusions would be
based on a comparison of costs (CMA) or a full economic evaluation (CUA). The non-inferiority margin
comprised 0.025 EQ-5D QALYs per patient-year, which is the smallest difference in health-state valuations that
could be measured in the study estimating the tariff for the EQ-5D utility measure.55,56 Conclusions about
whether or not ranibizumab is cost-effective compared with bevacizumab were, therefore, based on CMA,
unless the mean QALY difference between continuous (or discontinuous) ranibizumab and continuous
(or discontinuous) bevacizumab was ≥ 0.05 QALYs over the 2-year trial period.
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However, the cost-effectiveness of continuous vs. discontinuous therapy was evaluated for each drug using
CUA regardless of the magnitude or direction of the QALY difference. This was because the magnitude of
cost differences for this comparison were not known a priori and could have been sufficiently small that
differences in health outcomes could bias estimates of uncertainty and/or give misleading conclusions.
Therefore, the primary outcome measure for economic analyses comparing treatment regimens comprised
the cost per QALY gained.
Conclusions about whether or not continuous treatment is cost-effective compared with discontinuous
treatment and about which treatment regimen maximises net benefits were based on a £20,000 per QALY
‘ceiling ratio’. In other words, we assumed that the maximum the NHS is willing to pay to gain one
QALY was £20,000 and that the NHS is also willing to accept the loss of one QALY to achieve savings of
£20,000.57 Net benefits were also calculated as QALYs multiplied by ceiling ratio minus cost.
The primary research questions and objectives of the IVAN economic evaluation were:
l To estimate the incremental cost-effectiveness of continuous ranibizumab compared with discontinuous
ranibizumab, and of continuous bevacizumab compared with discontinuous bevacizumab. For each
drug, continuous therapy would be considered cost-effective relative to discontinuous therapy if it cost
< £20,000 per QALY gained, or saved > £20,000 per QALY lost.57
l And:
¢ either – if the incremental QALY gain for ranibizumab vs. bevacizumab is ≤ 0.05 QALYs – to
estimate the incremental cost of continuous ranibizumab compared with continuous bevacizumab,
and of discontinuous ranibizumab compared with discontinuous bevacizumab. For each dosing
regimen, ranibizumab would be considered good value for money if the mean total cost was lower
than for bevacizumab
¢ or – if the incremental QALY gain for ranibizumab vs. bevacizumab is > 0.05 QALYs – to assess the
incremental cost-effectiveness of continuous ranibizumab compared with continuous bevacizumab,
and of discontinuous ranibizumab compared with discontinuous bevacizumab. Ranibizumab would be
considered good value for money if it cost < £20,000 per QALY gained compared with bevacizumab.
A secondary presentation of results used the same estimates of costs and QALYs in each arm, but
presented the four cells (see Table 1) as mutually exclusive strategies. This analysis followed the established
decision rules and methods for presenting uncertainty, including calculating incremental cost-effectiveness
ratios (ICERs) for each strategy relative to the next most effective non-dominated alternative58 and
presenting cost-effectiveness acceptability curves showing the probability that each treatment maximises
net benefits.59 This approach gives identical conclusions to the primary study question but provides a global
representation of uncertainty.
Economic evaluation overview
Data on HRQoL (measured using EQ-5D and HUI3) and health service resource use were collected
prospectively in the trial. Table 5 summarises the methods used in the economic evaluation, which are
discussed in more detail in subsequent sections.
Measurement of patient-reported health status and quality adjusted
life-years
Two multiattribute utility measures were used in the IVAN trial: the three-level EQ-5D56,60,61 and HUI3.33,62,63
EQ-5D was the main utility measure for the economic evaluation, as it has several advantages over HUI3.
First, the EQ-5D tariff is based on ‘time trade-off’ valuations by around 3000 members of the UK general
population.60,64 By contrast, the HUI3 value set is based on a mixture of visual analogue and ‘standard
gamble’ valuations by 256 members of the Canadian general population.33,63 The HUI3 tariff is, therefore,
less precise and less relevant to a UK setting than EQ-5D. Second, EQ-5D is recommended by NICE45 and is
used more widely than HUI3.65 ICERs calculated using the EQ-5D can, therefore, be directly compared with
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TABLE 5 Summary of methods used in economic evaluation
Aspect of
methodology Strategy used in base-case analysis
Alternative strategies used in
sensitivity analysis
Data set l All patients who were randomised and treated,
analysed on an intention-to-treat basis
l Complete case analysis
Time horizon l Two years, with no extrapolation beyond the
trial period
l 1-year time horizon
Form of economic
evaluation
l CUA for comparison between continuous and
discontinuous therapy
l CMA for comparisons between bevacizumab
and ranibizumab unless mean QALY
difference ≥ 0.05
l CUA for all comparisons
Approach to
factorial design
l Estimation of costs and QALYs for each cell
include interaction terms that are statistically
significant or large
l Draw conclusions based on comparisons
between the estimated costs and QALYs for
each factor combination
l Allow for interactions for all
outcome measures
l Include only statistically
significant interactions
Utility measurement l EQ-5D (administered at baseline, 3, 12 and
24 months, at exit and after SAEs)
l HUI3
QALY calculations l Assume that patients’ utility changed linearly
between routine utility measurements in the
absence of SAEs
l Model the EQ-5D profile after any SAE using
mixed models to allow for HRQoL reductions
from any SAE
l Alternative methods for
interpolating between HRQoL
measurements and allowing
for SAEs
Costs included
in analysis
l Study drug
l Drug administration and monitoring outcomes
(micro-costing estimates)
l Health-care costs, concomitant medication and
other health-care contacts (e.g. GP visits or
hospital admissions) associated with the study
eye, any expected AE or any expected SAE
All other health-care costs were excluded
l HRG or reference costs for drug
administration and monitoring
consultations
l Including health-care costs
associated with any (S)AE or all
resource use
Missing data l Multiple imputation l Complete case analysis
QALYs lost due to
deaths unrelated to
study medication
l KMSA. This analysis took account of between-
group differences in deaths considered
definitely/probably/possibly related to study
drug, but assumed that the risk of deaths
unlikely/not related to study drug was the same
in all groups
l Allowing for QALY loss from related
and unrelated deaths
Adjustment for
baseline utility
l Regression used to adjust QALY calculations for
differences in baseline utility
l No adjustment for baseline utility
GP, general practitioner; HRG, Healthcare Resource Group; KMSA, Kaplan–Meier sample averaging.
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ICERs calculated in a large number of other UK economic evaluations to help decision-makers ensure that
the most cost-effective treatments are provided. However, HUI3 was used in sensitivity analyses, as it
includes questions specifically relating to vision and may be more sensitive or responsive to changes in eye
disease than EQ-5D.66,67
The EQ-5D and HUI3 were both completed at 0, 3, 12 and 24 months. In addition, to assess the impact of
SAEs on utility, both instruments were administered at the next assessment attendance after any SAE or a
reduction in BCVA ≥ 15 letters. EQ-5D and HUI3 were also completed at/after withdrawal if the patient
opted to attend a full exit assessment. For EQ-5D, the published UK time trade-off valuation tariff was
used to value each health state64 and calculate ‘utilities’. The Canadian valuation tariff set33,68,69 was used
for HUI3. Missing utility data were imputed by using multiple imputation (see below).
Quality adjusted life-years were calculated as the area under the utility curve, i.e. EQ-5D utility multiplied
by length of time spent at that utility. In the absence of SAEs, utility was assumed to change linearly
between baseline and 3 months, between 3 and 12 months, and between 12 and 24 months (Figure 4),
which is supported by the trends for BCVA (see Figure 15).
As many patients had several different SAEs starting in a short space of time (e.g. angina, MI and bypass
graft in the same admission), SAEs occurring less than 1 week apart were grouped into a set associated
with a single post-SAE measurement and with a single onset date equal to the onset date of the first SAE
in that set (see Appendix 4). Of the 183 trial participants with SAEs starting before they left the trial or
attended visit 24, 129 had one set of SAEs, 37 had two, 15 had three and 2 had four.
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FIGURE 4 How QALYs were calculated. (a) In the absence of SAEs, EQ-5D utility was assumed to change linearly
between EQ-5D measurements. (b) As the EQ-5D measurement after this patient’s first set of SAEs is higher than
the line joining the baseline and 3-month measurements, we assumed that utility rose linearly between baseline
and the post-SAE measurement and between this measurement and 3 months. As utility is lower after SAE 2, we
draw a line through the post-SAE 2 measurement with a gradient equal to the recovery rate estimated in the
mixed model.
This line was used to estimate the utility on the day SAE 2 starts, and the time and the utility at which the patient
is expected to have recovered from SAE 2 and returned to the utility trend observed between visits three and 12.
The patient died 5 days after SAE 3; the utility was, therefore, assumed to follow the linear trend observed
between visit 12 and the value imputed at visit 24 up until the day before SAE 3. Utility was assumed then to fall
linearly to 0 over the last 5 days of life.
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For patients who experienced a SAE that reduced utility, the base-case analysis assumed that utility fell on
the day of the SAE and rose linearly afterwards. Similar profiles have been used previously to model
recovery from acute hepatitis70 and chronic obstructive pulmonary disease exacerbations.71 We used linear
profiles to simplify subsequent calculations and because models with quadratic terms did not fit as well. As
post-SAE utility measurements were taken, on average, 56 (range 0–182) days after a SAE, we used mixed
models to estimate the rate at which utility rose after each type of SAE (see Appendix 4). Coefficients
estimated in the mixed models were used to estimate utility on the day of the SAE and identify the point
at which utility returned to the level that would be expected from the utility measurements that were not
taken after SAEs (see Figure 4). However, some post-SAE measurements were higher than would have
been expected from other measurements for the patient (e.g. see Figure 4, SAE 1); in these cases, we
assumed that utility changed linearly between the routine measurements (see Figure 4). For patients dying
1–7 days after the latest SAE, utility was assumed to fall linearly to 0 between the date of the SAE and the
date of death. Full details of the methods are described in Appendix 4.
Collection of resource use and cost data
Data were collected on all major NHS resource uses for each patient using the trial CRFs. We included
resources associated with only the study eye or expected AEs or SAEs to avoid catastrophic episodes
involving high health-care costs unrelated to treatment (e.g. renal failure, cancer or extended psychiatric
admissions) swamping the main effect of treatment on costs.72 Expected SAEs and AEs comprise those
previously linked to bevacizumab or ranibizumab treatment, which are listed in Appendix 4. For the
purposes of the costing, death was not considered to be an expected SAE unless the primary cause
of death comprised one of the expected SAEs or AEs; this was done to ensure that costs unrelated to
anti-VEGF treatment (e.g. the cost of treating cancer) are excluded from the analysis, regardless of whether
or not the patient died during the study period.
Unit costs (see Appendix 4) were combined with resource volumes to obtain the total cost per patient per
3-month period or quarter. Three categories of cost were considered: anti-VEGF study medication; drug
administration and monthly monitoring visits; and NHS costs associated with expected AEs and expected
SAEs. An index year of 2011 was used for costs. All costing analyses followed guidelines for economic
evaluation.53,73 Following NICE guidance,45 value added tax (VAT) was excluded from the base-case
economic evaluation but was included in budget impact estimates. The boundaries between quarters
were based on study visits rather than calendar months to minimise random variations in costs between
quarters: for example, quarter 1 included the first three injections and all resource use accrued before visit
3 regardless of whether or not this visit was conducted early or late.
Following NICE guidance,45 the base-case analysis used the list price for ranibizumab (£742.17 per dose51).
Although the Department of Health and Novartis have agreed a reduced price that the NHS pays for
ranibizumab,74 this discount is commercially sensitive and confidential, and may vary between hospitals.
The cost of bevacizumab syringes for intravitreal injection (£49 per dose) was based on the price typically
charged in other trials by the not-for-profit NHS compounding pharmacy where bevacizumab was
repackaged. This cost includes transport and delivery and was based on micro-costing work conducted by
this pharmacy for a subsequent trial. The cost of both drugs was varied in the sensitivity analysis. In the
IVAN trial, some anti-VEGF was wasted as a result of it exceeding the shelf life or being booked out of
pharmacy and not used. However, most of this in-trial wastage was due to the trial protocol, and our pilot
resource use questionnaires demonstrated that the amount of wastage in routine clinical practice is likely
to be minimal. Our base-case analysis therefore assumed that no bevacizumab or ranibizumab would be
wasted, although a sensitivity analysis allowed for the same amount of wastage observed in the trial.
Accurate estimation of the cost of administering anti-VEGF inhibitors and monitoring outcomes of
treatment required micro-costing work for several reasons. First, the only gross costs available at present
include all ophthalmology outpatient consultations,75 not just those for nAMD, whereas anti-VEGF
injections are covered by local tariffs rather than the Healthcare Resource Group (HRG)76 Payment by
Results scheme. Second, no available gross cost or HRG tariff distinguishes between consultations in which
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an anti-VEGF drug is administered and consultations to monitor outcomes without treatment. The
difference between such consultations is likely to be one of the main drivers of the cost-effectiveness of
continuous treatment compared with discontinuous treatment. As a result, the base-case analysis used
micro-costing to estimate the cost of consultations to administer bevacizumab/ranibizumab and to monitor
outcomes. The impact of using reference cost and HRG estimates was evaluated in sensitivity analyses.
Data on the cost associated with drug administration and monitoring were collected using two
questionnaires (see Appendix 4). These were completed by the staff at IVAN centres, who were responsible
for running clinics in which bevacizumab and/or ranibizumab are administered in routine clinical practice,
with additional data being provided by clinicians and other staff at each centre. To exclude protocol-driven
resource use, centres were asked about the resources used for routine NHS consultations, rather than
IVAN trial visits. The questionnaires were developed following discussions with a consultant at one IVAN
centre, observational work at another centre and a pilot of draft questionnaires at three centres (including
the two mentioned previously). The set-up cost questionnaire (see Appendix 4) collected data on the
resource use and costs associated with purchasing equipment and setting up a clinic to monitor nAMD
patients and administer intravitreal injections. The operating cost questionnaire (see Appendix 4) collected
data on: the number of staff and rooms needed to run each clinic session (separating out those staff and
rooms involved in intravitreal injections and those involved in FFA); the cost of any pre-prepared injection
packs used; overheads; and the tests and investigations routinely conducted to monitor the outcomes of
anti-VEGF therapy. As set-up costs were unlikely to be major cost drivers, the set-up cost questionnaire
was completed by six IVAN centres. Other IVAN centres provided basic details on the number of rooms of
each type that were set up or modified in order to provide anti-VEGF therapy, which were valued using
the cost per room estimates obtained from the six centres completing the set-up cost questionnaire. Total
set-up costs were annuitised over the lifetime of the facilities and divided by the total number of patients
likely to use such facilities. The operating cost questionnaire was sent to all 19 centres recruiting ≥ 10
patients and was completed by 12 centres. Estimates of the number of staff hours and costs were returned
to each centre to check their accuracy.
Hourly costs were estimated for each grade and type of staff by replicating the costing calculations used by
the Personal Social Services Research Unit77 using Agenda for Change salaries78 (see Appendix 4). Total staff
costs per clinic were divided by the average number of patients typically attending each clinic to give the
average staff cost per patient visit. The costs of reagents used to administer intravitreal injections or conduct
FFA (£1.29 per intravitreal injection and £1.91 per FFA; see Appendix 4) were estimated from resource-use
estimates provided by two centres and were assumed to be the same for all centres. Total consultation
costs per intravitreal injection, per monitoring consultation and per FFA were calculated for each clinic as
the sum of staff costs; set-up costs; the cost of pre-prepared injection packs; and the mean cost of reagents.
The percentage of overheads applicable to each centre was then added to the total cost. Costs were then
averaged over all centres to obtain five unit costs (Table 6).
In the trial, all participants attended monthly clinic consultations including study questionnaires (when
scheduled), VA assessment, OCT and (if necessary) FFA and intravitreal injections. However, costing
analyses excluded protocol-driven resource use by assuming that patients would not require OCT or FFA
unless this would affect treatment decisions. As such, patients on discontinuous treatment were assumed
not to require OCT at the second or third visit in a course of three injections (Table 7). Similarly, patients
on continuous treatment were assumed to require monitoring consultations (with OCT and/or FFA) only
once every 3 months. Although IVAN participants had FFA at visit 12, this is no longer done in routine
clinical practice. We therefore excluded any FFAs undergone at visit 12, unless FFA was needed to evaluate
the treatment failure criteria for patients in the discontinuous group. In the base-case analysis, missed visits
were assumed to accrue no NHS cost, as many clinics overbook patients; however, this assumption was
varied in sensitivity analysis.
DOI: 10.3310/hta19780 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 78
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Chakravarthy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
27
TABLE 6 Methods used to calculate consultation costs
Type of cost estimate Description
F: cost per FFA Included only reagents, consumables, staff and facilities directly
involved in FFA
M: cost per monitoring consultation excluding FFA and
any resources associated with the intravitreal injection
Although seven centres ran separate injection and monitoring
clinics as well as, or instead of, a one-stop service by which
patients attend clinic for monitoring and receive injections that
day if they need them, the cost of monitoring (excluding
resources attributable to FFA and injections) was similar for
one-stop and monitoring-only clinics
MF: cost per monitoring consultation including a
fraction of patients receiving FFA
Estimated by multiplying the cost of FFA at each centre by the
proportion of patients who typically have FFA done in any given
monitoring consultation, and adding it to the monitoring
consultation cost excluding FFA
IM: cost per intravitreal injection given
alongside monitoring
Calculated as the incremental cost of giving an intravitreal
injection in a consultation in which monitoring (e.g. OCT)
was also provided, which was based on the average across
one-stop clinics
IO: cost of intravitreal injection not alongside
monitoring consultation
The cost of separate injection consultations at two-stop services
was typically slightly higher than the incremental cost of giving
an injection at a one-stop clinic. We therefore estimated the
average cost of injection consultations across all injection-only
clinics to reflect the cost of a consultation in which VA is
assessed before the injection, but OCT is not conducted
F, cost of fundus fluorescein angiography; IM, cost of intravitreal injection given alongside monitoring consultation;
IO, cost of intravitreal injection not alongside monitoring consultation; M, cost per monitoring consultation excluding FFA
and any resources associated with the intravitreal injection; MF, cost of a monitoring consultation including a fraction of
patients receiving FFA.
The codes for consultation types relate to those shown in Table 7.
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As the number of patients recruited to IVAN does not reflect the number of patients that each centre
treats in routine clinical practice, average costs were applied to all patients regardless of which centre they
attended. However, to allow for the substantial variability in unit costs between centres, we drew repeated
values from the distribution of clinic costs for each patient in each multiple imputation (see Appendix 4).
At each monthly visit, all IVAN participants were asked to give details of all hospital stays, contacts with
community health-care providers and hospital outpatient attendances and all changes in their medications. The
base-case analysis included only those resources directly attributable to AEs or SAEs that have previously been
linked with bevacizumab or ranibizumab and were classed as ‘expected’ in the trial protocol (see Appendix 4).
The dates of any hospital admissions were reviewed to identify which SAE they related to; AE dates were
reviewed if the admission dates did not match any SAE. Free text from the SAE form was also reviewed to
TABLE 7 Assumptions made about the frequency of injection and monitoring consultations within the
costing analysis
Patient Visit 0a 1a 2a 3 4 5 6 7 8 9 10 11
Patient A:
continuous treatmentb
Injection ✓ ✓ ✓ ✓ ✓ ✓ ✗ ✓ ✓ ✓ ✓ ✓
IM IO IO IM IO IO IO IO IM IO IO
Monitoring
consult
✓ ✓ ✗ ✓
MF MF MF
FFA ✓ ✗
F
Patient B:
discontinuous treatmentc
Injection ✓ ✓ ✓ ✓ ✓ ✓ ✓
IM IO IO IM IO IO IM
Monitoring
consult
✓ ✓ ✓ ✗ ✓ ✓ ✓ ✓
MF M M M M M M
FFA ✓ F ✗
F
✓, Relevant consultation cost was applied; ✗, no consultation cost was applied as the trial participant missed the visit
(highlighted by shading); F, cost of fundus fluorescein angiography; IM, cost of intravitreal injection given alongside
monitoring consultation; IO, cost of intravitreal injection not alongside monitoring consultation; M, cost per monitoring
consultation excluding FFA and any resources associated with the intravitreal injection; MF, cost of a monitoring
consultation including a fraction of patients receiving FFA.
Notes
a All patients receive monitoring, injection and FFA (costs M, IM and F) at visit 0 and attend injection-only consultations
(cost IO) at visits 1 and 2 (which include no OCT, as this will not change the treatment decision).
b Patients randomised to continuous treatment accrued the cost of injections alongside monitoring (costs MF and IM) at
visit 3 and every 3 months thereafter; the cost of these monitoring consultations (MF) included a fraction of the cost of
FFA to allow for the proportion of patients who receive FFA in routine clinical practice. However, patient A missed visit
6 and accrued no cost at that visit. All patients randomised to continuous treatment accrued the cost of injection-only
consultations (IO) at visits that are not a multiple of three (unless the visit was missed).
c The consultations required by patients on discontinuous treatment depend on when they met treatment failure criteria;
patient B met the retreatment criteria at visits 0, 7 and 11 and required FFA alongside OCT to evaluate treatment failure
criteria at visit 4. The cost of monitoring consultations (cost M) was, therefore, accrued at visits 3, 4, 6, 7, 10 and 11, at
which treatment failure criteria were evaluated; the cost of FFA was accrued at visit 4 (as occurred in the trial). The cost
of injections given alongside monitoring (cost IM) was accrued on visits 7 and 11 when the patient met the treatment
failure criteria, whereas the cost of injection-only consultations (IO) was applied at visits 8 and 9 (the second and third
injections in the course). Patient B missed visit 5 and accrued no cost at that visit.
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identify hospitalisations and admission/discharge dates associated with SAEs that were not reported at monthly
visits (e.g. those occurring between a patient’s last visit and their death). Hospitalisations linked to expected
SAEs (or expected AEs) were valued using Department of Health reference costs75 (see Appendix 4), whereas
those linked to other events were excluded from the base-case analysis but included in sensitivity analyses.
Consultations with general practitioners (GPs), GP nurses, district nurses, hospital doctors or nurses and
other health-care professionals were valued using published cost data,76,77 (see Appendix 4) and were
included in the analysis if they were either marked as being related to ocular conditions or if they occurred
< 30 days after the onset of an expected AE or an expected SAE. Consultations with community
optometrists or dentists were excluded, as study medication is not expected to change the frequency
and not all such consultations will be funded by the NHS. The 30-day cut-off was determined through
discussions with clinicians.
The cost of concomitant medications applied to the study eye and those that are licensed for the
treatment of expected AEs or expected SAEs were included in the analysis and costed using list prices.51
All drugs for prevention or treatment of CVD, any antibiotic, any influenza medication (other than
vaccination) and all medications specifically licensed for an expected AE or expected SAE were included
in the analysis. Drugs for unrelated conditions (e.g. cancer or arthritis) were excluded from the analyses.
The total cost of medication changes was calculated relative to baseline.
Costs associated with reduced vision were excluded from the analysis. The cost of NHS-funded transport
to clinic for treatment/monitoring or for management of AEs was excluded from the analysis, as there was
no statistically significant difference between drugs or treatment regimens in the number of NHS-funded
journeys accrued during the study period (p≥ 0.169). In particular, both continuous and discontinuous
treatment require monthly consultations for monitoring and/or intravitreal injection, and so reducing
injection frequency would not per se be expected to reduce the number of patient journeys required.
Handling missing values
Multiple imputation using a series of chained regression equations was used to impute missing data on
utilities.79–84 Following recent guidelines,81 multiple imputation was conducted using the ice command in
Stata (version 1.9.4).85
Multiple imputation was not required for resource use, as such data were missing for only 2% (330 out
of 13,398) of attended visits; methods for imputing such data are described in Appendix 4.
The EQ-5D and HUI3 utilities were imputed at scheduled time points (0, 3, 12 and 24 months), at study exit
and after SAEs (see Appendix 4). Although only 3.6% (82 out of 2305) of EQ-5D measurements at scheduled
visits were missing, EQ-5D utilities were missing for 54% (32 out of 59) of exit visits and 41% (89 out of 231)
of SAEs. Overall, 152 patients (25%) had missing EQ-5D data at ≥ 1 time points. White et al.81 recommend that
the number of imputed data sets is at least equal to the percentage of patients with missing data; however,
we generated and analysed 100 imputed data sets to maximise robustness. See Appendix 4 for further details.
Handling censoring and mortality
Given the elderly trial population, it was anticipated that some patients would die during the study, either
from events previously linked to study medication (e.g. MI or stroke) or from other causes (e.g. cancer).
Although deaths unrelated to study medication were expected to be randomly distributed across study
groups, it was anticipated that one or more study group could, by chance, have substantially more deaths
unrelated to treatment than the other groups. Although differences are unlikely to be statistically
significant, chance differences in unrelated deaths could have substantially affected incremental QALY
estimates and reduced statistical power as the patients dying early in the trial would have been assigned
zero utility for the remainder of the trial period. The base-case economic evaluation therefore excluded any
between-group differences in deaths unrelated to study medication using an adaptation of Kaplan–Meier
sample averaging (KMSA). Deaths were categorised as either drug related (i.e. classified by a study clinician
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as definitely/probably/possibly related to study medication) or not (i.e. classified by a study clinician as
unlikely to be/not related to study medication).
Using KMSA, the mean costs or QALYs accrued by the total sample in any given time interval are
calculated by multiplying the mean costs for those patients who are alive and non-censored in that period
by the Kaplan–Meier estimate of the proportion of patients alive at the start of that time period.58,86,87 The
Kaplan–Meier survival functions used in KMSA are normally based on the number of deaths occurring in
each study group. Instead, we used a novel adaptation of this technique, whereby the probability of being
alive at time ‘t’ was based on (1) the number of potentially drug-related deaths observed in the study
group in question and (2) the number of unrelated deaths that would be expected based on the average
risk of unrelated deaths across all four study groups. For each of the four treatment groups, the costs
and QALYs accrued in each quarter were averaged across all patients who were alive at the start of that
quarter and who did not withdraw from the trial by the end of that quarter (see Appendix 4). Quarterly
outcomes were then multiplied by the probability of being alive at the start of the quarter. This method
provides an unbiased estimate of total costs and QALYs providing that treatment allocation has no impact
on deaths considered unlikely to be/not related to study medication.
Statistical methods and analysis for the within-trial economic evaluation
Patient-level data on costs and QALYs were analysed in Stata version 12. Non-parametric bootstrapping
was used to quantify the degree of uncertainty around costs, QALYs and ICERs. The analysis also
propagated uncertainty around imputed values, excluded chance differences in deaths unrelated to study
medication and adjusted for any imbalance in baseline utility and any interactions for costs or QALYs that
are statistically significant or could change the conclusions of the analysis.
The final estimates of costs and QALYs for each of the four groups are interpreted ‘inside the table’52 as
mutually exclusive alternatives. However, estimation of mean costs and QALYs for each study group allowed
for important interactions to avoid bias46,88 but ignored negligible interactions to maximise statistical power.46,52
Costs were divided into drug costs, administration/monitoring costs and medication/medical service costs to
enable different assumptions about interactions to be used for different types of cost.
Interactions were included for those components of costs or QALYs where interactions were either statistically
significant or had an absolute magnitude larger than either the main effect for treatment regimen or the main
effect for drug (see Appendix 4). However, interactions that were both non-significant and smaller than both
main effects were excluded from the analysis to avoid loss of statistical power. Analyses of the costs and
QALYs accrued in the first quarter assumed zero interaction and zero difference between continuous and
discontinuous therapy, as all patients received monthly injections in that quarter.
Baseline utility was included as a covariate in all analyses of QALYs to adjust for any imbalance in baseline
utility.89 This was important, as imbalances in baseline utility introduce substantial bias into economic
evaluations as baseline utility is directly included in QALY calculations and normally strongly predicts
on-treatment utility.89 Such bias could be particularly influential for IVAN as the differences in
post-treatment utility are small and even very small imbalances in baseline utility could change the
conclusions. Regression adjustment also allows for regression to the mean and increases precision.
The costs and QALYs accrued in each group of the trial were estimated using regression analyses
conducted on data for each quarter, which were repeated for 130 bootstrap replicates on each of the 100
imputed data sets (see Appendix 4). Regression predictions from each bootstrap replicate on each data
set were multiplied by the Kaplan–Meier survival estimates and summed over all quarters to give total costs
and QALYs in each group. Costs and QALYs accrued in year 2 were discounted at 3.5% per year, with a
sensitivity analysis at 1.5%.45,90 The bootstrapping process outlined in Appendix 4 was also repeated on
the resource use quantities shown later in Table 28; interaction terms were included in analyses of those
resource use items that fell into cost categories for which interactions were large or statistically significant.
Bootstrap analyses were also replicated for the sensitivity analyses shown later in Table 31.
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The impact of the five prespecified clinical subgrouping variables (see Statistical methods) and an additional
variable indicating whether or not VA in the study eye was > 5 letters better than the fellow eye at
baseline was also evaluated post hoc using the methods described in Appendix 4.
Unless otherwise specified, all means reported in Chapter 8 represent the predictions from the regression
analyses outlined in Appendix 4, adjusted for mortality and discounting, and averaged across the 100
imputed data sets. Similarly, all SEs reported in Chapter 8 were calculated from the same regression
analyses on 130 bootstrap replicates on each of 100 imputed data sets, combined using Rubin’s rule.
The p-values and 95% CIs were calculated from the SEs.
Patient and public involvement
The IVAN trial continued a long-standing association with the Macular Society (previously the Macular
Disease Society). The Macular Society is ‘the national UK charity for anyone affected by central vision loss’
(www.macularsociety.org/How-we-help/About-us). Although the charity raises funding from corporate
sponsors, it receives no government funding or donations from pharmaceutical companies. Professor
Chakravarthy and other members of the research team approached the Macular Society in 2003 in relation
to the VPDT for the UK. As the IVAN trial grew out of the VPDT, it was natural to continue the
collaboration when we were seeking funding for the IVAN trial. The collaboration continued once funding
was awarded, when the trial was being set up and throughout its conduct through the Society’s membership
of the TSC. Mr Bremridge, the Society’s chief executive at the time, was a member of the TSC at inception.
Following his retirement, Helen Jackman (the current chief executive) or Cathy Yelf, the Society’s head of
communications and external relations, have represented the Society on the TSC.
We consulted with the Macular Society, directly with Tom Bremridge, Helen Jackman and Cathy Yelf, but
also (through the Society) with some of their members, on several aspects of the trial:
(a) the need for such a trial
(b) the design of the trial
(c) information given to patients at the outset who were being approached about the trial (construction of
the patient information leaflet that was approved by a NHS research ethics committee) and subsequent
revisions to this information
(d) information about the first-year findings of the IVAN trial and those of the CATT35
(e) information about possible risks that emerged during the trial and which were communicated to
participants who had not completed the study
(f) on study completion, letters to participants thanking them for their involvement and unmasking them
to the drug assignment.
The advice of the Macular Society was most important with respect to (a), (b) and (d). The decision to use
a discontinuous treatment regimen requiring cycles of three injections given monthly was substantially
based on discussions with Mr Bremridge about the need to minimise the risk of participating in the trial.
Mr Bremridge also advised in detail about how to describe the possible risks and benefits of treatment
with each drug.
It was vital to have views about how to communicate the trial objectives fairly and to describe what the
trial involved in the patient information leaflet. In this context, it should be remembered that the first few
months of recruitment to the trial straddled NICE’s publication of its final appraisal determination for
ranibizumab; ranibizumab was not widely available at the time that the trial started to recruit and,
once ranibizumab was recommended by NICE, the possibility of being treated with bevacizumab was
extremely controversial.
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In the spring of 2012, the chairperson of the DMSC asked the trial statistician to combine the most
up-to-date information from the IVAN trial with information available from the CATT.35 This synthesis
found a statistically significant increased risk of having a systemic SAE with bevacizumab compared with
ranibizumab. At the next meeting, the committee reviewed the information and recommended that the
trial should continue but the information should be disseminated to the minority of patients who were still
continuing in the trial. This recommendation was discussed at length, during the following TSC, with
Cathy Yelf, who concurred. The research team drafted a letter to patients (describing the information, the
recommendation and giving the opportunity to withdraw) and sought edits and comments on the content
from the Macular Society before finalising it. Given the sensitive nature of the information, it is testament
to the quality of the patient and public involvement in the IVAN trial that none of the participants
remaining in the trial asked to withdraw.
Management of investigational medicinal product
All drugs were purchased centrally by the Liverpool pharmacy, that is standard commercially available
ranibizumab 0.23-ml vials and bevacizumab 4-ml vials. Ranibizumab vials as commercially supplied were
labelled for use as investigational medicinal product (IMP) in the trial. Pre-filled bevacizumab syringes were
manufactured in the aseptic manufacturing facility, packaged in a box and also labelled for use as IMP
in the trial. Both drugs were distributed by courier to each centre. Drugs were dispatched bearing study
labels approved by the Medicines and Healthcare products Regulatory Agency (MHRA). Each ranibizumab
vial ordered and each bevacizumab syringe manufactured by the Liverpool pharmacy was logged on the
appropriate product log sheet. The fate of each dose was recorded against each batch (e.g. which hospital
they were dispatched to, used for quality control, etc.).
The central coordinating centre managed drug stock at each site. When drug supplies were required by
a site, the coordinating centre communicated to the Liverpool pharmacy the drug type, quantity and
destination to which they should be dispatched. The product log was completed, stating to which hospital
the drug was to be dispatched and the date of dispatch. Drugs were packed for dispatch with cool packs
to maintain a temperature of 2 °C to 8 °C. Packs included a temperature monitor to allow temperature
breaches during transit to be identified. The Liverpool pharmacy confirmed that drugs had been dispatched
via the trial database.
Each batch of study drug received at a site was logged in the IVAN study drug receipt log. On arrival the
package was checked for temperature breaches and/or damage to study drugs; if either had occurred,
the coordinating centre was contacted to arrange redelivery. All shipments were transferred immediately to
a fridge (2 °C to 8 °C) for storage.
Any study medication that exceeded its expiry date before being used was logged and kept until it was
checked by IVAN monitors. Expired drugs were recorded on the drug receipt log by pharmacies at local
sites; if drugs expired prior to dispatch to site, this was recorded on the appropriate product log sheet by
the Liverpool pharmacy.
On receipt of a study prescription, the correct drug was taken from a fridge and the expiry date checked
to ensure that the drug was within shelf life. The IVAN study number and visit number were completed on
the study label on the outside packaging of the study drug. The prescription log was completed, detailing
the expiry date and batch number for each patient and visit number. The drug was concealed in an
unmarked bag ready for collection by clinic staff/delivery to clinic.
Used vials and syringes were returned from clinic to pharmacy at the end of each clinic and checked and stored
until after monitoring had taken place and accountability completed, when instructions to destroy them would
be issued by the trial monitoring team. The trial monitoring team inspected returned packaging to check that
the correct drug had been dispensed and that the drug had been given (i.e. that the vial/syringe was empty).
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Emergency unmasking
Emergency unmasking was provided by the coordinating centre during office hours (Monday to Friday,
9 a.m. to 5 p.m.). Outside office hours, the pharmacy prescribing the study drug provided unmasking.
An unmasking pro forma was provided for the recording of the event.
Study drug recall
If a batch of bevacizumab needed to be recalled, the Liverpool pharmacy notified the co-ordinating centre,
which then notified the pharmacy contact at each participating site. The pharmacy was asked to check its
stock for any syringes in the recalled batch, notify the coordinating centre and label each box as recalled.
The coordinating centre arranged collection of the recalled batch from sites, which were returned to the
central pharmacy. Recall of a batch of ranibizumab could come from the Liverpool pharmacy or through
local recall procedures. If this happened, they were asked to notify the central coordinating centre.
The procedure followed following notification was the same for both drugs.
Contractual and financial arrangements
At the time funding was being sought and the trial was being set up, the costs of the trial had to be
attributed as research, service support and treatment (including excess treatment) costs (www.gov.uk/
government/news/attributing-the-costs-of-health-social-care-research-development-acord). The task was
complex for the IVAN trial because trial set-up and initial recruitment spanned a period of time when
(1) ranibizumab had not been recommended for use in the NHS91 and (2) the dispersion of service support
costs to participating hospitals through the Comprehensive Research Network had not been completely
implemented. Consequently, the attribution of the costs of the trial changed dramatically before and after
NICE issued guidance.
Before NICE issued guidance, treatment with ranibizumab represented an estimated excess treatment cost
of £15,000–30,000 per patient over the 2-year duration of follow-up (depending on whether a patient
was allocated to continuous or discontinuous treatment); the corresponding range for bevacizumab was
estimated to be £6000–7000 per patient. After NICE issued guidance, discontinuous ranibizumab
approximately represented ‘usual care’, continuous ranibizumab represented an excess treatment cost of
£15,000 per patient and bevacizumab a saving in treatment cost of about £8000–9000.
Service support costs (additional tests and other NHS resources used in the course of the trial that were
related to the patient’s care but which were not required purely for the research) were estimated to
represent a further £2830 per patient over 2 years. These costs were unaffected by the NICE guidance
but still had to be reimbursed to hospitals to cover the full cost of the hospitals taking part.
The previous experience of several members of the research team including the chief investigator in
evaluating an earlier technology for nAMD (VPDT)92 meant that, in the IVAN trial, the research team was
determined to ensure that all costs for the trial were truly in place, namely research, service support and
treatment costs, before starting to recruit. The team was also committed to ensuring that reimbursement
to hospitals for trial activity related to reviewing and treating trial participants was conditional on carrying
out the trial according to the protocol and providing valid data; these two conditions were written into
contracts between the sponsor and participating hospitals.
Several unusual features of the trial followed from these decisions:
l There was a need to put in place service level agreements with commissioning organisations
(63 primary care trusts in England and four health boards in Northern Ireland; some agreements were
negotiated with consortia of commissioning organisations) to provide the treatment costs (as, at the
time, these were excess treatment costs). These agreements required ‘up front’ payment (at the start of
the financial year) to enable trial activity to happen.
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l A mechanism had to be established for treatment costs to be paid to hospitals separately from the
usual contracts with commissioners, to ensure that the funding for treatment in trial ‘followed
the patient’, that is it was made available to the hospital ophthalmology department delivering the trial.
l A mechanism had to be established to ensure that hospitals did not ‘double count’ activity relating to
trial participants, that is, charge their treatment to the trial and also to commissioners under the usual
contract for nAMD services. This mechanism ensured that ‘savings’ from using bevacizumab were truly
reflected in the funding commissioners paid for treatment of trial participants after ranibizumab was
recommended by NICE.
l There was a need to establish a ‘bank’ to manage service level agreements with primary care trusts,
hold their payments in advance on credit against future trial-related activity, and manage reimbursement
for trial activity by participating trusts.
These features and requirements were further complicated by:
l The requirement for the IMP to be provided from a single, central, manufacturing pharmacy, which
necessitated splitting the clinic/hospital costs from the drug costs. Contracts with participating hospitals
to reimburse for trial activity were restricted to the clinic/hospital costs, with the IMP being provided to
hospitals ‘free’ for use in the trial. The bank separately contracted with the central manufacturing
pharmacy to supply the IMP to participating trusts. The central, manufacturing pharmacy was unwilling
to bear the uncertainty of the costs of cold-chain transport (which were expensive, with cost per dose
dependent on the number of doses being transported) in this contract, so the bank also had to pay
separately for the transport costs.
l The fact that an element of the clinic/hospital costs represented research costs, which required the
grant holder [Queen’s University Belfast (QUB)] to pay this sum to the bank, to be passed on to
participating hospitals pro rata to trial activity.
l A research partnership consisting of four universities and two NHS trusts who were collaborating to
deliver the research. The grant holder (QUB) was responsible for establishing non-commercial contracts
with each partner, defining the role and responsibilities of each partner and the proportion of the
research costs the partner would receive in return.
The NHS sponsor for the trial (Belfast Health and Social Care Trust) agreed to take on the risks and
responsibilities (to administer income from primary care trusts and expenditure in relation to trial activity)
associated with being the bank, in addition to its responsibilities for research governance, trial oversight
and contracts with participating hospitals. The trial benefited from advance, in-depth discussions with
the National Specialised Commissioning Group about the likelihood of NICE recommending ranibizumab
and the future potential benefit to commissioners of having evidence about the cost-effectiveness of
bevacizumab. These discussions were instrumental in persuading commissioning organisations to sign
the service-level agreements required. The trial also benefited from the services of some very committed
individuals involved in commissioning when drafting the service-level agreement and in negotiating these
agreements on behalf of the trial with several primary care trusts. The contracting and monitoring
arrangements, and the flows of finances and data in the trial, are shown in Figures 5–7.
The importance of this infrastructure to the ultimate success of the trial cannot be overemphasised. The trial
team extends its gratitude in equal measure to the individuals and organisations that made the trial possible.
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FIGURE 5 Contracts and monitoring. TCC, Trial Coordinating Centre.
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FIGURE 6 Finance flow chart. HTA, Health Technology Assessment; ICH-GCP, International Conference on
Harmonisation Good Clinical Practice guidelines.
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FIGURE 7 Data flow to and from the Trial Coordinating Centre (TCC). The image grading centre is shown for
completeness. It does not appear in Figures 5 and 6 because the centre was located in Belfast, and financing and
contractual arrangements were managed locally.
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Chapter 3 Trial cohort
Screened patients
Patients were prescreened to exclude those with no interest in the trial; because of the different ways in which
centres did this, data describing all patients approached were not available. Screening data were provided for
693 patients. Of these, 65 patients were excluded; 28 were found to be ineligible (reasons include BCVA of
< 25 letters and presence of other ocular disease causing concurrent vision loss) (Figure 8) and the other
37 were excluded for unknown reasons. The remaining 628 patients were randomised into the trial.
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FIGURE 8 Recruitment rate. Recruitment is cumulative. Only participants included in the IVAN cohort are
represented on this graph.
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Recruitment
Patients were recruited to the IVAN trial between 27 March 2008 and 15 October 2010, and the last
patient follow-up visit was on 7 November 2012. The 628 randomised participants were recruited from
23 centres (see Appendix 1 for details). Five of these 628 participants were randomised in error and a
further 13 were not treated, leaving 610 cases who received at least one injection. These 610 participants
make up the IVAN study cohort. Recruitment was steady throughout the course of the trial (Figure 9).
The number of participants in the IVAN cohort recruited at each of the centres is shown in Figure 10.
Patient withdrawals
There were 60 participants who withdrew from follow-up after their first injection and before visit 24,
that is the scheduled end of the trial. The rate of withdrawal was constant over the first 18 months of the
follow-up period (Figure 11). The most common reason for withdrawal was that the patient was too ill to
attend (participant-reported reason) or had experienced a SAE (clinician-reported reason) (Table 8).
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Considered for inclusion in trial (n= 693)a
Patients excluded (n= 65)
Ineligible (n= 28)b
Age < 50 years (n= 0), best corrected VA < 25 letters (n= 5), no neovascular
lesion involving the centre of the fovea (n= 8),  fibrosis > 50% of the total lesion
(n= 6), a greatest linear diameter > 6000 µm (n= 2), thick blood involving the 
centre of the fovea (n= 0), > 8 dioptres of myopia (n= 1), other active ocular 
disease causing concurrent vision loss (n= 6), previous treatment (argon laser 
within 6 months, PDT or a VEGF inhibitor to the study eye) (n= 0), pregnant 
(n= 0), no contraception female (n= 0), no contraception male (n= 0), not new
referral (n= 5), unknown (n= 1)
Other (n= 37)
No reason given/no data in study database (n= 37).  These patients may include
some who finally decided not to take part despite showing initial interest 
Allocated to ranibizumab (n= 323)
Withdrawalsc (n= 9)
• Patient ineligible, n= 0
• Patient withdrew consent, n= 0
• On clinical advice, n= 1
• Randomised in error, n= 1
• Reason unknown, n= 7
Treatment received (n= 314) Treatment received (n= 296)
Randomised (n= 628)
Allocated to bevacizumab (n= 305)
Allocated to
continuous treatment
(n= 157)  
• Reached visit 24, n= 134
• Attended visit 24, n= 133
Allocated to
discontinuous 
treatment (n= 155) 
• Reached visit 24, n= 137
• Attended visit 24, n= 135
Randomised to
discontinuous
treatment (n= 145)
• Reached visit 24, n= 127
• Attended visit 24, n= 124
Reached 3-month visit (n= 312) Reached 3-month visit (n= 293)
Withdrawalsc (n= 9)
• Patient ineligible, n= 0
• Patient withdrew consent, n= 0
• On clinical advice, n= 0
• Randomised in error, n= 4
• Reason unknown, n= 5
Withdrawals before
completion of first course
of three injectionsd (n= 2)
• Patient withdrew consent, n= 2
• On clinical advice, n= 0
• Patient died, n= 0 
Withdrawals before
completion of first course
of three injectionsd (n= 3)
• Patient withdrew consent, n= 1
• On clinical advice, n= 1
• Patient died, n= 1 
Randomised to
continuous treatment
(n= 148)
• Reached visit 24, n= 127
• Attended visit 24, n= 126
FIGURE 10 Flow of participants.
a, More patients are likely to have been considered for the trial, and the exclusions section is therefore likely to be
incomplete, because some sites did not enter full screening data.
b, Some patients may be ineligible for more than one reason.
c, Details of other withdrawals (i.e. patients that withdrew but data collection will still continue) will be given as
footnotes.
d, Of the patients who did not drop out, not all of them completed all three treatments.
Source: © 2013 Chakravarthy et al.93 Open Access article distributed under the terms of CC-BY-NC-SA
(http://creativecommons.org/licenses/by-nc-sa/3.0/). Published by Elsevier Ltd.
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FIGURE 11 Time from randomisation to withdrawal (excluding deaths).
TABLE 8 Withdrawals
Reason for
withdrawal
Randomised to
Overall
(n= 60)
Ranibizumab
(n= 30)
Bevacizumab
(n= 30)
Continuous
(n= 38)
Discontinuous
(n= 22)
n % n % n % n % n %
Any withdrawala 30 30 38 22 60
Clinician’s advice 9 9 10 8 18
Very poor VA 0/9 0 2/9 22 1/10 10 1/8 13 2/18 11
SAE 6/9 67 4/9 44 6/10 60 4/8 50 10/18 56
Other reason 3/9 33 4/9 44 3/10 30 4/8 50 7/18 39
Patient’s choice 24 22 31 15 46
Too ill to attend 10/24 42 8/22 36 9/31 29 9/15 60 18/46 39
Unhappy with trial
procedures
4/24 17 3/22 14 7/31 23 0/15 0 7/46 15
Difficulties with
transport or support
from friends/relatives
0/24 0 2/22 9 1/31 3 1/15 7 2/46 4
Wanted treatment
outside trial
1/24 4 1/22 5 1/31 3 1/15 7 2/46 4
Reason not given 1/24 4 3/22 14 2/31 6 2/15 13 4/46 9
Other 11/24 46 5/22 23 14/31 45 2/15 13 16/46 35
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Protocol deviations
Protocol deviations in the IVAN trial included visits on which a participant did not receive the allocated
drug, non-adherence to the treatment regimen, missing visits and visits outside the 28- to 35-day window.
Table 9 shows the number of times each deviation occurred, and in how many participants. The wrong
study drug was administered on 2 out of 12,761 follow-up visits. The allocated treatment regimen was not
adhered to on 133 out of 12,761 visits (1.0%) (see Table 9). Further details on protocol deviations are
given in Appendix 3. Overall, 57% of participants missed at least one visit, excluding visits missed because
a participant died or withdrew early.
Patient follow-up
Of the 610 study participants, 525 completed the trial. Overall, 87% of all scheduled visits were attended
(12,761 out of 14,640). Over 60% of patients attended 23 or more visits and 37% attended all 25 visits. Of the
525 participants who completed the trial, 518 attended the 24-month final visit; the other seven did not attend
the 24-month visit, but did not withdraw, and survived beyond the scheduled 24-month visit date. The pattern
of missed visits was similar for the two drugs and two treatment regimens (Figure 12). The distribution of
number of visits attended, by drug and treatment frequency, is shown in Figure 13. Appendix 3 shows
the number of participants at each centre, along with the breakdown of the number of visits attended, the
number of injections administered and the number of missed visits at each centre.
TABLE 8 Withdrawals (continued )
Reason for
withdrawal
Randomised to
Overall
(n= 60)
Ranibizumab
(n= 30)
Bevacizumab
(n= 30)
Continuous
(n= 38)
Discontinuous
(n= 22)
n % n % n % n % n %
NHS/private treatment
to continue?
No 11/30 37 5/30 17 9/38 24 7/22 32 16/60 27
Yes 18/30 60 22/30 73 26/38 68 14/22 64 40/60 67
Missing 1/30 3 3/30 10 3/38 8 1/22 5 4/60 7
Willing to attend study
follow-up at 3, 12
and/or 24 months
No 19/30 63 16/30 53 21/38 55 14/22 64 35/60 58
Yes 7/30 23 8/30 27 11/38 29 4/22 18 15/60 25
Missing 4/30 13 6/30 20 6/38 16 4/22 18 10/60 17
Months to last attended
visit (median, IQR)
9.7 (5.7–13.6) 11.3 (6.0–15.6) 8.7 (4.9–13.6) 12.3 (6.9–16.3) 10.5 (5.8–14.5)
a Excluding withdrawals due to death.
Data are number and percentage unless otherwise stated.
Participants may have withdrawn for a number of reasons therefore categories relating to reason for withdrawal are not
mutually exclusive.
Source: © 2013 Chakravarthy et al.93 Open Access article distributed under the terms of CC-BY-NC-SA
(http://creativecommons.org/licenses/by-nc-sa/3.0/). Published by Elsevier Ltd.
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FIGURE 12 Distribution of the number of missed visits per visit (a) by drug and (b) by treatment regimen. Note that
all patients attended visit 0, as this was a requirement for inclusion in the IVAN cohort.
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FIGURE 13 Distribution of the number of visits attended per participant (a) by drug and (b) by treatment regimen.
The minimum number of visits attended was 1 and the maximum was 25. This does not include exit visits.
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Numbers analysed
A total of 610 participants in the analysis population were included in tables of demographic
characteristics, analyses of the primary outcome and secondary outcomes measured at multiple time
points, time to treatment failure and of safety outcomes. The 525 participants who were classified
as completing the trial (with BCVA at 2 years) are included in the descriptive outcome tables. Of the 525,
518 attended the month 24 exit visit; the remaining seven missed the month 24 exit visit (see Patient
follow-up, above).
The 90 participants who withdrew (60 withdrawals) or who died (30 deaths) are reconciled with the 525
with data at 2 years as follows:
l One participant was recorded as having withdrawn, who then died within 105 days; this participant
was classified both as a withdrawal and a death.
l Two participants completed visit 24 and died within 105 days; these participants are included in the
2-year cohort in the summary outcome tables and are also classified as deaths.
l Two participants missed visit 24 (but did not withdraw: see above) and died within 105 days of what
would have been their visit-24 date; these participants are also included in the 2-year cohort and are
classified as deaths.
Baseline data
Baseline characteristics of the trial cohort by drug and treatment regimen are shown in Table 10. The
mean age was 77.7 years (SD 7.4 years) and 244 (40%) patients were male. Many (64%) were current or
past smokers and almost one-fifth had a history of dyspnoea (19%). Characteristics were similar between
the two groups, although slightly more participants in the bevacizumab group than the ranibizumab group
had a history of angina (17% vs. 11%). Baseline visual function is described in Chapter 4. Baseline
characteristics of nAMD lesions are described in Chapter 5.
Treatment received
Over 10,000 injections were given and, overall, participants received a median of 18 injections during the
trial (IQR 12–23 injections). The number of injections received was similar by drug, the ranibizumab group
receiving a median of 18 injections (IQR 11–23 injections) and the bevacizumab group receiving a median
of 19 injections (IQR 12–23 injections). As anticipated, participants randomised to continuous treatment
received a higher number of injections [median 23 injections (IQR 21–24 injections)] than those
randomised to the discontinuous regimen [median 13 injections (IQR 8–17 injections); Figure 14].
Success of masking
Regarding adequacy of masking, ophthalmologists reported not knowing which drug participants were
receiving on 97.9% (555 out of 567) of visits 3, 98.7% (514 out of 521) of visits 12, 98.8% (506 out of
512) of visits 24, and 100% (22 out of 22) of exit visits. At visit 3, 4 out of 12 ophthalmologists who
reported the treatment that they thought the patient received were incorrect, with 2 out of 7 incorrect
and 2 out of 5 incorrect at visits 12 and 24, respectively.
Participants reported not knowing which drug they were receiving on 99.3% (560 out of 564) of visits 3,
98.7% (509 out of 516) of visits 12, 97.8% (499 out of 510) of visits 24, and 100% (21 out of 21) of exit
visits. At visit 3, 2 out of 4 participants who reported the treatment that they thought they were receiving
were incorrect, with 4 out of 7 incorrect and 5 out of 11 incorrect at visits 12 and 24, respectively.
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FIGURE 14 Distribution of the number of injections received per participant (a) by drug and (b) by treatment
regimen. The minimum number of injections given was 1 and the maximum was 24 (patients were not given an
injection at the 24-month visit). This does not include exit visits.
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Drug accountability and unmasking
Drug accountability
Drug stocks and usage was checked during monitoring visits by the central coordinating centre and
from stock returned at the end of the trial. In total, 288 vials of ranibizumab were wasted over the total
duration of the trial. There were two main reasons. A pharmacy refrigerator broke down at one site (so all
drugs were lost because the required temperature was not maintained). The pharmacy at another site
refused to reissue vials that had been dispensed but not used for a previous participant (e.g. participant in
the discontinuous group who did not require treatment to be restarted); unfortunately, the pharmacy’s
refusal to reissue the drug was not communicated to the coordinating centre until a large number of
ranibizumab vials had been wasted.
Unmasking
There were occasions when unmasking was considered but, after discussion with staff at the centre, on
each occasion it was agreed that unmasking was not required, usually because it was accepted that
knowing the drug allocation would not influence the management of the participant.
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Chapter 4 Visual function
Best corrected distance visual acuity
The mean baseline BCVA in the study eye was 61.4 letters (SD 15.3 letters). The BCVA was similar for
ranibizumab and bevacizumab groups (mean 61.1 vs. 61.8 letters), but the average BCVA was almost 3 letters
higher in the discontinuous group than in the continuous group (62.9 vs. 60.1 letters) (Table 11). For the
majority of participants the study eye had poorer vision than the fellow eye at recruitment (see Table 11).
The BCVA in the study eye by treatment group and visit is shown in Figure 15. The mean BCVA at 1 year
was 69.1 and 66.2 letters in ranibizumab and bevacizumab groups, respectively, and 66.9 and 68.5 in
continuous and discontinuous groups. On average, there was little change in BCVA from 1 to 2 years; the
mean BCVA at 2 years was 67.8 and 66.1 letters in ranibizumab and bevacizumab groups, respectively,
and 66.6 and 67.3 letters in continuous and discontinuous groups. Change in BCVA in the study eye from
baseline by treatment group and visit is shown in Figure 16. Bands of VA at baseline and 2 years by
treatment group are shown in Appendix 3.
At 1 year, the estimated difference between drugs (bevacizumab minus ranibizumab, estimated from
the mixed regression model) was –1.99 letters (95% CI –4.04 to +0.06 letters; p= 0.056) and between
treatment regimens (discontinuous minus continuous) –0.35 letters (95% CI –2.40 to +1.70 letters;
p= 0.74).26 The comparison by drug was inconclusive; bevacizumab was neither inferior (because the
CI includes zero) nor non-inferior (because the CI includes the non-inferiority margin) to ranibizumab using
the 3.5-letter limit, but discontinuous treatment was equivalent to continuous treatment. At the primary
outcome point of 2 years, mean BCVA did not differ significantly either by drug or by regimen. The
difference between drugs (bevacizumab minus ranibizumab) was –1.37 letters (95% CI –3.75 to +1.01 letters;
p= 0.26) and between treatment regimens (discontinuous minus continuous) –1.63 letters (95% CI – 4.01 to
+0.75 letters: p= 0.18). Bevacizumab was neither inferior nor non-inferior to ranibizumab, and discontinuous
was neither inferior nor non-inferior to continuous treatment, using the 3.5-letter non-inferiority margin
(Figure 17).
The sensitivity analyses outlined in Chapter 2 (see Statistical methods) gave results consistent with the
main analysis.
In the analysis restricting visits to those during which other functional outcomes were assessed, the mean
difference (MD) for the drug effect was estimated at –1.70 letters (95% CI –4.08 to +0.68 letters; p= 0.16).
The analysis excluding deferred visits gave an estimate of –1.35 letters (95% CI –3.73 to +1.03 letters;
p= 0.26). The corresponding estimated effects for the treatment regimen comparison are –1.59 letters
(95% CI –3.97 to +0.79 letters; p= 0.19) for the sensitivity analysis restricting the visits included, and
–1.60 letters (95% CI –3.98 to +0.78 letters; p= 0.19) for the analysis excluding deferred visits.
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FIGURE 15 Best corrected distance visual acuity in the study eye by visit (a) by drug and (b) by treatment regimen.
The circles indicate the mean and the bars indicate one SD either side of the mean. The numbers in parentheses
are the number of observations.
Source: © 2013 Chakravarthy et al.93 Open Access article distributed under the terms of CC-BY-NC-SA
(http://creativecommons.org/licenses/by-nc-sa/3.0/). Published by Elsevier Ltd.
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FIGURE 16 Change from baseline in BCVA in the study eye by visit (a) by drug and (b) by treatment regimen.
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Secondary measures of visual function
Visual function at baseline was similar for the two drug groups, but, as was observed for BCVA, the
discontinuous group had slightly better reading ability compared with the continuous group (40.0 vs.
33.1; Table 12).
Near visual acuity in the study eye by treatment group and visit is shown in Figure 18. Corresponding data for
reading index and contrast sensitivity are shown in Figures 19 and 20. Binocular vision is shown in Appendix 3.
At 1 year, NVA was 8% worse in the bevacizumab group (GMR 0.92, 95% CI 0.84 to 1.00; p= 0.058) but did
not differ by treatment regimen.26 By the end of year 2, the average difference by drug was no longer
significant (GMR 0.94, 95% CI 0.85 to 1.04; p= 0.23). However, NVA was better when the treatment had
been administered monthly for 2 years (GMR 0.90, 95% CI 0.82 to 0.99; p= 0.04). The reading index which
takes into account the reading speed and the NVA threshold (by adjusting for size of the print being read)
was, however, similar between both drug and regimen groups (see Table 12). Contrast sensitivity did not differ
significantly by either drug or regimen groups at 1 year. However, although the drugs were similar, continuous
treatment resulted in better outcomes at 2 years (MD –1.07, 95% CI –1.90 to –0.25; p= 0.011; Figure 21).
Treatment failure
Overall, 475 (78%) participants met the criteria for retreatment (treatment failure) during their participation in
the trial. The median time from randomisation to first treatment failure was 5.1 months (IQR 3.7–16.8 months)
in the ranibizumab group and 4.9 months (3.2 to 14.0 months) in the bevacizumab group. For those
randomised to continuous treatment the median time to first treatment failure was 7.6 months (lower
quartile 3.2 months) compared with 4.4 months in the discontinuous group (IQR 3.2–6.9 months; Figure 22).
Comparing the time to first treatment failure from visit 2 (end of loading dose phase of the trial), no
difference in the risk of treatment failure was found between the drugs [HR (bevacizumab–ranibizumab)
1.13, 95% CI 0.94 to 1.36; p= 0.18). In contrast, the risk of treatment failure was significantly
higher for participants randomised to discontinuous treatment rather than continuous treatment
[HR (discontinuous–continuous) 1.95, 95% CI 1.61 to 2.35; p< 0.001].
MD –1.37, 95% CI –3.75 to 1.01; p= 0.26            Ranibizumab vs.bevacizumab
–4 –3 –2 –1 0 1 2 3 4
MD –1.63, 95% CI –4.01 to 0.75; p= 0.18            
Continuous vs.
discontinuous
–4 –3 –2 –1 0 1 2 3 4
Favours discountinuousFavours continuous
Favours bevacizumabFavours ranibizumab
FIGURE 17 Difference in BCVA at 2 years. Negative values reflect a better mean VA in the ranibizumab or
continuous groups. CIs extending beyond the non-inferiority limit of –3.5 letters indicate that the comparison of
the two groups is inconclusive (ranibizumab vs. bevacizumab and continuous vs. discontinuous). Difference is
estimated using data from visits 0, 3, 6, 9, 12, 15, 18, 21 and 24 adjusted for centre size. Circles=MD. 95% CIs are
illustrated by horizontal bars.
Source: © 2013 Chakravarthy et al.93 Open Access article distributed under the terms of CC-BY-NC-SA
(http://creativecommons.org/licenses/by-nc-sa/3.0/). Published by Elsevier Ltd.
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FIGURE 18 Near visual acuity in the study eye by visit (a) by drug and (b) by treatment regimen. The direction of
the logMAR scale for NVA is opposite to that for BCVA (letters), i.e. small logMAR values represent better vision.
The circles indicate the median and the bars indicate the IQR. The numbers in parentheses are the number
of observations.
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FIGURE 19 Reading index in the study eye by visit (a) by drug and (b) by treatment regimen. The circles indicate
the median and the bars indicate the IQR. The numbers in parentheses are the number of observations.
DOI: 10.3310/hta19780 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 78
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Chakravarthy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
57
15
20
25
30
35
(a)
M
ea
n
 c
o
n
tr
as
t 
se
n
si
ti
vi
ty
 ±
 S
D
0
(n = 608)
3
(n = 570)
6
(n = 553)
12
(n = 525)
18
(n = 503)
24
(n = 504)
Months since randomisation
Ranibizumab
Drug
Bevacizumab
(b)
(n = 608) (n = 570) (n = 553) (n = 525) (n = 503) (n = 504)
Months since randomisation
20
25
30
35
M
ea
n
 c
o
n
tr
as
t 
se
n
si
ti
vi
ty
 ±
 S
D
0 3 6 12 18 24
Continuous
Discontinuous
Treatment regimen
FIGURE 20 Contrast sensitivity in the study eye by visit (a) by drug and (b) by treatment regimen. The circles
indicate the mean and the bars indicate one SD either side of the mean. The numbers in parentheses are the
number of observations.
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FIGURE 21 Difference in secondary measures of visual function at 2 years (a) by drug and (b) by treatment
regimen. Negative values of MD and GMR values of < 1 reflect a better outcome in the ranibizumab or continuous
groups. Difference is estimated using data from visits 0, 3, 6, 12, 18 and 24 adjusted for centre size. Circles=MD or
GMR. 95% CIs are illustrated by horizontal bars.
Source: © 2013 Chakravarthy et al.93 Open Access article distributed under the terms of CC-BY-NC-SA
(http://creativecommons.org/licenses/by-nc-sa/3.0/). Published by Elsevier Ltd.
DOI: 10.3310/hta19780 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 78
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Chakravarthy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
59
Subgroup analyses
Differences in BCVA by drug and treatment regimen in the five pre-planned subgroups are shown in
Figure 23. No statistically significant differences by subgroup were found for the drug or treatment
regimen comparisons, that is all tests for interaction were not significant (p≥ 0.26). Two additional
subgroups, which were not specified in the protocol, were also considered: (1) whether or not the vision
in study eye was at least 5 letters better than in the fellow eye at baseline and (2) whether or not a
haemorrhage was present at baseline. No statistically significant differences between these subgroups
were found for the drug or treatment regimen comparisons (see Appendix 3).
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FIGURE 22 Time to first treatment failure (a) by drug and (b) by treatment regimen.
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FIGURE 23 Best corrected distance visual acuity in the study eye at 2 years by subgroup (a) by drug and (b) by
treatment regimen. Negative values of MD reflect a better mean VA in the ranibizumab or continuous groups.
Difference is estimated using data from visits 0, 3, 6, 9, 12, 15, 18, 21 and 24, adjusted for centre size. Circles=MD.
95% CIs are illustrated by horizontal bars. Circle size is relative to the size of the subgroup.
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Meta-analysis
As described in Chapter 2 (see Statistical methods), meta-analyses were carried out to place the IVAN trial
findings in the context of the wider evidence base. There was no intention to carry out a formal systematic
review and findings from these analyses are, therefore, not reported in line with PRISMA guidelines.
The meta-analysis of BCVA was complicated by the fact that triallists have used different ways to analyse
BCVA data and to report their findings. With the aim of being as inclusive as possible, we have performed
a single meta-analysis including trials that had 1- or 2-year follow-up, using the findings for the longest
duration (as BCVA changes very little between 1 and 2 years). We used results from presentations at
international conferences when final journal publications were not available.
Figure 24 shows meta-analyses of the trial findings for seven trials [including IVAN, CATT, BRAMD
(presented at the 2013 meeting of EURETINA) GEFAL, LUCAS (presented at the 2013 meeting of the
American Association for Ophthalmology), MANTA and Subramanian et al.]22,42–44 for changes in distance
BCVA by drug and of the CATT22 and IVAN trial findings for changes in distance BCVA by treatment
regimen. The analyses use the 2-year findings for the CATT22 and IVAN, and 1-year findings for all other
studies. The pooled BCVA point estimate shows that bevacizumab was statistically non-inferior to
ranibizumab judged by the stricter IVAN margin [–0.38 letters; 95% CI –1.47 to +0.70 letters; p= 0.49;
heterogeneity chi-squared (χ2)= 4.08; degrees of freedom (df)= 6; p= 0.666; I2= 0.0%]. Acknowledging
the slight difference between the CATT22 and IVAN trial in their ‘as needed’ treatment regimens,
discontinuous treatment was significantly inferior to continuous (–2.23 letters; 95% CI –3.93 to –0.53
letters; p= 0.010).
Summary
The visual function at baseline was similar by drug, but the discontinuous group had slightly better BCVA and
reading ability than the continuous group. For the majority of participants their vision was poorer in their study
eye than their fellow eye. At the primary outcome point of 2 years, the BCVA was, on average, 1.37 letters
worse with bevacizumab than ranibizumab, and 1.63 letters worse with discontinuous than continuous
treatment. However, bevacizumab was neither inferior nor non-inferior to ranibizumab, and discontinuous was
neither inferior nor non-inferior to continuous treatment, using the 3.5-letter non-inferiority margin. At 2 years,
NVA and contrast sensitivity were similar by drug, but better in the group receiving continuous treatment.
Reading index was similar by drug and treatment regimen at 2 years. Time to first treatment failure was similar
for the two drugs, but the risk of failure was significantly higher with discontinuous treatment than with
continuous treatment. No differences by subgroup were found. Meta-analyses of the IVAN data with other
available trials comparing bevacizumab with ranibizumab show that acuity outcomes are equivalent for the two
drugs, and that the confidence limits and point estimates of the observed difference lies well within the IVAN
trial prespecified non-inferiority margin of 3.5 letters. Only the CATT22 and IVAN trials compared continuous
and discontinuous treatment regimens; meta-analyses of the findings of these trials showed that discontinuous
treatment is significantly inferior to continuous treatment.
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Chapter 5 Lesion morphology
Morphological characteristics of lesions
At baseline, 76% of participants had a lesion with foveal centre involvement and 7% had GA. The
discontinuous group, as well as having better BCVA and reading ability than the continuous group (see
Chapter 4) also had fewer participants with a lesion with foveal centre involvement (73% vs. 78%; Table 13).
Other morphological characteristics were balanced across the groups at baseline, with the exception of fibrosis,
which was more common in the ranibizumab group than in the bevacizumab group (29% vs. 24%;
see Table 13).
There were no significant differences between drugs for dye leakage on FFA, a measure of lesion activity,
at both years 1 and 2. However, dye leakage on FFA was observed less frequently in the continuous
treatment group than in the discontinuous treatment group at 1 year (OR 0.51, 95% CI 0.33 to 0.78;
p= 0.0017).26 This difference was not maintained into year 2, when the OR increased to 0.74
(95% CI 0.51 to 1.07; p= 0.11; Figure 25). At 1 year, fewer participants had fluid on OCT in the
ranibizumab group (52% vs. 57%), and at 2 years a similar pattern was observed (50% vs. 58%; p= 0.065).
When compared by treatment regimen, significantly fewer participants had fluid on OCT in the continuous
group at both 1 and 2 years (45% vs. 62%; OR 0.47, 95% CI 0.33 to 0.67; p< 0.001 at 2 years; see Figure 25).
The choice of drug had no effect on the odds of an active neovascular lesion being present in year 1 or
year 2. However, compared with discontinuous treatment, continuous treatment protected against an
active lesion being present at both times (52% vs. 65% at 1 year, 51% vs. 61% at 2 years; OR 0.65,
95% CI 0.45 to 0.95; p= 0.024 at 2 years; see Figure 25). Despite this finding, the median neovascular
lesion area – when an active lesion was judged to be present – was similar in the two groups (Table 14).
Several OCT metrics were measured and they are summarised in Table 15. Treatment effects were only
estimated for total thickness at the fovea and retinal plus subfoveal fluid thickness at fovea (see Figure 25).
Neither of these metrics differed by drug but both were statistically significantly better (smaller mean
thickness) in the continuous group compared with discontinuous group at 2 years; they were, on average,
9% and 8% less thick for participants receiving continuous treatment (GMR= 0.91, 95% CI 0.85 to
0.97; p= 0.004; and GMR= 0.92, 95% CI 0.84 to 1.00; p= 0.046; see Figure 25).
At baseline, GA was present in 7% of participants and in 51% of cases it was within the lesion. All colour
and FFA images were regraded (again, masked to treatment allocation) after the end of the study in order
to identify whether or not new GA had developed during the course of the study. It was found that 30%
of participants had developed new GA during the trial. There was no difference in the frequency of new
GA between the drug groups (28% for ranibizumab vs. 31% for bevacizumab; OR 0.87, 95% CI 0.61 to 1.25;
p= 0.46), but significantly more participants receiving continuous treatment developed new GA (34% vs.
26%; OR 1.47, 95% CI 1.03 to 2.11; p= 0.03).
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FIGURE 25 Secondary morphological outcomes at 2 years (a) by drug and (b) by treatment regimen. Ratios of < 1
reflect better outcomes in the ranibizumab or continuous groups. Circles=GMR or OR. 95% CIs are given in
parentheses and illustrated by horizontal bars. (continued )
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Meta-analyses of lesion morphology characteristics
Figure 26 shows meta-analyses of the BRAMD, CATT,22 GEFAL42 and IVAN trial findings for changes in
total retinal thickness at the fovea. The analyses use the 2-year findings for the CATT22 and IVAN trials and
1-year findings for the BRAMD (presented at the 2013 meeting of EURETINA) and GEFAL42 trials. All trials
contributed to the analysis by drug; the pooled point estimate suggests a non-statistically significant
difference in favour of ranibizumab (p= 0.12; heterogeneity χ2= 0.12, df= 3; p= 0.99; I2= 0.0%). Only
the CATT22 and IVAN trials contributed to the analysis by treatment regimen, for which the pooled point
estimate showed a statistically significant difference in favour of continuous treatment (p= 0.001;
see Figure 26).
Only the CATT22 and IVAN trials contributed to the meta-analysis of development of new GA over 2 years.
The point estimates for the two trials were substantially different for the drug comparison (pooled OR
1.05, 95% CI 0.81 to 1.37; p= 0.70) but similar for the comparison by treatment regimen, showing that
new GA developed significantly more often during follow-up among participants treated continuously
(OR 1.56, 95% CI 1.20 to 2.03; p= 0.001; Figure 27).
Summary
Drug comparisons showed that both ranibizumab and bevacizumab were similar with respect to
morphological outcomes. Regimen comparisons found that OCT thickness measurements were lower and
an active neovascular lesion was less likely to be present in the continuous group than in the discontinuous
group at 2 years. These findings were unchanged in the meta-analysis of the CATT22 and IVAN results. In
total, 30% of participants developed new GA during the trial, and this occurred more frequently when
receiving continuous treatment, a finding that was also confirmed in the meta-analysis of the CATT22 and
IVAN results.
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FIGURE 26 Meta-analysis of change in total retinal thickness at the fovea from baseline (a) by drug and (b) by
treatment regimen. Change in total retinal thickness at the fovea= 2 years minus baseline or 1 year minus baseline,
as indicated in the figures. Negative values for differences reflect better outcomes in the ranibizumab or continuous
groups. 95% CIs are given in parentheses and illustrated by horizontal bars. WMD, weighted mean difference.
Source: © 2013 Chakravarthy et al.93 Open Access article distributed under the terms of CC-BY-NC-SA
(http://creativecommons.org/licenses/by-nc-sa/3.0/). Published by Elsevier Ltd.
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FIGURE 27 Meta-analysis of GA (a) by drug and (b) by treatment regimen. Ratios of ≤ 1 reflect better outcomes in
the ranibizumab or continuous groups. 95% CIs are given in parentheses and illustrated by horizontal bars.
Source: © 2013 Chakravarthy et al.93 Open Access article distributed under the terms of CC-BY-NC-SA
(http://creativecommons.org/licenses/by-nc-sa/3.0/). Published by Elsevier Ltd.
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Chapter 6 Safety
Serious adverse events
Over the course of the trial, at least one SAE – defined as an event that is life-threatening, causes
hospitalisation (initial or prolonged), disability or permanent damage, a congenital anomaly or birth defect,
or death – was reported for 171 participants and, of these, 30 participants died. The frequency of the
primary safety end point, an ATE or HF or death from a vascular cause, did not differ significantly between
the drugs (OR 1.69, 95% CI 0.80 to 3.57; p= 0.16) and between the treatment regimens drugs (OR 0.56;
95% CI 0.27 to 1.19; p= 0.13) (Table 16 and Figure 28). Of the 30 deaths, 15 participants were the
ranibizumab group (4.8%) and 15 in the bevacizumab group (5.1%). By treatment regimen, there were
more deaths in the discontinuous treatment group [20 (6.6%) vs. 10 (3.2%), OR 0.47, 95% CI 0.22 to 1.03;
p= 0.05] (see Figure 28). Causes of death, determined from the participant death certificates are
summarised in Table 17.
Serious adverse events grouped by MedDRA system organ class are shown in Table 18. The most
commonly reported type of SAE was cardiac disorders. Tests of the frequency of SAEs for different organ
systems (when there were more than 10 participant-specific events) showed a statistically significant
difference in SAEs coded as general disorders and administration site conditions (which includes all deaths)
by treatment regimen (continuous 3.2%; discontinuous 7.0%; p= 0.03) but not for any other organ
system by drug or treatment regimen (Figure 29). SAEs coded as gastrointestinal disorders were more
frequent with bevacizumab but the difference was less marked than at 1 year.26 Serious ocular AEs in the
study eye were extremely rare (14 participants; see Table 18), as were events in the non-study eye
(five participants; Table 19).
The percentages of patients having any systemic SAE were very similar by drug (ranibizumab 26%;
bevacizumab 27%; OR 0.96; 95% CI 0.66 to 1.39; p= 0.82) and by treatment regimen (continuous 24%;
discontinuous 29%; OR 0.77; 95% CI 0.53 to 1.11; p= 0.16). In total, 39 non-ocular SAEs were classified
as possibly, probably or definitely related to treatment (Table 20).
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OR 0.96, 95% CI 0.66 to 1.39; p= 0.82
OR 1.36, 95% CI 0.80 to 2.29; p= 0.25
OR 1.65, 95% CI 0.90 to 3.01; p= 0.10
OR 1.69, 95% CI 0.80 to 3.57; p= 0.16
OR 0.96, 95% CI 0.46 to 2.02; p= 0.91
Any systemic
event
Any vascular
event or death
Any vascular
event
Arteriothrombotic
or HF
Death from
any cause
(a)
0.25 0.5 1 2 4
Favours bevacizumabFavours ranibizumab
Any systemic
event
Any vascular
event or death
Any vascular
event
Arteriothrombotic
or HF
Death from
any cause
(b)
OR 0.77, 95% CI 0.53 to 1.11; p= 0.16
OR 0.64, 95% CI 0.38 to 1.09; p= 0.10
OR 0.69, 95% CI 0.38 to 1.24; p= 0.21
OR 0.56, 95% CI 0.27 to 1.19; p= 0.13
OR 0.47, 95% CI 0.22 to 1.03; p= 0.05
0.25 0.5 1 2 4
Favours discontinuousFavours continuous
FIGURE 28 Safety outcomes at 2 years (a) by drug and (b) by treatment regimen. ORs of < 1 reflect fewer SAEs
during the 2 years of follow-up in the ranibizumab or continuous groups. Circles indicate ORs and bars indicate
95% CIs. Vascular events include arteriothrombotic events, HF, deep-vein thrombosis, pulmonary embolism,
transient ischaemic attack, hospitalisation for angina, and non-ocular haemorrhage.
Source: © 2013 Chakravarthy et al.93 Open Access article distributed under the terms of CC-BY-NC-SA
(http://creativecommons.org/licenses/by-nc-sa/3.0/). Published by Elsevier Ltd.
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TABLE 17 Causes of death by drug and regimen combination
Ranibizumab monthly Ranibizumab as needed Bevacizumab monthly Bevacizumab as needed
Left ventricular failure
Pulmonary oedema
Metastatic neoplasm
Bladder transitional cell
carcinoma
Ovarian cancer
Metastatic neoplasm
Subdural haematoma
Cerebrovascular accident
Haemorrhage
Cardiac failure
Lower respiratory tract infection
Pneumonia
Lung neoplasm malignant
Prostate cancer metastatic
Colon cancer
PE
Pneumonia
Multiorgan failure
Metastatic neoplasm
Pericardial haemorrhage
Cardiac arrest
Cardiac arrest
Acute pulmonary oedema
Pulmonary oedema
Cor pulmonale
Lung neoplasm malignant
Mantle cell lymphoma
Hepatic neoplasm
malignant
Colon cancer
Ovarian cancer
PE, pulmonary embolism.
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OR 1.03, 95% CI 0.53 to 1.99; p= 0.94
OR 0.31, 95% CI 0.08 to 1.16; p= 0.06
OR 0.89, 95% CI 0.43 to 1.85; p= 0.76
OR 0.70, 95% CI 0.29 to 1.69; p= 0.42
OR 1.14, 95% CI 0.49 to 2.70; p= 0.76
OR 0.74, 95% CI 0.33 to 1.67; p= 0.47
OR 1.06, 95% CI 0.40 to 2.79; p= 0.91
OR 1.10, 95% CI 0.39 to 3.07; p= 0.86
OR 1.09, 95% CI 0.52 to 2.28; p= 0.82
OR 0.83, 95% CI 0.24 to 2.81; p= 0.76
Cardiovascular
disorders
Gastrointestinal
disorders
General disorders and
administration site conditions
Infections and
infestations
Injury, poisoning and
procedural complications
Neoplasms benign,
malignant and unspecified
Nervous system
disorders
Respiratory, thoracic and
mediastinal disorders
Surgical and
medical procedures
Vascular
disorders
(a)
0.06 0.25 1 4 16
Favours bevacizumabFavours ranibizumab
Cardiovascular
disorders
Gastrointestinal
disorders
General disorders and
administration site conditions
Infections and
infestations
Injury, poisoning and
procedural complications
Neoplasms benign,
malignant and unspecified
Nervous system
disorders
Respiratory, thoracic and
mediastinal disorders
Surgical and
medical procedures
Vascular
disorders
(b)
OR 0.66, 95% CI 0.34 to 1.28; p= 0.21
OR 0.99, 95% CI 0.31 to 3.11; p= 0.98
OR 0.45, 95% CI 0.21 to 0.97; p= 0.03
OR 0.87, 95% CI 0.36 to 2.11; p= 0.76
OR 0.81, 95% CI 0.35 to 1.91; p= 0.63
OR 0.76, 95% CI 0.34 to 1.70; p= 0.50
OR 0.40, 95% CI 0.14 to 1.14; p= 0.07
OR 1.12, 95% CI 0.40 to 3.14; p= 0.82
OR 0.85, 95% CI 0.41 to 1.78; p= 0.67
OR 0.55, 95% CI 0.16 to 1.93; p= 0.34
0.06 0.25 1 4 16
Favours discontinuousFavours continuous
FIGURE 29 Safety outcomes classified by MedDRA system organ class at 2 years (a) by drug and (b) by treatment
regimen. ORs of < 1 reflect fewer SAEs during the 2 years of follow-up in the ranibizumab or continuous groups.
Circles indicate ORs and bars indicate 95% CIs.
Source: © 2013 Chakravarthy et al.93 Open Access article distributed under the terms of CC-BY-NC-SA
(http://creativecommons.org/licenses/by-nc-sa/3.0/). Published by Elsevier Ltd.
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Non-serious adverse events
Over the course of the trial, non-serious AEs were reported for 570 (93.4%) of the 610 participants.
Almost 83% of participants had one or more non-ocular event and 69% had at least one ocular AE.
Frequencies were similar by drug and treatment regimen (Table 21). Details of the events, by MedDRA
system organ class, are given in Table 21. Ocular AEs in the non-study eye are given in Table 22.
Meta-analyses
Figure 30 shows meta-analyses of safety outcomes from the CATT, GEFAL, IVAN, LUCAS (presented at the
2013 meeting of the American Association for Ophthalmology), MANTA and Subramanian et al. trials
comparing ranibizumab and bevacizumab22,42–44 (available information for the BRAMD trial reported only by
MedDRA System Organ Class and did not distinguish deaths from other SAEs). The CATT22 and IVAN trials
followed participants for 2 years, and the other four trials reported data to 1 year after recruitment. Pooled
estimates of safety outcomes showed no differences by drug for deaths (heterogeneity χ2= 0.76; df= 5;
p= 0.98; I2= 0%) or ATEs (heterogeneity χ2= 3.21; df= 3; p= 0.36; I2= 7%) but a significantly increased
risk of any systemic SAE for bevacizumab (OR 0.77, 95% CI 0.64 to 0.92; p= 0.004; heterogeneity
χ2= 1.85; df= 3; p= 0.61; I2= 0%) (see Figure 30). The comparison by treatment regimen (IVAN 2-year data
and CATT 1-year data only22) showed consistent increases in mortality (OR 0.49, 95% CI 0.27 to 0.86;
p= 0.014) and the risk of any systemic SAE (OR 0.81, 95% CI 0.65 to 1.01; p= 0.063) with discontinuous
treatment (see Figure 30).
A post hoc meta-analysis of gastrointestinal SAEs, including the studies listed above, with the addition of
BRAMD for the drug comparison, was performed. This meta-analysis was prompted by a report from the
CATT22 that such events occurred more often when participants were treated with bevacizumab than when
treated with ranibizumab; the IVAN interim analysis was also consistent with this observation.26 The pooled
estimate for the drug comparison showed a significantly increased risk of gastrointestinal SAEs in the
bevacizumab group (OR 0.53, 95% CI 0.33 to 0.85; p= 0.009; heterogeneity χ2= 5.13, df= 5; p= 0.40;
I2= 3%) but no difference by treatment regimen (OR 0.88, 95% CI 0.44 to 1.78; p= 0.73) (Figure 31).
Summary
At least one SAE was reported for 171 participants, and 30 participants died. The frequency of the primary
safety end point did not differ by drug or treatment regimen. There were 15 deaths in each of the ranibizumab
and bevacizumab groups, but twice as many deaths with discontinuous as continuous treatment regimens
(20 deaths compared with 10). We examined the reasons for death by both drug and regimen and we did not
observe any clustering of cause for mortality by drug or by regimen. There was also a statistically significant
difference in the frequency of SAEs coded as general disorders and administration site conditions (which
includes all deaths), with about twice as many of these SAEs observed to occur in the discontinuous treatment
group. SAEs coded as ‘gastrointestinal’ were more frequent with bevacizumab in the IVAN trial. Serious ocular
AEs were extremely rare. The number of participants having any systemic SAE was similar across the groups.
Over 90% of participants reported at least one non-SAE.
Meta-analyses of safety outcomes showed a significantly increased risk of any systemic SAEs and
gastrointestinal events for bevacizumab, and consistent increases in mortality and the risk of any systemic
SAE with discontinuous treatment across trials.
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Chapter 7 Patient-reported outcomes and
other information
Patient-reported outcomes are secondary outcomes. Other information, not specified as secondaryoutcomes, was collected and monitored by the DMSC. This information is reported here.
Patient-reported outcomes
For the EQ-5D utility index and the MacTSQ, an instrument designed to assess patients’ satisfaction with
treatment for nAMD, higher summary scores represent better utility and a higher treatment satisfaction,
respectively. For the MacDQol, an instrument designed to assess macular disease-specific quality of life, lower
scores represent less impact of nAMD on quality of life. HUI3 data were also collected, but have been used
only for the health economics analysis. Baseline median EQ-5D utilities were similar by drug and treatment
frequency (Table 23). Median MacDQoL and MacTSQ scores and EQ-5D utilities were also very similar at 1 and
2 years (see Table 23). The distribution of responses to individual EQ-5D questions at baseline and 2 years by
drug and treatment regimen is given in Appendix 3. EQ-5D was dichotomised as ‘perfect health’ (EQ-5D score
of 1) compared with less than perfect health, and MacTSQ was dichotomised at the median (i.e. <median vs.
≥median). There were no significant differences in the odds of a patient having perfect health by either drug
or treatment regimen (p= 0.51 and 0.64, respectively), or of a patient having ‘good’ treatment satisfaction
compared with ‘low’ treatment satisfaction (p= 0.23 and p= 0.47) (Figure 32). When analysing the MacDQoL
score, this outcome was analysed on a reverse scale as outlined in Chapter 2 (see Statistical methods). As with
EQ-5D score, there were no significant differences between groups (p= 0.74 for the drug comparison and
p= 0.73 for the treatment regimen comparison) (see Figure 32).
In addition to comparing scores across the cohort as a whole, we also investigated whether or not utility,
macular disease-specific quality of life and treatment satisfaction differed between the subgroups of
participants when vision in the study eye was > 5 letters better than in the non-study eye (i.e. vision in the
study eye better than the fellow eye vs. the same or worse). The results of this post hoc subgroup analysis
are shown in Figure 33. For all three patient-reported outcomes, no statistically significant difference
between the subgroups was found.
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OR 0.89, 95% CI 0.64 to 1.25; p = 0.51EQ-5D score = 1
0 1 2
GMR 1.05, 95% CI 0.78 to 1.42; p = 0.74MacDQOL
(a)
0 1 2
OR 0.79, 95% CI 0.54 to 1.16; p = 0.23MacTSQ
0 1 2
Favours bevacizumabFavours ranibizumab
(b)
OR 0.92, 95% CI 0.66 to 1.29; p = 0.64               EQ-5D score = 1
0 1 2
GMR 0.95, 95% CI 0.70 to 1.28; p = 0.73               MacDQOL
0 1 2
OR 1.15, 95% CI 0.79 to 1.68; p = 0.47               MacTSQ
0 1 2
Favours discontinuousFavours continuous
FIGURE 32 The EQ-5D utility, macular disease-specific quality of life and treatment satisfaction scores (a) by drug
and (b) by treatment regimen. Ratios of < 1 reflect better score in the ranibizumab or continuous groups.
Circles=GMR or OR. Point estimates and 95% Cls are quantified on the right-hand side of the figure and 95% CIs
are illustrated by horizontal bars.
Source: © 2013 Chakravarthy et al.93 Open Access article distributed under the terms of CC-BY-NC-SA
(http://creativecommons.org/licenses/by-nc-sa/3.0/). Published by Elsevier Ltd.
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Interactions:
p = 0.71
p = 0.28
p = 0.16
EQ-5D [OR (95% CI)]
MacTSQ [OR (95% CI)]
MacDQoL [GMR (95% CI)]
(a)
Study eye > 5 letters better (n = 159)
Study eye < 5 letters better (n = 434)
Study eye > 5 letters better (n = 159)
Study eye < 5 letters better (n = 434)
Study eye > 5 letters better (n = 159)
Study eye < 5 letters better (n = 434)
0 0.5 1 2 3
Favours bevacizumabFavours ranibizumab
(b)
EQ-5D [OR (95% CI)]
MacTSQ [OR (95% CI)]
MacDQoL [GMR (95% CI)]
Study eye > 5 letters better (n = 159)
Study eye < 5 letters better (n = 434)
Study eye > 5 letters better (n = 159)
Study eye < 5 letters better (n = 434)
Study eye > 5 letters better (n = 159)
Study eye < 5 letters better (n = 434)
Interactions:
p = 0.54
p = 0.55
p = 0.99
0 0.5 1 2 3
Favours discontinuousFavours continuous 
FIGURE 33 The EQ-5D utility, macular disease-specific quality of life and treatment satisfaction scores for subgroups
of participants with vision in the study eye > 5 letters better and ≤ 5 letters better (a) by drug and (b) by treatment
frequency. Ratios of < 1 reflect better scores in the ranibizumab or continuous groups. Circles=GMR or OR.
95% CIs are illustrated by horizontal bars. The circle size reflects the number of patients in the subgroup.
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Blood pressure
Descriptive summaries of blood pressure measurements were regularly reviewed by the DMSC throughout
the trial. Average diastolic and systolic blood pressure at baseline, 1 year and 2 years are given in Table 24.
Serial measurements by group are shown in Figures 34 and 35; there did not appear to be any differences
in blood pressure over time by drug or by treatment regimen. These data were not formally compared
at 2 years.
TABLE 24 Blood pressure
Blood pressure
Randomised to:
Overall
(n= 610 at
baseline,
n= 563 at
1 year, n= 525
at 2 years)
Ranibizumab
(n= 314 at
baseline,
n= 288 at
1 year, n= 271
at 2 years)
Bevacizumab
(n= 296 at
baseline,
n= 275 at
1 year, n= 254
at 2 years)
Continuous
(n= 308 at
baseline,
n= 276 at
1 year, n= 261
at 2 years)
Discontinuous
(n= 302 at
baseline,
n= 287 at
1 year, n= 264
at 2 years)
Mean SD Mean SD Mean SD Mean SD Mean SD
Systolic blood pressure (mmHg)
Baseline 141.9 19.5 143.0 19.5 143.2 19.8 141.7 19.1 142.5 19.5
1 year 138.1 17.3 138.8 18.0 138.3 18.2 138.5 17.1 138.4 17.6
2 years 137.5 18.3 139.9 18.3 139.4 18.8 137.9 17.9 138.6 18.4
Change from baseline at
1 year
–3.8 17.1 –4.8 18.1 –5.6 16.1 –3.0 18.9 –4.3 17.6
Change from baseline at
2 years
–3.8 20.1 –3.1 19.7 –4.1 20.3 –2.8 19.6 –3.4 19.9
Diastolic blood pressure (mmHg)
Baseline 76.4 10.2 77.1 9.9 77.4 10.1 76.2 10.0 76.8 10.1
1 year 74.4 9.7 75.0 9.6 74.9 9.2 74.5 10.1 74.7 9.6
2 years 74.0 9.9 74.8 10.3 75.3 9.8 73.5 10.4 74.4 10.1
Change from baseline at
1 year
–1.9 10.0 –2.3 10.7 –2.8 10.0 –1.4 10.6 –2.1 10.3
Change from baseline at
2 years
–2.6 11.1 –2.5 10.4 –2.5 10.9 –2.6 10.7 –2.5 10.8
Missing data (numbers for ranibizumab continuous, ranibizumab discontinuous, bevacizumab continuous, bevacizumab
discontinuous groups, respectively):
l Systolic blood pressure: at 1 year, 42 patients with missing values (5, 12, 12, 13); at 2 years, 12 patients with missing
values (3, 3, 3, 3); change from baseline at 1 year, 42 patients with missing values (5, 12, 12, 13); change from baseline
at 2 years, 12 patients with missing values (3, 3, 3, 3).
l Diastolic blood pressure: at 1 year, 42 patients with missing values (5, 12, 12, 13); at 2 years, 12 patients with missing
values (3, 3, 3, 3); change from baseline at 1 year, 42 patients with missing values (5, 12, 12, 13); change from baseline
at 2 years, 12 patients with missing values (3, 3, 3, 3).
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FIGURE 34 Systolic blood pressure by visit (a) by drug and (b) by treatment regimen.
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FIGURE 35 Diastolic blood pressure by visit (a) by drug and (b) by treatment regimen.
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Changes in best corrected distance visual acuity between
consecutive visits
Changes in BCVA between consecutive visits were monitored throughout the trial. In particular, a
decrease of ≥ 15 letters in the number of letters read on a ETDRS chart (equivalent to the loss of three
lines of letters) was considered to be a visually significant event. BCVA was measured at every visit but
a refraction to check the optical correction was carried out at intermediate visits only if the VA dropped
by ≥ 15 letters or a refractive change was suspected. Overall, 127 participants (21%) experienced a drop
of ≥ 15 letters between visits on at least one occasion. A breakdown by group is shown in Table 25.
Worsening angina
Incident or worsening angina, defined as a change of two or more classes, or from class 3 to hospital
admission for angina, using the Canadian Cardiovascular Society (CCS) classification, was also monitored.
However, incident or worsening of angina was not defined as a SAE. (Hospital admission for angina
was, by definition, considered to be a SAE.) Worsening angina was reported for just eight participants
(Table 26).
Summary
Scores for generic and disease-/treatment-specific HRQoL were similar by drug and treatment regimen
at both 1 and 2 years. No differences for subgroups of participants with better or worse vision in the study
eye were found for any of the three HRQoL measures. No differences over time or between groups were
observed for blood pressure. Overall, 127 participants (21%) experienced a drop of ≥ 15 letters between
consecutive visits at some point during follow-up.
TABLE 25 Number and percentage of patients in each group with a decrease of ≥ 15 letters between consecutive
visits during the trial
Randomised to:
Overall (n= 610)
Ranibizumab
(n= 314)
Bevacizumab
(n= 296)
Continuous
(n= 308)
Discontinuous
(n= 302)
n % n % n % n % n %
54/314 17 73/296 25 55/308 18 72/302 24 127/610 21
TABLE 26 Number and percentage of patients in each group reporting worsening angina during the trial
Randomised to:
Overall (n= 610)
Ranibizumab
(n= 314)
Bevacizumab
(n= 296)
Continuous
(n= 308)
Discontinuous
(n= 302)
n % n % n % n % n %
4/314 1 4/296 1 5/308 2 3/302 1 8/610 1
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Chapter 8 Results of the economic evaluation
Microcosting of consultation costs
Twelve of the 23 IVAN trial centres completed operating cost questionnaires providing data on the
resource use and costs associated with managing patients receiving intravitreal anti-VEGF injections for
nAMD. Five centres ran a ‘one-stop’ service in which patients attended clinic to have monitoring and
(if required) intravitreal injection in the same visit, three centres ran ‘two-stop’ services with separate
monitoring and injection clinics, and four centres used a mixture of two-stop and one-stop clinics.
The 12 centres ran a total of 40 different types of clinic that differed in staffing levels.
Monitoring consultations without FFA were found to cost an average of £72 per attendance, and each
intravitreal injection cost on average £61 (Table 27 and Figure 36). Consultations (such as visit 0 in IVAN)
involving monitoring, intravitreal injection and FFA therefore cost £171.92 (£71.83+ £60.65+ £39.44) in total.
TABLE 27 Cost of consultations for intravitreal injections and evaluating response to treatment
Cost per evaluation or injection Number of clinicsa Weighted average (£) SD (£) Range (£)
Monitoring consultation excluding FFA 33 71.83 40.84 12.94–284.01
Monitoring consultation including the cost of
FFA for the 0–30% of patients who receive FFA
33 75.95 40.90 13.39–288.62
Intravitreal injection given alongside monitoring,
in one-stop clinics
16 60.65 17.57 34.30–145.25
Intravitreal injection in a separate injection-only
consultation without OCT
7 60.93 11.28 43.56–83.93
FFA: includes reagents, consumables, staff and
facilities directly involved in FFA
33 39.44 15.61 20.46–102.92
a Number of clinics providing data: for centres that run several different types of clinic with different resource use, all
clinics of that type are included in this figure. The weight given to each clinic in weighted averages was based on the
average number of patients attending that clinic each week.
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FIGURE 36 Distribution of consultation costs across IVAN centres. (a) Monitoring consultations excluding FFA;
(b) injection consultations alongside monitoring; (c) injection consultations without monitoring; and (d) FFA. (continued)
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FIGURE 36 Distribution of consultation costs across IVAN centres. (a) Monitoring consultations excluding FFA;
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Analysis of resource use and costs
Resource use (Table 28) and costs (Tables 29 and 30) were compared between randomised groups. Unless
otherwise stated, all figures represent the mean cost or resource use per patient over the entire 2-year
trial and include discounting to adjust for time preference.
After allowing for censoring and discounting, discontinuous treatment involved nine fewer injections over the
2-year trial period than continuous treatment (p< 0.001; Table 28). However, the discontinuous regimen
evaluated in IVAN also required six additional monitoring consultations (p< 0.001) assuming that discontinuous
patients receive monitoring consultations on all visits when they did not meet treatment failure criteria the
previous month or the month before, while continuous patients receive monitoring every 3 months regardless
of outcomes. Bevacizumab-treated patients received 0.3 more injections (p= 0.354) and 0.5 fewer monitoring
consultations (p= 0.055) than those randomised to ranibizumab; this trend may be due to chance, particularly as
it is seen in the groups randomised to continuous treatment as well as those on discontinuous treatment. There
were no significant differences between groups for inpatient stays (p≥ 0.338), ambulatory consultations with
GPs, nurses or hospital clinicians (p≥ 0.359), or changes in medication (p≥ 0.718).
Quarterly costs and QALYs were examined to evaluate the statistical significance of interactions between
drug and treatment regimen and to explore how costs and QALYs varied over time (see Table 29). Figures
were divided into quarters (rather than years or months) to match the KMSA analyses used to adjust for
censoring. Within this table and Table 30, ‘drug costs’ comprise the cost of bevacizumab or ranibizumab;
‘administration/monitoring costs’ comprise the cost of injection consultations, monitoring consultations and
FFA; and ‘medication/medical service costs’ comprise the cost of hospitalisations for expected SAEs,
changes in medications licensed for expected AEs or expected SAEs, and outpatient/GP visits that were for
ocular conditions or occurred within 30 days of the date of onset of an expected AE or expected SAE.
In the continuous treatment groups, costs and QALYs were similar across all eight quarters (see Table 29);
the small decrease in costs and QALYs over time is due to mortality and discounting of values in year 2 to
allow for time preference. By contrast, in the groups randomised to discontinuous treatment, the cost of
anti-VEGF drugs was around twice as high in quarter 1 (when patients received monthly injections) and
fluctuated over time, depending on the number of patients meeting treatment failure criteria. The cost of
administering intravitreal injections and monitoring outcomes to evaluate treatment failure criteria also fell
slightly after quarter 1. Conversely, SEs around drug costs and drug administration/monitoring were
smallest in quarter 1 (when almost all patients receive three injections) and were smaller for continuous
and discontinuous treatment. The combined cost of medication changes, ambulatory consultations and
hospitalisations linked to expected AEs or SAEs (referred to hereafter as medication/medical service costs)
fluctuated substantially in all groups, being greatly affected by costly hospitalisations in a minority
of patients.
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TABLE 29 Breakdown of costs and QALYs per patient by quarters
Outcome Quarter
Mean (SE), £
Interaction (95% CI), £
Continuous
ranibizumab
Discontinuous
ranibizumab
Continuous
bevacizumab
Discontinuous
bevacizumab
Drug cost 1 2189 (15) 2207 (9) 144 (1) 145 (1) –18 (–52 to 17)
2 2113 (23) 953 (69) 137 (2) 78 (5) 1101 (957 to 1245)a
3 2097 (27) 1164 (66) 137 (2) 80 (5) 877 (736 to 1017)a
4 2110 (26) 890 (69) 136 (2) 77 (5) 1160 (1016 to 1304)a
5b 1994 (31) 1084 (68) 128 (2) 75 (5) 857 (710 to 1003)a
6b 1927 (38) 997 (65) 128 (2) 64 (5) 866 (721 to 1011)a
7b 1936 (34) 1018 (66) 126 (2) 68 (5) 859 (716 to 1002)a
8b 1912 (41) 926 (69) 128 (2) 65 (5) 924 (768 to 1081)a
Administration
and monitoring
1 296 (6) 298 (6) 295 (7) 296 (7) 0 (–25 to 24)
2 251 (6) 246 (12) 246 (7) 239 (12) –3 (–40 to 35)
3 250 (6) 224 (10) 246 (7) 227 (11) 6 (–29 to 41)
4 251 (6) 220 (11) 245 (7) 221 (11) 7 (–29 to 44)
5 238 (7) 221 (11) 230 (7) 215 (11) 2 (–33 to 37)
6 229 (7) 212 (10) 230 (7) 209 (12) –4 (–40 to 32)
7 232 (7) 208 (11) 228 (7) 210 (11) 5 (–30 to 40)
8 226 (7) 209 (11) 230 (7) 209 (12) –4 (–41 to 32)
Medications and
medical service use
1 43 (13) 27 (16) 62 (26) 19 (5) –26 (–91 to 39)
2 31 (9) 72 (23) 106 (84) 36 (9) –111 (–283 to 61)
3 18 (4) 102 (71) 21 (4) 42 (18) –63 (–208 to 81)
4 34 (8) 26 (6) 52 (32) 49 (24) 4 (–76 to 84)
5b 75 (34) 23 (4) 45 (21) 22 (5) 29 (–51 to 109)
6b 58 (25) 81 (45) 32 (8) 230 (186) 175 (–204 to 554)
7b 47 (12) 55 (18) 223 (133) 74 (49) –157 (–441 to 127)
8b 36 (8) 38 (8) 65 (29) 32 (13) –34 (–100 to 32)
QALYs 1 0.206 (0.002) 0.207 (0.002) 0.206 (0.002) 0.204 (0.003) –0.003 (–0.010 to 0.004)
2 0.207 (0.003) 0.209 (0.004) 0.209 (0.003) 0.205 (0.004) –0.006 (–0.019 to 0.006)
3 0.205 (0.004) 0.206 (0.004) 0.208 (0.003) 0.204 (0.004) –0.005 (–0.018 to 0.007)
4 0.205 (0.004) 0.204 (0.004) 0.205 (0.003) 0.203 (0.004) –0.001 (–0.015 to 0.013)
5b 0.198 (0.004) 0.194 (0.004) 0.199 (0.003) 0.194 (0.004) –0.001 (–0.015 to 0.012)
6b 0.197 (0.003) 0.190 (0.004) 0.197 (0.003) 0.194 (0.003) 0.005 (–0.008 to 0.017)
7b 0.195 (0.003) 0.187 (0.004) 0.192 (0.004) 0.192 (0.004) 0.008 (–0.006 to 0.021)
8b 0.195 (0.004) 0.185 (0.005) 0.189 (0.004) 0.188 (0.004) 0.009 (–0.007 to 0.024)
a Statistically significant (p< 0.05).
b Costs and QALYs accrued in year 2 were discounted at 3.5% per annum.
The results shown in this table were calculated from an analysis that included all interactions between drug and treatment
regimen for all variables in all quarters to illustrate the pattern of interactions seen in the data. Numbers for administration/
monitoring and costs/outcomes in quarter 1, therefore, differ slightly from those in subsequent tables.
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Statistically significant interactions between drug and treatment regimen were observed for drug costs
in quarters 2–8 (p< 0.001; see Table 29 and Figure 37); as expected, these interactions were larger than the
difference between continuous and discontinuous treatment and were super-additive in that the difference
between continuous ranibizumab and discontinuous bevacizumab is larger than the sum of the individual
treatment effects. Analyses of drug cost, therefore, allowed for interactions in quarters 2–8 (see Chapter 2).
Allowing for interactions, drug costs differed significantly between all four groups (p< 0.001). The continuous
ranibizumab group accrued the highest drug cost (£16,286, 95% CI £16,011 to £16,562), which was £15,222
(95% CI £14,948 to £15,495; p< 0.001) higher than the cost in the continuous bevacizumab group and
£7057 (95% CI £6364 to £7750; p< 0.001) higher than the cost for the discontinuous ranibizumab group
(see Table 29 and Figure 37). Although the difference was substantially smaller, the continuous bevacizumab
group also accrued significantly higher costs than the discontinuous bevacizumab group (difference £413,
95% CI £365 to £462; p< 0.001).
For administration and monitoring costs, interactions were non-significant (p≥ 0.70) and substantially smaller
than the main effects of drug or treatment regimen; drug and treatment regimen were therefore assumed to
have additive effects on administration and monitoring costs and differences between drugs are therefore
averaged across treatment regimens (see Chapter 2). Administration and monitoring costs were £130
(95% CI £20 to £239; p= 0.021) higher with continuous treatment than with discontinuous treatment, as
continuous treatment increased the number of injection consultations more than it decreased the number of
monitoring consultations (see Table 28). There was no statistically significant difference in administration and
monitoring costs between ranibizumab and bevacizumab (MD £16, 95% CI –£109 to £141; p= 0.80).
Interactions for the medication/medical service costs associated with expected AEs or expected SAEs were
non-significant (p≥ 0.206), although the overall interaction across all eight quarters was larger than the
difference between drugs (see Table 30). These interactions were qualitative in that the sign (not just the
magnitude) of the effect of treatment regimen changes depending on which drug was used: for example,
the continuous ranibizumab group accrued substantially lower medication/medical service costs than the
discontinuous ranibizumab group, whereas the continuous bevacizumab group accrued higher medication/
medical service costs than the discontinuous ranibizumab group. Interactions were, therefore, included in the
base-case analysis of medication/medical service costs in quarters 2–8, as they could change conclusions
about which treatment is most cost-effective (see Chapter 2). Medication/medical service costs were highest
for the continuous bevacizumab group £585 (95% CI £250 to £919) and lowest for the continuous
ranibizumab group £334 (95% CI £215 to £452). The variability within each group was large, mainly due to
the high cost of hospitalisations in a handful of patients. As a result, neither drug (p≥ 0.163) nor treatment
regimen (p≥ 0.363) had a statistically significant effect on medication/medical service costs.
Anti-VEGF drug costs accounted for 80–88% of costs among patients randomised to ranibizumab,
compared with 22–30% for the bevacizumab groups (Table 31 and see Figure 37). Among patients
randomised to bevacizumab, however, administration and monitoring costs were the greatest cost driver,
accounting for 54% of costs with continuous therapy and 61% of costs with discontinuous (vs. 11–16%
for the ranibizumab groups).
DOI: 10.3310/hta19780 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 78
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Chakravarthy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
125
20 18 16 14 12 10 8 6 4 2 0
Mean cost per patient over the 2-year trial period (£000)
C
o
n
ti
n
u
o
u
s
ra
n
ib
iz
u
m
ab
C
o
n
ti
n
u
o
u
s
b
ev
ac
iz
u
m
ab
D
is
co
n
ti
n
u
o
u
s
b
ev
ac
iz
u
m
ab
D
is
co
n
ti
n
u
o
u
s
ra
n
ib
iz
u
m
ab
M
ed
ic
at
io
n
s 
an
d
m
ed
ic
al
 s
er
vi
ce
 u
se
A
d
m
in
is
tr
at
io
n
 a
n
d
m
o
n
it
o
ri
n
g
A
n
ti
-V
EG
F 
m
ed
ic
at
io
n
Tr
ea
tm
en
t
FI
G
U
R
E
37
B
re
ak
d
o
w
n
o
f
co
st
s
fo
r
ea
ch
tr
ea
tm
en
t.
Er
ro
r
b
ar
s
sh
o
w
SE
s
ar
o
u
n
d
to
ta
l
co
st
.
RESULTS OF THE ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
126
TA
B
LE
31
R
es
u
lt
s
o
f
se
n
si
ti
vi
ty
A
n
al
ys
is
Ex
p
ec
te
d
N
B
at
a
20
,0
00
p
er
Q
A
LY
ce
ili
n
g
ra
ti
o
(S
E)
In
cr
em
en
ta
lc
o
st
C
o
n
t
ra
n
vs
.C
o
n
t
b
ev
(S
E,
p
ro
b
ab
ili
ty
co
st
-s
av
in
g
,%
)
C
o
st
p
er
Q
A
LY
C
o
n
t
b
ev
vs
.D
is
c
b
ev
(p
ro
b
ab
ili
ty
co
st
-e
ff
ec
ti
ve
,
%
)
St
ra
te
g
y
w
it
h
h
ig
h
es
t
N
B
(p
ro
b
ab
ili
ty
m
ax
im
is
es
N
B
,%
)
C
o
n
ti
n
u
o
u
s
ra
n
ib
iz
u
m
ab
(C
o
n
t
ra
n
),
£
D
is
co
n
ti
n
u
o
u
s
ra
n
ib
iz
u
m
ab
(D
is
c
ra
n
),
£
C
o
n
ti
n
u
o
u
s
b
ev
ac
iz
u
m
ab
(C
o
n
t
b
ev
),
£
D
is
co
n
ti
n
u
o
u
s
b
ev
ac
iz
u
m
ab
(D
is
c
b
ev
),
£
Ba
se
-c
as
e
an
al
ys
is
13
,5
76
(4
12
)
20
,1
42
(6
02
)
28
,4
80
(4
75
)
28
,6
83
(4
98
)
14
,9
89
(2
38
,
0)
30
,2
20
(3
7)
D
is
c
be
v
(6
3)
1-
ye
ar
tim
e
ho
riz
on
67
80
(2
18
)
10
,0
75
(2
98
)
14
,7
41
(2
37
)
14
,8
14
(2
42
)
78
68
(1
22
,
0)
26
,8
46
(3
9)
D
is
c
be
v
(6
1)
C
om
pl
et
e
ca
se
an
al
ys
is
:
ex
cl
ud
in
g
al
lp
at
ie
nt
s
w
ith
an
y
m
is
si
ng
da
ta
14
,3
40
(4
24
)
21
,1
96
(6
84
)
29
,3
10
(4
75
)
29
,8
28
(4
95
)
15
,3
43
(1
97
,
0)
98
,6
91
(1
8)
D
is
c
be
v
(8
2)
In
cl
ud
in
g
di
ff
er
en
ce
s
in
de
at
hs
un
re
la
te
d
to
st
ud
y
m
ed
ic
at
io
n
13
,5
80
(4
21
)
20
,1
83
(6
12
)
28
,5
91
(4
86
)
28
,5
03
(5
54
)
14
,9
79
(2
65
,
0)
17
,5
77
(5
5)
C
on
t
be
v
(5
5)
A
llo
w
in
g
fo
r
in
te
ra
ct
io
ns
in
al
lc
os
t
an
d
Q
A
LY
ca
lc
ul
at
io
ns
13
,5
75
(4
12
)
20
,1
43
(6
04
)
28
,4
81
(4
75
)
28
,6
82
(4
99
)
14
,9
91
(2
39
,
0)
30
,1
16
(3
7)
D
is
c
be
v
(6
3)
In
cl
ud
in
g
on
ly
st
at
is
tic
al
ly
sig
ni
fic
an
t
in
te
ra
ct
io
ns
13
,5
30
(3
86
)
20
,1
86
(5
55
)
28
,5
29
(4
39
)
28
,6
34
(4
52
)
15
,0
69
(2
14
,
0)
25
,1
10
(4
1)
D
is
c
be
v
(5
9)
Be
va
ci
zu
m
ab
co
st
s
£1
00
/d
os
e
13
,5
76
(4
12
)
20
,1
42
(6
02
)
27
,3
72
(4
73
)
28
,0
05
(4
94
)
13
,8
81
(2
37
,
0)
51
,9
22
(1
4)
D
is
c
be
v
(8
6)
Be
va
ci
zu
m
ab
co
st
s
£3
0/
do
se
13
,5
76
(4
12
)
20
,1
42
(6
02
)
28
,8
93
(4
76
)
28
,9
35
(4
99
)
15
,4
02
(2
38
,
0)
22
,1
36
(4
7)
D
is
c
be
v
(5
3)
U
se
on
e
4-
m
lv
ia
lo
f
be
va
ci
zu
m
ab
pe
r
pa
tie
nt
(£
24
2.
66
51
),
w
ith
th
e
re
m
ai
nd
er
th
ro
w
n
aw
ay
13
,5
76
(4
12
)
20
,1
42
(6
02
)
24
,2
73
(4
68
)
26
,1
09
(4
92
)
10
,7
82
(2
37
,
0)
11
2,
62
5
(0
)
D
is
c
be
v
(1
00
)
Re
du
ci
ng
th
e
pr
ic
e
of
ra
ni
bi
zu
m
ab
by
25
%
17
,6
48
(4
15
)
22
,4
49
(5
71
)
28
,4
80
(4
75
)
28
,6
83
(4
98
)
10
,9
18
(2
19
,
0)
30
,2
20
(3
7)
D
is
c
be
v
(6
3)
Re
du
ci
ng
th
e
pr
ic
e
of
ra
ni
bi
zu
m
ab
by
50
%
21
,7
19
(4
22
)
24
,7
56
(5
50
)
28
,4
80
(4
75
)
28
,6
83
(4
98
)
68
46
(2
03
,
0)
30
,2
20
(3
7)
D
is
c
be
v
(6
3)
In
cr
ea
si
ng
th
e
pr
ic
e
of
ra
ni
bi
zu
m
ab
by
25
%
95
05
(4
11
)
17
,8
34
(6
42
)
28
,4
80
(4
75
)
28
,6
83
(4
98
)
19
,0
61
(2
61
,
0)
30
,2
20
(3
7)
D
is
c
be
v
(6
3)
Ex
cl
ud
in
g
th
e
co
st
of
ra
ni
bi
zu
m
ab
be
yo
nd
th
e
14
th
in
je
ct
io
n
to
ea
ch
ey
e.
Th
is
an
al
ys
is
re
fle
ct
s
th
e
or
ig
in
al
20
08
N
IC
E
pa
tie
nt
ac
ce
ss
sc
he
m
e
in
w
hi
ch
th
e
m
an
uf
ac
tu
re
r
pa
id
fo
r
al
li
nj
ec
tio
ns
be
yo
nd
th
e
14
th
do
se
91
19
,6
49
(4
25
)
21
,3
68
(5
62
)
28
,4
80
(4
75
)
28
,6
83
(4
98
)
89
16
(1
97
,
0)
30
,2
20
(3
7)
D
is
c
be
v
(6
3)
A
ss
um
in
g
th
at
5.
3%
of
ra
ni
bi
zu
m
ab
vi
al
s
an
d
15
.9
%
of
be
va
ci
zu
m
ab
sy
rin
ge
s
ar
e
w
as
te
d
(b
as
ed
on
th
e
pr
op
or
tio
ns
ob
se
rv
ed
in
IV
A
N
)
12
,6
69
(4
11
)
19
,6
28
(6
10
)
28
,2
78
(4
75
)
28
,5
59
(4
97
)
15
,6
94
(2
43
,
0)
34
,1
76
(3
2)
D
is
c
be
v
(6
8) c
on
tin
ue
d
DOI: 10.3310/hta19780 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 78
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Chakravarthy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
127
TA
B
LE
31
R
es
u
lt
s
o
f
se
n
si
ti
vi
ty
(c
o
n
ti
n
u
ed
)
A
n
al
ys
is
Ex
p
ec
te
d
N
B
at
a
20
,0
00
p
er
Q
A
LY
ce
ili
n
g
ra
ti
o
(S
E)
In
cr
em
en
ta
lc
o
st
C
o
n
t
ra
n
vs
.C
o
n
t
b
ev
(S
E,
p
ro
b
ab
ili
ty
co
st
-s
av
in
g
,%
)
C
o
st
p
er
Q
A
LY
C
o
n
t
b
ev
vs
.D
is
c
b
ev
(p
ro
b
ab
ili
ty
co
st
-e
ff
ec
ti
ve
,
%
)
St
ra
te
g
y
w
it
h
h
ig
h
es
t
N
B
(p
ro
b
ab
ili
ty
m
ax
im
is
es
N
B
,%
)
C
o
n
ti
n
u
o
u
s
ra
n
ib
iz
u
m
ab
(C
o
n
t
ra
n
),
£
D
is
co
n
ti
n
u
o
u
s
ra
n
ib
iz
u
m
ab
(D
is
c
ra
n
),
£
C
o
n
ti
n
u
o
u
s
b
ev
ac
iz
u
m
ab
(C
o
n
t
b
ev
),
£
D
is
co
n
ti
n
u
o
u
s
b
ev
ac
iz
u
m
ab
(D
is
c
b
ev
),
£
A
pp
ly
in
g
H
RG
fo
r
op
ht
ha
lm
ol
og
y
co
ns
ul
ta
tio
n
(£
65
76
)t
o
al
lv
is
its
in
st
ea
d
of
us
in
g
m
ic
ro
co
st
in
g
es
tim
at
es
14
,0
84
(4
10
)
20
,5
43
(5
97
)
28
,9
89
(4
75
)
29
,0
85
(4
95
)
14
,9
89
(2
29
,
0)
24
,8
66
(4
4)
D
is
c
be
v
(5
6)
H
RG
fo
r
m
in
or
vi
tr
eo
us
re
tin
al
pr
oc
ed
ur
e
fo
r
in
je
ct
io
n
an
d
m
on
ito
rin
g
(£
14
57
6 )
12
,2
85
(4
09
)
18
,7
75
(5
93
)
27
,2
13
(4
72
)
27
,3
35
(4
88
)
15
,0
13
(2
34
,
0)
26
,1
59
(4
2)
D
is
c
be
v
(5
8)
A
pp
ly
in
g
re
fe
re
nc
e
co
st
pr
ic
e
fo
r
op
ht
ha
lm
ol
og
y
co
ns
ul
ta
tio
n
(£
11
7.
43
75
)
to
al
l
vi
si
ts
in
st
ea
d
of
us
in
g
m
ic
ro
co
st
in
g
es
tim
at
es
12
,9
05
(4
10
)
19
,3
84
(5
94
)
27
,8
25
(4
73
)
27
,9
38
(4
90
)
15
,0
05
(2
32
,
0)
25
,7
14
(4
3)
D
is
c
be
v
(5
7)
D
ou
bl
in
g
ad
m
in
is
tr
at
io
n/
m
on
ito
rin
g
co
st
s
11
,6
06
(4
17
)
18
,3
04
(6
08
)
26
,5
29
(4
77
)
26
,8
58
(5
01
)
15
,0
08
(2
67
,
0)
36
,6
25
(3
0)
D
is
c
be
v
(7
0)
H
al
vi
ng
ad
m
in
is
tr
at
io
n/
m
on
ito
rin
g
co
st
s
14
,5
61
(4
11
)
21
,0
61
(6
00
)
29
,4
56
(4
76
)
29
,5
95
(4
99
)
14
,9
80
(2
29
,
0)
27
,0
18
(4
1)
D
is
c
be
v
(5
9)
In
cl
ud
in
g
th
e
co
st
of
pr
ot
oc
ol
-d
riv
en
re
so
ur
ce
us
e
(m
on
th
ly
O
C
T
an
d
vi
si
t
12
FF
A
in
al
l
pa
tie
nt
s)
12
,5
05
(4
18
)
19
,5
11
(6
12
)
27
,3
99
(4
80
)
28
,0
41
(5
00
)
14
,9
78
(2
58
,
0)
52
,3
89
(1
4)
D
is
c
be
v
(8
6)
A
ss
um
in
g
no
FF
A
do
ne
be
yo
nd
vi
si
t
0
14
,9
99
(4
13
)
20
,9
95
(5
93
)
29
,9
21
(4
79
)
29
,5
56
(5
01
)
15
,0
08
(2
33
,
0)
15
86
(7
2)
C
on
t
be
v
(7
2)
A
ss
um
in
g
th
at
m
is
se
d
vi
si
ts
ac
cr
ue
th
e
sa
m
e
ad
m
in
is
tr
at
io
n/
m
on
ito
rin
g
co
st
as
at
te
nd
ed
vi
si
ts
(b
ut
ze
ro
dr
ug
co
st
)
13
,4
87
(4
11
)
20
,0
65
(6
03
)
28
,3
69
(4
76
)
28
,5
84
(5
00
)
14
,9
67
(2
37
,
0)
30
,8
70
(3
6)
D
is
c
be
v
(6
4)
In
cl
ud
in
g
am
bu
la
to
ry
co
ns
ul
ta
tio
n
co
st
s
w
ith
in
30
da
ys
of
an
y
A
E
or
SA
E
an
d
in
cl
ud
in
g
ho
sp
ita
lis
at
io
ns
fo
r
an
y
SA
E
(e
xp
ec
te
d
or
ot
he
rw
is
e)
13
,0
74
(4
56
)
19
,1
30
(6
85
)
27
,5
74
(5
46
)
27
,8
24
(5
52
)
14
,5
85
(3
46
,
0)
32
,6
02
(3
6)
D
is
c
be
v
(6
4)
In
cl
ud
in
g
al
lh
os
pi
ta
lis
at
io
n
an
d
am
bu
la
to
ry
co
ns
ul
ta
tio
n
co
st
s
re
ga
rd
le
ss
of
th
ei
r
pr
ox
im
ity
to
an
y
(S
)A
Es
12
,9
21
(4
60
)
18
,9
59
(6
87
)
27
,3
90
(5
52
)
27
,6
69
(5
53
)
14
,5
54
(3
55
,
0)
34
,0
73
(3
5)
D
is
c
be
v
(6
5)
In
cl
ud
in
g
20
%
V
A
T
on
al
lc
os
ts
98
58
(4
15
)
17
,8
42
(6
39
)
27
,7
60
(4
93
)
28
,0
82
(5
13
)
17
,9
87
(2
86
,
0)
36
,2
65
(3
1)
D
is
c
be
v
(6
9)
D
is
co
un
tin
g
co
st
s
an
d
Q
A
LY
s
in
ye
ar
2
at
1.
5%
(n
ot
3.
5%
)
13
,7
10
(4
16
)
20
,3
40
(6
08
)
28
,7
51
(4
81
)
28
,9
56
(5
04
)
15
,1
29
(2
41
,
0)
30
,2
56
(3
7)
D
is
c
be
v
(6
3)
RESULTS OF THE ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
128
A
n
al
ys
is
Ex
p
ec
te
d
N
B
at
a
20
,0
00
p
er
Q
A
LY
ce
ili
n
g
ra
ti
o
(S
E)
In
cr
em
en
ta
lc
o
st
C
o
n
t
ra
n
vs
.C
o
n
t
b
ev
(S
E,
p
ro
b
ab
ili
ty
co
st
-s
av
in
g
,%
)
C
o
st
p
er
Q
A
LY
C
o
n
t
b
ev
vs
.D
is
c
b
ev
(p
ro
b
ab
ili
ty
co
st
-e
ff
ec
ti
ve
,
%
)
St
ra
te
g
y
w
it
h
h
ig
h
es
t
N
B
(p
ro
b
ab
ili
ty
m
ax
im
is
es
N
B
,%
)
C
o
n
ti
n
u
o
u
s
ra
n
ib
iz
u
m
ab
(C
o
n
t
ra
n
),
£
D
is
co
n
ti
n
u
o
u
s
ra
n
ib
iz
u
m
ab
(D
is
c
ra
n
),
£
C
o
n
ti
n
u
o
u
s
b
ev
ac
iz
u
m
ab
(C
o
n
t
b
ev
),
£
D
is
co
n
ti
n
u
o
u
s
b
ev
ac
iz
u
m
ab
(D
is
c
b
ev
),
£
M
ak
in
g
no
ad
ju
st
m
en
t
fo
r
ba
se
lin
e
ut
ili
ty
13
,7
36
(4
88
)
19
,9
51
(6
67
)
28
,7
13
(5
44
)
29
,0
63
(5
82
)
14
,9
89
(2
38
,
0)
48
,1
14
(3
2)
D
is
c
be
v
(6
8)
U
si
ng
H
U
I3
ut
ili
tie
s
in
pl
ac
e
of
EQ
-5
D
92
91
(6
44
)
14
,4
95
(7
83
)
22
,5
24
(7
54
)
22
,3
46
(7
50
)
14
,9
89
(2
38
,
0)
15
,4
23
(5
8)
C
on
t
be
v
(5
8)
Si
m
pl
y
in
te
rp
ol
at
in
g
be
tw
ee
n
sc
he
du
le
d
EQ
-5
D
m
ea
su
re
m
en
ts
(s
ee
A
pp
en
di
x
4)
13
,5
34
(4
24
)
20
,2
16
(6
04
)
28
,4
51
(4
87
)
28
,6
89
(5
10
)
14
,9
89
(2
38
,
0)
33
,1
99
(3
5)
D
is
c
be
v
(6
5)
Ex
cl
ud
in
g
th
e
po
st
-S
A
E
EQ
-5
D
m
ea
su
re
m
en
ts
an
d
in
te
rp
ol
at
in
g
be
tw
ee
n
th
e
no
n-
SA
E
m
ea
su
re
m
en
ts
(s
ee
A
pp
en
di
x
4)
13
,5
43
(4
22
)
20
,1
95
(6
04
)
28
,4
72
(4
86
)
28
,6
79
(5
09
)
14
,9
89
(2
38
,
0)
30
,6
10
(3
7)
D
is
c
be
v
(6
3)
Li
ne
ar
in
te
rp
ol
at
io
n
be
tw
ee
n
al
lE
Q
-5
D
m
ea
su
re
m
en
ts
(s
ee
A
pp
en
di
x
4)
13
,6
18
(4
08
)
20
,1
90
(5
99
)
28
,4
20
(4
78
)
28
,6
37
(5
01
)
14
,9
89
(2
38
,
0)
31
,4
00
(3
7)
D
is
c
be
v
(6
4)
Su
bt
ra
ct
in
g
Q
A
LY
lo
ss
fr
om
ex
pe
ct
ed
SA
Es
bu
t
no
t
un
ex
pe
ct
ed
SA
Es
(s
ee
A
pp
en
di
x
4)
13
,5
63
(4
20
)
20
,1
78
(6
04
)
28
,5
07
(4
78
)
28
,6
70
(5
01
)
14
,9
89
(2
38
,
0)
27
,5
06
(3
9)
D
is
c
be
v
(6
1)
D
ou
bl
in
g
th
e
Q
A
LY
im
pa
ct
of
SA
Es
fo
r
w
hi
ch
th
er
e
is
no
EQ
-5
D
m
ea
su
re
m
en
t
w
ith
in
2
m
on
th
s
of
th
e
SA
E
(s
ee
A
pp
en
di
x
4)
13
,5
47
(4
26
)
20
,0
64
(6
13
)
28
,4
60
(4
80
)
28
,6
80
(5
01
)
14
,9
89
(2
38
,
0)
31
,5
99
(3
6)
D
is
c
be
v
(6
4)
D
ou
bl
in
g
th
e
Q
A
LY
im
pa
ct
of
al
lS
A
Es
an
d
do
ub
lin
g
th
e
to
ta
lm
ed
ic
at
io
n/
m
ed
ic
al
se
rv
ic
e
co
st
s
(s
ee
A
pp
en
di
x
4)
13
,2
76
(4
35
)
19
,6
56
(6
42
)
27
,9
04
(5
80
)
28
,1
60
(5
97
)
14
,7
38
(3
90
,
0)
32
,7
70
(3
7)
D
is
c
be
v
(6
3)
Be
st
ca
se
an
al
ys
is
fo
r
ra
ni
bi
zu
m
ab
:
l
50
%
di
sc
ou
nt
of
f
al
lr
an
ib
iz
um
ab
vi
al
s
l
A
ss
um
in
g
th
at
15
.9
%
of
be
va
ci
zu
m
ab
(a
s
oc
cu
rr
ed
in
th
e
tr
ia
l)
bu
t
no
ra
ni
bi
zu
m
ab
is
w
as
te
d
l
Be
va
ci
zu
m
ab
co
st
s
£1
00
pe
r
do
se
l
In
cl
ud
in
g
re
so
ur
ce
us
e
as
so
ci
at
ed
w
ith
ex
pe
ct
ed
an
d
un
ex
pe
ct
ed
A
Es
an
d
SA
Es
21
,2
17
(4
68
)
23
,7
45
(6
34
)
26
,0
54
(5
42
)
26
,8
94
(5
49
)
49
22
(3
23
,
0)
62
,3
75
(1
1)
D
is
c
be
v
(8
9)
C
on
t
be
v,
co
nt
in
uo
us
be
va
ci
zu
m
ab
;
C
on
t
ra
n,
co
nt
in
uo
us
ra
ni
bi
zu
m
ab
;
D
is
c
be
v,
di
sc
on
tin
uo
us
be
va
ci
zu
m
ab
;
D
is
c
ra
n,
di
sc
on
tin
uo
us
ra
ni
bi
zu
m
ab
;
N
B,
ne
t
be
ne
fit
at
a
20
,0
00
/Q
A
LY
ce
ili
ng
ra
tio
.
DOI: 10.3310/hta19780 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 78
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Chakravarthy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
129
Analysis of health outcomes
Mean EQ-5D baseline utility was 0.82 (SD 0.21) across all groups: slightly higher than the national average
utility for 65- to 74-year-olds (0.78; SD 0.2694) or people aged ≥ 75 years (0.73; SD 0.2794), which may be
because patients with serious/life-threatening conditions and those who could not be expected to attend
monthly consultations were excluded from the trial. Ordinary least squares (OLS) regression, using the mim
command to combine results over the 100 imputed data sets demonstrated that mean EQ-5D utility rose
by around 0.018 (SE 0.008; p= 0.02) between visits 0 and 3, and fell by 0.025 (SE 0.009; p= 0.006)
between visits 3 and 24. There was marked, but non-significant (p≤ 0.429), imbalance in EQ-5D utility at
baseline, with lower utility in the group randomised to discontinuous ranibizumab and higher utility in
the group randomised to discontinuous bevacizumab. The base-case analysis therefore used regression
analyses to adjust for this imbalance, which is likely to have arisen by chance but could (in the absence of
appropriate adjustment) have introduced bias into QALY calculations.
Mixed models demonstrated that EQ-5D utility was significantly lower after cardiovascular (p= 0.002)
and cancer (p< 0.001) SAEs, although the effect of ocular (p= 0.491) or other (p= 0.248) SAEs was
non-significant (see Appendix 4). However, averaged across all study arms, taking account of post-SAE EQ-5D
measurements and the profile of EQ-5D utility changes around SAEs reduced the mean QALYs accrued over
the 2-year trial period by just 0.0001.
Interactions between drug and treatment regimen were non-significant for QALYs (p≥ 0.274), although the
overall interaction across all eight quarters was larger than the difference between drugs (see Table 29). As for
medication/medical service costs, the interactions for QALYs was qualitative, with the continuous ranibizumab
group accruing more QALYs across all eight quarters than the continuous bevacizumab group, whereas
the discontinuous ranibizumab group accrued marginally fewer QALYs than discontinuous bevacizumab.
The base-case analysis therefore allowed for interactions on QALYs for quarters 2–8 (see Chapter 2).
All four treatment groups accrued around 1.6 QALYs over the 2-year trial period (see Table 30), reflecting the
mean utility of 0.8. All treatment groups accrued fewer QALYs during year 2 as a result of discounting and
mortality (see Table 29). There were no statistically significant differences in QALYs between drugs (p≥ 0.87)
or treatment regimens (p≥ 0.361). However, there was a trend towards patients randomised to continuous
therapy accruing around 0.02 additional QALYs than those randomised to discontinuous therapy over the
2-year study period. This trend was consistent across all quarters other than quarter 1, in which all patients
receive monthly injections (see Table 29). However, this difference was very small compared with the SEs
around QALY differences and could have arisen by chance.
Results of the base-case economic evaluation
Base-case comparison between ranibizumab and bevacizumab
The SAP prespecified that CMA would be used to compare ranibizumab and bevacizumab unless the absolute
difference in EQ-5D QALYs was > 0.05 (see Chapter 2). The observed MD was 0.004 for continuous therapy
and 0.002 for discontinuous therapy (see Table 30), which is substantially smaller than this non-inferiority
margin and is so small in relation to cost differences that assuming equivalent efficacy is highly unlikely to bias
the conclusions.54 Conclusions about the cost-effectiveness of ranibizumab and bevacizumab were, therefore,
primarily based on differences in cost, assuming that there was no difference in health outcomes.
The total cost accrued by patients randomised to continuous ranibizumab was £18,590
(95% CI £18,258 to £18,922), £14,989 (95% CI £14,522 to £15,456; p< 0.001) more than continuous
bevacizumab, which equates to a fivefold difference in cost. The average cost per patient in the group
randomised to discontinuous ranibizumab was £11,500 (95% CI £10,798 to £12,202), nearly four times
higher than the cost in the discontinuous bevacizumab group (£3002, 95% CI £2601 to £3403), giving an
absolute difference of £8498 (95% CI £7700 to £9295; p< 0.001). None of the 13,000 bootstrap
replicates found total costs to be lower among patients randomised to ranibizumab than among those
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randomised to bevacizumab, indicating that we can be more than 99.99% confident that substituting
bevacizumab for ranibizumab would save the NHS money and (based on CMA) would be cost-effective.
Broadening the analysis to consider both costs and QALYs demonstrates that continuous ranibizumab
costs £3.5M per QALY gained compared with continuous bevacizumab. This ICER is 175 times higher than
the £20,000 per QALY ceiling ratio below which treatments are generally considered to be cost-effective,57
indicating that continuous ranibizumab represents very poor value for money.
This conclusion is confirmed by the scatter graph plotting bootstrap estimates of the joint distribution of
incremental costs and QALYs (Figure 38). This indicates that, for both continuous and discontinuous
treatment, the entire distribution of costs lies well above the x-axis (indicating significantly higher costs for
ranibizumab), whereas the incremental QALYs are evenly distributed either side of zero.
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FIGURE 38 Differences in costs for ranibizumab against the difference in QALYs for (a) continuous treatment and
(b) discontinuous treatment. The black square represents the MD in cost and QALYs and the green dots represent
individual bootstrap replicates.
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Bootstrapping results were also used to estimate cost-effectiveness acceptability curves plotting the probability
that ranibizumab is cost-effective compared with bevacizumab at different ceiling ratios representing the
maximum that the NHS is willing or able to pay to gain one QALY (Figure 39). The probability of ranibizumab
being cost-effective can be read off the curve at any ceiling ratio of interest. For example, if the NHS were
willing to pay £200,000 per QALY gained (10 times higher than NICE’s stated threshold57), the probability of
ranibizumab being cost-effective is 8% for discontinuous treatment and 0.3% for continuous treatment. The
probability of ranibizumab being cost-effective compared with bevacizumab remained < 0.01% at all ceiling
ratios of < £80,000 per QALY gained: four times higher than the £20,000 per QALY ceiling ratio typically used
in NHS decision-making.57 This analysis demonstrates that ignoring QALY differences has no impact on the
conclusions, as the probability that ranibizumab is cost-effective is < 0.01% at a £20,000 per QALY ceiling
ratio as well as in a CMA that assumes no QALY gains.
Base-case comparison between continuous and discontinuous treatment
As prespecified in the SAP, continuous and discontinuous treatment were compared using CUA. It is
important to take account of non-significant differences in QALYs and evaluate the joint distribution of costs
and QALYs, as assuming no difference in health outcomes has been shown to give misleading conclusions
unless the difference in cost is so large that no plausible difference in health effects could change the
conclusions.53,54,95 For both ranibizumab and bevacizumab, the point estimate (the black squares in Figure 40)
lay in the north-east quadrant of the cost-effectiveness plane, as continuous therapy was significantly more
costly (p≥ 0.021) and non-significantly more effective (p≥ 0.381) than discontinuous therapy.
Dividing the incremental cost for continuous vs. discontinuous bevacizumab (£599) by the incremental QALY
gain (0.02) gave an ICER of £30,220 per QALY gained. This figure is above the £20,000 per QALY ceiling
ratio below which treatments are generally considered to be cost-effective,57 suggesting that continuous
bevacizumab is not cost-effective, although it is only just above the £20,000–30,000 per QALY range above
which additional considerations are required to justify adoption.57 To facilitate statistical analysis, costs and
QALYs were also combined to estimate net benefits, which equal QALYs multiplied by the ceiling ratio minus
costs. At a £20,000 per QALY ceiling ratio, discontinuous bevacizumab had £203 (95% CI –£967 to £1372;
p= 0.734; see Table 30) higher net benefits than continuous bevacizumab, indicating that continuous
bevacizumab is not cost-effective. However, this difference was not significant and there was substantial
uncertainty around both incremental costs and QALYs (see Figure 40).
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FIGURE 39 Pairwise cost-effectiveness acceptability curves for ranibizumab vs. bevacizumab. The vertical dotted
line represents a ceiling ratio of £20,000 per QALY gained.
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However, as the higher ranibizumab drug costs substantially increased the difference in cost between
continuous and discontinuous therapy, continuous ranibizumab cost £270,217 per QALY gained compared
with discontinuous ranibizumab (£7090 ÷ 0.026). This is 13 times higher than the amount the NHS would
normally consider cost-effective, indicating that continuous ranibizumab is not cost-effective. Discontinuous
ranibizumab was associated with significantly higher net benefits than continuous ranibizumab (p< 0.001).
Bootstrapping results were also used to estimate cost-effectiveness acceptability curves, which demonstrated
that there is a 37% chance that continuous bevacizumab is cost-effective compared with discontinuous
bevacizumab at a £20,000 per QALY ceiling ratio (Figure 41). This figure rises to 50% at a £30,000 per QALY
ceiling ratio and asymptotes towards 77% (the probability that continuous bevacizumab generates more
QALYs than discontinuous bevacizumab). By contrast, the probability of continuous ranibizumab being
cost-effective compared with discontinuous ranibizumab remained at < 0.001% unless the NHS were willing
to pay at least £60,000 per QALY gained.
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FIGURE 40 Incremental costs and outcomes for continuous vs. discontinuous treatment for (a) ranibizumab and
(b) bevacizumab. The black squares represent the MD in costs and QALYs and the green dots represent individual
bootstrap replicates.
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Base-case four-way comparison
Considering the four cells of the factorial design as mutually exclusive alternative strategies for managing
nAMD gives the same conclusions as the base-case analysis, but enables us to consider the joint
distribution around the entire decision, considering both drug and treatment regimen simultaneously.
Considering the four treatments simultaneously demonstrates that discontinuous ranibizumab is ‘strongly
dominated’ by both continuous and discontinuous bevacizumab, that is patients in this group accrued
(slightly) fewer QALYs and (substantially) higher costs (Figure 42). Of the three non-dominated treatments
that lie on the cost-effectiveness frontier (the black line in Figure 42), continuous bevacizumab costs
£30,220 per QALY gained compared with discontinuous bevacizumab, whereas continuous ranibizumab
costs £3.5M per QALY gained compared with continuous bevacizumab. Discontinuous bevacizumab is,
therefore, the most cost-effective of the four treatments evaluated in IVAN if the NHS is willing to pay no
more than £20,000–30,000 per QALY gained, although continuous bevacizumab would be considered the
most cost-effective strategy at ceiling ratios between £30,220 and £3.5M per QALY gained. However,
there remains substantial uncertainty around differences in QALYs between the four treatment strategies,
as shown by the substantial overlap in the distribution of QALYs in Figure 42; by contrast, the differences
in costs are substantial and statistically significant.
Figure 43 plots the probability that each treatment has highest net benefits across all four treatment
strategies against the ceiling ratio. The probability of each treatment having highest net benefits out of
the four strategies evaluated in IVAN can be read off the graph at any ceiling ratio. For example, at a
£20,000 per QALY ceiling ratio, there is a 63% chance that continuous bevacizumab has highest net
benefits and a 37% chance that discontinuous bevacizumab is best, whereas the probability of either
ranibizumab strategy having the highest net benefits is < 0.01%. Indeed, this analysis demonstrates that
we can be > 99.99% confident that neither continuous nor discontinuous ranibizumab is good value for
money unless the NHS are willing to pay > £60,000 per QALY gained.
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RESULTS OF THE ECONOMIC EVALUATION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
134
20
18
Continuous ranibizumab
Continuous bevacizumab
Discontinuous ranibizumab
Discontinuous bevacizumab
16
14
12
10
8
6
4
2
0
1.45 1.5 1.55 1.6 1.65 1.7
M
ea
n
 c
o
st
 p
er
 p
at
ie
n
t 
(o
ve
r 
2 
ye
ar
s)
 (
£0
00
)
Mean QALYs per patient (over 2 years)
FIGURE 42 Total costs against total QALYs for each of the four treatments. The pale crosses represent the mean
costs and mean QALYs for each of the four treatment strategies, while the smaller dots represent individual
bootstrap replicates. Bootstrap results for discontinuous bevacizumab are shown with blue dots to distinguish
them from the overlapping cluster representing continuous bevacizumab. The black line represents the
cost-effectiveness frontier.
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FIGURE 43 Cost-effectiveness acceptability curves for multiple comparisons based on comparisons between all
four treatment strategies. The thin dashed blue line that follows the curve for discontinuous bevacizumab at
ceiling ratios below £30,220 per QALY and then follows the curve for continuous bevacizumab (and is shifted
slightly upwards in the figure for clarity) represents the cost-effectiveness frontier, i.e. the probability that the
treatment maximising expected net benefits is best value for money. The vertical dashed line represents a ceiling
ratio of £20,000 per QALY gained.
DOI: 10.3310/hta19780 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 78
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Chakravarthy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
135
Sensitivity analyses
Thirty-four different sensitivity analyses were conducted to evaluate the impact of changing the
assumptions or methods used in the base-case analysis (see Table 31). The rationale and results of each
sensitivity analysis are discussed in turn.
The impact of a shorter time horizon was evaluated to assess whether or not costs and/or benefits
changed over time. Taking a 1-year time horizon and excluding costs and benefits accrued in year 2
reduced net benefits (as only 1 year of QALYs is included) but had minimal effect on the conclusions.
A complete case analysis excluding the 59 patients withdrawing from the study early and the 114 other
patients with missing data on any EQ-5D utilities (except after death) confirmed the base-case conclusion
that discontinuous bevacizumab is the most cost-effective strategy evaluated in IVAN. This analysis
suggests that the conclusions are not sensitive to the methods used to impute missing data, although this
analysis should be interpreted with caution, as it excludes 54% of patients with SAEs and over-represents
patients who died early in the study.
The base-case analysis used a variant on KMSA to exclude differences in deaths that investigators
considered not or unlikely to be related to study medication. If the Kaplan–Meier survival estimates
were based solely on the number of deaths observed in each treatment arm in each quarter (rather than
being based on the number of potentially drug-related deaths and a common rate of unrelated deaths),
the ICER for continuous bevacizumab versus discontinuous bevacizumab fell to £17,577 per QALY, making
continuous bevacizumab cost-effective.
Allowing for interactions in administration and monitoring costs as well as drug costs, medication/medical
service costs and QALYs had minimal effect, although including only statistically significant interactions
(namely those for drug cost but not those for QALYs or medication/medical service costs) decreased the ICER
for continuous bevacizumab compared with discontinuous bevacizumab to £25,110 per QALY gained.
The price of bevacizumab (£49 per dose in the base case) was varied over the range of prices charged by
different suppliers. Varying the cost over this range did not change the conclusions, although the ICER for
continuous bevacizumab compared with discontinuous bevacizumab was found to be £22,136 per QALY if
bevacizumab cost £30 per dose and £112,625 per QALY if bevacizumab cost £243 per dose (the list price
for a 4-ml vial used to treat colorectal cancer). Similarly, the price of ranibizumab was varied by ±25% and
reduced by 50% to evaluate the impact of different discounts that hospitals may receive off the list price.
Reducing the price of ranibizumab increased net benefits for ranibizumab-treated groups but did not
change the conclusion that we can be more than 99.99% confident that ranibizumab is poor value for
money compared with bevacizumab at a £20,000 per QALY ceiling ratio. Although there is a nationally
agreed discount price for ranibizumab, this is commercially sensitive, so could not be evaluated as a
sensitivity analysis; however, it is unlikely that the discount is > 50%. However, we were able to evaluate
the patient access scheme previously negotiated by NICE in the original 2008 NICE appraisal,91 in which
the manufacturer supplied ranibizumab free of charge after patients’ 14th injection; this increased net
benefits for continuous ranibizumab, but had less effect on discontinuous ranibizumab, as fewer patients
on discontinuous therapy had more than 14 injections and did not change the conclusions.
One-way sensitivity analysis was conducted to evaluate the impact of varying the difference in cost between
the two drugs on the ICER for continuous ranibizumab versus continuous bevacizumab (Figure 44). This
suggested that although reducing the price difference between the two drugs could reduce the ICER from
the base-case estimate of £3.5M per QALY gained, the price of ranibizumab would need to cost just
£63.46 per dose (£14.46 more than bevacizumab) to be cost-effective at a £20,000 per QALY ceiling ratio.
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The base-case analysis assumed, based on discussions with ophthalmologists, that no anti-VEGF
medication was wasted. However, within the trial 5.3% of ranibizumab doses and 15.9% of bevacizumab
doses dispensed were not administered to patients. The main reason for such wastage was that the
medication was dispensed by the pharmacy for patients who did not attend or did not need treatment,
and could not be given to other patients: either because of pharmacy regulations or preparation of the
medication for masked administration. Wastage also resulted from the careful monitoring of temperature
and storage conditions during transportation. The shelf life of the bevacizumab syringes after repackaging
by the compounding pharmacy at Liverpool also caused wastage early in the trial: initially the product had
an expiry time from manufacture of 14 days. After 15 months, this expiry time was increased to 90 days.
A sensitivity analysis using the wastage rates observed within the trial increased costs and reduced net
benefits, but did not change the conclusions. Furthermore, drug wastage in routine clinical practice is likely
to be minimal compared with that observed in the trial, as bevacizumab now has a longer shelf life and
drugs dispensed in routine clinics can more easily be administered to other patients if the intended patient
does not attend or does not need an injection.
We also conducted a sensitivity analysis using the HRG and reference cost estimates of the cost of
ophthalmology consultations or the HRG for minor vitreous procedures in place of the micro-costing estimates
used in the base-case analysis; this changed the costs for continuous treatment more than discontinuous
treatment, although discontinuous bevacizumab remained the most cost-effective treatment. Similarly, neither
halving nor doubling administration/monitoring costs changed the conclusions.
We also varied the assumptions used to identify which resources incurred in follow-up visits were driven by the
protocol rather than reflecting routine clinical practice. Including the cost of conducting OCT monthly, and
assuming that all patients would have FFA at visit 12, increased costs and reduced net benefits in all treatment
arms, but had a disproportionately greater effect in the discontinuous arm, increasing the ICER for continuous
bevacizumab compared with discontinuous bevacizumab to £52,000 per QALY. The base-case analysis
included the cost of FFAs conducted in the discontinuous arm to evaluate treatment failure criteria, in addition
to including the cost of FFA for a proportion of patients in the continuous arm at each visit. Excluding the cost
of all post-baseline FFAs increased the net benefits accrued in the continuous groups more than the
discontinuous groups, which meant that continuous bevacizumab (not discontinuous) became the most
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FIGURE 44 Two-way sensitivity analysis showing the impact of drug cost on the incremental cost-effectiveness of
continuous ranibizumab vs. continuous bevacizumab.
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cost-effective treatment, costing £1600 per QALY compared with discontinuous bevacizumab. Including
the cost of consultations (but not anti-VEGF medication) for visits that patients missed increased costs and
decreased net benefits, but did not change the conclusions.
The base-case analysis focused on hospitalisations and ambulatory consultations within 30 days of
expected AEs or SAEs; sensitivity analyses including a wider range of medical service costs reduced net
benefits slightly, but did not change the conclusions. Similarly, including VAT or changing the rate at
which costs and QALYs accrued in year 2 were discounted to adjust for time preference had no effect on
the conclusions.
However, measuring utilities using HUI3 rather than EQ-5D substantially changed the conclusions and
reduced all net benefits, as HUI3 utilities were around 16% lower than EQ-5D utilities, but followed a very
similar profile. When HUI3 utilities were used in place of EQ-5D, the difference in QALYs between
continuous and discontinuous bevacizumab was larger, and the ICER was decreased to £15,423 per QALY,
suggesting that continuous bevacizumab is the most cost-effective treatment considered in the analysis.
The difference in HUI3 QALYs between continuous ranibizumab and bevacizumab (0.088) was larger than
the non-inferiority margin (0.05) determining whether or not the comparison between drugs was based on
CMA or CUA; however, continuous ranibizumab, nonetheless, cost £170,742 per QALY gained compared
with continuous bevacizumab. Six other sensitivity analyses varying the methods used to estimate QALYs
were also conducted (see Appendix 4), although these had negligible effects.
The incidence of SAEs within IVAN was substantially lower than that observed in CATT.22 We therefore
evaluated the impact of doubling the impact of SAEs on QALYs and (simultaneously) doubling the total
cost of medication changes and medical service use costs associated with expected AEs and expected
SAEs. However, this had negligible impact on the results.
A final analysis using the cost assumptions most favourable to ranibizumab in combination confirmed the
base-case analysis finding that ranibizumab is highly unlikely to be good value for money.
Overall, none of the 34 sensitivity analyses changed the conclusion that we can be more than 99%
confident that ranibizumab is not cost-effective compared with bevacizumab, although three analyses
(using HUI3 utilities, including differences in deaths unrelated to treatment and assuming that FFA would
not be done after baseline) found continuous bevacizumab to be cost-effective compared with
discontinuous bevacizumab.
Subgroup analyses
The impact of six subgrouping variables was evaluated: baseline VA in the study eye ≥ 55 letters read;
baseline CNV size of six or more disc areas; ≥ 50% classic CNV; RAP present; ≥ 75 letters read by the
fellow eye at baseline; and VA in the study eye of > 5 letters better than the fellow eye at baseline. None
of these subgrouping variables had a statistically significant effect on treatment effects for drug costs,
administration/monitoring costs, medication/medical service costs or QALYs accrued in any quarter at the
0.0001 level that was identified using a Bonferroni correction. Incremental costs and QALYs for each
subgroup are therefore not shown.
However, some statistically significant effects were seen at the 0.01 level. In particular, in two 3-month
periods, the difference in drug cost between continuous and discontinuous treatment was greater in patients
with ≥ 55 letters VA in the study eye (p≤ 0.008), whereas in three quarters the difference in drug cost
between continuous and discontinuous treatment was smaller for patients with ≥ 50% classic CNV (p≤ 0.01).
However, these findings should be interpreted with caution as they could have arisen as a result of chance.
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Chapter 9 Discussion
Main findings, including meta-analyses
Visual function
After 2 years in the IVAN trial, the prespecified primary time point, the comparison of bevacizumab and
ranibizumab for BCVA, was inconclusive when judged against the prespecified non-inferiority margin of
3.5 letters. The comparison of continuous and discontinuous treatment regimens for BCVA was also
inconclusive. However, the MDs between groups, tending to favour ranibizumab and continuous treatment,
were small (< 2 letters) and estimated to within 2.4 letters.
Non-inferiority for both comparisons would have been established had we used the CATT22 non-inferiority
margin of 5 letters. Moreover, the treatment effects for BCVA for the drug comparison were homogeneous
across several head-to-head trials. The increased precision gained when all of the comparative effectiveness
trials that have been reported were included in a meta-analysis showed clearly that bevacizumab is
non-inferior to ranibizumab. However, only IVAN and CATT22 had follow-up to 2 years and are also the only
trials to have included arms for drug and treatment regimen comparisons. The treatment effects for BCVA
were consistent even when data from only IVAN and CATT22 were included for the drug comparisons.
However, the meta-analysis found that discontinuous treatment was inferior to continuous treatment.
The secondary visual function outcomes did not differ by drug. However, the differences in NVA and
contrast sensitivity by treatment regimen indicated that discontinuous treatment was inferior to continuous
treatment, consistent with the meta-analysis finding for BCVA. Taken together, these findings show that
continuous treatment every month gives slightly better visual function than discontinuous treatment. The
importance of these findings and their relevance to the patient is unclear, as the differences in secondary
visual function outcomes were not reflected in self-reported HRQoL and the difference in BCVA was
apparent only in the meta-analysis of IVAN and CATT22 data. Our view is that, although discontinuous
treatment is inferior to continuous treatment from a statistical perspective, the magnitude of the observed
difference is not clinically important or may not be perceived by patients.
Morphology
With respect to lesion morphology, there were no significant differences between drugs at 2 years, but
consistent differences for several morphology indices (lesion present; total lesion thickness at the fovea;
retinal plus SRF thickness at the fovea; any fluid on OCT; dye leakage on angiogram) favouring continuous
treatment. The meta-analysis of total lesion thickness at the fovea estimated this parameter more precisely.
The CATT 2-year report22 suggested differences between drugs and treatment regimens in the development
of new GA in the study eye during follow-up and we regraded colour and FA images in an attempt to
replicate this finding. We found no difference in the odds of developing new GA in the study eye between
drugs in the IVAN trial alone or when CATT22 and IVAN data were combined. However, our analysis showed
a consistent and substantial increase in the risk of developing new GA with continuous compared with
discontinuous treatment.
Patient-reported outcomes
There was no evidence at all of any clinically important differences in EQ-5D utility, macular disease-specific
quality of life or treatment satisfaction by drug or treatment regimen. The former two findings are consistent
with our view that the differences in BCVA and secondary visual function found in the comparisons between
treatment regimens may not translate into perceptible differences. The similarity of treatment satisfaction
with continuous and discontinuous treatment regimens implies that the differing frequency of injection did
not markedly influence treatment satisfaction.
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Safety
In the IVAN trial, there were no differences in the frequencies of deaths or SAEs between drugs. However,
we observed that mortality was higher at 2 years with discontinuous treatment than continuous treatment.
In meta-analyses of available safety data, there was a statistically significant difference in the risk of any
systemic SAE by drug, with bevacizumab tending to confer a higher risk. Although the pooled estimate is
strongly weighted by the CATT data (as in a previous meta-analysis of CATT and IVAN data93), the GEFAL42
and MANTA43 trials reported non-significant tendencies consistent with the CATT.22,96 The finding that SAEs
classified as gastrointestinal (a subset of any systemic SAE) occurred more often with bevacizumab than
ranibizumab, observed in IVAN and CATT,22,93 was not seen in four other trials that also compared the two
drugs42,43 (LUCAS, presented at the 2013 meeting of the American Association for Ophthalmology; BRAMD,
presented at the 2013 meeting of EURETINA). Nevertheless, in a post hoc meta-analysis including all of the
trials, the finding persisted because the CATT22 and IVAN trials contributed most of the information to
the analysis.
The rerandomisation that was undertaken in the CATT22 at the end of year 1 introduced an additional layer
of complexity in the study, which resulted in 2-year CATT22 data on SAE and deaths not being reported by
treatment regimen. Therefore, the meta-analysis of different treatment regimens that we performed included
only the 2-year IVAN data and 1-year data from CATT.22 This meta-analysis confirmed the finding that the odds
of mortality were approximately half for continuous compared with discontinuous treatment, with the OR for
the CATT 1-year data22 being very similar to the OR for the IVAN 2-year data. Interestingly, the meta-analysis
of the odds of any systemic SAE by treatment regimen also tended to favour continuous treatment, again with
the estimates from the two trials being similar. The comparisons of treatment regimens were not masked in
either trial, but it seems implausible that bias should lead to an increased frequency of SAEs with discontinuous
treatment. Given the almost universal implementation of some form of discontinuous treatment, these findings
are worrying and appear counterintuitive when viewed in a conventional dose–response framework. However,
in the context of biological therapies, the possibility of immunological sensitisation with intermittent dosing
needs to be considered.97 In addition, it is important to remember that one cannot easily relate the relative risk
between treatment regimens to a ‘control’ risk of mortality for the trial populations without any anti-VEGF
treatment; the estimated OR could imply a doubling in baseline risk with discontinuous treatment, or a halving
in baseline risk with continuous treatment.
Economic evaluation
The main finding from the economic evaluation is that ranibizumab is not cost-effective compared with
bevacizumab if the NHS is willing to pay up to £20,000–30,000 per QALY gained. Continuous ranibizumab
cost £3.5M per QALY gained compared with continuous bevacizumab. Discontinuous ranibizumab was
dominated by bevacizumab, being both more costly and accruing fewer QALYs. The conclusion that
ranibizumab is not cost-effective was robust across all sensitivity analyses, including an analysis halving
the ranibizumab price, doubling the bevacizumab price and allowing for the cost of managing unexpected
AEs and SAEs. The price of ranibizumab would need to be well under £70 per dose in order for it to
be cost-effective compared with bevacizumab. Our findings confirm previous threshold analyses by
Raftery et al.,98,99 which showed that the price of ranibizumab would have to be drastically reduced for it to
be cost-effective.
Assuming about 17,295 eyes are likely to require treatment for nAMD each year,100 and extrapolating from
the difference in cost between discontinuous ranibizumab and discontinuous bevacizumab at 1 year, we
estimate that switching all patients from ranibizumab to bevacizumab would save about £102M per year
(including 20% VAT).
The economic evaluation suggested that discontinuous bevacizumab is better value for money than
continuous bevacizumab unless the NHS is willing to pay ≥ £30,200 to gain a QALY. However, there was
substantial uncertainty around this estimate and we can at present be only 63% confident that discontinuous
bevacizumab represents best value for money at a £20,000 per QALY ceiling ratio. In particular, this analysis
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was sensitive to the assumptions used in the analysis. The cost-effectiveness of continuous bevacizumab
compared with discontinuous bevacizumab is likely to be particularly sensitive to the way that clinics monitor
patients and assess treatment failure, and to the relative cost of consultations for monitoring disease
progression and those for administering injections, which vary substantially between clinics.
Strengths and limitations
Applicability and validity of the IVAN trial findings
There are important strengths of the IVAN trial. It was pragmatic, having been carried out in the usual care
setting in many hospitals in the NHS, and so directly informs the use of anti-VEGF drugs in similar settings.
The factorial design was efficient and provided high statistical power for the primary outcome, despite the
fact that the IVAN trial had only half as many participants as CATT.22 We studied a range of secondary
functional outcomes that support the VA findings. Participants, professionals and research staff remained
masked to the drug being used with very few exceptions. Adherence to the randomised allocation of drug
and treatment regimen was excellent. Retention overall was good given the elderly population, with only
10% withdrawing over the course of the 2 years. Although over half of the participants missed one or more
visits, missed visits did not differ by group and most scheduled visits were attended. All participants who were
randomised and who had at least one injection in the trial were included in the analysis of the primary
outcome. We assessed the resources used to administer treatment and carried out a full health-economic
evaluation based on prospectively collected data on costs and QALYs.
We procured bevacizumab for the trial from a compounding pharmacy that manufactured single dose,
pre-filled syringes from aliquoting the drug from large-volume commercially available vials. Manufacturing
adhered to protocols for tests of potency and sterility approved by the MHRA. As many hospitals that treat
patients with bevacizumab do so by dispensing bevacizumab locally for immediate use (as opposed to
procuring a ‘manufactured’ product), our findings should be generalised only to bevacizumab sourced
from a manufacturing pharmacy. The manufacturing pharmacy should have quality control processes in
place to validate stability, potency and sterility that have been approved by a drug regulatory agency.
The interpretation of the meta-analyses is limited by the appropriateness of pooling of available trials.101 The
IVAN and CATT22 were planned to be similar in design, and we described our intention from the outset to
pool the findings from the two trials. One-year BCVA and safety results for other trials have been published42–44
or presented at major international meetings [LUCAS, presented at the 2013 meeting of the American
Association for Ophthalmology; BRAMD, presented at the 2013 meeting of EURETINA] in recent months.
We reasoned that the methods of data collection for these outcomes should be comparable across trials
(BCVA is a standard clinical assessment and recording of SAEs is subject to standard regulatory conditions
across jurisdictions) so have included data from these trials to ensure that our analyses are as relevant as
possible. We have included findings for the longest duration of follow-up available (1 or 2 years) because
all trial results show that VA remains effectively stable over this period. We would like to acknowledge that
the meta-analyses of safety were prompted by the IVAN and CATT22 data monitoring committees while the
trial was still in progress.
Unique design features of the IVAN trial: the ‘IVAN treatment regimen’
The IVAN trial included two design features that were unusual at the time and differed from the CATT22
(which was designed in parallel).
(a) All patients were treated (monthly) for the first 3 months.
(b) After the first 3 months, participants allocated to discontinuous treatment restarted treatment if the
lesion in the study eye met one or more of the retreatment criteria. The decision to restart treatment
initiated a further cycle of three injections over 3 months.
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We made the first decision because the ANCHOR and MARINA trials had shown clearly that most of the
benefit from ranibizumab was achieved in the first 3 months of treatment.7,8 In the CATT,22 all participants
had treatment on their first visit (when an active lesion had to be present in order for a participant to
be eligible) but, subsequently, a decision about the need for retreatment was made at each visit for
participants allocated to the prn treatment group.
We made the second decision because we wanted to ensure that participants had the least possible risk of
disadvantage from discontinuous treatment. We felt that this would remove some of the uncertainty about
treatment (for clinicians and patients) and reduce the need for diagnostic investigations compared with
higher drug cost/over treatment. Interestingly, it had the unforeseen benefit of avoiding the need to make a
decision about retreatment on the subsequent two monthly visits when treatment was mandated as part of
the 3-month cycle. At the outset, we were concerned that the IVAN discontinuous treatment regimen might
result in more treatment than strictly necessary, i.e. compared with the CATT22 prn treatment regimen.
In the event, the total number of injections required were very similar in the IVAN discontinuous
(median= 13 injections) and CATT22 prn (mean 13.3 injections) treatment regimens, suggesting that it
takes 3 months of treatment to make a reactivated lesion quiescent or that the cycle of three mandatory
injections over 3 months in some way defers lesion reactivation that would have occurred if only a single
treatment had been given. It is also plausible that clinicians withhold treatment when very subtle signs of
lesion activity are present. An alternative explanation may be that the tomographic outputs do not reveal
very low levels of lesion activity.
Our findings suggest that longer periods of lesion inactivity may arise as a consequence of using the
modified prn approach in IVAN, where retreatment decision making was restricted to a limited number of
visits. We had hypothesised that clinicians might not recognise subtle signs of lesion activity when present
and that this could induce variability in decision-making. Thus the IVAN design, which mandated treatment
in cycles of three on detecting signs of lesion activation, supports our aforementioned hypothesis. However,
it is important to point out that this discussion relates to an indirect (non-randomised) comparison and the
trial-specific differences between treatment regimens are within the precision of the estimated differences
in numbers of treatments. Anecdotally, the benefit of avoiding the need to review patients for two visits
appears to be attractive to ophthalmologists, as several have adopted 3-month cycles of treatment for
reactivated lesions, calling this the ‘IVAN regimen’.
Avoiding the need to review an eye for 2 months is one minor way to relieve some of the workload of
reviewing and treating patients with nAMD in busy clinics. The design of the CATT22 tested a different aspect
of the cost of treatment by rerandomising participants allocated to monthly treatment during year 1 to prn
treatment during year 2. This intervention largely failed, in that the VA of participants treated monthly in
year 1 and prn in year 2 converged during year 2 to the VA of participants treated prn in both years.
A continuing focus on workload and cost is vital in this area, as the total number of patients with nAMD
being treated or monitored has not yet reached a steady state.
Other benefits of the IVAN trial
The IVAN trial has many unique and important features. The IVAN trial is among the first trials of an
interventional medicinal product in the field of retina with a non-commercial sponsor, for which the
entire budget was obtained from NHS sources. It compared two biological agents made by the same
manufacturer yet with widely differing costs. It has had a plethora of spin-off benefits. It facilitated the
establishment of a network of investigators and clinical sites, who had previously never engaged in
research of this nature, increasing research expertise in several ophthalmology departments that had not
previously taken part in a RCT. The strength of the network is evidenced by excellent attendance of IVAN
principal investigators at a special session of the last investigators’ meeting to identify and prioritise new
trials that this network could undertake. Through their involvement in the construction of the study
protocol, development of the algorithms for retreatment and participation in the conduct of the trial, many
of the IVAN investigators have enhanced both their research skills and their understanding of the disease
itself. This process continues as IVAN investigators contribute to the scientific outputs arising from
this study.
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The IVAN trial also helped to increase clinical expertise directly. As in the case of the VPDT cohort study,92
the IVAN trial required investment in training of investigators and their teams. Although intravitreal
injection of a drug is a standard clinical technique, expertise in the detailed assessment of retinal images in
order to make decisions about the need for retreatment was not. We also believe that the attention to
detail required when doing research and providing training for non-medical staff, for example in
photography and visual function assessment, enhanced general professional skills. Training was
undertaken through initial meetings when developing the protocol, visits to hospitals when initiating
and monitoring and a programme of regular investigators’ meetings. In these meetings, comparing
clinical and reading centre image assessments became a standard tool to improve consensus about
retreatment decisions.
The pragmatism of the IVAN trial drew on the unique nature of the NHS. Some participating sites were
teaching hospitals and others were not. About half of the local principal investigators had experience of
participating in commercial trials but very few had participated in a non-commercial trial. About half of the
local research teams were assembled de novo to carry out the IVAN trial. Not surprisingly, therefore,
participants were managed in diverse ways at participating sites, for example being reviewed and treated
in usual care nAMD/retina clinics or in dedicated research clinics.
The status of the IVAN trial as a NIHR-funded study was also hugely beneficial, as the concurrent
development of the Ophthalmology specialty group of the UK Clinical Research Network was instrumental
in ensuring appropriate resourcing and targeting of support to research-naive and less experienced clinical
sites. The arrangements and structure of IVAN led to enhanced collaborative working across the devolved
nations and was instrumental in expanding the network activities.
The complex contracting and financing arrangements were developed both as a consequence of our
previous experience in the VPDT cohort study92 and as a matter of necessity for research governance.
Although they may appear complicated, in general the arrangements worked despite the need for good
communication across organisations. During the course of the trial, because some sites were able to recruit
and manage more participants than others, service level agreements with health board/primary care trusts
often needed renegotiation with respect to the number of patients for which the provider organisations
were willing to pay. This typically involved the CTEU requesting approval to invoice for a higher number
than originally contracted, and involved the contract team in Belfast issuing a revised agreement and
receiving the signed copy back. At times, this caused delays. If we were to use a similar system again,
we would want to find a way of managing contracts that was less cumbersome. Nevertheless, the overall
success of the arrangement is demonstrated by the fact that the bank obtained all of the treatment and
service support costs to reimburse participating trusts, purchase the drugs for the trial, and pay for other
costs, such as drug transport through the service-level agreements.
Making all reimbursement for treatment in the trial (research, service support and treatment costs)
conditional on supplying the data and complying with the protocol was also a success, probably because the
treatment costs represented a large amount of money that was due to the participating trusts. Through
the trial database, the CTEU was able to produce regular reports of activity by participating trust; these
reports were shared both with the participating trusts and the bank, and provided the basis for invoices to
the bank. The criteria for classifying activity as complete (and hence payment due) were not very sophisticated,
and activity was sometimes reimbursed before the data for a visit was complete. For example, imaging for a
particular visit may have been deferred because of an equipment failure but payment for the visit was
authorised. The investment in information and technology made by the CTEU during the course of the trial
has allowed the CTEU to improve the sophistication of the checks before authorising payment in a more
recent trial (requiring that all data validation queries for a particular trial activity must be resolved).
DOI: 10.3310/hta19780 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 78
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Chakravarthy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
143
Research in context
Comparisons of outcomes by drug
Overall, the findings for the IVAN trial and CATT,22 and other recent trials, consistently show that
bevacizumab has very similar efficacy to ranibizumab. With seven trials of the head-to-head comparison
between ranibizumab and bevacizumab having now reported, the lower confidence limit of the pooled
estimate for the difference is < 2 letters.
With respect to safety, even with data from most of the seven head-to-head trials, it is still not possible to
rule out clinically important differences. What is clear is that ocular SAEs are extremely rare and do not
differ by drug. There is also no differential risk of an ATE by drug, although there is still uncertainty about
whether or not regular intraocular injections of an anti-VEGF drug increase this risk compared with not
having injections. In the first year of the IVAN trial, such events appeared more frequent in patients treated
with ranibizumab, but this finding disappeared over the course of year 2; the GEFAL42 and LUCAS
(presented at 2013 meeting of the American Association for Ophthalmology) trials contributed relatively
little information, so the pooled estimate is mainly influenced by the CATT and IVAN data.
However, there is uncertainty about SAEs that were not expected at the outset and which were not
generally considered to be related to the drugs by IVAN investigators at the time they arose. Two
persistent safety signals emerge from the meta-analyses, namely an increased risk of (1) any systemic SAE
and (2) a gastrointestinal SAE (i.e. a SAE classified as MedDRA gastrointestinal system organ class). These
two findings are complicated by the fact that gastrointestinal SAEs are a subset of all systemic SAEs and,
hence, we discuss the gastrointestinal SAEs first.
The findings for gastrointestinal SAEs appear to differ in CATT and IVAN compared with the more recent
trials (see Figure 31), with a clear safety signal from the former but not the latter. The combined size of the
CATT and IVAN trials means that the fixed effects combined estimate is statistically significant. Although
the data for CATT and IVAN are for 2 years’ duration of follow-up, not 1 year, this does not explain the
difference because the increased risk of these events was apparent at 1 year in both IVAN and CATT.
However, the events are collectively quite rare (1–2% per year, less frequent than events in some other
system organ classes; gastrointestinal SAEs have incidence of about 2%, with incidences of other system
organ classes ranging from 0% to 5%),23,26 and do not appear to increase the risk of death (as neither
CATT or IVAN found any suggestion that bevacizumab increased mortality) and are extremely diverse
(see Table 18).23 To the extent that an underlying mechanism for these events has not been advanced, it is
difficult to interpret their clinical importance or speculate about the possible underlying mechanisms.
The finding that the risk of any SAE is increased by bevacizumab is similarly complicated to understand.
In IVAN, gastrointestinal events were the main driver of the difference (see Figure 29). This does not appear
to have been so clearly the case in the CATT, where the incidences of SAEs classed as ‘infections and
infestations’ and ‘surgical and medical procedures’ were also higher in participants treated with bevacizumab.23
Incidences by system organ class in the GEFAL42 and MANTA43 trials were less clearly reported but do not
appear to show any pattern that fits with the CATT data.
Two earlier systematic reviews investigating the safety of anti-VEGF drugs do not include most of the
current evidence from head-to-head trials.102,103 Other findings about the relative safety of ranibizumab
and bevacizumab have been reported, based on large analyses of routinely obtained data.104–106 However,
these reports focused on cardiovascular arterial thrombotic events. Their findings vary and are at risk
of confounding.101
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
144
Comparisons of outcomes by treatment regimens
Only the CATT and IVAN trials compared continuous/monthly treatment with discontinuous/prn treatment
regimens. Nevertheless, the estimates of efficacy were remarkably consistent for both visual function and
lesion morphology outcomes, showing that discontinuous treatment is slightly, but statistically significantly,
inferior to continuous treatment. The only exception to this pattern of findings was for the lesion morphology
outcome of new GA, the risk of which is consistently higher with continuous treatment. As described above,
with respect to safety, continuous treatment appears to protect against all-cause mortality; this finding is
counterintuitive but was observed, also consistently, in both the IVAN trial and CATT.
We have already reported our opinion that the slightly better visual function with continuous compared
with discontinuous treatment is unlikely to be of importance to patients. The finding that continuous
treatment carries a 50% increase in the risk of developing new GA reinforces this view; as GA is itself
potentially sight threatening, the visual benefit from continuous treatment may not anyway be maintained
in the long term.
The finding that mortality was higher at 2 years with discontinuous treatment than continuous treatment
is worrying. The uncertainty of this finding is about the same as for the possible association between
bevacizumab and SAEs classified as gastrointestinal22,26 (see Figures 28 and 29). [The fact that there was an
increase in the risk of any systemic SAE (0.81; p= 0·063) with discontinuous treatment is partly explained
by the fact that deaths were included as systemic SAEs.] The comparisons of discontinuous and continuous
regimens were not masked in either trial, but it seems implausible that bias should lead to an increased
frequency of SAEs with discontinuous treatment. However, as previously stated, the possibility of
intermittent dosing with a biological therapy causing immunological sensitisation has been suggested.
One might argue – given that most of the data described in this report are in the public domain and have
been widely debated by ophthalmologists – that adoption into clinical practice is a pragmatic ‘test’ of
safety. Use of bevacizumab to treat nAMD clearly passes this test, as there is no apparent reluctance to use
the drug in many countries in the world. In the USA, bevacizumab was first used to treat nAMD before
ranibizumab was licensed, and its use continued at about the same level as ranibizumab up to the end of
2006.104 If anything, use of bevacizumab has increased recently following changes in the arrangements for
reimbursing ophthalmologists under Medicare.
Limitations of findings about the safety of drugs and treatment regimens
When reviewing the safety data, it is important to bear in mind that none of the trials had satisfactory
power to detect differences in safety outcomes. Trials, even those carried out to support marketing
authorisations, are usually unable to rule out the possibility of a clinically important difference in a safety
outcome. Even with data from multiple trials, the total sample size is still relatively small in relation to
detecting a clinically important difference in a rare SAE. Nevertheless, there are now many more data for
trial participants with nAMD randomised to the head-to-head comparison between ranibizumab and
bevacizumab (n> 3300) than for the comparisons between ranibizumab and sham treatment or VPDT
(ANCHOR+MARINA+ FOCUS*+ PIER= 1485) or between aflibercept (Eylea, Bayer) and ranibizumab
[VIEW** 1+ VIEW 2 (n= 1240)= 2457].7,8,107–109 Interpretation of safety data may have been clouded by
the emergence of possible signals not consistent with expectation, which has prompted many statistical
comparisons. It is difficult to assign an appropriate level of significance to these statistical tests and the
possible safety signals that have arisen need to be interpreted in the knowledge that a large number of
comparisons have been carried out which were not prespecified.
*Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular
degeneration; **VEGF Trap-Eye: Investigation of Efficacy and Safety in Wet AMD.
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Lessons learned and implications for practice
The IVAN trial aimed to be pragmatic and achieved this at least with respect to the setting of usual NHS
care and the inclusiveness of the population. However, in another respect it was probably too closely
modelled on commercially sponsored Phase III trials carried out to obtain evidence to support applications
for marketing authorisation. This model was largely adopted because it was that which several IVAN
investigators and their local teams were familiar and because the trial was considered at the outset to be
‘high risk’, requiring extreme diligence and care from a research governance perspective. We were also
aware that, when the trial was being set up, a campaign of disinformation was mounted with a view to
discrediting the trial among potential investigators (www.ivan-trial.co.uk). Future retina trials seeking to
answer important uncertainties about clinical practice face difficult choices. Decisions will inevitably be
influenced by the precise research question and funder [e.g. NIHR Efficacy and Mechanism Evaluation
(EME) vs. Health Technology Assessment (HTA) programmes] but the ophthalmological community has not
shifted much towards the pragmatic end of the spectrum by taking part in IVAN. The familiarity of
commercially sponsored Phase III trials is likely to continue to influence future Chief Investigators to adopt
this template (regular monitoring, intensive scrutiny of multiple outcomes), which may not always
be appropriate.
A crucial design decision that ophthalmology investigators need to make concerns the choice between
recruiting only one or both eyes. Most commercially sponsored trials recruit only a single study eye. This
decision can be justified on two main grounds: first, there is always a risk to the treated eye when using
an intervention about which relatively little is known and it is sensible to limit this risk exposure to only
one eye; second, in the context of an unlicensed medicinal product, the intervention is very unlikely to be
available to treat the fellow eye outside the trial (such treatment of the fellow eye is one risk of studying
a single eye).
These grounds are less applicable to non-commercial trials that are usually studying an intervention about
which quite a lot is known, which may be already being used in clinical practice or at least be available
if requested by a patient and in comparison with an active comparator. Neither option is straightforward. If
studying only one eye, decisions need to be made in advance about the number of data to be collected for
the fellow eye (e.g. depending on whether an intervention is topical or systemic), how to manage incident
disease in fellow eye, etc. A disadvantage of studying one eye is that it can lead to undue emphasis on the
effect of treatment on the eye, rather than the patient. If studying both eyes, decisions need to be made in
advance about whether or not patients with uniocular disease are eligible, whether patient or eye should be
randomised, whether or not there should be special considerations about safety when treating both eyes
(e.g. again depending on whether an intervention is topical or systemic). This last point is extremely pertinent
to the evaluation of anti-VEGF drugs. The commercial trials carried out for licensing purposes treated only
one eye and were careful not to inject ranibizumab more than once every 28 days. By contrast, in usual care,
ophthalmologists were quick to adopt the practice of treating both eyes, when indicated, at the same visit
without having carefully collected data about safety on which to base this strategy. It seems likely that this
decision was driven by convenience to patients and health services, as the disadvantages of the alternative,
namely alternate injection of each eye at 2-weekly intervals, are clear. Our experience suggests that, if
patients are appropriately counselled, they would wish to receive the same treatment to both eyes if the
second eye were to develop neovascular AMD during time on study; in terms of monitoring patient
outcomes, it would also make it far simpler if both eyes were randomised to the same treatment regimen. In
the IVAN trial, patients who developed nAMD in the fellow eye were treated with the standard of care which
was usually ranibizumab. The use of different drugs in the two eyes of some patients made it difficult to
interpret systemic AEs and data on quality of life.
Two major NIHR projects (this trial and the VPDT cohort study92) have now reported data to inform the
association between VA and HRQoL/utility in this population. Both have highlighted the extent to which
economic models used by NICE in technology appraisals of VPDT and ranibizumab1,91 have underestimated
the cost per QALY of the respective technologies by relying on a small US study about the disutility of sight
loss.110 Brown et al.110,111 elicited preferences directly from patients with AMD. Preferences were markedly
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skewed in contrast to scores on preference-based utility measures derived from societal valuations, an
observation that is consistent with some patients refusing to trade years of life for improved vision, and
raises concern about the validity of the method. When making comparisons of HRQoL across interventions
in different disease areas, it is more appropriate to value health states with preference weights from the
general population rather than specific groups.45,112
Using methods of determining utility recommended by NICE itself, it is now clear that the gradient of this
association is much shallower than previously reported. We strongly recommend that more robust recently
reported associations estimated from large data sets are used in future appraisals of interventions for
nAMD and, possibly, for other eye conditions. The finding reported here about the risk of developing
new GA, and evidence of deteriorating vision emerging from other long-term follow-up studies in trial
participants’ treatment with anti-VEGF drugs,113,114 also suggest that longer-term follow-up of IVAN
participants may be warranted, and future model-based economic evaluations assessing the
cost-effectiveness of interventions for chronic eye conditions should use a long time horizon and avoid
making unrealistic assumptions about the durability of treatment response.
Future research
Research to improve the clinical effectiveness and cost-effectiveness of
treatment for neovascular age-related macular degeneration
It seems unlikely that an inexpensive treatment (other than unlicensed use of bevacizumab) for nAMD will
emerge in the next 10 years. The most recent anti-VEGF option, aflibercept,108 has been priced at a very
similar level to ranibizumab, taking into account a halving of the dosing interval. Combinations of
anti-VEGF injections and intraocular brachytherapy (requiring vitrectomy) have been evaluated with
disappointing results115 (http://public.ukcrn.org.uk/search/StudyDetail.aspx?StudyID = 7680). An innovative,
stereotactic, low-voltage X-ray system is currently of interest.116 It is likely to require a hub-and-spoke
model of delivery (newly diagnosed patients attending a first visit at a hub centre and returning to a local
spoke centre for subsequent review and further anti-VEGF if required) because of the high capital cost and
maintenance of the device. If this method of delivering radiotherapy were to reduce markedly the need
for further anti-VEGF injections it could be a cost-effective way of reducing both drug costs and the
workload of managing patients with nAMD. However, the device has not yet been trialled and the
manufacturer is likely to price the device to undercut anti-VEGF drugs only marginally. Other interventions
that have shown promise include an inhibitor of platelet derived growth factor used in combination with
ranibizumab, or angiostatin (to induce vessel regression) used in combination with ranibizumab.
Not surprisingly, commercial interest in new ways to treat nAMD is focused on new products, as this is
how manufacturers generate profits. However, it is clear that there are major opportunities to achieve
savings for health services, and improved convenience and possibly HRQoL for patients, through research
on the delivery of nAMD care. Key research needs to be carried out to investigate different models of
service provision with a view to reducing workload to the Hospital Eye Service and inconvenience to
patients, and improving cost-effectiveness.
The current licence for ranibizumab describes a prn treatment regimen that was not evaluated in the two
trials carried out to support the application for marketing authorisation (both evaluated continuous
monthly injections over 2 years).7,8 Moreover, although the manufacturer of ranibizumab evaluated an
alternative regimen (three doses given over consecutive months at the start of treatment followed by
treatment once every 3 months), showing that this regimen had poorer efficacy,117 other dosing
frequencies have not been investigated in RCTs, only in single group studies.118 Manufacturers have a
vested interest in treatment regimens that maximise the use of treatment for tolerable safety, rather than
regimens that minimise treatment for non-inferior effectiveness.92 The opportunities are clear; simply
extending the treatment/review interval to 6 weeks rather than 4 weeks would reduce the number of
outpatient appointments by one-third. As many NHS hospitals have struggled to provide monthly
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appointments since the introduction of anti-VEGF therapy, nAMD care in the NHS over the last 5 years
represents a natural experiment on extending the treatment interval (by necessity). Therefore, there may be
an opportunity to investigate the effect of extending the treatment interval on BCVA observationally using
routinely collected data. Data on time-to-treatment failure (time to lesion reactivation), and BCVA at this
time, for IVAN participants allocated to the discontinuous treatment regimen (and for CATT participants
allocated to the prn treatment) are also likely to be useful to inform this question.
Ophthalmology departments in some NHS hospitals have experimented with ‘treat-and-extend’ regimens
to manage their workloads. This type of regimen is based on the assumption that the probability of lesion
reactivation reduces as the time since the lesion became quiescent increases, extending the time interval to
the next review appointment if the nAMD lesion remains inactive. The principle behind this strategy has
not been researched. Again data on time-to-treatment failure for IVAN and CATT participants allocated to
the discontinuous/prn treatment regimens are likely to be able to provide a test of this principle.
Continuous treatment regimens for nAMD are unlikely to be cost-effective in the UK as long as treatment
using ranibizumab or aflibercept remains mandated. However, a continuous regimen using bevacizumab
could be more cost-effective than discontinuous treatment, depending on the treatment interval
(see above) and the frequency of review visits, for example if review using retinal imaging technologies
were required only annually; if treatment decision-making were not required, there may be additional
opportunities to streamline the provision of treatment only, perhaps offering such clinics in locations more
convenient for patients.
A final important area of uncertainty concerns when to give up treating nAMD, which has not been
researched. This decision could be based on lesion morphology or visual function. There will always be
some patients who continue to lose vision despite treatment (estimated to be 5–10%7,8). The question is:
Under what circumstances is it no longer ‘worth’ (both in terms of inconvenience to the patient and cost
to health services) continuing to treat an eye that will not deteriorate much further? It may be that health
services should switch their effort to preserving vision in the fellow eye. Clearly, this issue needs to be
investigated with great sensitivity, focusing on the views of patients.
Research on the long-term consequences of antivascular endothelial growth
factor treatment for neovascular age-related macular degeneration
There is a dearth of information about the long-term consequences of anti-VEGF treatment for nAMD.
The importance of such information is highlighted by our findings, and those of the CATT, about the
development of new GA; although this adverse effect did not appear to impact on BCVA during 2 years
after starting treatment, it would be expected to reduce BCVA eventually.
Two open-label industry-sponsored studies have followed up participants involved in the clinical trials that
were undertaken to support marketing authorisations for ranibizumab, namely HORIZON114 (following up
participants in the ANCHOR, MARINA and FOCUS trials)7,8,107 and SECURE113 (following up participants in
the SUSTAIN and EXCITE trials118,119). These extension studies observed a decrease in the VA benefit of
ranibizumab in the long term. Given the findings about the development of new GA in the course of the
CATT and IVAN trial, we hypothesise that this gradual fall-off in the benefit can be attributed to atrophy of
the macular tissue, which is a component of the disease process itself but could also be accentuated and
accelerated by anti-VEGF treatment. Unfortunately, both HORIZON and SECURE suffer from a number of
limitations: (1) criteria for treatment during follow-up were inconsistently applied; (2) treatment regimens
used in these initial trials were ‘continuous’ (monthly) and therefore there is no opportunity to examine for
possible preconditioning by discontinuously administered treatment at disease inception; (3) there was low
recruitment to the follow-up studies (< 40% in SECURE) and or high attrition during follow-up (> 30%
among recruits to the follow-up studies in HORIZON); and (4) the primary objective of these follow-up
studies was to document long-term safety.
DISCUSSION
NIHR Journals Library www.journalslibrary.nihr.ac.uk
148
Research to validate standard measures of utility in people with vision loss
The lack of impact of effective treatment on utility (measured using methods recommended by NICE) is a
key lesson learned in the trial. It remains unclear whether or not this finding reflects inadequacies in the
method, for example lack of sensitivity of the EQ-5D to loss of visual function, or truly represents a
relatively minor impact on utility compared with treatments for other conditions commonly associated with
pain or loss of mobility, for example coronary artery bypass grafting120 or total knee or hip replacement.121
Given the importance of valid measures of utility in economic models to estimate the cost-effectiveness of
treatments for nAMD, and the likelihood of new technologies emerging in the near future, we consider
that investigating which of these explanations is correct should be a research priority.
Further health-economic research
There are three areas of further health-economic research that would be worthwhile.
First, the consultation costs micro-costed within the trial varied between centres and differed from readily
available costs, such as reference costs or HRGs. Although sensitivity analyses showed that the conclusions
were unaffected by the source of consultation costs, further research to identify the reasons for these
differences would be informative.
Second, the analysis in this report focused on costs incurred by the NHS. In reality, treatment for nAMD is
also likely to improve working patients’ productivity, reduce their need for personal and social care, and
impose costs on patients and their families when attending treatment, especially in centres running a
‘two-stop’ service with separate injection and monitoring clinics. Therefore, it would be useful for future
studies to explicitly examine the non-NHS costs associated with different models of clinic organisation.
Third, we measured quality of life using the three-level EQ-5D questionnaire because the five-level EQ-5D
was not available when IVAN participants were recruited. One of the reasons for developing the five-level
version was because of the concern that the three-level version may be too insensitive for some conditions,
such as eye disease. A vision-specific bolt-on to the three-level EQ-5D has also been developed.122 It would,
therefore, be interesting to investigate the five-level questionnaire and vision-specific bolt-on in current eye
trials to see whether or not these discriminate changes in HRQoL better than the three-level questionnaire.
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Chapter 10 Conclusion
Anti-VEGF drugs look set to remain the mainstay treatment for nAMD for the foreseeable future,despite the rapid increase in potential new treatments. Concerns have been raised about the safety
of aflibercept,123 despite evidence of efficacy,108 and the results of brachytherapy in combination with
anti-VEGF drugs have so far been disappointing.115 Photodynamic therapy or radiotherapy options used in
combination might yet allow reductions in treatment frequency, but it will be important to study these
treatment strategies in comparison with monthly treatment, in view of our finding of possible risks of
discontinuous treatment.
It is instructive to reflect on the choice of drug and treatment regimen if there were no resource
constraints. With respect to drug, given the possibility of poorer safety of bevacizumab, ranibizumab would
probably be preferred. With respect to treatment regimen, the choice is not so obvious, because of the
possibility of increased mortality with discontinuous treatment and the increased risk of developing new
GA with continuous treatment, as well as the risks of many more intraocular injections. However, within a
health-care system that has a fixed budget, such as the NHS, the resources required to provide treatment
have to be considered in the wider context of competing demands on resources, both to treat other eye
diseases and non-eye diseases, such as cancer and CVD. It is therefore essential that treatment decisions
take account of cost and cost-effectiveness, as well as clinical efficacy and safety. Our economic evaluation
demonstrates that ranibizumab represents very poor value for money, costing £3.5M per QALY gained
compared with bevacizumab. The analysis also suggested that discontinuous bevacizumab is likely to be
better value for money than continuous bevacizumab.
In conclusion, the IVAN trial and meta-analyses of data from other trials show that the choice of anti-VEGF
treatment strategy is less straightforward than previously thought. Bevacizumab and ranibizumab have
similar efficacy and can be considered equivalent in this respect in the treatment of nAMD, although
bevacizumab provides much better value for money. The possibility of an increased risk of death with
discontinuous treatment should probably outweigh the increased risk of new GA that was observed with
continuous treatment. The slightly better functional outcomes with continuous treatment are a bonus.
Continuous treatment also avoids the need to monitor disease activity on every visit. An important
consideration when choosing to give treatment continuously is the high cost of ranibizumab which, at a
cost of £270,000 per QALY gained compared with discontinuous ranibizumab, may be unaffordable for
publicly funded health systems.
It is disappointing that the findings of the IVAN trial have not changed practice in the UK, where it has been
argued that legislation prohibits the use of an unlicensed treatment to treat a condition for which another
product has a licensed indication. Despite the investment in the IVAN trial, the UK has one of the lowest uses
of bevacizumab for ophthalmic conditions among comparable developed countries. Nevertheless, the
findings of the IVAN trial may have indirectly contributed to benefits to the NHS, for example through patient
access schemes that are being offered to the NHS.
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protocol describing the purpose, methods and analysis of the secondary research, for example a protocol
for a Cochrane systematic review.
However, potential users of the IVAN data set should note that the raw data are extremely complicated,
spanning a large number of visits per patient. For example, the database functionality did not support a
decision made during the conduct of the trial to allow deferral of collection of some data to a later visit if
visit was missed. Code to manage these issues is, typically, contained within existing analysis programmes.
Hence there is no single ‘flat’ file (or multiple flat files) with a defined data dictionary; expert knowledge of
the data structure is required to interrogate the database. It would be possible to create a set of definitive
files for export to a third party, if funding were available (this would be required as the data do not exist in
such a format). The Clinical Trials and Evaluation Unit would prefer to enter into a formal collaboration
with a third party wanting to investigate a new research question using the IVAN data.
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Appendix 1 IVAN study investigators
Trial sites
Aintree University Hospital
Investigators: Mr Ahmed Kamal, Thomas Papathomas and Ahmed Khalil.
Research team: Pauline Guinness, Richard Hancock, Maria Dangler-Harles, Jane Blocksage and
Samantha Lorenson.
Aston University, Birmingham;a Optegra Birmingham Eye Hospitalb
Investigators: Mr JM Gibson,a Katie Pedwella and Jane Pitt.b
Research team: Ajith Kumar, S Al-Husainy, S Sreekantam, M Hanratty and Tara Clark.
Queen’s University Belfast;a Belfast Health and Social Care Trustb
Investigators: Professor Usha Chakravarthy,a Dr Lisa Kellyb and Dr Karen Gilvray.b
Research team: Ms Pamela Jamison, Mrs Georgina Sterret, Mr Vittorio Silvestri, Dr Deirdre Burns,
Ms Rebecca Denham, Mrs Joanne Grattan, Mrs Teresa Rice and Mrs Lenore Ponisi.
Aston University, Birmingham;a Birmingham and Midland Eye Centreb
Investigators: Mr JM Gibson,a Katherine Brownb and Bethan Swain.b
Research team: A Kumar, G Bliss, P Cikatricis and K Damer.
Royal Blackburn Hospital
Investigators: Mrs Salwa Abugreen, Mohamed Alarbie and Debra Myerscough.
Research team: H Patel, N Nixon, M Anderson, T Thompson and P Richardson.
Bradford Teaching Hospitals NHS Foundation Trust
Investigators: Mr Faruque Ghanchi, Mrs Helen Devonport and Miss Nicci Atkinson.
Research team: Julie Dixon, Tony Dook, Cara Phillips, Tomas Cudrnak, Charlotte Hazel and Mary Elliott.
Sussex Eye Hospital
Investigators: Mr Anthony Casswell, Dr Gek Ong and Mr Edward Hughes.
Research team: Mrs Susan Bennett, Mr Nick White, Mrs Catriona Gardiner, Mr Stephen Turner and
Mrs Tenesa Sargent.
Bristol Eye Hospital
Investigators: Miss Claire Bailey.
Cambridge University Hospitals NHS Foundation Trust
Investigators: Mr Douglas Newman and Mr Kevin McNally.
Research team: Haris Papanikolaou, Dawn Russell-Hermanns, Katherine Martin and Jo Fielden.
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Frimley Park Hospital NHS Foundation Trust
Investigators: Mrs Geeta Menon, Mrs Manju Chandran and Mr Gulrez Ansari.
Research team: Mrs Bhavani Mathapati, Mr Nitin Jain, Mrs Lorraine North, Mrs Jincy Jose and
Nadeem Rob.
The Queen Elizabeth Hospital, King’s Lynn NHS Foundation Trust
Investigators: Mr R J Pushapanathan and Mr I Ali.
Department of Eye and Vision Science, Institute of Ageing and Chronic
Disease, University of Liverpool;a St Paul’s Eye Unit, Royal Liverpool and
Broadgreen University Hospitals NHS Trustb
Investigators: Professor Simon P Harding,a Sandra Taylorb and Valerie Tompkin.b
Research team: Karen Hawkins, Jerry Sharp, Stephen Pearson, Martin Hodgson, William Hooley and
Gillian Lewis.
Maidstone Hospital
Investigators: Mr Frank Ahfat and Mr Luke Membrey.
Research team: Mrs Margaret Gurney, Mr Clive Wood, Dr Shabeeba Hannan, Mr Syed Idris Haider and
Mr Paul Adley.
Central Manchester University Hospitals NHS Foundation Trust,
Manchester Academic Health Sciences Centre & School of Biomedicine,
University of Manchester
Investigators: Mr Paul N Bishop and Tariq M Aslam.
Research team: Ekaterina Varimezova-Georgieva.
Newcastle upon Tyne Hospital Foundation Trust
Investigators: Mr S James Talks and Rajeev Kak.
Research team: Alan Branon, Kapka Nenova and Kevin Gales.
Nottingham University Hospitals NHS Trust
Investigator: Mr Alexander Foss.
Research team: Karen Armstrong-Owen.
Oxford Eye Hospital, Oxford University Hospitals
Investigators: Miss Susan Downes, Miss Shahrnaz Izadi and Mr Robert Purbrick.
Research team: Mrs Alexina Fantato, Mrs Ivy Samuel, Miss Vicky Hart, Mrs Anna Rudenko, Mr Lewis Smith,
Mr Charles Cottriall and Miss Paula Hedges.
Sheffield Teaching Hospitals NHS Foundation Trust;a South Warwickshire
NHS Foundation Trustb
Investigators: Mr Christopher Brand,a Dr Hibba Abdulkarim,a Mrs Uma Thakur.b
Research team: Mrs Helen Pokora, Mr Andy Jubb, Mrs Katy Kelly, Mr Fahd Quhill, Mrs Mary Freeman.
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Southend University Hospital NHS Foundation Trust
Investigators: Mr Niral Karia and Mr A Krishnan.
Research team: Ms Maria Shipman, Mr John Williams and Mr Chris Johnson.
Faculty of Medicine, University of Southampton;a Wellcome Trust Clinical
Research Facility, University Hospital Southampton NHS Foundation Trust;b
Southampton Eye Unit, University Hospital Southampton NHS
Foundation Trustc
Investigators: Professor Andrew John Lotery,a Marie Anne Nelsonb and Suresh Thulasidharan.c
Research team: Claire O’Brien, Kevin Oxlade, Caitrin Watkins, Maria Gemenetzi and Gabriella De Salvo.
Institute of Genetic Medicine, Newcastle University;a Sunderland Eye
Infirmary, Sunderlandb
Investigators: Mr David Steel,a,b Eoghan Millarb and Vinna Manjunath.b
Research team: Steve Dodds, Shelagh Thomson, Martyn Hallowell, Hugh Harris and Paula Foley.
Torbay Hospital
Investigators: Mr Mick Cole, Yinka Osoba and Sanjay Dhir.
Research team: Annette Field, Sharon Criddle, Karin Tilley, Eddy Doyle and Debbie Knowles.
Royal Wolverhampton NHS Trust
Investigators: Mr Yit C Yang, Nirodhini Narendran and Swathi Paneerselvam.
Research team: Jas Purewal, Mary Stott, Bhogal Bhogal, Sharon Hughes and Gurminder Sahota,
Jenny Nosek.
Resource centres
Trial Management Centre, Clinical Trials and Evaluation Unit, University of Bristol: Professor Barnaby C Reeves,
Dr Lucy A Culliford, Dr Chris A Rogers, Dr Jodi Taylor, David Hutton, Rachel Nash, Lauren Scott,
Dr Alessandro Cardinali, Dr Michael Arnott, Ms Wendy Underwood and Jon Williams.
Health Economics Research Centre, University of Oxford: Dr Sarah Wordsworth, Ms Helen Dakin and
Ms Giselle Abangma.
Health Economist consultant to the trial: Professor James Raftery.
Macular disease-specific Patient-reported Outcome consultants to the trial: Professor Clare Bradley and
Dr Jan Mitchell.
Centre for Experimental Medicine, Queen’s University Belfast: Josephine Glenn and Philip Earle.
Reading Centre, Belfast; Queen’s University Belfast: Professor Usha Chakravarthy, Dr Alyson Muldrew,
Dr Liam Patton, Mrs Barbra Hamill, Mr Frank Picton and Mr Graham Young.
Reading Centre; Department of Eye and Vision Science, University of Liverpool; and St Paul’s Eye Unit,
Royal Liverpool University Hospitals Trust: Professor Simon Harding, Jayashree N Sahni, Pauline M Lenfestey,
David Parry and John Deane.
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Reading Centre, London; NIHR Biomedical Research Centre for Ophthalmology, at Moorfields Eye Hospital
NHS Foundation Trust; and UCL Institute of Ophthalmology: Dr Tunde Peto, Irene Leung and Peter Blows.
Manufacturing Pharmacy, Royal Liverpool and Broadgreen University Hospitals Trust: Shakeel Herwitker.
National Health Service (NHS) Public Health Consultant, negotiating contracts for treatment costs with
Primary Care NHS Trusts: Dr Daphne Austin.
Comprehensive Clinical Research Network and Health and Social Care Research and Development
Northern Ireland: provision of research support costs.
Participating primary care NHS trusts
Ashton Leigh & Wigan.
Bath & North Somerset.
Birmingham East & North.
Blackburn with Darwen.
Bradford & Airedale.
Brighton & Hove.
Bristol.
Bury.
Cambridge.
Central & Eastern Cheshire.
Central Lancashire.
Cornwall & Isles of Scilly.
County Durham.
Devon.
Dudley.
East & North Hertfordshire.
East Berkshire.
East Coast & Kent.
East Health & Social Services Board, Northern Ireland (HSSB, NI).
East Lancashire.
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East Sussex Downs & Weald.
Halton & St Helens.
Hampshire.
Hastings & Rother.
Heart of Birmingham.
Knowsley.
Liverpool.
Manchester (East Lancashire).
Medway.
Newcastle.
Norfolk.
North Cumbria.
North HSSB, NI.
North Somerset.
North Tyneside.
North Yorkshire & Yorkshire.
Northumberland.
Nottingham.
Oxford.
Sandwell.
Sefton.
Sheffield (Barnsley).
Shropshire.
Solihull.
South Birmingham.
South East Essex.
South Gloucestershire.
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South HSSB, NI.
South Staffordshire.
Southampton City.
Sunderland.
Surrey.
Torbay Care Trust.
Walsall.
Warrington.
Warwickshire.
West Berkshire.
West Cheshire.
West HSSB, NI.
West Kent.
West Sussex.
Wirral.
Wolverhampton City.
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Appendix 2 IVAN committees
IVAN Data Monitoring and Safety Committee
Professor Sheila Bird (chairperson), Dr Hugh McIntyre, Mr Richard Wormald and Mr Roger Gray.
IVAN Trial Steering Committee
Mr John Sparrow (chairperson), Ms Helen Jackman, Mr Robert Coates, Professor Andrew Dick,
Dr Sue Richards, Professor Usha Chakravarthy, Professor Simon Harding, Dr Barnaby Reeves,
Dr Lucy Culliford, Dr Peter Davidson and Professor Ian Young.
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Appendix 3 Additional data tables
TABLE 32 Further details on protocol deviations
Type of breach Allocated treatment group Further details
Did not receive allocated
drug
Bevacizumab continuous Patient given ranibizumab instead of bevacizumab at visit 11
Ranibizumab continuous Patient given bevacizumab instead of ranibizumab at visit 9
Patient did not receive
allocated regimen
Ranibizumab discontinuous Patient treated as continuous throughout the study
Patient ineligible but
treated
Ranibizumab continuous Exudative AMD not present at visit 0
Ranibizumab discontinuous Exudative AMD not present at visit 0
Ranibizumab discontinuous Exudative AMD not present at visit 0
Ranibizumab discontinuous Exudative AMD not present at visit 0
Bevacizumab continuous Exudative AMD not present at visit 0
Bevacizumab discontinuous Exudative AMD not present at visit 0
Bevacizumab discontinuous Exudative AMD not present at visit 0
Bevacizumab discontinuous Exudative AMD not present at visit 0
Bevacizumab discontinuous Patient had BCVA of < 25 letters at visit 0
Source: © 2013 Chakravarthy et al.93 Open Access article distributed under the terms of CC-BY-NC-SA
(http://creativecommons.org/licenses/by-nc-sa/3.0/). Published by Elsevier Ltd.
Eligibility criteria were not met in nine patients. One patient read < 25 letters and eight patients did not
meet the angiographic eligibility criteria, although two of these had fluid on OCT, indicative of an active
lesion. Of the remaining six patients, two had early drusen – but did not have exudative lesions – and four
were misdiagnosed.
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FIGURE 45 Binocular vision by visit (a) by drug and (b) by treatment regimen. The circles indicate the median and
the bars indicate the IQR. The numbers in parentheses are the number of observations.
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Interactions:
p = 0.38
Baseline DVA:
(a)
Study eye >5 letters better (n = 159)
Study eye < 5 letters better (n = 434)
–8 –6 –4 –2 0 2 4 6 8
Favours bevacizumab
Mean difference (95% CI)
Favours ranibizumab
Interactions:
p = 0.99
Baseline DVA:
(b)
Study eye > 5 letters better (n = 159)
Study eye < 5 letters better (n = 434)
–8 –6 –4 –2 0 2 4 6 8
Favours discontinuous
Mean difference (95% CI)
Favours continuous
FIGURE 46 Best corrected distance visual acuity in the study eye at 2 years by subgroup, with baseline BCVA in
study eye better than fellow eye vs. the same or worse (a) by drug and (b) by treatment regimen. Negative values
of MD reflect a better mean VA in the ranibizumab or continuous groups. Difference is estimated using data from
visits 0, 3, 6, 9, 12, 15, 18, 21 and 24, adjusted for centre size. Circles=MD. 95% CIs are illustrated by horizontal
bars. The circle size is relative to the size of the subgroup.
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Interactions:
p = 0.97
Baseline haemorrhage:
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Mean difference (95% CI)
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Interactions:
p = 0.34
Baseline haemorrhage:
Present (n = 174)
Absent (n = 426)
–8 –6 –4 –2 0 2 4 6 8
Favours discontinuous
Mean difference (95% CI)
Favours continuous
FIGURE 47 Best corrected distance visual acuity in the study eye at 2 years by subgroup with haemorrhage in the
study eye at baseline present vs. absent (a) by drug and (b) by treatment regimen. Negative values of MD reflect a
better mean VA in the ranibizumab or continuous groups. Difference is estimated using data from visits 0, 3, 6, 9,
12, 15, 18, 21 and 24, adjusted for centre size. Circles=MD. 95% CIs are illustrated by horizontal bars. The circle
size is relative to the size of the subgroup.
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Appendix 4 Additional information about the
health-economic evaluation
MedDRA codes for the adverse events and serious adverse
events classed as expected in costing analyses
MedDRA codes counted as expected serious adverse events within the
economic evaluation
l Angina pectoris.
l Arthralgia.
l Cardiac arrest.
l Cardiac failure.
l Cardiovascular disorder.
l Cataract traumatic.
l Cerebrovascular accident.
l Coronary artery bypass.
l Deep-vein thrombosis (DVT).
l Endophthalmitis.
l Haemorrhage.
l Intraocular pressure (IOP) increased.
l Left ventricular failure.
l MI.
l Nausea.
l Pulmonary embolism.
l Retinal detachment.
l Retinal pigment epithelial tear.
l Retinal vein occlusion.
l Transient ischaemic attack.
l Upper respiratory tract infection.
l Urinary tract infection.
l Uveitis.
For the purposes of the costing analysis, death was not considered to be an expected SAE unless the
primary cause of death comprised one of the expected SAEs or AEs listed, to ensure that costs unrelated to
treatment (e.g. the cost of treating cancer) are excluded from the analysis regardless of whether or not the
patient died during the study period. Events with a MedDRA code of ‘Visual acuity reduced’ were not
counted as SAEs in any costing analysis.
MedDRA codes counted as expected adverse events within the
economic evaluation
l Angina pectoris.
l Arthralgia.
l Bronchitis.
l Cardiac disorder.
l Cataract.
l Cataract cortical.
l Cataract nuclear.
l Cataract operation.
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l Cataract traumatic.
l Conjunctival haemorrhage.
l Cough.
l Eye inflammation.
l Eye irritation.
l Eye pain.
l Haemorrhage.
l Hallucination, visual.
l Headache.
l Hypertension.
l Influenza.
l IOP increased.
l Lacrimation increased.
l Nasopharyngitis.
l Nausea.
l Pulmonary embolism.
l Retinal detachment.
l Retinal pigment epithelial tear.
l Retinal vein occlusion.
l Sinusitis.
l Transient ischaemic attack.
l Upper respiratory tract infection.
l Urinary tract infection.
l Uveitis.
l Visual impairment.
l Vitreous detachment.
l Vitreous floaters.
Events with a MedDRA code of ‘Visual acuity reduced’ were not counted as AEs in any costing analysis.
Methods used to estimate the utility profile around serious
adverse events and estimate quality-adjusted life-years for
each patient
Within IVAN, EQ-5D and HUI3 utilities were measured at:
l 0, 3, 12 and 24 months (referred to hereafter as ‘scheduled’ time points)
l at study exit (if the patient chose to attend a full exit visit)
l at the next visit after SAEs or 15-letter drop in VA (referred to hereafter as ‘post-SAE measurements’)
l around 24 patients also completed EQ-5D at other times not planned in the trial protocol (referred to
hereafter as ’unscheduled visits’).
As the base-case analysis calculates QALYs using EQ-5D utilities, this appendix refers to EQ-5D
measurements and utilities throughout. However, analyses were replicated using HUI3 utilities in a
sensitivity analysis utilising identical methodology.
Most trial-based economic evaluations measure utility at fixed time points and either assume that utility
changes linearly between assessments, or assume that utility remains constant at the level last observed
until the next measurement.124,125 A third assumption (assuming that utility changes midway between
EQ-5D measurements) is also cited in the literature,124,125 but is equivalent to assuming linear changes in
utility between measurements.
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In the absence of SAEs, we assumed that EQ-5D utility changed linearly between the baseline and
3 months, between 3 and 12 months and between 12 and 24 months (Figure 48a), which is supported by
the trends for VA (see Figure 15). However, within IVAN, patients also completed EQ-5D and HUI3 after
SAEs or ≥ 15-letter reductions in VA in order to more accurately estimate the impact of these events on
QALYs. We are not aware of any previous studies making such additional measurements, which introduce
unique challenges into the estimation of QALYs, although some papers have explicitly modelled the profile
of changes after specific events (e.g. hepatitis70 or chronic obstructive pulmonary disease exacerbations71).
Assuming that EQ-5D utility changed linearly between all observed utility measurements (see Figure 48b),
including those after SAEs, would not be clinically realistic and would overestimate the impact of SAEs by
assuming that utility began to fall immediately after the measurement preceding the SAE. Similarly,
applying a constant utility between the onset and resolution dates would be unrealistic and is likely to
underestimate the impact of SAEs. Patients’ estimates of the date their SAE resolved may also not
necessarily be reliable: particularly for intermittent symptoms, permanent conditions and cases in which
patients continue to have worse health than before the SAE until long after the main symptoms resolve.
For many SAEs, the EQ-5D profile is instead likely to be more similar to Figure 48c, with a sudden fall in
utility at the start of the event, followed by gradual recovery. EQ-5D utility is, therefore, at its worst point
on the date of onset. This profile is similar to that proposed by Luyten et al.70 and Spencer et al.71 after
acute hepatitis or chronic obstructive pulmonary disease exacerbations, although both studies also consider
logarithmic recovery curves that were not explored in the current study owing to their complexity.
As EQ-5D is rarely completed on the day of onset, as patients are generally too sick to attend the IVAN
clinic and the true resolution date is generally unknown, we used mixed models to estimate the rate of
recovery after different types of SAE. These recovery rates were then used to back-calculate the EQ-5D
utility on the day of SAE onset, and to identify the time and utility at which the line showing recovery from
the SAE crosses the line joining two other EQ-5D measurements. The base-case analysis allowed for the
reductions in quality of life associated with all SAEs, whether or not expected or unexpected, in order to
use all available EQ-5D data.
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FIGURE 48 Possible assumptions for estimating the EQ-5D profile around SAEs. (a) No SAE: linear interpolation
between routine HRQoL measurements – used in base-case and sensitivity analyses for patient with no SAEs;
(b) SAE: assume linear interpolation including point where SAE occurred (the ‘average’ assumption outlined by
Ganiats et al.124 used in sensitivity analyses; and (c) SAE: assume sudden drop in quality of life on the day when SAE
occurred, followed by a linear increase in quality of life between SAE and the time when the SAE effect ends –
base-case assumption.
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This appendix first outlines the methods used to estimate mixed models, followed by the methods used to
group SAEs into sets, then the methods used to impute missing data, and, finally, the methods and
assumptions used to calculate EQ-5D profiles and QALYs.
Mixed models of quality of life after serious adverse events
We defined a basic model of how SAEs affect EQ-5D utility and identified 19 prespecified variations on
this model, which were evaluated to assess whether or not they improved model fit [i.e. reduced Akaike
information criterion (AIC)]. The basic model assumed that each type of SAE that patients had experienced
reduced EQ-5D utility, but that utility rose by a fixed amount with each day that passed after each
type of SAE to allow for patients’ recovery. EQ-5D utility was also assumed to be a function of time, as
randomisation, treatment and baseline EQ-5D utility (centred by subtracting the mean baseline utility
across all patients):
EQ5Dij = Constanti þ βBL(BLEQ5Dij − MeanBLEQ5D)þ βTimeTimeij
þβbevacizumabBevacizumabiþ βDiscontinuousDiscontinuousi
þβInteractBevacizumabiDiscontinuousi
þβCVD;iCVDij þ βCVDrecoveryTimeSinceCVDij
þβOcular;iOcularij þ βOcularRecoveryTimeSinceOcularij
þβOther;iOtherij þ βOtherRecoveryTimeSinceOtherij,
(1)
where terms are defined in Appendix 4, Table 38.
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TABLE 36 Variables included in mixed models
Variable Definition Rationale
EQ-5D EQ-5D utility Dependent variable
Time Date EQ-5D measured minus randomisation
date
Allows for any systematic rise or fall in utility
over time. For simplicity, the basic mixed model
assumed that utility rose or fell at a constant
rate for all patients. The effect of time since
randomisation was assumed to be linear to
simplify QALY calculations
BaselineEQ5DCentred EQ-5D at baseline minus the mean EQ-5D at
baseline across the trial population
Strong predictor of on-treatment utility.
Centred to improve convergence and make
predictions easier
Ever Had Type X SAE 1= Patient has experienced a SAE of type X in
the trial to date
0= Patient has not experienced a SAE of this
type
In the basic model, three types of SAE were
considered: ocular, cardiovascular and other,
although these categories were broken down
further in additional analyses
Coefficient reflects the drop in utility on the
day of onset of this SAE, but is not used in
QALY calculations
Time Since Type X SAE Days since date of onset of the most recent
SAE of type X. In the basic model, three types
of SAE were considered: ocular, cardiovascular
and other, although these categories were
broken down further in additional analyses
Coefficient gives the rate of recovery. Used to
calculate utility on day of SAE onset and day of
recovery in QALY calculations
Bevacizumab 1= randomised to
bevacizumab; 0= ranibizumab
Treatment indicators allow for the fact that
patients’ quality of life may be higher with
some treatment regimens than others, and
ensure that imputed utilities are not biased by
omission of treatment indicators included in
subsequent analyses.81 For consistency with the
main analysis, all patients were treated as
having continuous therapy up to visit 3
Discontinuous 0= randomised to continuous treatment, or
this measurement is before visit 3, when all
patients have continuous therapy
1= randomised to discontinuous arm, if visit 3
or beyond
Interaction = bevacizumab × discontinuous
In the basic model, random parameters were applied to the constant term and the falls in utility associated
with each type of SAE to allow for variations between patients. However, random slopes were not
estimated, as it would not be possible to estimate both random slopes and random intercepts for patients
with only one post-SAE measurement. The model assumed that different classes of SAE have additive
effects on EQ-5D utility and on recovery rates: for example, if CVD events reduce utility by 0.2, with a
recovery rate of 0.01/day, while ocular events reduce utility by 0.1 with a recovery rate of 0.005/day, having
had angina and endophthalmitis 10 days ago will reduce utility by 0.24 (0.1+ 0.2–0.01 × 10–0.005 × 10).
Which event is most recent is assumed to have no effect on utility, except for the number of days of
recovery time that are applied. However, for simplicity having two events in the same class on the same
date is assumed to have the same impact on utility as having just one event; nonetheless, having a second
event of the same type some time after the first will reduce utility to the same level observed immediately
after the first event. The model assumed that utility improved linearly to simplify subsequent calculations,
although we did evaluate the impact of non-linear functions in sensitivity analysis.
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Serious adverse events were initially divided into three main categories:
(a) ‘Cardiovascular events’, which included all events in the MedDRA category of ‘Cardiac disorders’, plus
the systemic expected SAEs listed in the previous section [cerebrovascular accident, coronary artery
bypass (which was accompanied by MI), DVT, haemorrhage, pulmonary embolism and transient
ischaemic attack]. There were 68 events in this category, after which there were 78 EQ-5D
measurements in 47 patients.
(b) ‘Ocular events’, which included all events in the MedDRA category of ‘Eye disorders’, plus IOP
increased. This category included 48 events, after which there were 72 EQ-5D measurements in
36 patients. Subsequent analyses explored the impact of considering VA reduced as a separate type of
event, as this was not classed as a SAE (27 events, with 42 EQ-5D measurements).
(c) ‘Other’ included all SAEs not included in either of the above categories, giving 168 events with
170 EQ-5D measurements in 93 patients afterwards. In the basic model, this category was considered
to be one homogeneous group, although subsequent analyses explored the impact of dividing it into
smaller MedDRA categories:
– ‘Neoplasms benign, malignant and unspecified (including cysts and polyps)’: 24 events, with
14 EQ-5D measurements in 10 patients afterwards.
– ‘Infections and infestations’: 25 events, with 29 EQ-5D measurements in 13 patients.
– ‘Gastrointestinal or hepatobiliary disorders’: 19 events, with 29 EQ-5D measurements in 14 patients.
– ‘Surgical and medical procedures’ and ‘Investigations’ (excluding evaluation of IOP, which was
classed as ocular, or coronary artery bypass): 32 events, with 51 EQ-5D measurements in
29 patients.
– ‘Injury, poisoning and procedural complications’ or ‘Musculoskeletal and connective tissue disorders’:
28 events, with 31 EQ-5D measurements in 22 patients.
– Other unexpected events (those not falling into any of the above categories): 40 events, with
49 EQ-5D measurements in 27 patients.
Mixed models were fitted in Stata version 12 using xtmixed on all post-baseline utility measurements in the
2-year data set. Models were run initially on EQ-5D utilities (including 1732 EQ-5D measurements on
601 patients) to inform base-case analyses. The final model specification was rerun using HUI3 utilities
(including 1306 HUI3 measurements on 556 patients) to inform sensitivity analyses. Mixed models were fitted
only on observed (not imputed) utility measurements to simplify the analysis and ensure that mixed-model
estimates were not affected by the assumptions made in the imputation model. However, to avoid omitting
observations that had post-baseline EQ-5D but were missing baseline EQ-5D, we assumed that the
centred baseline EQ-5D utility for that patient was equal to the difference between their 3-month EQ-5D
utility and the mean 3-month EQ-5D utility if this patient had no SAEs before an observed 3-month EQ-5D
measurement. This was applied to three patients missing baseline EQ-5D and 146 patients missing
baseline HUI3.
The basic model used autocorrelated residuals to allow for the fact that utility measurements for the same
patient are correlated and that these correlations are likely to reduce over time. Visit number was used as a
measure of the time of EQ-5D measurement, with exit visit utilities being assigned the visit number closest
to the date of exit. The basic model also assumed that the random parameters are independent (zero
covariance): i.e. that the amount that EQ-5D utility falls after a certain type of SAE is not correlated with
the constant term for this patient before the event, or with the utility reduction that the same patient had
before a different event. This assumption was necessary as only 19 patients had two different types of SAE
during the trial and only one had all three types; as a result, a model with unstructured covariance and
three random SAE parameters did not converge.
We evaluated 19 variations on the basic model in four stages to assess whether or not any improved
model fit (i.e. reduced AIC by any amount); details are available on request. At each stage, we adopted
any variations that reduced model fit and conducted the next step using the best-fitting model from the
previous step. We also conducted sensitivity analyses to evaluate the impact of two variations, which were
not considered candidates for the final model.
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The model with the lowest AIC divided SAEs into ‘ocular disease’, ‘CVD’, ‘cancer’ and ‘other’, and
included random effects parameters for the time since randomisation, time since ocular events and the
time since cancer or other SAEs. CVD and cancer significantly decreased EQ-5D utility, although the impact
of ocular or other SAEs was non-significant (Table 37). The non-significant coefficient for ocular disease
may reflect previous evidence suggesting a weak correlation between EQ-5D and VA,126 and the tendency
towards EQ-5D correlating best with patients’ better-seeing eye,91 which may not necessarily be the one
affected by an ocular SAE or the study eye that shows a ≥ 15-letter drop in VA. The rate of recovery after
each type of SAE was positive (indicating that EQ-5D utility is worst immediately after the event and
improves over time), but was not statistically significant for any class of SAE other than cancer. Model
predictions suggested that EQ-5D utility declined with each class of SAEs and increased gradually over
time, with different classes of SAEs having an additive effect on EQ-5D utility (Figure 49).
TABLE 37 Results of the best-fitting models for EQ-5D and HUI3
Variable
Mean (SE) coefficient
InterpretationEQ-5D HUI3
Fixed coefficients
Time since randomisation –0.00003 (0.00001) –0.00007 (0.00002)a Change in utility per day
Baseline utility (centred) 0.56 (0.025)a 0.636 (0.043)a Impact of increasing baseline
utility from 0 to 1
Ever had ocular SAE or VA drop –0.019 (0.028) –0.066 (0.044) Decrease in utility on the day
this event begins
Ever had CVD SAE –0.084 (0.027)a –0.263 (0.042)a
Ever had cancer –0.311 (0.07)a –0.245 (0.116)a
Ever had other SAE –0.027 (0.024) –0.148 (0.038)a
Time since most recent ocular event 0.00003 (0.00008) 0.00009 (0.00013) Increase in utility with every
day that passes after an event
of this typeTime since most recent CVD event 0.0002 (0.0001) 0.00062 (0.00016)
a
Time since most recent cancer SAE 0.0011 (0.00034)a 0.00084 (0.00043)
Time since most recent other event 0.00003 (0.00007) 0.00028 (0.0001)a
Bevacizumab –0.002 (0.014) –0.065 (0.024)a Effect of treatment
Discontinuous –0.002 (0.014) –0.047 (0.024)
Interaction –0.00036 (0.02045) 0.05737 (0.03427)
Constant 0.842 (0.011)a 0.771 (0.018)a Constant: predicted utility on
day 1 without SAEs for
patient with the mean utility
Random-effects parameters
SD: Time since randomisation 0.0001 (0.00002) 0.00012 (0.00004) Between-patient variability in
temporal trend
SD: Ever had ocular SAE or VA drop 0.027 (0.08) 0.07 (0.078) Between-patient variability in
fall in utility associated with
each of the main types of SAESD: Ever had cancer OR another SAE 0.116 (0.022) 0.168 (0.034)
SD: Constant 0.088 (0.006) 0.161 (0.009) Between-patient variability
in constant
Residual: AR(1)
rho 0.027 (0.129) 0.467 (0.128) Correlation between errors for
consecutive visits
sd(e) 0.132 (0.003) 0.161 (0.005) Residual
AR, autoregressive.
a p< 0.05.
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Grouping serious adverse events into sets
The analysis of QALYs excluded six SAEs that started after the patient withdrew from the study, and
14 SAEs that occurred after the patient attended visit 24. These SAEs were excluded because they cannot
influence the EQ-5D measurements observed within the 24-month trial period.
A minority of patients within IVAN had up to seven SAEs within the trial, although many of these events
began at the same time or in close succession. For example, a patient may have broken their wrist and
clavicle in the same fall during year 1, and the following year have experienced a worsening of angina
followed by a MI 3 days after angina symptoms worsened, which resulted in death 6 days later. No patients
completed EQ-5D or HUI3 between SAEs that occurred < 7 days apart. We therefore grouped SAEs with
onset dates < 7 days after the last SAE into the same ‘set’. In the aforementioned example, the broken wrist
and clavicle would be classed as this patient’s first set of SAEs, whereas angina, MI and death would be
classed as their second set of SAEs (with an onset date equal to the date the angina symptoms worsened).
After grouping SAEs in this way (and after excluding SAEs occurring after withdrawal or visit 24), 129 trial
participants were considered to have one set of SAEs, 37 had two sets, 15 had three sets and two had four
sets. A set of SAEs was considered to be ‘fatal’ if death was one of the SAEs included within it and was
considered ‘non-fatal’ if the patient survived for > 7 days after the last SAE in that set. For the purposes of
QALY calculations and costing analyses, the onset date for death was assumed to be equal to the date of
death, rather than the date of onset for the cause of death. The next EQ-5D (or HUI3) measurement taken
after each set of SAEs was considered to be the post-SAE measurement for that SAE set, providing that the
next measurement was within 6 months of the SAE onset and before the next set of SAEs began.
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FIGURE 49 The effect of model coefficients on EQ-5D utility for a hypothetical patient who experienced a
cardiovascular SAE on day 90, an ocular SAE on day 150, an unexpected SAE on day 205, a second cardiovascular
SAE on day 330 and a cancer SAE on day 629.
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Outline of approach to missing data
Missing data are frequently more common for economic evaluation than for clinical end points16,23 and
cost-effectiveness is measured using a composite of numerous types of resource use and multiple utility
measurements. As a result, the approach used in the primary clinical analysis (mixed models of data on all
patients with at least one post-baseline outcome measure) could not be used for the economic evaluation.
Although only 3.6% (82/2305) of EQ-5D measurements at scheduled visits, 54% (32/59) of exit visit
EQ-5D measurements and 41% (88/216) of EQ-5D measurements after patients’ first or second set of
SAEs were missing. Missing utility data were imputed using multiple imputation using a series of chained
regression equations (see Chapter 2). This standard, validated approach imputes missing data based on a
wide range of covariates and allows for the uncertainty around imputed values by generating multiple
imputations sampled from the posterior distribution of predicted values for each patient.
As discussed in Chapter 2, utilities at 0, 3, 12 and 24 months were imputed for all patients, whereas exit visit
utilities were imputed for all patients who withdrew from the study within 2 years of randomisation. As some
patients who missed visit 3 or 12 completed EQ-5D and/or HUI3 at the following visit, five measurements
taken at visit 4 and one measurement taken at visit 5 were moved to visit 3 before multiple imputation was
conducted, and seven measurements taken at visit 13 and three measurements from visit 14 were moved to
visit 12; measurements were moved only if the patient had not experienced any SAEs in the last 30 days.
Post-SAE utilities were imputed for patients who had no EQ-5D measurement that was within 6 months of
the onset of each SAE set, and which occurred before their next set of SAEs began. Each missing post-SAE
utility was assigned a time interval between the SAE and the post-SAE measurement. This interval was equal
to the date when the next scheduled measurement or exit visit was due minus the SAE onset date, if this was
within 6 months and before the patient’s next SAE. When there was no scheduled visit within this interval,
the post-SAE measurement was assumed to take place X days after the SAE, where X is whichever is smallest
out of the following: the day before the next set of SAEs; and the average interval between SAE onset and
the next EQ-5D measurement across patients who experienced that type of SAE.
The EQ-5D and HUI3 utilities after patients’ first set of SAEs were imputed using multiple imputation for all
patients who had at least one non-fatal set of SAEs, as were EQ-5D utilities after patients’ second set of SAEs
for those patients with at least two non-fatal sets of SAEs. Multiple imputation models included variables
indicating the types of SAEs and the time since each type of SAEs to mirror the final mixed model. However,
only one patient was missing EQ-5D after a third set of SAEs. As only 15 patients had three or more sets of
non-fatal SAEs, EQ-5D utility after this patient’s third set of SAEs (CVD) was imputed by adding to the
estimated EQ-5D utility the day before the SAE, the mixed-model estimate of the change in EQ-5D on the
day of a cardiovascular SAE plus the product of the time interval between the SAE and the post-SAE
measurement, multiplied by the rate of recovery associated with the SAEs that this patient had experienced.
As there were insufficient HUI3 measurements to use multiple imputation to impute HUI3 utilities after
patients’ second or third sets of SAEs, the utility imputed for the next scheduled/exit visit was used as a
measure of post-SAE utility in 11 of these 33 measurements with scheduled/exit visit measurements due
within 6 months of the SAE. For the remaining 22 missing measurements, HUI utility was imputed from
EQ-5D values using a simple OLS mapping model that estimated HUI3 utility as a function of EQ-5D utility
and a constant term, which was estimated on data from all time points for which both HUI3 and EQ-5D
utilities were available. This model suggested that HUI3 utility= –0.006+ 0.844 × EQ-5D utility.
In the 15 cases in which the post-SAE measurement was missing but was assumed to have occurred on the
same date as the next scheduled/exit measurement, utility at the scheduled/exit visit and the post-SAE
measurement were imputed independently in multiple imputation. To ensure that each patient had only one
utility value on each day, utility at the scheduled measurement was changed to equal the utility imputed for
the post-SAE measurement. For example, if a patient had SAE 1 on day 60 and was missing – the visit 3 utility
assigned as their post-SAE measurement – utility at visit 3 and post-SAE 1 utilities were imputed independently,
and this patient’s visit 3 utility was changed to equal the post-SAE utility imputed for the same date. Post-SAE
utilities were used in preference to the scheduled measurements because they are imputed specifically for the
subset of patients who had SAEs and are therefore likely to better represent post-SAE utility.
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In addition to EQ-5D and HUI3 utilities, the imputation model included demographic characteristics, VA,
costs, indicators of random assignment to bevacizumab, discontinuous therapy and an interaction term as
additional covariates to avoid bias and improve the accuracy of imputations. For consistency and to best
reflect the available data, the imputation model allowed for the effect of SAEs using the same functional
form that was used in the mixed model. The model therefore also included variables capturing the time
from randomisation to death, time from randomisation to withdrawal, dummies for which SAE types had
occurred before each measurement and variables capturing the time since each type of SAE. For simplicity
and as indicators of utility on the day before death, utilities at visits 0, 3, 12 and 24 were imputed for all
patients, regardless of whether or not they had died or withdrawn before that time point. Ten imputation
cycles were used and predictive mean matching was used to allow for the non-normal distribution of
utilities and ensure that plausible utility values (between –0.594 and 1 for EQ-5D) were imputed.
Calculating quality-adjusted life-years
The number of QALYs accrued by each patient in each quarter was approximated by estimating EQ-5D
utilities at different time points, joining them with straight lines and calculating the area under the curve.
All EQ-5D measurements taken within IVAN and those imputed at visits 0, 3, 12 or 24, at study exit or
after SAEs were used in QALY calculations, including those not scheduled in the trial protocol.
Quality-adjusted life-year calculations assumed that EQ-5D measurements taken at visit ‘v’ were measured
exactly v × (365/12) days after randomisation, regardless of the exact date of utility measurement: for
example, baseline utilities were assumed to have been taken on the day of randomisation, whereas visit 3
utilities were assumed to have been measured 91.25 days later. Exit visit utilities were assumed to have
been measured exactly on the date of exit. These assumptions were made to simplify calculations and
ensure that utility measurements covered the entire period from randomisation to exit or 24 months. They
also avoid the variability and bias that could result from using the exact timing of utility measurements and
(as a result) assuming that patients who happen to have had visit 3 utility measured on day 105 have a
more gradual increase in utility (and therefore accrue fewer QALYs) than those who happen to have the
visit on day 84. [The trial protocol permitted intervals of 28–35 days between study visits; as a result,
patients following the protocol could have visit 3 as late as 105 days or as early as 84 days after
randomisation.] To ensure that SAEs were correctly ordered with respect to the utility measurement either
side of them and that the time interval between the SAE and the subsequent EQ-5D measurement was
maintained, QALY calculations used adjusted measures of the time to each SAE, whereby non-fatal SAEs
with observed (not imputed) post-SAE EQ-5D measurements were assumed to start on day v × (365/
12) – X, where ‘v’ indicates the visit number for the post-SAE measurement and ‘X’ indicates the interval
between SAE onset and the post-SAE measurement. The exact interval between randomisation and SAE
onset was used for fatal SAEs and those with imputed EQ-5D measurements.
After adjusting the visit number for 15 patients completing visit 3 or visit 12 EQ-5D questionnaires a
month or two late and imputing utilities at scheduled time points, study exit and after SAEs, QALY
calculations used a complete set of:
l 2305 EQ-5D measurements taken at scheduled time points (of which 2223 were observed)
l 59 at study exit (of which 27 were observed and five coincided with scheduled visits), 231
measurements after non-fatal SAEs (of which 142 were observed and 28 coincided with scheduled
time points or exit visits)
l 37 measurements at time points not scheduled in the trial protocol; of these, 16 were from one small
IVAN centre, which initially conducted monthly EQ-5D and HUI measurements; the remaining 21
unscheduled measurements could have been made in error or measured by staff who were unsure
whether or not a patient had experienced a SAE. However, all measurements (scheduled or otherwise)
were included in base-case QALY calculations to make use of available data.
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The base-case analysis assumed that utility changed linearly between all EQ-5D measurements that were
not the next measurement after a SAE. However, the analysis divided SAE sets into four types determined
by the effect of the SAEs on EQ-5D utility:
l SAEs for which the post-SAE EQ-5D measurement is lower than the profile of the other measurements
(e.g. SAEs 1–3 in Figure 50): utility was assumed to drop suddenly on the day of the SAE, before
recovering at the rate estimated in the mixed model. A total of 136 SAEs fell into this category.
l SAEs for which the post-SAE EQ-5D measurement is above the profile of other measurements: for
example, SAEs 4–5 in Figure 50: utility was assumed to change linearly from the measurement before
the SAE up to the post-SAE measurement and then from the post-SAE measurement to the next
measurement. This category included 56 sets of SAEs for which the post-SAE measurement was above
the straight line joining patients’ previous measurement and the next measurement that was not
post-SAE (e.g. SAE 5 in Figure 50), in addition to 39 sets of SAEs for which the post-SAE measurement
was no higher than the trajectory of other measurements, but where extrapolating back to the day of
the SAE using the gradient from the mixed model would suggest that the utility the day of the SAE
was higher than that the day before (e.g. SAE 4 in Figure 50).
l SAE sets in which the patient died on the day of onset. In these cases, patients’ utility was assumed to
drop immediately to zero as soon as the SAE starts and remain at zero for the rest of the trial. There
were 19 SAEs within 2 years of randomisation in which the patient died immediately.
l SAEs sets in which the patient died 1–7 days after the most recent SAE in that set began (e.g. SAE 6 in
Figure 50): utility was assumed to fall linearly from the value estimated the day before the SAE to 0
between the date of onset and the date of death. This simplifying assumption avoided the need to
impute utilities in patients’ last week of life and allowed for the poor quality of life experienced by
patients who are dying. This simplification is unlikely to have any significant effect on the results, as it
affected only EQ-5D estimates for a few days in six patients. Four deaths occurring > 2 years after
randomisation were excluded from the QALY calculations, as they were outside the time horizon.
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FIGURE 50 Illustration of the methods used to infer the EQ-5D profile and calculate QALYs for a hypothetical
patient with six SAEs and three unscheduled measurements.
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The coefficients for the interaction between time and SAE type that were estimated in the mixed model
were used as a measure of the rate at which utility recovered after each type of SAE. To allow for
uncertainty around the mixed model coefficients, 100 sets of correlated model coefficients were drawn
from the distribution estimated within the model by using the Cholesky decomposition of the
variance–covariance matrix and assuming that coefficients were normally distributed. Each of the 100 sets
of correlated coefficients was used for one of the 100 multiply imputed data sets, such that, for example,
imputation 1 was assigned the first set of coefficients and the rate of recovery after ocular SAEs was the
same for all patients at any given imputation, but differed between imputations. This approach preserved
the correlations between coefficients and propagated the uncertainty within the mixed-model results. As
the recovery rates for ocular, cardiovascular and other SAEs were not statistically significantly different from
zero, > 2.5% of imputed data sets have negative slopes, suggesting that EQ-5D utility decreases over time.
Following the additive assumption made within the mixed model, the recovery rate after each set of SAEs
was estimated for each patient in each imputation by adding up the recovery rates for all types of SAEs that
each patient had had up until the end of the current set of SAEs. For example, a patient who had ocular
and cardiovascular events within SAE set 1 and experienced a cardiovascular event and cancer within SAE
set 2 would have a gradient after SAE set 2 equal to the slope for ocular events, plus the slope for
cardiovascular events, plus the slope for cancer. The coefficients estimating the fall in utility after each type
of SAE were also sampled from the variance–covariance matrix, but were not used in the analysis except to
impute EQ-5D utility after one patient’s third set of SAEs.
To estimate utility profiles around SAEs, three additional EQ-5D utilities were estimated for each set
of SAEs:
1. EQ-5D utility on the day before the SAE (points a1–6 on Figure 50):
i. For fatal SAEs and SAEs reducing utility, this was assumed to lie on a straight line joining the EQ-5D
measurement before the SAE with the next measurement after the SAE that was at scheduled time
point, at study exit or at an unscheduled time point that was not the next measurement after a SAE.
Imputed values were used for the measurement before the SAE or after the SAE when either of
these measurements was missing. The next EQ-5D measurement was also imputed after fatal SAEs;
for example, Figure 50, SAE 6, the utility the day before death is assumed to lie on the line between
the observed visit 12 utility and the imputed utility at visit 24. In cases where the measurement
before SAE set s was the one taken after SAE Set s-1 (e.g. for SAE 3 in Figure 50), the utility the day
before SAE s (e.g. point a3) was estimated by extrapolating from the post-SAE s-1 measurement
using the recovery rate estimated in the mixed model.
ii. For SAEs where the post-SAE EQ-5D measurement was higher than would be expected from the
profile of other measurements (e.g. points a4 or a5 in Figure 50), utility the day before the SAE was
assumed to lie on a straight line joining the most recent measurement before the SAE with the
post-SAE measurement.
2. EQ-5D utility on the day of the SAE (points b1–6 on Figure 50):
i. For SAEs reducing utility, utility on the day of the SAE was estimated from the first post-SAE
measurement by extrapolating backwards using the recovery rate associated with that set of SAEs
(e.g. points b1–3). Values above 1 (which arose in cases for which the post-SAE utility was close to 1
and the recovery rate was negative) were set to 1.
ii. For SAEs increasing utility, utility on the day of the SAE was assumed to lie on the straight line
joining the most recent measurement before the SAE with the post-SAE measurement (e.g. points
b4 and b5).
iii. For SAEs when the patient died immediately, EQ-5D utility on the day of the SAE was zero. For SAEs
where the patient died 1–7 days after the start of the latest SAE, EQ-5D utility on the first day was
assumed to lie on the line between the utility the day before the SAE set began and zero utility on
the day of death (e.g. point b6).
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3. The time when the patient recovered from the SAE and the EQ-5D utility on that day (points c1–6 on
Figure 50):
i. For SAEs increasing utility, the effect of that SAE on utility was assumed to end at the next
measurement after the post-SAE measurement (e.g. points c4 and c5).
ii. The effect of fatal SAEs was assumed to end on the day of death with a utility of zero
(e.g. point c6).
iii. For non-fatal SAEs decreasing utility, the effect of the SAE was assumed to end at whichever was
soonest out of the following:
– The day before the next set of SAEs started (e.g. point c2). In cases for which the effect of one
SAE set ended the day before the next SAE set, the utility on the day of recovery was estimated
from the post-SAE measurement using the recovery rate estimated in mixed model.
– At the time of the next EQ-5D measurement that was not post SAE, whether that was a routine
time point, study exit or an unscheduled visit (e.g. point c1).
– At the point where a straight line running through the post-SAE measurement with a gradient
equal to the recovery rate from the mixed model crossed the straight line joining the patient’s
previous non-post-SAE measurement with their next non-post-SAE measurement. The time at
which the two lines crossed was estimated by solving the simultaneous equations for the
two lines (e.g. point c3).
After estimating points a–c for each SAE, utility at any point in time could be estimated by joining points
a–c and all imputed or observed EQ-5D measurements with straight lines. We then estimated utility at the
interval for each quarter by interpolation, and calculated the number of QALYs accrued between each pair
of points by taking the average between the EQ-5D measurements at the start and end of each period
and multiplying that by the duration of each period in years.
In addition to the base-case analysis, seven other estimates of the number of QALYs accrued by each
patient were generated for sensitivity analysis, of which three make different assumptions about the
EQ-5D profile (Figure 51). These analyses differ in the types of EQ-5D measurements included in QALY
calculations and the way in which utility was assumed to change between measurements. In the absence of
SAEs, utility was assumed to change linearly between measurements. All sensitivity analysis used the same
run of multiple imputation. The EQ-5D profile and the number of QALYs accrued for the 392 patients who
did not exit the study early/had no SAEs/had no unscheduled EQ-5D measurements was identical in all
analyses except (1), although the different analysis gave different profiles and different QALY estimates for
the other 218 patients.
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1. HUI3 Replicating all analyses in the same way as the base case, but using HUI3 utilities in place of
EQ-5D.
2. Simply interpolating between scheduled EQ-5D measurements (see Figure 51, row 2) This analysis
included only EQ-5D measurements at 0, 3, 12 and 24 months, and assumed that EQ-5D utility
changed linearly between these measurements. Utility the day before death or study exit was assumed
to lie on the straight line between the patient’s last measurement and the next scheduled measurement
that was imputed after the patient had died/withdrawn. EQ-5D utility was assumed to be zero after
death and QALYs that ended after the patient had withdrawn from the study were excluded from the
analysis. This analysis indicates the QALYs that would have been accrued within the study if data were
collected only at scheduled time points.
3. Excluding the post-SAE measurements and interpolating between the non-SAE measurements
(including exit visits and unscheduled measurements (see Figure 51, row 3) Measurements identified as
the first one after a SAE were excluded from this analysis (unless they coincided with a scheduled visit
or an exit visit), although EQ-5D utilities measured at unscheduled time points or measured/imputed at
exit visits were included. Utility was assumed to change linearly between all measurements. Exit visit
utilities were assumed to indicate utility on the day of study withdrawal, although utility the day before
death was assumed to lie on the straight line between the patient’s last measurement and the next
scheduled measurement that was imputed after the patient had died/withdrawn. This analysis indicates
the QALYs that would have been accrued if post-SAE measurements had not been taken.
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FIGURE 51 Assumptions made in the base-case analysis and the three main sensitivity analyses about the
EQ-5D profile.
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4. Linear interpolation between all EQ-5D measurements (see Figure 51, row 4) This analysis included all
observed EQ-5D measurements and those imputed at 0, 3, 12 and 24 months, study exit and after
SAEs. EQ-5D utility was assumed to change linearly between all measurements. However, this analysis
included only those post-SAE measurements actually observed after SAEs and excluded post-SAE
measurements that were imputed at time points other than scheduled/exit visits. This was done to
evaluate the impact of imputing post-SAE utilities and modelling changes in EQ-5D utility. This analysis
is therefore likely to overestimate the impact of SAEs by assuming that EQ-5D utility starts to decrease
long before the SAE starts.
5. Subtracting the QALY loss from expected SAEs but not unexpected SAEs (compare with the base-case
analysis, which included the impact of all SAEs, whether or not expected or unexpected) Within this
analysis, the number of QALYs accrued in any given quarter was assumed to be equal to the estimate
from the base-case analysis if there were either no SAEs that started, ended or spanned that quarter or
if there were any expected SAEs, and equalled the number of QALYs accrued in analysis (3) if the only
SAEs starting, ending or spanning that quarter were unexpected. This analysis aims to mirror the
costing analysis, which included only the costs of expected SAEs, not unexpected events.
6. Doubling the QALY impact of SAEs for which there is no EQ-5D measurement within 2 months of the
SA Within this analysis, the QALY impact of SAEs within each quarter was doubled and added on to
the QALYs accrued in analysis (3) for any quarters in which there were any SAEs lacking observed
post-SAE EQ-5D measurements, or any SAEs with a delay of > 2 months before the next observed
EQ-5D measurement. This analysis aims to evaluate the impact of missing not at random data on
post-SAE utilities and the impact of underestimating recovery rates for severe SAEs.
7. Doubling the QALY impact of all SAEs The impact of SAEs on the number of QALYs accrued in each
quarter was calculated by subtracting the number of QALYs accrued in each quarter in analysis (3) from
the number accrued in the base-case analysis. Within this analysis, the QALY impact of SAEs within
each quarter was doubled and added on to the QALYs accrued in analysis (3) for all patients. This
analysis aims to evaluate what the cost-effectiveness results might be if the analysis underestimated the
number or QALY impact of SAEs.
Strengths and limitations of the base-case approach
The base-case analysis takes account of all observed EQ-5D measurements, allows for uncertainty around
imputed values and attempts to make clinically realistic assumptions about changes in utility before and
after SAEs that account for the frequently unobserved poor utility on the day of the SAE without
overestimating the period for which the SAE affects utility.
However, this analysis assumes that the interval between the SAE and utility measurements varies at
random and that there was no correlation between this interval and the severity of the SAE. In practice,
this assumption may not be the case as patients with SAEs that have the greatest impact on utility may
miss more IVAN clinic visits than those with mild SAEs and extremely minor SAEs (e.g. reductions in VA)
may not be noticed until the patient attends the clinic for a VA check and completes EQ-5D on the same
day. A positive relationship between the interval between the event and measurement would cause the
mixed models to underestimate recovery rates, which would mean that QALY calculations overestimate
EQ-5D utility on the day the SAE starts and (in many cases) overestimate the time until the patient recovers
from the SAE. In many cases, these effects would cancel out, although for very severe SAEs, it may have
the effect of underestimating the impact of SAEs on QALYs.
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Furthermore, the analysis uses only the available data to impute missing post-SAE utilities and assumes
that data are missing at random after controlling for the type and timing of SAEs and other variables. In
practice, post-SAE utilities may be missing not at random, as, patients with more severe SAEs within any
given category may be less likely to return to the IVAN clinic to complete EQ-5D. For example, within the
CVD category, only seven of the 10 patients who had permanent stroke had any EQ-5D measurements
after the stroke.
The analysis is also limited by missing data on post-SAE utility. Out of 230 non-fatal SAEs, there were only
62 EQ-5D measurements that occurred within 30 days and before the patient’s next set of SAEs.
Unit costs
TABLE 38 Unit costs used in the economic evaluation
Resource (units) Unit cost (£) Reference
Ranibizumab (per 0.5-mg dose) 742.17 List price, British National Formulary51
Bevacizumab (per 1.25-mg dose) 49.00 Price typically charged by the not-for-profit NHS manufacturer
for bevacizumab in other trials, which was based on micro-
costing work conducted by the manufacturer to estimate actual
costs, including transport and delivery
Antibiotic drops (per injection in which
antibiotic drops were given)
1.75 One 10-ml bottle of chloramphenicol 0.5%.51 Given the 28-day
shelf life, a new bottle will be needed for each injection
Reagents and consumables used for
FFA (per FFA)
1.91 The types and quantities of reagents and consumables used
were obtained from two IVAN centres. Based on their responses,
it was assumed that all patients required: 1 minim of 1–2%
fluorescein (£0.3851); a 2-ml ampoule of sterile water (£0.1851);
1% tropicamide dilating drops (£0.47/injection51); and a Venflon
(£0.63 based on price from manufacturer). In addition, 52.5% of
patients (all those at one centre and 5% at the other) also
receive a minimum of 2.5% phenylepinephrine (£0.4951)
Reagents used for injection
(per injection)
1.29 The types and quantities of reagents and consumables used
were obtained from two IVAN centres. Based on their responses,
it was assumed that all patients receive a minim of 1%
tropicamide dilating drops (£0.47/injection51); 52.5% of patients
(all those that one centre and 5% at the other) also receive a
minim of 2.5% phenylepinephrine (£0.4951); all require an
average of 13 (range 0.8–25)ml povidone–iodine antiseptic
solution (£0.0951), diluted in a 25-ml sachet of 0.9% normasol
(£0.2551) in 50% of cases (all those at one centre); one minim of
0.4% benzoate (£0.4651) used in 50% of cases (all those at one
centre); one minim of 0.5% proxymetacaine (£0.4951) used in
25% of cases (50% at one centre)
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TABLE 38 Unit costs used in the economic evaluation (continued )
Resource (units) Unit cost (£) Reference
Staff involved in setting up and running clinics to administer and monitor VEGF injections
Administrator grade 3 (per hour) 13.55 Gross annual salary78 December 2010: £17,600; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on administrator: clinical support worker band 2 (hospital)
(p. 19577), but with no staff overheads or qualifications
Administrator grade 5 (per hour) 18.94 Gross annual salary78 December 2010: £24,600; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on administrator: clinical support worker band 2 (hospital)
(p. 19577), but with no staff overheads or qualifications
Assistant practitioner/unqualified
nurse/HCA grade 4 (per hour)
15.93 Gross annual salary78 December 2010: £20,600; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on assistant therapy worker band 3 (hospital) (p. 18777)
Associate specialist grade (per hour) 87.67 PSSRU, 2011,77 p. 202
Clerical officer grade 2 (per hour) 12.39 Gross annual salary78 December 2010: £16,100; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on administrator: clinical support worker band 2 (hospital)
(p. 19577), but with no staff overheads or qualifications
Clerk grade 2 (per hour) 12.39 Gross annual salary78 December 2010: £16,100; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on administrator: clinical support worker band 2 (hospital)
(p. 19577), but with no staff overheads or qualifications
Clerk grade 3 (per hour) 13.55 Gross annual salary78 December 2010: £17,600; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on administrator: clinical support worker band 2 (hospital)
(p. 19577), but with no staff overheads or qualifications
Consultant (medical) (per hour) 109.40 PSSRU 2011,77 p. 203
Consultant microbiologist grade 8a–c
(per hour)
51.37 Gross annual salary78 December 2010: £55,033; ratio of salary to
on-costs, qualifications, overhead and capital overheads and
direct–indirect time based on hospital pharmacist band 6,77 p. 186
Eye clinic liaison officer grade 4
(per hour)
15.93 Gross annual salary78 December 2010: £20,600; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on assistant therapy worker band 3 (hospital) (p. 18777)
Eye clinic liaison officer grade 6
(per hour)
22.81 Gross annual salary78 December 2010: £29,500; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on assistant therapy worker band 3 (hospital) (p. 18777)
Eye clinic liaison officer grade 3
(per hour)
13.61 Gross annual salary78 December 2010: £17,600; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on assistant therapy worker band 3 (hospital) (p. 18777)
Foundation house officer 1 grade
(per hour)
28.86 PSSRU, 2011,77 p. 199
Foundation house officer 2 grade
(per hour)
35.46 PSSRU, 2011,77 p. 200
HCA/clinical support worker grade 2
(per hour)
11.90 PSSRU, 2011,77 p. 195
HCA/clinical support worker grade 3
(per hour)
13.76 PSSRU, 2011,77 p. 187
Hospital pharmacist grade 6 (per hour) 29.88 PSSRU, 2011,77 p. 186
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TABLE 38 Unit costs used in the economic evaluation (continued )
Resource (units) Unit cost (£) Reference
Macular coordinator grade 4
(per hour)
16.32 Gross annual salary78 December 2010: £21,200; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on administrator: clinical support worker band 2 (hospital)
(p. 19577) band 2, but with no staff overheads or qualifications
Maintenance and works employee
grade 1 (per hour)
11.09 Gross annual salary78 December 2010: £14,400; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on maintenance: clinical support worker band 2 (hospital)
(p. 19577) band 2, but with no staff overheads or qualifications
Maintenance and works employee
grade 2 (per hour)
12.01 Gross annual salary78 December 2010: £15,600; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on maintenance: clinical support worker band 2 (hospital)
(p. 19577) band 2, but with no staff overheads or qualifications
Maintenance and works employee
grade 3 (per hour)
14.01 Gross annual salary78 December 2010: £18,200; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on maintenance: clinical support worker band 2 (hospital)
(p. 19577) band 2, but with no staff overheads or qualifications
Maintenance and works employee
grade 4 (per hour)
16.78 Gross annual salary78 December 2010: £21,800; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on maintenance: clinical support worker band 2 (hospital)
(p. 19577) band 2, but with no staff overheads or qualifications
Microbiologist grade 6 (per hour) 29.88 Assumed to be equivalent to Hospital pharmacist
Microbiologist/pharmacist grade 5
(per hour)
22.96 Gross annual salary78 December 2010: £24,600; ratio of salary to
on-costs, qualifications, overhead and capital overheads and
direct–indirect time based on hospital pharmacist band 677 (p. 186)
Microbiologist/pharmacist grade 7
(per hour)
33.88 Gross annual salary78 December 2010: £36,300; ratio of salary to
on-costs, qualifications, overhead and capital overheads and
direct–indirect time based on hospital pharmacist band 677
(p. 186)
Nurse advanced grade 8a (per hour) 42.92 Gross annual salary78 December 2010: £44,600; ratio of salary to
on-costs, qualifications, overhead and capital overheads and
direct–indirect time based on nurse team manager band 777 (p. 191)
Nurse advanced grade 8b (per hour) 49.75 Gross annual salary78 December 2010: £51,700; ratio of salary to
on-costs, qualifications, overhead and capital overheads and
direct–indirect time based on nurse team manager band 777 (p. 191)
Nurse advanced grade 8c (per hour) 58.89 Gross annual salary78 December 2010: £61,200; ratio of salary to
on-costs, qualifications, overhead and capital overheads and
direct–indirect time based on nurse team manager band 777 (p. 191)
Nurse advanced grade 8d (per hour) 70.63 Gross annual salary78 December 2010: £73,400; ratio of salary to
on-costs, qualifications, overhead and capital overheads and
direct–indirect time based on nurse team manager band 777 (p. 191)
Ophthalmic Imaging Specialists grade 5
(per hour)
21.52 Gross annual salary78 December 2010: £22,700; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on radiographer band 577 (p. 185)
Ophthalmic photographer grade 8a
(per hour)
42.95 Gross annual salary78 December 2010: £45,300; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on radiographer band 577 (p. 185)
Ophthalmic photographer grade 8b
(per hour)
51.67 Gross annual salary78 December 2010: £54,500; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on radiographer band 577 (p. 185)
Ophthalmic photographer grade 8c
(per hour)
61.91 Gross annual salary78 December 2010: £65,300; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on radiographer band 577 (p. 185)
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TABLE 38 Unit costs used in the economic evaluation (continued )
Resource (units) Unit cost (£) Reference
Ophthalmic photographer/technician
grade 4 (per hour)
19.72 Gross annual salary78 December 2010: £20,800; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on radiographer band 577 (p. 185)
Ophthalmic photographer/technician
grade 5 (per hour)
21.52 Gross annual salary78 December 2010: £22,700; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on radiographer band 577 (p. 185)
Ophthalmic photographer/technician
grade 6 (per hour)
28.92 Gross annual salary78 December 2010: £30,500; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on radiographer band 577 (p. 185)
Ophthalmic photographer/technician
grade 7 (per hour)
38.11 Gross annual salary78 December 2010: £40,200; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on radiographer band 577 (p. 185)
Optician grade 7 (per hour) 34.23 Gross annual salary78 December 2010: £36,300; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on dietitian band 577 (p. 184)
Optometrist grade 6 (per hour) 28.76 Gross annual salary78 December 2010: £30,500; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on dietitian band 577 (p. 184)
Optometrist grade 7 (per hour) 34.23 Gross annual salary78 December 2010: £36,300; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on dietitian band 577 (p. 184)
Optometrist grade 8a (per hour) 42.71 Gross annual salary78 December 2010: £45,300; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on dietitian band 577 (p. 184)
Optometrist grade 8b (per hour) 51.38 Gross annual salary78 December 2010: £54,500; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on dietitian band 577 (p. 184)
Optometrist grade 8c (per hour) 61.57 Gross annual salary78 December 2010: £65,300; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on dietitian band 577 (p. 184)
Optometrist grade 8d (per hour) 76.18 Gross annual salary78 December 2010: £80,800; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on dietitian band 577 (p. 184)
Orthoptist grade 5 (per hour) 23.19 Gross annual salary78 December 2010: £24,600; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on dietitian band 577 (p. 184)
Orthoptist or optometry assistant
grade 3 (per hour)
14.04 Calculated from salary – see AFC sheet
Photographer grade 5 (per hour) 21.52 Gross annual salary78 December 2010: £22,700; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on radiographer band 577 (p. 185)
Photographer grade 7 (per hour) 38.11 Gross annual salary78 December 2010: £40,200; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on radiographer band 577 (p. 185)
Receptionist grade 2 (per hour) 12.39 Gross annual salary78 December 2010: £16,100; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on administrator: clinical support worker band 2 (hospital)
(p. 19577) band 2, but with no staff overheads or qualifications
Registrar (per hour) 47.70 PSSRU 2011,77 p. 201
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TABLE 38 Unit costs used in the economic evaluation (continued )
Resource (units) Unit cost (£) Reference
Secretary/administrative coordinator
grade 4 (per hour)
16.32 Gross annual salary78 December 2010: £21,200; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on administrator: clinical support worker band 2 (hospital)
(p. 19577) band 2, but with no staff overheads or qualifications
Senior ophthalmic science practitioner
grade 6 (per hour)
28.92 Gross annual salary78 December 2010: £30,500; ratio of salary to
on-costs, qualifications, overhead and capital overheads based
on radiographer band 577 (p. 185)
Sister grade 7 (per hour) 37.45 PSSRU 2011,77 p. 191
Staff nurse grade 5 (per hour) 26.62 PSSRU 2011,77 p. 193
Staff nurse grade 6 (per hour) 32.48 PSSRU 2011,77 p. 192
Surgeon (per hour) 108.72 PSSRU 2011,77 p. 204
Resources from the medical services form
GP (per surgery consultation lasting
11.17 minutes)
31.00 PSSRU 2011,77 pp. 148–9. Includes qualifications, but excluded
direct staff costs (as GP nurses are costed separately)
General practice nurse
(per consultation)
13.18 PSSRU 2011,77 p. 146. Corrected, based on revised PSSRU
downloaded 1 February 2012
District nurse (per consultation) 20.00 PSSRU 2011,77 p. 141. PSSRU 2011 does not give length of
consultation, but PSSRU 2010 states that this is 20 minutes per
home visit,127 so this figure is used to calculate the cost per
district nurse consultation
GP home visit (per home visit lasting
23.4 minutes, including travel time)
104.00 PSSRU 2011,77 pp. 148–9. Includes qualifications, but excluded
direct staff costs (as GP nurses are costed separately)
GP telephone consultation
(per phone call)
19.00 PSSRU 2011,77 pp. 148–9. Includes qualifications, but excluded
direct staff costs (as GP nurses are costed separately)
Nurse practitioner (per surgery
consultation)
25.00 p. 147:77 cost per surgery consultation for nurse advanced. Text
in table demonstrates that this includes nurse practitioners
General practice nurse telephone
consultation (per phone call)
6.04 PSSRU 2011,77 p. 146. Calculated based on a 7.1-minute telephone
call (the same as GPs average, based on p. 149 of PSSRU)
Average non-consultant outpatient
consultation: mean cost across all
face-to-face outpatient attendances
recorded as non-consultant led
(first and follow-up)
59.36 DH reference costs 2010–1175 sheet total – OPATT
Non-ophthalmology outpatient
consultation: consultant (averaged
across consultant led first or follow-up
if non-admitted face to face)
116.84 DH reference costs 2010–1175 sheet total – OPATT
Non-ophthalmology outpatient
consultation: consultant plus
multiprofessional (consultant led:
first or follow-up attendance
multiprofessional non-admitted)
147.89 DH reference costs 2010–1175 sheet total – OPATT
Non-ophthalmology outpatient
consultation: non-consultant
(non-consultant led first or follow-up
attendance non-admitted face to face)
58.82 DH reference costs 2010–1175 sheet total – OPATT
Non-ophthalmology outpatient
consultation: non-consultant plus
multiprofessional (non-consultant led:
first or follow-up attendance
multiprofessional non-admitted)
81.87 DH reference costs 2010–1175 sheet total – OPATT
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TABLE 38 Unit costs used in the economic evaluation (continued )
Resource (units) Unit cost (£) Reference
Ophthalmology appointment (mean
cost across all non-consultant-led
ophthalmology outpatient
attendances)
62.55 DH reference costs 2010–1175 sheet total – OPATT
Ophthalmology outpatient consultation:
consultant (consultant-led follow-up
attendance non-admitted face to face)
77.21 DH reference costs 2010–1175 sheet total – OPATT
Ophthalmology outpatient consultation:
consultant plus multiprofessional
(consultant led: follow-up attendance
multiprofessional non-admitted)
117.43 DH reference costs 2010–1175 sheet total – OPATT
Ophthalmology outpatient consultation:
non-consultant (non-consultant led
follow-up attendance non-admitted
face to face)
56.54 DH reference costs 2010–1175 sheet total – OPATT
Ophthalmology outpatient consultation:
non-consultant plus multiprofessional
(non-consultant led: follow-up
attendance multiprofessional
non-admitted)
79.75 DH reference costs 2010–1175 sheet total – OPATT
Ophthalmology outpatient consultation:
average (total–weighted average across
all face-to-face follow-up attendances)
75.30 DH reference costs 2010–1175 sheet total – OPATT
Accident and emergency attendance 106.00 PSSRU 2011,77 p. 91: accident and emergency treatments
(not admitted)
Counsellor (per consultation) 60.00 PSSRU 2011,77 p. 41: cost per counselling session
CT scan (per attendance) 110.12 Weighted average cost across all non-inpatient CT scans.
DH reference costs 2010–1175 sheets TPCTDIAGIM_OP,
TPCTDIAGIM_Oth and TPCTDIAGIM_DA
DXA scan (per scan) 71.76 Mean cost of non-inpatient DXA scan in reference costs.
DH reference costs 2010–1175 sheet TPCTDIAGIM_OP,
TPCTDIAGIM_Oth and TPCTDIAGIM_DA
Echocardiography (per attendance) 48.68 Weighted average cost across all echocardiogram scans in
reference costs. DH reference costs 2010–11,75 average
across sheets
Hospital physiotherapy
(per consultation)
36.00 PSSRU77 p. 181: using data from the NHS reference costs
MRI scan (per scan) 173.22 Weighted average cost across all outpatient MRI scans in
reference costs. DH reference costs 2010–1175 sheets
TPCTDIAGIM_OP, TPCTDIAGIM_Oth and TPCTDIAGIM_DA
Occupational therapist 60.00 p. 182:77 using data from the NHS reference costs, the mean
average cost for a non-consultant led (non-admitted) follow-up
occupational therapy attendance in 2010 was £60, with the
minimum for 25% of services being £38 and the maximum
being £65. Costs have been uprated using the HCHS Pay and
Prices Inflator
PET scan (per attendance) 232.15 Weighted average across all nuclear medicine scans in reference
costs, across direct access, outpatient and other. DH reference
costs 2010–1175 sheets TPCTDIAGIM_OP, TPCTDIAGIM_DA
and TPCTDIAGIM_Oth
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The total cost of medication changes was calculated relative to baseline: patient’s daily medication cost on
day 0 was set to zero and any changes to medication that occurred during the trial increased or decreased
the daily medication cost. Regardless of the timing of visit 24, medication costs were calculated over a
730-day period and quarterly costs of medication changes were calculated based on exact dates of
changes. The cost of short courses of drugs licensed for expected AEs/SAEs (e.g. antibiotics) that started
and ended in the same month was included in the analysis, regardless of date, with any short courses
prescribed after day 730 being included in quarter 8.
TABLE 38 Unit costs used in the economic evaluation (continued )
Resource (units) Unit cost (£) Reference
Pharmacist (per consultation) 4.69 Cost was based on the crude average cost per hour of direct
patient contact between community and hospital pharmacist.
Assumed consultation lasts for 2 minutes 30 seconds, based on
a survey in 1992128
Physiotherapist (per consultation):
community or hospital
41.50 Mean price across hospital and community physiotherapy
consultations: PSSRU77 pp. 133 and 181
Podiatrist or chiropodist
(per consultation)
39.00 PSSRU 2011,77 p. 136: 9.4 community chiropodist/podiatrist
using data from the NHS reference costs,75 the mean average
cost for a contact in chiropody/podiatry services for 2010–11 was
£39, with the minimum range for 25% of services being £31
and the maximum £45. Costs have been inflated using the
HCHS Pay and Prices Inflator
Practice nurse home visit 19.89 Assumed to last 11.4 minutes, plus 12 minutes’ travel time,
like GP visit, but costed based on practice nurse time
Scan, unspecified (per attendance) 96.51 Weighted average cost across all scans in DH reference costs
2010–1175 sheets TPCTDIAGIM_OP, TPCTDIAGIM_Oth
and TPCTDIAGIM_DA
Ultrasound (per attendance) 54.73 Weighted average cost across all outpatient ultrasound scans in
DH reference costs 2010–1175 sheets TPCTDIAGIM_OP,
TPCTDIAGIM_Oth and TPCTDIAGIM_DA
Walk-in clinic (per attendance) 41.00 PSSRU 2011,77 p. 91: walk-in services (not admitted)
X-ray (per consultation) 34.48 X-rays have been removed from reference costs since 2007–8.
Cost was based on the weighted average of codes RA28Z,
RA29Z, RA30Z and RA31Z across direct access (TPCTRADGYDA),
outpatient (TPCTRADGYOP) and other (TPCTRADGYOth) from
2006 to 2007, NHS and trusts combined (www.dh.gov.uk/
prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/
digitalasset/dh_118336.xls), inflated to 2010–11 values
using HCHS77
AFC, Agenda for Change; CT, computerised tomography; DXA, dual-energy X-ray absorptiometry; DH, Department of
Health; HCA, health-care assistant; HCHS, Hospital & Community Health Services; MRI, magnetic resonance imaging;
PET, positron emission tomography; PSSRU, Personal Social Services Research Unit.
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TABLE 39 Cost per admission
(Serious) AE name Cost/bed-day,a £ Cost/admission,b £ Reference
Endophthalmitis 413.27 1040.80 DH reference costs 2010–11.75 Mean
cost/bed-day and mean cost per hospital
admission of related HRGs for non-elective
inpatient stays for non-surgical
ophthalmology, across sheets TPCTNEI_L,
TPCTNEI_L_XS and TPCTNEI_S
Uveitis 413.27 1040.80
Retinal detachment 413.27 1040.80
RPE tear 413.27 1040.80
Retinal vein occlusion 413.27 1040.80
Other ocular admission 413.27 1040.80
Cataract traumatic 631.79 1239.82 DH reference costs 2010–11.75 Mean
cost/bed-day and mean cost per hospital
admission of related HRGs for non-elective
inpatient stays for cataract procedures,
across sheets TPCTNEI_L, TPCTNEI_L_XS
and TPCTNEI_S
IOP increased 767.28 1475.20 DH reference costs 2010–11.75 Mean
cost/bed-day and mean cost per hospital
admission of related HRGs for non-elective
inpatient stays for glaucoma, across sheets
TPCTNEI_L, TPCTNEI_L_XS and TPCTNEI_S
Angina pectoris 996.68 3582.99 DH reference costs 2010–11.75 Mean
cost/bed-day and mean cost per hospital
admission of related HRGs for non-elective
inpatient stays for percutaneous coronary
interventions or CABG, across sheets
TPCTNEI_L, TPCTNEI_L_XS and TPCTNEI_S
Coronary artery bypass 996.68 3582.99
Cerebrovascular accident 316.04 2267.47 DH reference costs 2010–11.75 Mean
cost/bed-day and mean cost per hospital
admission of related HRGs for non-elective
inpatient stays for stroke-related HRGs,
across sheets TPCTNEI_L, TPCTNEI_L_XS
and TPCTNEI_S
Cardiac arrest 336.41 1007.69 DH reference costs 2010–11.75 Mean
cost/bed-day and mean cost per hospital
admission of related HRGs for non-elective
inpatient stays for cardiac arrest, across
sheets TPCTNEI_L, TPCTNEI_L_XS and
TPCTNEI_S
Cardiac failure 301.13 1641.66 DH reference costs 2010–11.75 Mean
cost/bed-day and mean cost per hospital
admission of related HRGs for non-elective
inpatient stays for HF, across sheets
TPCTNEI_L, TPCTNEI_L_XS and TPCTNEI_S
Left-ventricular failure 301.13 1641.66
Cardiovascular disorder 301.13 1641.66
DVT 314.22 1170.18 DH reference costs 2010–11.75 Mean
cost/bed-day and mean cost per hospital
admission of related HRGs for non-elective
inpatient stays for pulmonary embolus or
DVT, across sheets TPCTNEI_L, TPCTNEI_L_XS
and TPCTNEI_S
Pulmonary embolism 314.22 1170.18
Transient ischaemic attack 347.76 780.17 DH reference costs 2010–11.75 Mean
cost/bed-day and mean cost per hospital
admission of related HRGs for non-elective
inpatient stays for TIA, across sheets
TPCTNEI_L, TPCTNEI_L_XS and TPCTNEI_S
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TABLE 39 Cost per admission (continued )
(Serious) AE name Cost/bed-day,a £ Cost/admission,b £ Reference
MI 331.88 1236.05 DH reference costs 2010–11.75 Mean
cost/bed-day and mean cost per hospital
admission of related HRGs for non-elective
inpatient stays for confirmed or suspected
acute MI, across sheets TPCTNEI_L,
TPCTNEI_L_XS and TPCTNEI_S
Haemorrhage 35.69 968.81 DH reference costs 2010–11.75 Mean
cost/bed-day and mean cost per hospital
admission of related HRGs for non-elective
inpatient stays for gastrointestinal bleeds,
across sheets TPCTNEI_L, TPCTNEI_L_XS
and TPCTNEI_S
Urinary tract infection 415.81 N/A DH reference costs 2010–11.75 Mean
cost/bed-day and mean cost per hospital
admission of related HRGs for non-elective
inpatient stays for kidney or urinary tract
infections, across sheets TPCTNEI_L,
TPCTNEI_L_XS and TPCTNEI_S
Accident and Emergency
admission < 1 day
140.95 N/A DH reference costs 2010–11,75 Index sheet.
Unit cost for Accident and Emergency
Services: leading to Admitted
Upper respiratory tract
infection
470.55 535.03 DH reference costs 2010–11.75 Mean
cost/bed-day and mean cost per hospital
admission of related HRGs for non-elective
inpatient stays for acute upper respiratory
tract infection and common cold, across
sheets TPCTNEI_L, TPCTNEI_L_XS and
TPCTNEI_S
Unexpected SAE 506.49 1667.78 DH reference costs 2010–11.75 Mean
cost/bed-day and mean cost per hospital
admission of all elective and non-elective
admissions: TPCTEI, TPCTEIXS, TPCTNEI_L,
TPCTNEI_L_XS, TPCTNEI_S
Arthralgia 506.49 1667.78
Nausea 506.49 1667.78
DH, Department of Health; N/A, not available.
a Cost per bed-day was calculated for the TPCTEI, TPCTNEI_L and/or TPCTNEI_S sheets by dividing the national average
unit costs by the average length of stay for each indication that was included in that hospitalisation. For the sheets
TPCTNEI_L_XS and TPCTEIXS, the cost/bed-day equalled the national average unit cost. The weighted average cost was
then calculated, weighted by the number of bed-days.
b The weighted average cost per hospital admission was calculated by averaging the national average unit cost, weighted
by activity.
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CONFIDENTIAL
Health Economics Research Centre
A RANDOMISED CONTROLLED TRIAL OF ALTERNATIVE 
TREATMENTS TO INHIBIT VEGF IN AGE-RELATED 
CHORIODAL NEOVASCULARISATION (IVAN)
Treatment Set-Up Cost Questionnaire
Date on which questionnaire was completed: ………………………
Main respondent’s contact details
Contact Name:
Job Title:
Centre:
Telephone Number:
Email Address:
Additional staff providing information:
Contact Name:
Job Title:
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Email Address:
Question(s) completed:
Contact Name:
Job Title:
Email Address:
Question(s) completed:
Contact Name:
Job Title:
Email Address:
Question(s) completed:
PLEASE DO NOT DETACH THIS PAGE
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SET UP COST QUESTIONNAIRE
Thank you for taking time to complete this questionnaire.  Your answers will be kept 
confidential and will only be used for the IVAN study. 
The aim of this research is to collect information on the predicted resource use and costs 
associated with setting up clinics to perform intra-vitreal injections of bevacizumab and 
ranibizumab for the treatment of neovascular age-related macular degeneration (nAMD) 
and monitor outcomes in routine NHS clinical practice (i.e. outside of clinical trials). 
Any facilities or equipment that were set up/obtained specifically for IVAN or other 
clinical trials and are not used in routine clinical practice should not be mentioned in this 
questionnaire.
We are interested in identifying all of the equipment and resources that are required to 
offer bevacizumab/ranibizumab in routine clinical practice and calculating the total cost 
required to modify your facilities so that you could offer these treatments and associated 
monitoring. We would like to capture all of the equipment or resources that you needed 
(or will need) to offer bevacizumab/ranibizumab from the point at which your centre 
decided to offer bevacizumab/ranibizumab to the point at which your clinic is entirely set 
up and running at full capacity.
In a few months time, we will send you (or someone who you nominate) a second 
questionnaire on the resources required to run the clinics in which 
bevacizumab/ranibizumab are administered or in which patients are monitored. 
If you don’t know the answer to any given question, please complete all questions that 
you can answer and forward the questionnaire to others at your centre so that they can 
complete additional sections. Duplicate questionnaires may be obtained from the address 
below. 
If nobody at your centre has the information required to answer a particular question, 
please leave it blank and complete and return the remainder of the questionnaire. In 
particular, we would be extremely grateful if you could give details of the quantities of 
resources purchased even if you do not know their cost. Where we ask for estimated or 
approximate values, we would be grateful for your best guess at the value in question. 
We have assumed that all costs given in the questionnaire include VAT.  If you prefer to 
give some/all costs excluding VAT, please state clearly which costs exclude VAT.
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a) When did your clinic first start offering bevacizumab/ranibizumab outside clinical trials?  
……………………………………………………………………………... 
 
b) Please complete the below table to summarise the facilities you have that can be used for 
patients who have received bevacizumab/ranibizumab. 
 
If any of these functions uses a room mentioned higher up in the table (e.g. if FFA is 
conducted in the OCT room), please record this in the second column.  
Room No. rooms at 
your clinic 
that were 
used by pts 
with nAMD 
before you 
decided to 
offer 
bevacizumab/ 
ranibizumab  
No. new 
rooms set up 
in order to 
offer 
bevacizumab/ 
ranibizumab 
No. existing 
rooms 
modified in 
order to offer 
bevacizumab/ 
ranibizumab 
No. rooms set 
up at your 
clinic today 
that are used 
by pts who 
have had 
bevacizumab/ 
ranibizumab 
in the past 2 
years 
No. rooms 
that you plan 
to set up in 
the 
foreseeable 
future to cope 
with demand 
for 
bevacizumab/ 
ranibizumab 
Waiting 
rooms 
     
Sterile 
rooms 
suitable for 
intra-vitreal 
injections 
     
Visual 
testing lanes 
     
OCT room      
FFA room      
Consultation 
rooms 
     
Optometric 
assessment 
rooms 
     
SECTION A: SET UP/CAPITAL COSTS 
1. Summary of your facilities  
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Recovery 
rooms
Other 
(please 
specify)
Abbreviations: FFA, fundus fluorescein angiography; OCT, optical coherence tomography.
c) Do you plan to expand your service or increase the number of patients receiving 
bevacizumab/ranibizumab in the future?
YES/NO (please circle or underline the appropriate response to this and all subsequent 
yes/no questions)
d) If YES, when do you expect the number of patients receiving bevacizumab/ranibizumab
to have levelled out? ……………………………
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a) Did/would you need to set up or modify 1 or more sterile treatment room(s) to administer 
bevacizumab/ranibizumab? 
 
YES/NO  
 
b) If NO, where do you administer bevacizumab/ranibizumab? (Go to Q3) 
………………………………………………………………………………………..……. 
 
c) Approximately when was your newest sterile room set up? …….…………………………. 
 
d) List equipment/resources used to set up or modify an existing room into a sterile room and 
their cost.  Please only include equipment/resources that are used in the sterile room. 
Costs should include VAT 
Equipment/Resource 
Equipment 
purchase 
cost if 
known (inc 
VAT)‡ 
Total 
quantity 
required per 
treatment 
room 
Quantity 
purchased to 
offer 
bevacizumab/ 
ranibizumab 
Annual 
maintenance 
cost if known 
(inc VAT & 
service 
contracts)‡ 
Estimated 
likely life 
span (in 
years) 
Furniture (please specify)
     
     
     
     
Tonometer for 
measuring IOP 
    
Computer     
Networking     
Software (please specify)     
     
     
     
Printer     
Lighting     
Refrigerator     
Cupboards     
2.  Sterile room in which intra-vitreal injections are performed 
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Equipment/Resource
Equipment 
purchase 
cost if 
known (inc 
VAT)‡
Total 
quantity 
required per 
treatment 
room
Quantity 
purchased to 
offer 
bevacizumab/
ranibizumab
Annual 
maintenance 
cost if known 
(inc VAT & 
service 
contracts)‡
Estimated 
likely life 
span (in 
years)
Replacement of 
flooring
Replacement of 
ceiling
Air conditioning
Other (please specify)
‡ If any piece of equipment listed in this table is leased, please write “leased” in the equipment purchase cost 
column and record the annual lease in the maintenance cost column.
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e) What monitoring/tests/investigations (e.g. infection control visits or microbiological 
monitoring) were/would be conducted to ensure that the treatment room was sterile and 
suitable to be used to perform intra-vitreal injections?  Please provide as many details as 
possible, including how many visits were conducted, roughly how long each visit lasted, 
how many staff of each grade were involved and what tests were conducted.
…………………………..…………………………..…………………………..
…………………………..…………………………..…………………………..
…………………………..…………………………..…………………………..
…………………………..…………………………..…………………………..
…………………………..…………………………..…………………………..
…………………………..…………………………..…………………………..
…………………………..…………………………..…………………………..
…………………………..…………………………..…………………………..
f) Will the infection control/microbiology assessment of the sterile room need to be repeated 
periodically?
YES/NO (if NO, go to Q3)
g) If YES, how many times per year must the infection control/microbiological assessment 
be repeated? ……………………………………………………………
h) Will the routine microbiological checks of the sterile room be the same as the 
microbiological assessment that was required when the room was set up? 
………………………………………………………………………………………
i) If not, how will the routine assessments differ from the initial assessment?
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
…………………………..…………………………..………………………………
…………………………..…………………………..………………………………
…………………………..…………………………..………………………………
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 a) Before you decided to offer bevacizumab/ranibizumab, what facilities did you have that 
could be used to perform OCT? 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
b) Would/did you need to set up 1 or more new OCT room(s) or purchase additional OCT 
equipment to offer bevacizumab/ranibizumab? 
 
YES/NO (if NO, go to Q4) 
 
c) Approximately when was your newest OCT room or OCT equipment set up? …….…… 
 
d) List equipment/resources used and their cost to set up an OCT room or modify an existing 
room to use as an OCT room. 
 
Costs should include VAT.  
Equipment/Resource 
Equipment 
purchase 
cost if 
known (inc 
VAT)‡ 
Total 
quantity 
required 
per OCT 
room 
Quantity 
purchased to 
offer 
bevacizumab/ 
ranibizumab 
Annual 
maintenance 
cost‡ if known 
(inc VAT & 
service 
contracts) 
Estimated 
likely life 
span (in 
years) 
OCT machine      
Computer†      
Printer†      
Networking  N/A    
Software (please specify)*      
      
      
      
Furniture (please specify)      
      
      
      
Other (please specify)      
      
3.  Optical coherence tomography (OCT) room 
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Equipment/Resource
Equipment 
purchase 
cost if 
known (inc 
VAT)‡
Total 
quantity 
required 
per OCT 
room
Quantity 
purchased to 
offer 
bevacizumab/
ranibizumab
Annual 
maintenance 
cost‡ if known 
(inc VAT & 
service 
contracts)
Estimated 
likely life 
span (in 
years)
‡ If any piece of equipment listed in this table is leased, please write “leased” in the equipment purchase 
cost column and record the annual lease in the maintenance cost column. 
† If the stand, computer and/or printer were supplied free with the OCT machine, please 
record the equipment purchase cost of the stand/computer/printer as “N/A”.
* Please record software and software licences used in other rooms in the appropriate section; for example, 
if OCT software licences are required on each consulting room computer, please record these licences in 
Question 5 and record only the software licence that is on the OCT room computer in this section.
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a) Before you decided to offer bevacizumab/ranibizumab, what facilities did you have that 
could be used to perform FFA? 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
 
b) Is FFA conducted in one of the rooms that have already been mentioned?  
 
YES/NO  
 
c) If YES, what room is FFA conducted in? ………………………………...………… 
 
d) Did/would you need to set up 1 or more additional FFA room(s) or purchase any 
additional equipment for FFA in order to offer bevacizumab/ranibizumab? 
 
YES/NO (if NO, go to Q5) 
 
e) Approximately when was your newest FFA room/equipment set up? ……………………. 
 
f) List equipment/resources used to set up or modify an existing room into an FFA room or 
enable FFA to be conducted in another room. 
 
Costs should include VAT  
Equipment/Resource 
Equipment 
purchase 
cost if 
known (inc 
VAT)‡ 
Total 
quantity 
required 
per FFA 
room 
Quantity 
purchased to 
offer 
bevacizumab/ 
ranibizumab 
Annual 
maintenance cost‡ 
if known (inc VAT 
& service 
contracts) 
Estimated 
likely life 
span (in 
years) 
Camera     
Camera stand†     
Computer†     
Networking      
Printer†      
Storage space     
Software* (please specify)     
     
     
4.  Fundus fluorescein angiography (FFA) room 
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Equipment/Resource
Equipment 
purchase 
cost if 
known (inc 
VAT)‡
Total 
quantity 
required 
per FFA 
room
Quantity 
purchased to 
offer 
bevacizumab/
ranibizumab
Annual 
maintenance cost‡ 
if known (inc VAT 
& service 
contracts)
Estimated 
likely life 
span (in 
years)
Blood pressure monitor
Furniture (please specify)
Other (please specify)
‡ If you lease any piece of equipment listed in this table, please write “leased” in the 
equipment purchase cost column and record the annual leasing fee in the annual 
maintenance column. 
† If the stand, computer and/or printer were supplied free with FFA equipment, please record the equipment 
purchase cost of the stand/computer/printer as “N/A”.
* Please record software and software licences used in other rooms in the appropriate section; for example, 
if FFA software licences are required on each consulting room computer, please record these licences in 
Question 5 and include only the software licence that is on the FFA room computer in this section.
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a) Are consultations with clinicians conducted in any of the rooms mentioned previously? 
 
YES/NO  
 
b) If YES, what room are consultations conducted in? ……………………………….  
 
c) Did/would you need to set up 1 or more new consulting room(s) or purchase additional 
consulting room equipment in order to offer bevacizumab/ranibizumab? 
 
YES/NO (if NO, go to Q6) 
 
d) Approximately when was your newest consulting room set up? ………………………… 
e) List equipment/resources used to set up a consulting room for patients who have received 
bevacizumab/ranibizumab in the last 2 years or enable clinician consultations for patients 
who have received bevacizumab/ranibizumab to be conducted in another room. 
 
Costs should include VAT. Please include any licences for FFA or OCT software that are 
used in the consulting room(s) in this table, instead of in Q3 or Q4. 
Equipment/Resource 
Equipment 
purchase 
cost if 
known (inc 
VAT)‡ 
Total 
quantity 
required 
per 
consulting 
room 
Quantity 
purchased to 
offer 
bevacizumab/ 
ranibizumab 
Annual 
maintenance 
cost‡ if 
known (inc 
VAT & 
service 
contracts) 
Estimated 
likely life 
span (in 
years) 
Slit lamp      
Lenses      
Computer      
Printing      
Networking      
Software - including 
FFA/OCT licenses 
(please specify) 
     
      
      
      
5.  Consulting room 
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Equipment/Resource
Equipment 
purchase 
cost if 
known (inc 
VAT)‡
Total 
quantity 
required 
per 
consulting 
room
Quantity 
purchased to 
offer 
bevacizumab/
ranibizumab
Annual 
maintenance 
cost‡ if 
known (inc 
VAT & 
service
contracts)
Estimated 
likely life 
span (in 
years)
Furniture (please specify)
Other (please specify)
‡ If any piece of equipment listed in this table is leased, please write “leased” in the equipment purchase cost 
column and record the annual lease in the maintenance cost column.
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 a) Before your centre decided to offer bevacizumab/ranibizumab, what facilities did you 
have that could be used to assess visual function and/or perform optometric assessments 
on patients with nAMD? (Excluding the facilities described in Questions 2-5) 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
………………………………………………………………………………………
 
b) Did/would you need to set up 1 or more new optometric assessment room(s) or additional 
facilities for assessing visual function in order to offer bevacizumab/ranibizumab?  
 
YES/NO (if NO, go to Q7) 
 
c) If YES, what visual/optometric assessment facilities did/would you need to set up to offer 
bevacizumab/ranibizumab? 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
 
d) Please provide details on the equipment that was/would be required to set up your 
facilities for optometric assessment of patients who have received 
bevacizumab/ranibizumab in the past 2 years.  Please only include those pieces of 
equipment that are not listed elsewhere in the questionnaire and which are required in 
routine clinical practice for monitoring of patients who have had 
bevacizumab/ranibizumab in the last 2 years. Please exclude any equipment required for 
IVAN or other trials that is not used in routine clinical practice. 
 
Costs should include VAT 
 
Equipment 
 
Equipment 
purchase 
cost if 
known (inc 
VAT) 
Total quantity 
required 
across the 
clinic  
Quantity 
purchased to 
offer 
bevacizumab/ 
ranibizumab 
Annual 
maintenance cost‡ 
if known (inc VAT 
& service 
contracts) 
Estimated 
likely life 
span (in 
years) 
ETDRS 
6.  Visual assessment facilities 
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Equipment
Equipment 
purchase 
cost if 
known (inc 
VAT)
Total quantity 
required 
across the 
clinic 
Quantity 
purchased to 
offer 
bevacizumab/
ranibizumab
Annual 
maintenance cost‡ 
if known (inc VAT 
& service 
contracts)
Estimated 
likely life 
span (in 
years)
LogMAR 
visual acuity 
charts
Retro-
illuminated 
light box
Lens frame
Lens set
Bailey Lovie 
Near Word 
visual acuity 
charts
Light meter to 
measure 
luminance. 
e.g.  SPER 
Scientific
Testing lanes
Belfast 
reading 
speed charts
Table top 
light box 
Timer
Measuring 
stick
Pelli-Robson 
contrast 
sensitivity 
charts
Slit-lamp
LogMAR 
chart
Snellen chart
TV screen
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Equipment
Equipment 
purchase 
cost if 
known (inc 
VAT)
Total quantity 
required 
across the 
clinic 
Quantity 
purchased to 
offer 
bevacizumab/
ranibizumab
Annual 
maintenance cost‡ 
if known (inc VAT 
& service 
contracts)
Estimated 
likely life 
span (in 
years)
Tonometer
Computer
Networking
Software  
(please specify)
Printer
Blood 
pressure 
monitor
Lighting
Furniture 
(please specify)
Other (please 
specify)
‡ If any piece of equipment listed in this table is leased, please write “leased” in the equipment purchase cost 
column and record the annual lease in the maintenance cost column.
e) Approximately when was your newest assessment room set up? …………………………
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a) Did/would you need to set up additional waiting or reception area(s) or waiting room 
equipment for patients who have received bevacizumab/ranibizumab or purchase 
additional waiting room equipment? 
 
YES/NO (if NO, go to Q8) 
 
b) If YES, list equipment used and their cost to set up a waiting room or modify an existing 
room into a waiting area. 
 
Costs should include VAT.  
Equipment/ 
Resource 
Equipment 
purchase cost if 
known (inc 
VAT)‡ 
Total quantity 
required per 
waiting room 
Quantity purchased 
to offer 
bevacizumab/ 
ranibizumab 
Annual maintenance 
cost‡ if known (inc 
VAT & service 
contracts) 
Chairs     
Tables     
Computer     
Monitor     
Networking     
Printer     
Cupboards/ 
cabinets 
    
Other (please 
specify) 
     
     
     
     
     
     
     
‡ If any piece of equipment listed in this table is leased, please write “leased” in the equipment purchase cost 
column and record the annual lease in the maintenance cost column. 
 
c) Approximately when was your newest waiting room set up? …………………………… 
7. Waiting area 
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 a) Before your centre decided to offer bevacizumab/ranibizumab, what other facilities did 
you have that could be used by patients with nAMD? 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
………………………………………………………………………………………
 
b) Did you set up or modify any other room(s) in order to offer bevacizumab/ranibizumab? 
 
YES/NO (if NO, go to Q8f) 
 
c) If YES, how many rooms did you set up? ………………………………………… 
 
d) Please give details of what the room(s) was/were set up for and approximately when. 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
……………………………………………………………………………………… 
e) List equipment/resources used to set up or modify existing room(s) into the room(s) 
mentioned in 8d and their cost. 
 
Costs should include VAT. 
Equipment/Resource 
Equipment 
purchase 
cost if 
known (inc 
VAT)‡ 
Total 
quantity 
required 
(across 
all 
rooms) 
Quantity 
purchased to 
offer 
bevacizumab/ 
ranibizumab 
Annual 
maintenance 
cost‡ if 
known (inc 
VAT & 
service 
contracts) 
Estimated 
likely life 
span (in 
years) 
      
      
      
      
8.  Miscellaneous 
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Equipment/Resource
Equipment 
purchase 
cost if 
known (inc 
VAT)‡
Total 
quantity 
required 
(across 
all 
rooms)
Quantity 
purchased to 
offer 
bevacizumab/
ranibizumab
Annual 
maintenance 
cost‡ if 
known (inc 
VAT & 
service 
contracts)
Estimated 
likely life 
span (in 
years)
‡ If any piece of equipment listed in this table is leased, please write “leased” in the equipment purchase cost 
column and record the annual lease in the maintenance cost column. 
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f) If you needed to purchase any other equipment or incurred any other equipment costs in 
order to offer bevacizumab/ranibizumab that you have not mentioned previously, please 
record these resources here.
Equipment/Resource
Equipment 
purchase 
cost if 
known (inc 
VAT)‡
Total 
quantity 
required 
(across 
all 
rooms)
Total quantity 
purchased to 
offer 
bevacizumab/
ranibizumab
Annual 
maintenance 
cost‡ if 
known (inc 
VAT & service 
contracts)
Estimated 
likely life 
span (in 
years)
‡ If any piece of equipment listed in this table is leased, please write “leased” in the equipment purchase cost 
column and record the annual lease in the maintenance cost column.
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10. What percentage (%) of ‘On Costs’ or ‘overheads’ does your trust charge?
 
....................................................................................................................
a) Are overheads applied only to staff costs?            YES/NO  
 
b) If NO, what other resources are overheads applied to? .............................
....................................................................................................................
....................................................................................................................
 
 
11. Are there any other costs or resources that were incurred in order to offer
bevacizumab/ranibizumab that are not mentioned in the questionnaire? 
 
YES/NO  
 
12. If YES, provide details below 
……………………………………………………………………………
……………………………………………………………………………
……………………………………………………………………………
……………………………………………………………………………
……………………………………………………………………………
……………………………………… 
……………………………………………………………………………
……………………………………………………………………………
……………… 
……………………………………………………………………………
……………………………………………………………………………
……………… 
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………………………………………………………………………………………
……… 
………………………………………………………………………………………
……… 
………………………………………………………………………………………
……… 
………………………………………………………………………………………
……… 
 
13. If you have any comments on the questionnaire (such as difficulties that you 
encountered interpreting or finding the information for any specific sections, or 
any suggestions you may have for improving this questionnaire), please record 
them here. 
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
……………………………………………………………………………………… 
 
 
THANK YOU FOR TAKING THE TIME TO COMPLETE 
THIS QUESTIONNAIRE. 
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CONFIDENTIAL
Health Economics Research Centre
A RANDOMISED CONTROLLED TRIAL OF 
ALTERNATIVE TREATMENTS TO INHIBIT VEGF 
IN AGE-RELATED CHORIODAL 
NEOVASCULARISATION (IVAN)
Operating Cost Questionnaire
Date on which questionnaire was completed: ………………………
Main respondent’s contact details
Contact Name:
Job Title:
Centre:
Telephone Number:
Email Address:
Additional staff providing information:
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Contact Name:  
Job Title:   
Email Address:  
Question(s) completed:  
 
 
Contact Name:  
Job Title:   
Email Address:  
Question(s) completed:  
 
Contact Name:  
Job Title:   
Email Address:  
Question(s) completed:  
   
 
PLEASE DO NOT DETACH THIS PAGE 
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 Thank you for taking time to complete this questionnaire.  Your answers will be 
kept confidential and will only be used for the IVAN study. 
 
The aim of this research is to collect information on the costs and resources 
required to (a) administer intra-vitreal injections of ranibizumab or bevacizumab 
for the treatment of neovascular age-related macular degeneration (nAMD) and (b) 
monitor outcomes in patients who have received ranibizumab or bevacizumab at 
any point in the past 2 years.  
 
The information that you provide on this questionnaire is essential for us to assess 
the cost-effectiveness of ranibizumab or bevacizumab and the cost-effectiveness of 
the continuous and discontinuous therapy regimens evaluated in IVAN.  
Notes on filling in the questionnaire: 
· We are interested in the cost of treatment/monitoring in routine clinical 
practice, not the cost of IVAN clinics. 
· This questionnaire should be completed by someone (e.g. a clinic manager) 
who is involved in running NHS clinic sessions in which 
ranibizumab/bevacizumab are given or in which patients are monitored 
following ranibizumab/bevacizumab treatment.  
· If you don’t know the answer to any given question, please complete all 
questions that you can answer and pass the questionnaire on to others at your 
centre so that they can complete additional sections. If nobody at your centre 
has the information required to answer a particular question, please give your 
best guess wherever possible and otherwise leave it blank and complete and 
return the remainder of the questionnaire.  
· Please write “0” in response to any questions to which the answer is zero.  
· All costs should include VAT.  If you prefer to give costs excluding VAT, 
please state clearly which costs exclude VAT. 
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1a. Which of the following 5 options best describes the clinics you run for patients 
receiving ranibizumab/bevacizumab on the NHS (outside of clinical trials)? 
(please tick ( ) or underline the appropriate option)
A one-stop service in which monitoring and investigations for patients who have 
received ranibizumab/bevacizumab are conducted in the same clinic as 
ranibizumab/bevacizumab is administered.
Separate monitoring and treatment clinics run on different days, whereby 
patients attend the clinic for monitoring/investigations on a separate occasion 
from their intra-vitreal ranibizumab/bevacizumab injections.
Separate monitoring and treatment clinics run on the same day: e.g. a monitoring 
clinic run in the morning, followed by a treatment clinic in the afternoon of the 
same day.
A mixture of the first three options. 
(If you ticked this option, please answer the questions below)
a) What proportion of patients receiving intra-vitreal 
ranibizumab/bevacizumab injections attend one-stop clinics? 
………………..%
What determines whether a patient attends a one-stop clinic? 
…………………………………………………………………………..
…………………………………………………………………………..
None of these options (If you ticked this option, please provide details)
…………………………………………………………………………..
…………………………………………………………………………..
…………………………………………………………………………..
…………………………………………………………………………..
…………………………………………………………………………..
…………………………………………………………………………..
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2. Rooms and staff required to run each type of clinic
Question 3 should be answered for each of the 4 types of clinic defined in Question 3 
that apply to your centre. 
· If you run separate injection/monitoring clinics, please give details of your 
injection clinics in Q3A1 (pages 7-8) and your monitoring clinics in Q3A2 
(pages 9-10)
· If you run one-stop clinics, please give details of these in Q3B (pages 11-12)
· If you run any other types of clinic for ranibizumab/bevacizumab patients, 
please give details of these in Q3C (pages 13-14).
Please note that we are primarily interested in usual care clinics, rather than those run 
specifically for clinical trials. 
o If you run separate clinics exclusively for patients participating in clinical 
trials you do not need to describe the trial clinics here. 
o However, please do give details of clinics in which some but not all 
patients are enrolled in clinical trial(s).
If any of these 4 categories include clinics that require very different numbers of staff or 
rooms, please complete the questionnaire separately for each type of clinic that uses a 
different amount of resource use or requires a different number of staff, by printing out 
extra copies of these pages or by copying and pasting the relevant questions later in this 
Word document. For example, if you run 2 one-stop clinics each week, with 5-15
patients being seen at the smaller clinic and 20-40 being seen at the larger clinic, please 
fill in Question 2B separately for each clinic, recording your answers for your small 
one-stop clinic on pages 7-8 and answers for the large one-stop clinic on a different
sheet.
If you have used any continuation sheets for this question, how many continuation 
sheets have you used? ……………….
If you have used continuation sheets, please record below which clinics are described 
in each section (using the clinic names that you specified in Q3):
A1 (Injection clinics): …………………………………………………………………….
A2 (Review clinics): …………………………………………………………………….
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B (One stop clinics): …………………………………………………………………….
C (Other clinics): …………………………………………………………………….
Continuation sheet 1: …………………………………………………………………….
Continuation sheet 2: …………………………………………………………………….
A1) Injection clinic(s) in which most patients receive an intra-vitreal injection of 
ranibizumab or bevacizumab without also undergoing OCT, FFA or a detailed 
optometric assessment
i) How long does the average patient spend in the clinic at each visit? ……….…hours 
ii) Please provide details of the rooms that are used in each clinic session for your 
injection clinic(s).
If necessary, please give a range of values or complete this question separately for different 
types/sizes of injection clinic.
Name of room
Number of rooms 
of this type used 
per clinic session 
by pts who have 
had ranibizumab/
bevacizumab
Number of patients 
who have had/are 
having ranibizumab/
bevacizumab who use 
this type of room in 
the average clinic 
session
Number of other patients 
who use this type of room 
in the average session 
when your injection clinic 
is run (including pts attending 
other clinics running at the same 
time)
Sterile room(s) 
where injection is 
administered
OCT room(s) or 
machine(s)
FFA room(s) or 
machine(s)
Visual testing lanes
Consulting room(s)
Optometric 
assessment room(s)
Waiting area(s)
Recovery room(s)
Other (please specify)
Abbreviations: FFA, fundus fluorescein angiography; OCT, optical coherence tomography.
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iii) List in the table below all the staff who are involved in your injection clinic(s) each 
time they are run. 
If necessary, please give a range of values or complete this question separately for different 
types/sizes of injection clinic.
Staff type Post
Grade
/band
Room in 
which 
he/she is 
based
Role(s) in clinic
Number of 
staff
(e.g. no.
clinicians)
involved in 
injection 
clinic  
Proportion of 
their time during 
this clinic 
session that is 
spent on the 
injection clinic 
(rather than other 
clinics running at the 
same time)
Example of how to complete the table for Grade 5 nurses if three Grade 5 nurses will be involved in your injection 
clinic during any given clinic session, two of whom are also involved in other clinics run at the same time and spend 
around half of the clinic session on the injection clinic. 
EXAMPLE –
NURSES
Staff nurse 5 Treatment 
room
Helping with intra-
vitreal injections
1 100%
Staff nurse 5 Various Running clinic, 
visual testing, 
fluorescein 
injections
2 50%
Staff required for your clinic
Nurses 
Healthcare 
assistants
Clinicians
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Staff type Post
Grade
/band
Room in 
which 
he/she is 
based
Role(s) in clinic
Number of 
staff
(e.g. no.
clinicians)
involved in 
injection 
clinic  
Proportion of 
their time during 
this clinic 
session that is 
spent on the 
injection clinic 
(rather than other 
clinics running at the 
same time)
Optometrists
Ophthalmic 
photo-
graphers/ 
technicians
Administrative 
coordinators
Data 
collection & 
management 
support staff
Other 
administrative 
staff
Eye clinic 
liaison 
officers
Other (please 
specify)
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A2) Monitoring clinic(s) attended by one or more patients who have received 
ranibizumab and/or bevacizumab in the last 2 years but in which no pts 
receive ranibizumab or bevacizumab injections
i) How long does the average patient spend in the clinic at each visit? ……….…hours 
ii) Please provide details of the rooms that are used in each clinic session for your 
monitoring clinic(s).
If necessary, please give a range of values or complete this question separately for different 
types/sizes of monitoring clinic.
Name of room
No. rooms of this type 
used per clinic session by 
pts who have had 
ranibizumab/bevacizumab
No. patients who have 
had/are having  
ranibizumab/bevacizumab
who use this type of room 
in the average clinic 
session
No. other patients 
who use this type 
of room in the 
average session 
when your 
monitoring clinic 
is run (including pts 
attending other clinics 
running at the same 
time)
Sterile room(s) 
where injection 
is administered
OCT room(s) 
or machine(s)
FFA room(s) or 
machine(s)
Visual testing 
lanes
Consulting 
room(s)
Optometric 
assessment 
room(s)
Waiting area(s)
Recovery 
room(s)
Other (please 
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specify)
Abbreviations: FFA, fundus fluorescein angiography; OCT, optical coherence tomography.
iii) List in the table below all the staff who are involved in your monitoring clinic(s) 
each time they are run. 
If necessary, please give a range of values or complete this question separately for different 
types/sizes of monitoring clinic.
Staff type Post
Grade
/band
Room in 
which 
he/she is 
based
Role(s) in clinic
No. staff
(e.g. no.
clinicians)
involved in 
monitoring 
clinic  
Proportion of 
their time during 
this clinic 
session that is 
spent on the 
monitoring clinic 
(rather than other 
clinics running at the
same time)
Nurses 
Healthcare 
assistants
Clinicians
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Staff type Post
Grade
/band
Room in 
which 
he/she is 
based
Role(s) in clinic
No. staff
(e.g. no.
clinicians)
involved in 
monitoring 
clinic  
Proportion of 
their time during 
this clinic 
session that is 
spent on the 
monitoring clinic 
(rather than other 
clinics running at the
same time)
Optometrists
Ophthalmic 
photo-
graphers/ 
technicians
Administrative 
coordinators
Data 
collection & 
management 
support staff
Other 
administrative 
staff
Eye clinic 
liaison 
officers
Other (please 
specify)
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B) One stop clinic(s) during which most patients receive both monitoring (e.g. 
OCT, FFA and/or a detailed optometric assessment) AND an intra-vitreal 
injection of ranibizumab or bevacizumab
i) How long does the average patient spend in the clinic at each visit? ……….…hours 
ii) Please provide details of the rooms that are used in each clinic session for your one 
stop clinic(s).
If necessary, please give a range of values or complete this question separately for different 
types/sizes of one-stop clinic.
Name of room
No. rooms of this type 
used per clinic session by 
pts who have had 
ranibizumab/bevacizumab
No. patients who have 
had/are having  
ranibizumab/bevacizumab
who use this type of room 
in the average clinic 
session
No. other patients 
who use this type 
of room in the 
average session 
when your one 
stop clinic is run 
(including pts attending 
other clinics running at 
the same time)
Sterile room(s) 
where injection 
is administered
OCT room(s) or 
machine(s)
FFA room(s) or 
machine(s)
Visual testing 
lanes
Consulting 
room(s)
Optometric 
assessment 
room(s)
Waiting area(s)
Recovery 
room(s)
Other (please 
specify)
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Abbreviations: FFA, fundus fluorescein angiography; OCT, optical coherence tomography.
iii) List in the table below all the staff who are involved in your one stop clinic(s) each 
time they are run. 
If necessary, please give a range of values or complete this question separately for different 
types/sizes of one stop clinic.
Staff type Post
Grade
/band
Room in 
which 
he/she is 
based
Role(s) in clinic
No. staff
(e.g. no.
clinicians)
involved in 
1-stop clinic  
Proportion of 
their time during 
this clinic 
session that is 
spent on the 1-
stop clinic (rather 
than other clinics 
running at the same 
time)
Example of how to complete the table for Grade 5 nurses if three Grade 5 nurses will be involved in your one stop 
clinic during any given clinic session, two of whom are also involved in other clinics run at the same time and spend 
around half of the clinic session on the injection clinic.
EXAMPLE –
NURSES
Staff nurse 5 Treatment 
room
Helping with intra-
vitreal injections
1 100%
Staff nurse 5 Various Running clinic, 
visual testing, 
fluoroscein 
injections
2 50%
Staff required for your clinic
Nurses 
Healthcare 
assistants
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Staff type Post
Grade
/band
Room in 
which 
he/she is 
based
Role(s) in clinic
No. staff
(e.g. no.
clinicians)
involved in 
1-stop clinic  
Proportion of 
their time during 
this clinic 
session that is 
spent on the 1-
stop clinic (rather 
than other clinics 
running at the same 
time)
Clinicians
Optometrists
Ophthalmic 
photo-
graphers/ 
technicians
Administrative 
coordinators
Data 
collection & 
management 
support staff
Other 
administrative 
staff
Eye clinic 
liaison 
officers
Other (please 
specify)
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C) Other clinic(s) that don’t fit into the above categories but which are attended 
by (a) one or more patients who have received ranibizumab and/or 
bevacizumab in the last 2 years AND/OR (b) one or more patients who will be 
given ranibizumab or bevacizumab in this clinic
If necessary, please use continuation sheets to give details of different types of clinic falling into this 
category.
i) How long does the average patient spend in the clinic at each visit? ……….…hours 
ii) Please provide details of the rooms that are used in each clinic session for your 
other clinic(s).
If necessary, please give a range of values or use the continuation sheets to complete this question 
separately for different types/sizes of clinic.
Name of room
No. rooms of this type 
used per clinic session by 
pts who have had 
ranibizumab/bevacizumab
No. patients who have 
had/are having  
ranibizumab/bevacizumab
who use this type of room 
in the average clinic 
session
No. other patients 
who use this type 
of room in the 
average session 
when your other 
clinic is run 
(including pts attending 
other clinics running at 
the same time)
Sterile room(s) 
where injection 
is administered
OCT room(s) or 
machine(s)
FFA room(s) or 
machine(s)
Visual testing 
lanes
Consulting 
room(s)
Optometric 
assessment 
room(s)
Waiting area(s)
Recovery 
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room(s)
Other (please 
specify)
Abbreviations: FFA, fundus fluorescein angiography; OCT, optical coherence tomography.
iii) List in the table below all the staff who are involved in your other clinic(s) each time 
they are run. 
If necessary, please give a range of values or use the continuation sheets to complete this question 
separately for different types/sizes of clinic.
Staff type Post
Grade
/band
Room in 
which 
he/she is 
based
Role(s) in clinic
No. staff
(e.g. no.
clinicians)
involved in 
other VEGF 
clinic  
Proportion of their 
time during this 
clinic session that 
is spent on the 
other VEGF clinic 
(rather than other 
clinics running at the 
same time)
Example of how to complete the table for Grade 5 nurses if three Grade 5 nurses will be involved in your other clinic 
during any given clinic session, two of whom are also involved in other clinics run at the same time and spend around 
half of the clinic session on the injection clinic.
EXAMPLE –
NURSES
Staff nurse 5 Treatment 
room
Helping with intra-
vitreal injections
1 100%
Staff nurse 5 Various Running clinic, visual 
testing, fluoroscein 
injections
2 50%
Staff required for your clinic
Nurses 
Healthcare 
assistants
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Staff type Post
Grade
/band
Room in 
which 
he/she is 
based
Role(s) in clinic
No. staff
(e.g. no.
clinicians)
involved in 
other VEGF 
clinic  
Proportion of their 
time during this 
clinic session that 
is spent on the 
other VEGF clinic 
(rather than other 
clinics running at the 
same time)
Clinicians
Optometrists
Ophthalmic 
photo-
graphers/ 
technicians
Administrative 
coordinators
Data 
collection & 
management 
support staff
Other 
administrative 
staff
Eye clinic 
liaison 
officers
Other (please 
specify)
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3. Are there any afternoons or mornings in which your clinic facilities are not used at 
all? (e.g. weekends or Friday afternoons)
YES/NO (please circle or underline the appropriate response to this and all 
subsequent yes/no questions)
a) If YES, please state when your clinic facilities are not used at all:
………………………………………………………………………………………
………………………………………………………………………………………
a) Please provide details of average number of people using these facilities during 
clinic sessions in which no patients who have received ranibizumab or bevacizumab
in the last 2 years are seen. Please note that we do not require a detailed breakdown 
for these clinics: simply an indication of how much these rooms are used at times 
when they are not being used by patients who have had ranibizumab/bevacizumab.
Name of room
Approximate number of 
rooms of this type used per 
clinic session
Approximate number of 
patients who use each room of 
this type in the average clinic 
session
Sterile room(s) where 
injection is
administered
OCT room(s) or 
machine(s)
FFA room(s) or 
machine(s)
Visual testing lanes
Consulting room(s)
Optometric 
assessment room(s)
Waiting area(s)
Recovery room(s)
Other (please specify)
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5. What staff are required in the treatment room while intra-vitreal injections of ranibizumab
or bevacizumab are being administered? 
Please state post and grade for each role
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
a) How long are the treatment room and staff required for each patient receiving intra-
vitreal injection in one eye? 
(Please include any time spent preparing or cleaning the room between uses and any time spent 
completing paperwork or electronic records relating to the injection.)
The room is required for ………………………… minutes per injection
Nurse is required for …………………………….. minutes per injection 
Ophthalmologist is required for …………………. minutes per injection 
……………………...… is required for …………. minutes per injection
……………………...… is required for …………. minutes per injection
b) Would you consider giving intravitreal injections into both eyes during the same 
clinic visit? YES / NO
i) If YES, please give details of how this would be done. 
Please state: approximately what proportion of patients get often bilateral injections; whether the 
second injection would be given immediately or how long a gap would be left between injections; 
whether the patient would leave the treatment room between injections and (if not) how long the 
treatment room would be required for if both eyes were to be injected.
………………………………………………………………………………………
………………………………………………………………………………………
………………………………………………………………………………………
6. Are pre-prepared injection packs (containing the consumables and instruments required 
for injection) used for the administration of ranibizumab or bevacizumab injections? 
YES/NO
a) If YES, in approximately what proportion of injections are pre-prepared injection 
packs used ……………..%
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b) What is the cost per pre-prepared injection pack (including VAT)?  
…………………………………………………………
7. Please provide details of the staff involved in fundus fluorescein angiography (FFA), 
including any staff involved in preparing the patient for the test.
Staff role Post Grade
No. minutes spent 
per FFA conducted 
(including preparing 
patient for test)
Nurse(s)
Healthcare assistants
Ophthalmic technician/ 
photographer
Clinician(s)
Other (please specify)
8. Approximately how many people live in the area served by your hospital?
…………………………………………………………
9. What facilities did you set up or modify in order to offer ranibizumab/bevacizumab
injections to NHS patients?
Room Number of rooms of this type that you set up or modified in 
order to offer ranibizumab/bevacizumab
Waiting rooms
Sterile rooms suitable for 
intra-vitreal injections
Visual testing lanes
OCT rooms
FFA rooms
Consultation rooms
Optometric assessment 
rooms
Recovery rooms
Other rooms (please specify)
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Page A5-91 
  
  
Abbreviations: FFA, fundus fluorescein angiography; OCT, optical coherence tomography. 
 
10. What percentage (%) of ‘On Costs’ or ‘overheads’ does your trust charge? 
 
........................................................................................................................ 
 
c) Are overheads applied only to staff costs?            YES/NO  
 
d) If NO, what other resources are overheads applied to? ................................ 
........................................................................................................................ 
........................................................................................................................ 
 
11. Are there any other costs or resources that are required to run clinics for administering 
ranibizumab/bevacizumab or monitoring outcomes that you have not mentioned above?  
 
YES/NO 
 
a) If YES, provide details below 
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
……………………………………………………………………………………………… 
 
12. If you have any comments on the questionnaire (such as difficulties that you encountered 
interpreting or finding the information for any specific sections, or any suggestions you 
may have for improving this questionnaire), please record them here. 
………………………………………………………………………………………………
………………………………………………………………………………………………
………………………………………………………………………………………………
……………………………………………………………………………………………… 
 
 
THANK YOU FOR TAKING THE TIME TO COMPLETE THIS 
QUESTIONN IRE 
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Economic analysis: additional detail on themethods for analysing
costs and quality-adjusted life-years
Methods for assigning consultation costs
Microcosting work gave estimates of the cost of different types of consultation for administering/monitoring
anti-VEGF therapy for a sample of clinics of differing sizes (see Chapter 2). As the number of patients
recruited to IVAN does not reflect the number of patients that each centre treats in routine clinical practice,
average costs were applied to all patients regardless of which centre they attended. However, to allow for the
substantial variability in unit costs between centres, we drew repeated values from the distribution of clinic
costs for each patient in each of the 100 imputed data sets. This was conducted by assigning a weight to
each clinic equal to the number of patients attending that clinic in the average week, divided by the total
number of patients attending all clinics in the average week. We then generated random numbers from a
uniform distribution for each patient in each imputed data set for each type of clinic. Random numbers were
compared against the weights to determine which clinic cost each patient was assigned in that imputed
data set. As patients generally attend the same clinic throughout their course of treatment, unit costs
were assumed to be constant over the 24 visits within each patient for any given imputed data set. For
example, if the weight assigned to Liverpool’s one-stop clinic was 5% and the weight assigned to Bristol’s
monitoring-only clinic was 2%, the patient would be assigned the cost from Liverpool in imputation 1 if their
random number was < 0.05, and assigned to the cost from Bristol in imputation 2 if their random number
was between 0.07 and 0.05.
Methods for dealing with missing resource-use data
The amount of missing data on resource use was minimised by asking patients to provide details of all
medication changes and ambulatory consultations since their last visit at every IVAN consultation and by
collecting additional information from SAE forms and by telephone. However, these measures also meant
that it was generally not possible to identify which patients had accrued NHS costs but not reported them
at clinic visits. In general it was therefore assumed that the ‘Use of Medical Services’ form captured all
ambulatory consultations occurring during the trial period regardless of missed visits or the timing of visit 24.
However, if the patient answered ‘yes’ to the question ‘Has the patient made any visits to any hospital,
accident and emergency department, GP or NHS walk-in centre regarding (non-)ocular symptoms since their
last visit?’ but did not complete the ‘Use of Medical Services’ form at that visit, one episode of missing
resource-use data was imputed by randomly drawing costs from another medical services form for that
patient (or across all patients if this patient had no other medical services use), with independent draws
made for each patient in each of the 100 imputed data sets. Multiple imputation was not used for missing
resource-use data, as resource-use data were missing for only 2% (330/13,398) of attended visits.
Handling censoring using Kaplan–Meier sample averaging
Kaplan–Meier sample averaging assumes that censoring occurs at discrete time points on the boundaries
of each time interval. As IVAN participants could withdraw from the trial at any time (including part of
the way through a quarter), we excluded patients withdrawing during quarter ‘q’ from the mean costs for
this quarter, in order to avoid the bias that can arise from including partially observed quarters.84 This
recognised84 variant of KMSA captures one of the main advantages of another censoring analysis method
[inverse probability weighting (IPW129)], while excluding only 45 partially observed patient quarters (0.9%).
For QALYs and medication/medical service costs, quarters were excluded from the analysis if the patient
withdrew before the end of the quarter; for example, if a patient withdrew 0.45 years after randomisation
then the costs and medication/medical service costs they accrued during quarter 1 were included in the
analysis, but those accrued in quarter 2 were excluded from averages, as they were incomplete. Quarterly
drug costs and administration/monitoring costs cover the three visits included in that quarter; for example,
quarter 11 includes resource use from visits 0, 1 and 2, whereas quarter 2 includes resource use from
visits 3–5. Patients withdrawing after the third visit of any given quarter was due but before the end of that
quarter (e.g. those withdrawing between visits 5 and 6), were considered to have drug and administration/
monitoring costs fully observed for that quarter in order to maximise the amount of data used in the analysis.
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For example, the patient withdrawing 0.45 years after randomisation would be included in the analysis of
drug and administration/monitoring costs for quarters 1 and 2, although only their data for quarter 1 were
included in the analysis of QALYs and medication/medical service costs.
Methods for estimating mean costs and quality-adjusted life-years
The analysis outlined below was initially conducted with interactions for all four components of net
benefit: drug cost; administration/monitoring costs; medication and medical service use costs; and QALYs.
The analysis including interactions was used to assess the magnitude and statistical significance of
interactions, and identify for which of the four components of net benefit it could be assumed that drug
and treatment regimen have additive effects. This approach avoids reducing statistical power by allowing
for interactions unnecessarily,43,49 while ensuring unbiased43,85 estimation of costs and QALYs for each
treatment regimen.
Within the base-case analysis, interactions were included for those components of costs or QALYs where
interactions were either statistically significant or had an absolute magnitude larger than either the
main effect for treatment regimen or the main effect for drug. However, interactions that were both
non-significant and smaller than both main effects were excluded from the analysis to avoid loss of statistical
power. Lack of statistical significance was not considered sufficient grounds to ignore interactions, as
ignoring genuine interactions introduces bias43,85 and can give misleading conclusions.130 We evaluated
different methods for identifying important interactions on simulated trial data, which demonstrated that
including interactions that are larger than main effects outperformed using statistical significance or Bayesian/
Akaike information criteria for identifying influential interactions. The approach used had a lower probability
and a lower opportunity cost from failing to adopt the treatment that maximises true net benefits.
As the economic evaluation focuses on estimation rather than hypothesis testing and inference has been
argued to be irrelevant to decision-making based on the results of economic evaluation,131 no adjustment
was made for multiple comparisons.
The base-case economic evaluation and/or sensitivity analyses were analysed using the algorithm
shown below:
1. Multiple imputation was used to impute missing utility data (see Chapter 2), generating 100 imputed
data sets. The 100 data sets also had different randomly sampled values for missing resource use,
mixed-model recovery rate coefficients, and costs for injection and monitoring consultations.
2. Bootstrapping132 was used to allow for uncertainty and correlations between quarterly costs and QALYs
and to avoid parametric assumptions. The following steps were initially conducted for the original trial
sample in each of the 100 imputed data sets, as estimates for the original sample represent the best
estimate of likely outcomes.132 One hundred and thirty bootstrap samples were then drawn with
replacement from each of the 100 data sets (giving a total of 13,000 bootstraps) and the following
steps were repeated on each bootstrap of each imputed data set to provide an empirical estimate of
the distribution of costs and QALYs for each study arm.
i. Quarterly QALYs were estimated using OLS regression across all patients alive at the start of that
quarter, controlling for baseline utility and treatment allocation. Analysis of QALYs in quarter 1
included a dummy for drug but not treatment regimen or an interaction term. QALYs in subsequent
quarters included both treatment dummies, plus an interaction term if interactions for QALYs were
statistically significant or were larger than one or more main effect. Baseline utility was included in
all analyses of QALYs to adjust for any imbalance in baseline utility, thereby avoiding bias, allowing
for regression to the mean and increasing precision.86
ii. Mean quarterly drug costs, administration/monitoring costs and medication/medical service costs
were analysed using OLS regression for each of the four arms, across all patients alive at the start of
that quarter. Interaction terms were included for those cost components with significant interactions
for at least one quarter and those where interactions change the conclusions, although the
interaction term and the term for treatment regimen were omitted for quarter 1.
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iii. A Kaplan–Meier survival curve for all-cause mortality in each group was calculated as described in
Chapter 2 (assuming a common rate of deaths unrelated to study medication across all treatment
arms). The resulting proportions of patients alive at the start of each quarter was multiplied by the
quarterly costs and QALYs for each arm in each quarter (KMSA) to give overall mean quarterly costs
and QALYs in each arm.
iv. Costs and QALYs accrued in the second year of the trial were discounted at 3.5% per annum to
allow for time preference, in line with current recommendations.42,87
v. Steps a–d were repeated for each imputed data set to provide point estimates. An empirical estimate
of the distribution of costs and effects for each arm were obtained by repeating steps a–d for the
130 bootstrap replicates from each of the 130 data sets.
3. The 100 imputed data sets were combined using Rubin’s rule77 to estimate mean costs and QALYs for
each of the four study arms and SEs around each mean. The empirical distribution across the 13,000
replicates was used to generate cost-effectiveness acceptability curves and scattergraphs on the
cost-effectiveness plane and estimate the value of collecting additional information. Cost-effectiveness
acceptability curves are presented for the four pairwise comparisons defined in Chapter 2 by plotting
the proportion of the 13,000 replicates that find each treatment to have greater net benefits than its
comparator against ceiling ratio. Cost-effectiveness acceptability curves were also produced using a net
benefit framework to present the likelihood that each intervention produces highest net benefits across
all four arms at different ceiling ratios. In the construction of cost-effectiveness acceptability curves, it
was assumed that the NHS has symmetrical preferences for gains and losses – i.e. that the minimum
savings that they would require to accept the loss of one QALY are equal to the maximum cost they
would be willing to pay to gain one QALY.
4. Conclusions were drawn using the framework described in Chapter 2.
5. The impact of heterogeneity was evaluated by exploring the impact of the five prespecified clinical
subgrouping variables (see Chapter 2) and an additional variable indicating whether or not VA in the
study eye was > 5 letters better than the fellow eye at baseline. The impact of subgroups was evaluated
using OLS regression predicting drug costs, administration/monitoring costs, medication/medical service
costs and QALYs accrued in each quarter, conditional on drug, treatment regimen, subgroup, an
interaction between drug and subgroup, an interaction between treatment regimen and subgroup
and (for variables in which interactions were included in the base case) the interaction between drug and
treatment regimen and an interaction between drug, treatment regimen and subgroup; the impact
of treatment regimen and interactions were omitted for quarter 1 and imputed data sets were combined
using the min command. A Bonferroni correction was made to allow for the fact that multiple p-values
were reviewed across the six subgroups, four variables and eight quarters, which meant that statistical
significance was evaluated at the 0.0001 level. All subgroup analyses should be considered hypothesis
generating rather than confirmatory in nature.
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Appendix 5 Statistical analysis plan: analysis of
2-year results
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Acronym Details
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1. INTRODUCTION TO STATISTICAL ANALYSIS PLAN
1.1 Scope
This document details information regarding the statistical analysis of the IVAN trial and covers the 
formal 2 year analyses of trial data for primary publication.  It does not include the health economic 
evaluation or additional analyses not listed in the study protocol.
1.2 Editorial changes
Any changes made to this statistical analysis plan (SAP) after approval must be clearly justified and 
documented as an amendment at the end of this document. 
1.3 SAP document approval
The trial statistician should authorise this document.
1.4 Template tables and figures
Throughout this document references are made to any skeleton tables and figures to be used in the 
reporting of the trial (e.g. Figure F1 or Table T1).  Such tables and figures can be found in the 
appendix of this document, and are intended as a guide for study reporting. Final versions of the 
tables/figures may differ: tables may be combined, and/or their layout or numbering may differ. 
However the content should be consistent with the appendix.
2. STUDY OBJECTIVES 
IVAN is a multi-centre double blind randomised controlled trial (RCT). Two alternative treatments 
to inhibit VEGF in wet or neovascular age-related macular degeneration (nAMD), Lucentis 
(ranibizumab) and Avastin (bevacizumab) are compared at two different treatment regimes.  The 
two regimes are 2 years of continuous treatment versus a reduced treatment regimen.  The trial 
follows a factorial design, with each patient being randomised to one of four drug/treatment 
frequency combinations (Table 1).
Table 1IVAN treatment combinations
Lucentis Avastin
Continue treatment @ 3 months A B
Stop treatment @ 3 months C D
The objectives are to (a) compare the clinical efficacy of the two drugs; (b) compare the reduced 
treatment regimen versus two years of continuous treatment; (c) describe the cost effectiveness of 
different drugs and treatment regimens; (d) describe both eye-related and systemic side effects with 
different drugs and treatment regimens.
It is hypothesised that 
a) Avastin is not inferior to Lucentis with respect to the benefits of VEGF inhibition in 
maintaining /improving visual acuity in eyes with nAMD.
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b) Treatment with VEGF inhibition can be ‘safely’ withdrawn at 3 months with monthly review to 
detect reactivation, i.e. criteria for re-starting treatment can be pre-specified to prevent any
difference in average visual acuity compared with continuing monthly treatment.
It is not expected that Avastin will be more effective than Lucentis with respect to visual acuity. 
2.1 Treatment schedule
All patients receive a sequence of 3 injections at visits 0, 1, and 2.  From visit 3 onwards the 
treatment schedule varies between patients randomised to continuous treatment and those 
randomised to stop treatment.
For patients randomised to continuous treatment, VEGF inhibitor is administered at each visit (from 
baseline, month 0, to month 23).
Patients randomised to stop treatment continue to attend on a monthly basis for assessment of their 
visual outcome, in exactly the same way as participants allocated to continue treatment.  However, 
they do not receive treatment unless the clinician assessing lesion morphology (by clinical 
examination, OCT and FA) judges against pre-specified criteria (see section 4.2) that the lesion has 
reactivated and that treatment has failed. 
Patients showing signs of reactivation in the discontinuous arm re-start treatment according to their 
original treatment allocation for a further 3 month cycle, and then stop treatment again (see Figure 
1).  The determination of treatment failure is also made for eyes within the continuous pathway in 
the same way.
Figure 1 Treatment over time in patients allocated to continue or stop treatment at 3 
months
After 24 months, treatment will be stopped unless participants in a discontinuous arm are in the 
middle of a treatment cycle.
2.2 Follow-up schedule
Participants are followed monthly for 24 months from randomisation. 
The minimum interval between visits is 28 days and the maximum is 35 days (excluding any 
unscheduled breaks in treatment).
Illustration of treatment over time
continuous VEGF inhibitor 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes yes *
3 month VEGF inhibitor 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
yes yes yes no no no no yes yes yes no no no no no no no yes yes yes no no no no *
OR
yes yes yes no no yes yes yes no no no no no yes yes yes no no no yes yes yes no no *
OR
yes yes yes no no no no no no no yes yes yes no no no no no no no no no no no *
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2.3 Primary outcome 
The primary outcome is the best corrected distance visual acuity (BCVA, ETRDS chart letters read 
[1]), measured 24 months after the start of treatment (visit 24).  BCVA is also measured in the study 
eye at baseline before any treatment, and at every monthly visit. 
2.4 Secondary outcomes 
Secondary outcomes defined in the IVAN protocol are  
a) Frequencies of adverse effects of treatment; 
b) Generic health status and macular-disease specific quality of life; 
c) Treatment satisfaction; 
d) Cumulative resource use / cost, and cost-effectiveness; 
e) Other clinical measures of vision; 
f) Lesion morphology (from masked grading of FFAs and OCTs); 
g) Survival free from treatment failure (i.e. satisfying one or more of the criteria for retreatment) 
Clinical measures of vision comprise: contrast sensitivity (CS), near visual acuity and the reading 
index (words read per minute/size of print).  Lesion morphology and metrics include lesion area, 
presence of fluid, total thickness at the fovea, and retinal plus subfoveal fluid thickness.  
 
3. STUDY POPULATION 
The study population is patients aged 50+ years, newly referred for the treatment of nAMD in the 
first or second eye, with BCVA ≥25 letters read on a standard ETDRS chart. Participants must have 
a component of the neovascular lesion involving the centre of the fovea.   
Exclusion criteria include patients with long standing CNV (fibrosis >50% of the total lesion), a 
greatest linear diameter >6000μm, thick blood involving the centre of the fovea, 8 or more dioptres 
of myopia or other active ocular disease causing concurrent vision loss.  Previous treatment (argon 
laser within 6 months, VPDT or a VEGF inhibitor to the study eye) was also an exclusion criterion. 
This analysis will include all randomised patients who received at least one treatment injection.  A 
flowchart of patient recruitment and progress through the trial will be presented (see Figure F1). 
3.1 Randomisation 
Randomisation is stratified by centre.  Randomisation to both drug and treatment frequency occurs 
at recruitment, but the frequency (continuous or discontinuous) allocation is not revealed until the 
patient attends at 3 months. 
3.2 Protocol breaches  
We consider nine main protocol breaches: 
· Patient received the alternative drug treatment to that allocated on at least one occasion 
· Patient received alternative treatment regimen to that allocated 
· Patient did not meet the trial eligibility criteria but was treated in the trial 
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• Patient was mid-way through a cycle of treatment (discontinuous group) or was in the 
continuous group, and attended the clinic but treatment was not given.
• The patient was allocated to the discontinuous arm: treatment was restarted but the criteria for 
retreatment were not met
• The patient was allocated to the discontinuous arm: treatment was not restarted but the criteria 
for retreatment were met
• The patient was allocated to the discontinuous arm: treatment was extended beyond the 3-
months but the criteria for retreatment were either not assessed or not met at the visit(s) beyond 
the 3 months   
• Time between two consecutive visits was < 28 days or >35 days
• Missed visits (prior to trial exit)
The frequency of each type of breach will be described by group (Table T1) and full details  
(along with reasons) of each protocol breach will also be described (T2). This will allow for the
identification of any imbalances in protocol breach by group.
3.3 Flow of participants
The study population will be described via a flowchart, see Figure F1.
3.4 Withdrawals
A patient (or a clinician on the patient’s behalf) can withdraw from the trial at any time. In some 
cases patients may be happy for some follow-up to continue.  Data on all withdrawals is captured on 
a specific case report form (CRF), and will be presented in table form (grouped by reason and 
treatment allocation); see Table T3.
3.5 Analysis groups
The analysis population consists of all randomised patients excluding:
• Patients who were not treated
• Patients who withdrew (or were withdrawn) and who are unwilling for data collected to be used
This is illustrated in Figure F1. The analysis of the primary outcome will be performed on the basis of
the treatment allocation, which is consistent with the analysis of the CATT trial [2, 3].  For the interim 
analysis we intended to include adjustment for the amount treatment received, as a sensitivity analysis, 
to reflect the CONSORT guidelines for the reporting of non-inferiority hypotheses which suggest that 
non-inferiority comparisons on the basis of treatment allocation can increase the type I error [4].  
However, preliminary examination of the data indicated that including this additional covariate provided  
un-interpretable treatment estimates. We will therefore also exclude it from all analyses of the 2 year data. 
3.6 Safety population
The safety population is the same as the analysis population for the IVAN trial.  Reporting 
guidelines recommend that safety data is analysed by the treatment received [5].  As IVAN is a 
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masked trial with respect to drug allocation, the drug treatment received should equal the treatment 
allocated.  If the drug received differs by visit (i.e. the wrong treatment was given on one or more 
occasions) the patient will be grouped according to the drug received with greatest frequency.  
Grouping patients according to the amount of treatment received is less straightforward. For 
consistency of reporting (see section 4.5), patients will be grouped according to the treatment 
frequency allocated. 
4. IVAN DATA COLLECTION 
Data for IVAN is collected at each planned visit from months 0 to 24, at any additional unplanned 
visit because of an adverse event, and if a patient exits the trial.  Table 2 summarises the data 
collected at each visit. Quality of life data (EQ-5D and HUI3) are also collected when an SAE 
occurs.
4.1 Main study visits
The primary outcome BCVA in the study eye was recorded at all visits. For modelling purposes, 
visits 0, 3, 6, 9, 12, 15, 18, 21 and 24 will be used as ‘main study visits’ for BCVA and data from 
other visits will only be used if data from the previous main study visit is missing. All other visual 
outcomes are only collected at visits 0, 3, 6, 12, 18 and 24 so these are the ‘main study visits’ for 
these variables. As with BCVA, if main visits were missed and data was collected at the following 
visit, this data will be used instead.
4.2 Deferred visits
Deferred visits are those where visual outcome data is collected but the visit is not a ‘main study 
visit’. This usually occurs when the previous main study visit was missed. If this is the case, data 
from a deferred visit may be used in place of a main study visit. See sections 5.1 and 5.2 for details 
of how deferred visit data will be used. 
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5. DERIVATIONS
5.1 Primary outcome
The primary outcome is the distance BCVA (letters read) in the study eye.
If, at any assessment, no letters can be read the following scoring will be applied:
Value assigned
Counting fingers (CF) 0
Hand movements (HM) -15
Perception of light (PL) -30
A value of zero equates to no letters read at 1 metre.  The other values (which equate to a doubling 
of the visual angle) are chosen to allow the assignment of arbitrary points in deteriorating visual 
function to these categories. 
For modelling purposes, if distance BCVA is not recorded at the intermediate main study visits (i.e. 
visits 3, 6, 9, 12, 15, 18, 21), but is measured at the following visit (i.e. visit 4, 7, 10 etc.), the main 
study visit missing value(s) will be imputed using the ‘deferred visit’ value(s). If distance BCVA is 
missing for both the main study visit and the following visit, the data will be considered missing. 
Patients with BCVA measured on at least one of the main study visits 0, 3, 6, 9, 12, 15, 18, 21 or 
24, will be included in the analysis.
5.2 Secondary outcomes
For modelling purposes, if secondary outcome measures are not recorded at the intermediate main 
study visits (i.e. visits 3, 6, 12, 18), but are measured at the following visits, the main study visit 
missing value(s) will be imputed using the ‘deferred visit’ value(s). If both the main study visit data 
and the following visit data are missing, the data will be considered missing. Patients with outcome 
measures for at least one of the main study visits 0, 3, 6, 12, 18, or 24, will be included in the 
analysis.
5.2.1 Visual outcomes
The relationships between different measures of visual function will be examined and any apparent 
outliers identified. These will be discussed with the study clinician (maintaining the study blinding) 
to determine whether the values observed are plausible. Zero values for BCVA, contrast sensitivity, 
words read or Belfast reading index will also be investigated. Implausible values will be considered 
missing. 
5.2.1.1 Belfast reading index
The Belfast chart used to assess reading ability depends on the patient’s near vision (logMAR 
value). Any instances where the incorrect chart size has been used will be investigated. A chart of 1 
size larger or smaller than the correct size will be accepted (see Table below). A chart two or more 
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sizes larger or smaller than the correct size will be treated as missing data, and the reading index 
will not be calculated.
LogMAR Chart sizes used that will be treated 
as accurate data (N units)
0 2, 2.5, 3
0.1 2.5, 3, 4
0.2 3, 4, 5
0.3 4, 5, 6
0.4 5, 6, 8
0.5 6, 8, 10
0.6 8, 10, 12
0.7 10, 12, 16
0.8 12, 16, 20
0.9 16, 20, 25
1.0 20, 25, 32
1.1 25, 32, 40
1.2 32, 40, 50
1.3 40, 50, 63
1.4 50, 63, 80
1.5 63, 80
1.6 80
Patients with LogMAR of 1.6 may not have their reading ability measured as their vision is too 
poor. If there are any non-missing values of reading index for those with LogMAR of 1.6, the 
distribution of these will be investigated, and missing values will be imputed. The method of 
imputation will be guided by the observed distribution.  
In order to calculate the Belfast reading index, the data collected on the IVAN CRF (in N units) 
needs to be mapped to a new measurement scale (M units).  The mapping to be applied is shown in 
the table below. 
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Chart size (N units) Chart size for calculation (M units)
2 0.25
2.5 0.32
3 0.40
4 0.50
5 0.63
6 0.80
8 1.00
10 1.25
12 1.60
16 2.00
20 2.50
25 3.20
32 4.00
40 5.00
50 6.30
63 8.00
80 10.00
5.2.2 Additional secondary outcomes
Details for deriving any secondary outcome variables are given below:
New variable Rules
Dye leakage on angiogram (Using FA variables)
If CNV present=yes; then = Yes
If CNV  present=no; then = No
If CNV present=cant grade; then = can’t grade
Else missing
Fluid on OCT (Using OCT variables)
If OHRB SRF present OR Intra retinal cycts present; then = Yes
If OHRB SRF not present AND Intra retinal cycts not present; 
then = No
Else if OHRB SRF = cant grade or Intra retinal cycts = cant 
grade; then = can’t grade
Otherwise – Data missing
Lesion area (Using FA variables)
= Classic CNV + occult FPED + occult LLIO + RAP + blocked 
fluorescence + SPED
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New variable Rules
Total thickness at fovea (Using OCT variables)
=(neuroretinal foveal thickness + OHRB thickness at fovea + 
PED thickness at fovea + SRF thickness at fovea) * 1000
Retinal thickness plus 
subfoveal fluid thickness
(Using OCT variables)
= (neuroretinal foveal thickness + SRF thickness at fovea)* 1000
Any new GA If DeNovo GA at final visit = yes OR (GA within lesion at final 
visit = yes AND EITHER 1) GA in study eye at baseline = no 
OR 2) GA in study eye at baseline = yes AND GA location at 
baseline IS NOT within lesion; then = Yes
If DeNovo GA in study eye at final visit = no or n/a AND GA 
within lesion in study eye at final visit = no or n/a; then = No
Else missing
5.3 Safety outcomes
Safety data is collected at each visit.  In collating the safety data the following rules will be applied:
• Systemic serious adverse events (SAEs) will be grouped as per the CATT trial.
• Adverse events will be grouped using the MedDRA classification system.  For non-ocular 
events the MedDRA general term will be reported.  For ocular events the preferred term 
will be used.  
• Traumatic cataract1 and wound evisceration (in the eye), map to the MedDRA general term 
“Injury, poisoning and procedural complications”, and endophthalmitis and herpes (in the 
eye) map to MedDRA general term “infection”.  For the purposes of IVAN (and to allow 
appropriate identification of ocular SAEs) these events will be re-mapped to the general 
term “Eye disorders”
• The MedDRA preferred term will be used to describe both ocular and non-ocular treatment-
related serious adverse events.
• Non–serious adverse events will not be reported in the primary publication but will be 
included in the report to the funder.
• Dates of onset and resolution of events will be interrogated to minimise the chance of an 
event being counted more than once.  
• If the onset date is missing or incomplete then the following rules will be applied
1 defined in the IVAN protocol as an SAE
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Occurrence Rules 
First (either not reported 
previously, or previous 
occurrence is resolved) 
If 1) onset date = missing OR 2) onset day = missing AND onset month = 
missing AND onset year = year form completed OR 3) onset day = missing 
AND onset month = month form completed AND onset year =year form 
completed); then onset date = date form completed 
If onset day = missing AND onset month = missing AND onset year ≠ year 
form completed AND onset year = year form completed for previous visit 
attended; then onset day = 31 and onset month = 12 
If onset day = missing AND onset month = month form completed -1 AND 
onset year = year form completed; then onset day = 31 
If onset day = missing AND onset month = 12 AND month form completed = 
1 AND onset year = year form completed -1; then onset day = 31 
Otherwise = data query 
Second or subsequent 
report of an on-going 
event 
Onset date = date assigned for first report of the event as per rules outlined 
above 
• All serious adverse events including those reported at an unplanned visit or exit visit will be 
included. 
• A drop of 15+ letters in BCVA between 2 consecutive visits attended (i.e. current visit = 
previous visit + 1) with no associated cause, determined from the BCVA at each visit, will 
not be reported as an SAE. Any drop in VA reported explicitly as an SAE will be excluded. 
• A change in 2+ CCS or NYHA categories between 2 consecutive visits attended (i.e. 
current visit = previous visit + 1) not resulting in hospitalisation will not be reported as an 
SAE. Worsening angina not resulting in hospitalisation reported explicitly as an SAE will 
be excluded. 
• For the interim analysis, adverse event data was interrogated to determine if any ocular 
SAEs (as defined in the IVAN protocol) were recorded as adverse events. For the final 2 
year analysis, identification of unreported SAEs will be determined through on-site 
monitoring visits prior to the database lock. Therefore, further interrogation of the adverse 
event data will not be required for the 2 year analysis. 
Details for deriving serious adverse event variables are given below: 
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New variable Rules 
Time to death (days) If death = yes and date of resolution ≠ missing; then = Date of 
resolution – randomisation date 
If death = yes and date of resolution = missing; then = Date of 
onset – randomisation date 
Otherwise = missing 
Time to death event indicator 
variable 
If death = yes; then = Yes 
Otherwise = No  
Death from vascular causes  If death = yes and cause of death = MI, stroke or cardiac arrest; 
then = Yes 
Otherwise = No 
Venous thrombotic event  If PE or DVT = yes OR (free text leading to MedDRA preferred 
term = pulmonary embolism OR deep vein thrombosis) then = Yes 
Otherwise = No 
Primary safety endpoint (IVAN 
protocol) 
If MI = yes OR stroke = yes OR death from vascular cause = yes 
OR heart failure = yes OR (free text leading to MedDRA preferred 
term = myocardial infarction OR stroke OR  heart failure) then = 
Yes  
Otherwise = No 
Systemic serious adverse event  If SAE is classified into one of the MedDRA system organ classes 
(excluding eye disorders); then = Yes  
Otherwise = No 
Ocular serious adverse event If SAE MedDRA system organ class = eye disorders; then = Yes  
Otherwise = No 
Any serious adverse event If systemic SAE = yes OR ocular SAE = yes; then = Yes 
Otherwise = No 
SAE maximum intensity Maximum of intensity variable on all reports of an ongoing event 
(spanning >1 visit) ever classified as an SAE  (excluding a drop in 
BCVA without an associated cause or worsening angina not 
resulting in hospitalisation) 
SAE relatedness Maximum (worst case scenario) of relatedness variable on all 
reports of an ongoing event (spanning >1 visit) ever classified as 
an SAE  (excluding a drop in BCVA without an associated cause 
or worsening angina not resulting in hospitalisation) 
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5.4 Treatment failure 
A patient allocated to discontinuous treatment arm of the trial should be treated when they are 
eligible for treatment and the treatment failure criteria are met.   
The treatment failure criteria are NOT assessed when the patient is part way through a cycle of 
three treatments (patients allocated to discontinuous treatment) or if the failure criteria were met at 
either of the last two visits attended (patient allocated to continuous treatment). 
Component Rules 
Eligible for assessment 
of treatment failure 
Met treatment failure criteria at the previous visit (i.e. current visit -1) = 
No 
AND 
Met treatment failure criteria at (current visit – 2) = No; then = Yes 
Otherwise = No  
Treatment failure If currently in a 3 month cycle of treatment (question A) = No  
AND  
[(OCT evidence of sub-retinal fluid in the study eye (question B1) =   
Yes  
OR OCT evidence of an increase in intra-retinal fluid in the study eye 
(question B2) = Yes  
OR Fresh blood in the lesion in the study eye (question B3) = Yes)]; 
then = Yes 
 
Else if question A = No  
AND question B1 = No or not sure  
AND question B2 = No or not sure  
AND question B3 = No or not sure  
AND OCT evidence of persistent intra-retinal fluid in the study eye 
(question C1) = Yes  
AND VA dropped by ≥10 letters over the last 3 months (question C2) = 
Yes;  
then = Yes 
 
Else if question A = No  
AND question B1 = No or not sure  
AND question B2 = No or not sure  
AND question B3 = No or not sure  
AND  
(question C1 = Not sure OR question C2 = Not sure)  
AND  
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Component Rules 
[(evidence of extension of the CNV (question D1) = Yes  
OR leakage from >25% of the circumference of the CNV (question D2) 
= Yes)];  
then = Yes 
 
Else if question A = No  
AND question B1 = No or not sure  
AND question B2 = No or not sure  
AND question B3 = No or not sure  
AND  
[(question C1 = No AND question C2 = No) 
OR (question C1 = Yes AND question C2 = No)  
OR (question C1 = No AND question C2 = Yes)];  
then = No 
 
Else if question A = No  
AND question B1 = No or not sure  
AND question B2 = No or not sure  
AND question B3 = No or not sure  
AND   
(question C1 = Not sure OR question C2 = Not sure)  
AND question D1 = No  
AND question D2 = No;  
then = No 
 
If visit number = 0, 1 or 2 OR question A is Yes;  
then = N/A 
 
Failure visit = visit at which treatment failure = yes 
Visit at which first 
failure occurs 
= minimum(visit number) if treatment failure = yes 
= missing if patient never failed 
Treatment failure date = injection date if injection date ≠ missing & visit number = visit at which 
failure first occurs 
= injection form date if injection date = missing & visit number = visit at 
which failure first occurs 
= visual assessment form date if injection date = missing & injection form 
date = missing & visit number = visit at which failure first occurs 
= missing if patient never failed 
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Component Rules 
Time to treatment 
failure (days) 
If visit at which first failure occurs ≠ missing; then = Treatment failure 
date – randomisation date 
Otherwise = Last attended visit date – randomisation date 
Time to treatment 
failure event indicator 
variable 
If treatment failure date ≠ missing; then = Yes 
Otherwise = No  
 
5.5 Quality of life questionnaires 
5.5.1 EQ-5D 
A five digit ‘state score’ will be derived from the mobility, self-care, usual activities, 
pain/discomfort and anxiety/depression scores as follows: 
State = 10000*mobility score + 1000*self-care score + 100*usual activities score + 
10*pain/discomfort score + anxiety/depression score 
Each five digit state will then be assigned a single summary index score according to standard 
scales.  These index scores are numerical and range from -0.59 to 1.00, with a score of 1.00 
denoting perfect health. If any of the five components of the state score is missing, the overall score 
will be missing. 
Visual analogue scales are also collected.  Such scores range from 0 to 100 (with higher scores 
denoting higher QoL). 
5.5.2 MacDQoL 
An average weighted impact score will be calculated as follows:  
New variable Rules 
Weighted impact scores (for 
each question) 
Impact rating (-3 to 1) * importance rating (0 to 3) 
Possible range from -9 (maximum negative impact of MD on QoL) to 
+3 (maximum positive impact of MD on QoL) 
Average weighted impact (AWI) 
score (to be calculated from all 
domains except ‘work) 
(sum of weighted impact scores) / (number of applicable domains) 
Note AWI can be calculated providing at least 11 items have 
complete responses. If less than 11 items have been answered AWI is 
missing (based on Cronbach’s alpha calculation). 
 
5.5.3 MacTSQ 
Three summary measures will be calculated as follows: 
New variable Rules 
Subscale 1 (information 
provision and convenience) 
Contains questions 1, 10b, 11, 13, 14, and 15. 
Each question is scored 0 (not satisfied) to 6 (very satisfied), and are 
summed to give a subscale score of 0 to 36 where higher scores 
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New variable Rules 
reflect greater satisfaction. 
Note: If the answer to any of the six questions are missing, then 
subscale 1 = missing. 
Subscale 2 (Impact of treatment) Contains questions 2, 3, 4, 5, 6, and 9. 
Each question is scored 0 to 6, and are summed to give a subscale 
score of 0 to 36 where higher scores reflect greater satisfaction. 
Note: if the answer to one of the six questions is missing, we will use 
the summation of the other values. If answers to more than one 
question are missing then subscale 2 = missing (based on Cronbach’s 
alpha calculation). 
Single scale The 12 items from subscales 1 and to can be added together to 
produce a single scale from 0 to 72. The higher the score, the greater 
the satisfaction. 
Note: if answers to three or less of the twelve questions are missing, 
we will still use the summation of the other values. If answers to more 
than three question are missing then single scale= missing (based on 
Cronbach’s alpha calculation). 
 
5.6 Other variables 
Details for any other variables which will be derived for use in any other figures or tables are given 
below: 
New variable Rules 
Injection given If date of injection ≠ missing; then= Yes  
Reason for exclusion from trial If any eligibility criteria not met = Ineligible 
If all eligibility criteria met, but patient did not consent = Did not 
consent 
Otherwise = Other 
Protocol breach type 1 – patient 
didn’t receive allocated drug 
If identified in a “note to file” outside the database; then = Yes 
Otherwise = No 
Protocol breach type 2 – patient 
didn’t receive allocated regimen 
Identified by looking at patients in the discontinuous arm whose 
injection rate at attended visits >0.9, and continuous patients whose 
injection rate at attended visits <0.9. Retreatment criteria studied for 
these patients to identify genuine breaches. 
Protocol breach type 3 – patient 
ineligible but treated 
If either: 1) age <50 years OR 2) VA at visit 0 <25 letters AND 
injection given at visit 0 OR 3) exudative AMD not present ; then = 
Yes 
Otherwise = No 
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New variable Rules 
Protocol breach type 4 – 
attended the clinic but treatment 
was not given 
If missed visit ≠ yes AND current visit < 3 AND date of injection = 
missing AND clinical assessment of risk>benefit ≠ yes; then = Yes 
If missed visit ≠ yes AND current visit ≥ 3 and allocation = 
continuous AND date of injection = missing AND clinical assessment 
of risk>benefit ≠ yes; then = Yes 
If missed visit ≠ yes AND current visit  ≥ 3 and date of injection = 
missing AND allocation = discontinuous AND cycle number* ≠ 
missing AND clinical assessment of risk>benefit ≠ yes; then = Yes 
Otherwise = No 
 
Note: if a patient missed all 3 injections of a cycle, this is treated as a 
protocol breach type 6 and not type 4. 
 
* Cycle number is derived as follows:  
If allocation = discontinuous and current visit  ≥ 3 AND missed visit 
≠ yes AND treatment failure = yes AND date of injection ≠ missing; 
then = 1 
If allocation = discontinuous and current visit  ≥ 3 AND treatment 
failure at previous visit = yes AND [(failure visit = previous visit 
number AND missed visit ≠ yes) OR missed visit = yes]; then = 2 
If allocation = discontinuous and current visit  ≥ 3 AND treatment 
failure at current visit number – 2 = yes AND [(failure visit = current 
visit number - 2 AND missed visit ≠ yes) OR missed visit = yes]; 
then = 3 
 
Protocol breach type 5 – 
Treatment was restarted but the 
criteria for retreatment were not 
met 
If date of injection ≠ missing AND current visit ≥ 3 AND allocation = 
discontinuous AND eligible for assessment of treatment failure = yes 
AND treatment failure = no AND protocol deviation type 2 ≠ yes; 
then = Yes 
Otherwise = No 
 
Note: if treatment was restarted following a complete cycle of three 
but no further injections for that cycle were given, this will be treated 
as protocol breach type 7. 
Protocol breach type 6 – 
Treatment was not restarted but 
the criteria for retreatment were 
met 
If missed visit ≠ yes AND current visit  ≥ 3 and date of injection = 
missing AND allocation = discontinuous and eligible for assessment 
of treatment failure = yes AND treatment failure = yes; then = Yes 
Otherwise = No 
DOI: 10.3310/hta19780 HEALTH TECHNOLOGY ASSESSMENT 2015 VOL. 19 NO. 78
© Queen’s Printer and Controller of HMSO 2015. This work was produced by Chakravarthy et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
287
New variable Rules 
 
Note: if the first injection of a cycle of 3 was missed but the following 
2 injections were given, this will be treated as protocol breach type 4 
and not type 6. 
Protocol breach type 7 – 
treatment cycle extended beyond 
3 months  
If missed visit ≠ yes AND current visit  ≥ 3 and date of injection ≠ 
missing AND allocation = discontinuous AND (treatment failure not 
assessed OR treatment failure= no) AND patient failed at current visit 
number - 3; then = Yes 
Otherwise = No 
 
Note: If the additional treatment was taken to be the first of a cycle at 
the following two visits, this will be treated as a protocol breach type 
5 and not type 7. 
Protocol breach type 8 – time 
between consecutive visits 
outside range 
If (current visit injection date form completed (dfc)  – previous visit 
injection dfc) < 28 days AND current visit = previous visit + 1; then = 
Yes  
If (current visit injection dfc – previous visit injection dfc) > 35 days 
AND current visit = previous visit + 1; then = Yes  
Otherwise = No 
Protocol breach type 9 – missed 
visit 
If missed visit = yes; then = Yes 
Otherwise = No 
Last attended visit (LTV) date For the interim 1 year analysis, exit dates were calculated and used to 
identify patients who exited the trial before the 12 month cut off. For 
the final 2 year analysis, the calculation will be revised and the exit 
date will be replaced by ‘last attended visit date’. The reason for the 
change is that this will allow us to calculate a date for all patients, 
including those who have died and those who completed the study 
The exit date used in the interim analysis will not be calculated as all 
study data will be included so we will not need an exact date to 
determine whether withdrawals were prior to the 12 month time point.  
 
If a patient withdrew and attended an exit visit AND exit date form 
completed ≤105 days* after last attended study visit; then LTV date = 
exit date form completed 
If patient withdrew and did not attend exit visit OR patient withdrew 
and date form completed for exit visit >105 days after last attended 
study visit OR patient died OR patient did not withdraw from the 
study; then LTV date = date form completed of visual assessment 
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New variable Rules 
form of last attended study visit 
 
* A cut-off of 105 days has been chosen to identify patients who have 
exit form for an attended visit completed instead of an exit form for 
absent patients.  
Withdrawal indicator If exit form completed OR exit form for absent patient completed; 
then = Yes 
Orherwise = No 
Note: if an exit was due to death then this will be reported as an SAE 
of death not as a withdrawal 
Time of withdrawal (months) = (Last attended visit date – randomisation date) * 12/365.25 
Age = (Randomisation date – DOB)/365.25 
Non-white race If race = white; then = No 
If race = missing; then = Missing 
Otherwise = Yes 
Systolic BP If 1 reading is done (contrary to protocol); then = SBP1 
If 2 readings are done; then = (SBP1 + SBP2)/2 
If 3 readings done, take the mean of the two closest readings, i.e. 
order readings so that SBP1 ≤ SBP2 ≤ SBP3. If (SPB2 - SPB1) < (SPB3 
- SPB2) then = (SBP1 + SBP2)/2  
Otherwise (SBP2 + SBP3)/2  
Diastolic BP If 1 reading is done (contrary to protocol); then = DBP1 
If 2 readings are done; then (DBP1 + DBP2)/2 
If 3 readings done, take the mean of the two closest readings, i.e. 
order readings so that DBP1 ≤ DBP2 ≤ DBP3. If (DPB2 - DPB1) < 
(DPB3 - DPB2) then = (DBP1 + DBP2)/2  
Otherwise (DBP2 + DBP3)/2 
Angina pain If ever had angina = yes; then = Yes  
If ever had angina = no; then = No 
Otherwise = Missing 
Dyspnoea If NYHA = 0; then = No  
If NYHA =1, 2,3 or 4 = Yes 
Number of treatments received = number of injections given on visits 0 to 23 
Drop of 15+ letters in BCVA If (BCVA at previous visit – BCVA at current visit) ≥ 15 AND 
current visit number – previous visit number = 1; then = Yes 
Otherwise = No 
Worsening angina If (CCS class at previous visit  – CCS class at current visit) ≥ 2 AND 
current visit number- previous visit number =1; then = Yes 
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New variable Rules
Otherwise = No
Deferred visit indicator If data is from a deferred visit; then = Yes
Otherwise = missing
Choroidal neovascularisation (Using FA variables)
If (classic CNV present AND classic CNV location = subfoveal) OR 
(occult FPED present AND occult FPED location = subfoveal) OR 
(occult LLIO present AND occult LLIO location = subfoveal) OR 
(RAP present AND RAP location = subfoveal); then = Yes
Else if CNV present=yes/no AND FPED present=yes/no AND LLIO 
present=yes/no AND RAP present=yes/no; then = No
Otherwise = missing
Haemorrhage (Using Col variables)
If (classic sub retinal blood present AND sub retinal blood location =
(subfoveal or juxtafoveal)) OR (sub RPE blood present AND sub 
RPE location = (subfoveal or juxtafoveal)) OR (intra retinal blood 
present AND intra retinal blood location = (subfoveal or 
juxtafoveal)); then = Yes
Else if sub retinal blood present=yes/no AND sub RPE blood 
present=yes/no AND intra retinal blood present=yes/no; then = No
Otherwise = missing
Other foveal centre involvement (Using FA variables)
If (SPED present AND SPED location = subfoveal) OR (fibrosis 
present AND fibrosis location = subfoveal); then = Yes
Else if SPED present=yes/no AND fibrosis present=yes/no; then= No
Otherwise = missing
No choroidal neovascularisation 
or can’t grade
(Using FA variables)
If exudative AMD present = No OR exudative AMD = can’t grade; 
then = Yes
If exudative AMD present = Yes; then = No
Otherwise = missing
Area of active 
neovascularisation
(Using FA variables) 
= area of classic CNV + area of occult FPED CNV + area of occult 
LLIO CNV + area of RAP
= Missing if any of the above components are missing
Blood present (Using COL variables) 
If intra-retinal blood = yes OR sub-retinal blood = yes OR sub-RPE = 
yes; then = Yes
If intra-retinal blood = no AND sub-retinal blood = no AND sub-RPE 
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blood = no; then = No
Otherwise = missing
RPE tear If RPE tear/Rip (from FA) = yes OR RPE tear (from Col) = yes OR 
OHRB discontinuous due to RPE tear (from OCT) = yes; then = Yes
If RPE tear/Rip (from FA) = no AND RPE tear (from Col) = no AND 
OHRB discontinuous due to RPE tear (from OCT) = no; then = No
Otherwise = missing
Fibrosis If Fibrosis/atrophic scar (from Col) = yes OR Fibrosis (from FA) = 
yes; then = Yes
If Fibrosis/atrophic scar (from Col) = no AND Fibrosis (from FA) = 
no; then = No
Otherwise = missing
Area of fibrosis = Fibrosis area from FA 
Area of atrophy = atrophic scar area (from FA)
Note: = 0 if ‘Atrophic scar’ = No
Maximal retinal thickness = maximal retinal thickness (from OCT)
Neuroretinal foveal thickness = neuroretinal foveal thickness (from OCT) 
Atrophy If atrophic scar (from FA) = yes; then = Yes
If atrophic scar (from FA) = no; then No
Otherwise = missing
Height of PED = PED thickness (from OCT) 
GA present If GA (from FA) = yes; then = Yes
If GA (from FA) = no; then = No
Otherwise = missing
Area of SRF = Area of SRF (from FA)
6. STATISTICAL ANALYSES
6.1 Baseline characteristics and outcomes at 2 years
Baseline data (i.e. patient demography and past history), outcomes at 2 years and some change from 
baseline data will be described by treatment group (all Lucentis, all Avastin, all continuous and all 
discontinuous) for patients in the analysis population group.  
Continuous variables will be summarised using the mean and SD (or median and inter quartile 
range (IQR) if the distribution is skewed), and categorical data will be summarised as a number and 
percentage.  The summary statistic headings given in the tables are those we expect to use based on 
a-priori knowledge of the clinical measurements gained from the interim analysis and previous 
trials.  However, if distributional assumptions are not valid, changes will be made.  
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Any imbalances in the characteristics of the patients at the start of the study will be described but 
statistical tests for baseline imbalance will not be carried out. 
The results of statistical tests, comparing outcomes at 2 years, will not be included in the summary 
tables. Treatment effects will be reported graphically with 95% confidence intervals, and with the 
numerical details alongside (cf. Forest plot). 
6.2 Quantification of treatment effects
6.2.1 Adjustment in models
The intention is to adjust all models for the factor included in randomisation, i.e. study centre.  
However, for some low frequency outcomes (e.g. safety) it is expected that this will not be feasible.  
Therefore, for consistency, analyses will be adjusted for centre size, fitted as a fixed effect rather 
than being adjusted for centre. Centres will be grouped into 7 bands as outlined in Table 3. If the 
frequency of the event is sparse and fewer bands are needed to ensure estimation then the bands will
be examined to see where the estimation is not possible and adjacent bands will be combined.  It is 
anticipated that bands 1 and 2 and/or 5 and 6 may need to be combined.
Adjustment for the deferred indicator will also be included in the models if it is significant at the 
5% level. 
For continuous outcomes that are measured pre-injection at baseline as well as subsequently (e.g. 
visual acuity, other measures of vision, quality of life scores); baseline and subsequent values will 
be modelled jointly in preference to the baseline value being modelled as a covariate.  Joint 
modelling will avoid the necessity to either exclude cases with missing preoperative measures or to 
impute missing preoperative values.
Table 3 Centre banding according to size
Eligible patients 
recruited at centre
Number of centres
Total number of 
patients
Band
1-19 7 41 1
20-29 7 179 2
30-39 4 133 3
40-49 3 132 4
50-59 1 55 5
60-69 0 0 -
70-79 1 70 6
Total 23 610
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6.2.2 Drug by treatment frequency interactions 
The interaction of VEGF inhibitor and treatment frequency will be tested, but differences between 
Lucentis and Avastin will only be reported separately for the continuous and discontinuous 
treatment arms if the interaction term reaches statistical significance (two-sided) at the 5% level for 
outcomes where the results from the CATT trial suggested possible interaction (i.e. OCT measures 
of thickness of the fovea and fluid and presence of fluid on OCT).  For all other outcomes, where 
interactions are not anticipated, a statistical significance level of 1% (two-sided) will be used for the 
interaction term in order to reduce the type I error rate.  If the interaction is not statistically 
significant then the main effects of Lucentis vs. Avastin and of continuous vs. discontinuous 
treatment after 2 years will be reported. 
6.2.3 Analysis models 
General methods of presentation and assessing treatment effects are outlined below.  For all 
treatment comparisons, Lucentis and continuous treatment will be the reference groups.  Details 
specific to each outcome are described as appropriate. 
Binary outcomes will be compared between treatment groups using logistic regression with 
treatment estimates presented as odds ratios (OR) and 95% confidence intervals (95% CI).  Formal 
statistical comparisons of treatment effects will only be performed if more than ten patients in total 
experience the outcome. 
Categorical data measured at multiple time points (e.g. EQ-5D categories) will be presented at 
both the baseline and 2 year time points.  For these category component scores no formal 
comparisons will be made between the treatment groups.   
Continuous data measured at multiple times points (e.g. visual acuity, other measures of vision, 
EQ-5D single summary index) will be analysed using linear mixed effects methods.  Multivariate 
normal models will be fitted incorporating separate parameter estimates for the mean baseline 
response and for each treatment at each follow-up time-point measured (i.e. saturated model with 
time fitted as a categorical variable). Many possible structures are available for the 
variance/covariance matrix and will be compared using information criteria such as AIC or DIC and 
likelihood ratio tests. 
Time to event outcomes (e.g. time to first treatment failure) will be summarised by the median and 
IQR in each treatment group, estimated from survival modelling. Outcomes will be compared using 
Cox’s proportional hazards models. Treatment comparisons will be presented as hazard ratios (HR) 
with 95% confidence intervals (CI). The validity of the assumption of proportional hazards will be 
tested and, if this assumption is violated, alternative modelling methods will be tried. Time to 
treatment failure will be censored using the censoring variable treatment failure yes/no. 
Outcomes may also be presented graphically, if appropriate.  For continuous primary or secondary 
outcomes this will consist of graphs depicting mean differences/ odds ratios and 95% confidence 
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intervals, and may also show estimated means and standard deviations over time for each treatment 
group.   
6.2.4 Statistical significance 
For hypothesis tests of superiority, two-sided p-values<0.05 are considered statistically significant. 
For tests of non-inferiority (primary outcome), Avastin will be considered inferior to Lucentis and 
discontinuous treatment inferior to continuous treatment if the lower limit of the 95% confidence 
interval is <-3.5 (inferiority margin set at 3-4 letters). 
Likelihood ratio tests will be used in preference to Wald tests for hypothesis testing.   
6.2.5 Model assumptions 
For all methods outlined, underlying assumptions will be checked using standard methods, e.g. 
residual plots, etc.  If assumptions are not valid then alternative methods of analysis will be sought.  
If outlying observations are found which mean models do not fit the data adequately, such 
observations will be excluded from the main analyses. 
6.2.6 Subgroup analyses 
Planned subgroup analyses for the report to the funder (listed in study protocol) are: (i) baseline 
visual acuity in study eye (<55 vs. ≥55 letters read), (ii) baseline CNV size (<6 vs ≥6 disc areas); 
(iii) proportion of classic CNV (<50% vs. ≥50%); (iv) presence of RAP; (v) fellow eye status (<75 
vs. ≥75 letters read).     
6.2.7 Sensitivity analyses  
There are no planned sensitivity analyses defined in the study protocol. However, there are two 
sensitivity analyses on the primary outcome that will be considered: 
• Carrying out the primary analysis including only the study visits at which all functional 
outcomes were assessed (visits 0, 3, 6, 12, 18 and 24).  
• Carrying out the primary analysis including only data recorded at the study visit (i.e. not 
including data that was recorded at a deferred visit). 
6.2.8 Missing data 
For missing primary or secondary outcomes, see section 5.1 and 5.2 for explanations of how 
deferred visit data are used. It is anticipated that missing data will be low for the clinical outcomes, 
especially once deferred visit data is used. Missing data may be more common for some of the 
quality of life measures when some of the questions may not be directly applicable to the IVAN 
population, or the questionnaire may not have been completed.  
In all tables missing data will be indicated by footnotes.  The amount of missing data by group will 
be examined and if it differs substantially between groups potential reasons will be explored.  
Missing data in any analysis models is now discussed: 
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• For continuous data measured at multiple time points, baseline values will be modelled jointly 
with those measured after treatment, as described previously, thereby allowing all cases with at 
least one observation to be included. If appropriate (i.e. the level of missingness is >20%) any 
variables that are predictive of missingness will be identified. If an assumption of missing at 
random (MAR) given these variables is reasonable (especially likely if the variable was 
measured at baseline), then such variables will be adjusted for.  A model, which includes 
predictors of missingness, can be shown to provide unbiased estimates of the treatment effect 
and moreover multiple imputation approaches would not be expected to recover any additional 
information. 
• By design, there will be no missing predictor data, other than already discussed in the points 
above. 
6.2.9 Multiple testing 
No formal adjustment will be made for multiple testing.  The primary analysis (as specified here) 
will be clearly distinguished from secondary analyses.  When interpreting the results, consideration 
will be given to the number of statistical tests performed. 
6.3 Adverse events 
All reported post-randomisation serious adverse events will be tabulated for all patients in the safety 
population.  Events related to treatment will be described. For consistency, events will be presented 
grouped by the treatment allocated. 
Formal comparisons (logistic regression) between treatment groups will be made for primary safety 
endpoints and for all MedDRA system organ class terms for which more than 10 events occurred.  
6.4 Meta-analysis of CATT and IVAN trial results  
Meta-analysis of the IVAN trial data with the CATT [2, 3] results is planned for the following 
outcomes: BCVA at 2 years, serious adverse events, geographic atrophy and total lesion thickness 
at the fovea. The following SAE outcomes will be analysed: all-cause mortality, arteriothrombotic 
event: (MI, stroke, death from a vascular cause), and ≥ 1 systemic serious adverse event (MedDRA 
classification). For the outcomes BCVA at 2 years and total lesion thickness at the fovea, change 
from baseline will be used, as this is the way the data has been presented in the CATT trial. The 
results from CATT and IVAN will be combined in a fixed effects meta-analysis and the results 
summarised as a forest plot for the main effects Avastin vs. Lucentis and continuous vs. 
discontinuous (prn in CATT) treatment. For comparisons of safety by treatment frequency we will 
contact the CATT team to see if we are able to obtain safety data to two years (not included in 2-
year results paper [3]).  If the team are unable to provide the information the 1- year results [2] will 
be used. 
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8. AMENDMENTS TO SAP
Previous 
version
Previous 
date
New 
version
New date Brief summary of change
1.0 27/02/2013 2.0 2/12/2013 Section 2.4 – list of secondary outcomes 
excluded from the 2-year Lancet publication 
have been  added
1.0 27/02/2013 2.0 2/12/2013 Section 5.2.2 – ‘Any new GA’ has been added to 
as an additional secondary outcome, and the 
imaging form used to capture morphology 
outcomes has been added for clarity
1.0 27/02/2013 2.0 2/12/2013 Section 5.3 – rules for imputing onset/resolution 
dates of adverse events, when missing, have been 
included
1.0 27/02/2013 2.0 2/12/2013 Section 5.6 – derivations for additional 
morphology variables identified for inclusion in 
summary tables have been added, and the 
imaging form and the imaging form used to 
capture morphology outcomes has been added 
for clarity
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1.0 27/02/2013 2.0 2/12/2013 Section 6.2.3 – method for analysis of time to 
event outcomes has been added
1.0 27/02/2013 2.0 2/12/2013 Section 6.2.6 – sub-group analyses excluded 
from the 2-year Lancet publication have been  
added
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